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Abstract 
Systematic reviews can provide timely, reliable evidence on which to make informed 
decisions. In order to make balanced decisions, information is not only needed on 
the benefits of an intervention, but also on its adverse effects. Yet few systematic 
reviews incorporate adverse effects data in their analysis. There is currently a lack 
of guidance on how to identify adverse effects data, this may impede systematic 
reviewers. This thesis helps address this situation by evaluating and optimising the 
methods for retrieval of research evidence for systematic reviews of adverse effects. 
 
The first stage of this programme of research critically reviews the methodological 
literature relating to the retrieval and inclusion of adverse effects data, including 
aspects such as the impact of study design (for example RCTs and cohort studies), 
database search strategies (for example in MEDLINE and EMBASE), sources of 
data (including database and non-database sources), publication status and funding 
status. 
 
Second, the results of a survey of the literature searching methods used in 849 
systematic reviews of adverse effects are presented. Data were collated on aspects 
such as sources searched, search strategy design and the standard of reporting of 
the methods used. The reviews are published over a 17 year time period (1994-
2011) thus enabling time trends analysis. The methods used in these systematic 
reviews of adverse effects are also compared with those reported in surveys of 
other types of reviews. 
 
Further potentially relevant evidence is incorporated to address gaps identified in 
the literature. A detailed analysis is provided of the contribution of different sources 
of data for adverse drug reactions using 58 included studies from a case study 
systematic review. The same case study systematic review is then used to measure 
the performance of adverse effects search filters in MEDLINE and EMBASE. 
 
Finally 242 included papers from a series of 26 systematic reviews are evaluated to 
strengthen the evidence base regarding adverse effects search filters and to assess 
individual adverse effects search terms in MEDLINE, EMBASE, and Science 
Citation Index (SCI). 
 
The strengths and weaknesses of the analyses are discussed and implications for 
practice and guidance presented along with recommendations for future research.  
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Chapter 1 Introduction 
 Background 1.1
Pharmaceutical interventions have bought about many benefits to health, improving 
the population’s wellbeing and life expectancy. However, these interventions are not 
without potential harmful consequences. For over two thousand years, adverse 
effects of drugs have been known to cause significant morbidity and mortality.1 
While all healthcare interventions have the potential for harm, it is the adverse 
effects of pharmaceutical interventions that have received the most media 
attention.2 Although the adverse effects of thalidomide in the 1950s and 1960s are 
perhaps most well-known, other cases still appear frequently in the media. Recent 
cases include the postulated association of seroxat (paroxetine) with suicide, vioxx 
(rofecoxib) with heart attack or stroke, statins (HMG-CoA reductase inhibitors) with 
diabetes risk, avandia (rosiglitazone) with fluid retention, and herceptin 
(trastuzumab) with cardiovascular events. These all highlight the need for accurate 
and complete information on adverse drug reactions.3 
 
An explicit objective of the UK National Health Service (NHS) is to improve health 
and well-being.4 This involves maximising beneficial effects and minimizing harm in 
order to do ‘more good than harm’.5, 6 Decision bodies, such as the National Institute 
for Health and Care Excellence (NICE) in the UK, provide guidance on the ‘use of 
new and existing medicines, treatments and procedures within the NHS’.7 The 
decisions made by NICE aim to maximise health on a population basis. Other 
initiatives in the UK aim to move towards a healthcare system with more individual 
choice8 and more patient centred decision making.9 In order for patients, clinicians 
and other decision makers (such as NICE) to make informed, balanced decisions, 
appropriate information is needed on both the intended benefits and unwanted 
harms of an intervention.10, 11  
 
Currently, however, there is an absence of sufficient evidence-based information on 
the frequency and magnitude of adverse effects. Although there are long lists of 
potential adverse effects, there is little or no information available as to their 
severity, or of the probability of their occurrence.12-14 One potential solution to this 
problem would be to incorporate data on adverse effects into systematic reviews.15 
 
23 
 Systematic reviews and adverse effects 1.2
The main aim of implementing evidence-based healthcare is to objectively evaluate 
healthcare interventions in order to inform practice and thus enhance patient care. 
Great emphasis is placed on using the best available evidence. One of the most 
reliable forms of evidence is a well-conducted systematic review.2, 16-21  
 
A systematic review attempts to identify, evaluate and summarise all the empirical 
evidence that fits pre-specified eligibility criteria in order to answer a specific 
research question. It uses explicit transparent methods which aim to minimize bias, 
and provide more reliable findings from which conclusions can be drawn and 
decisions made.22, 23 
 
Synthesis is an important stage of a systematic review. Many systematic reviews 
contain a quantitative synthesis using meta-analysis. 
 
‘Meta-analysis is the use of statistical methods to summarize the results of 
independent studies. By combining information from all relevant studies, 
meta-analyses can provide more precise estimates of the effects of health 
care than those derived from the individual studies included within a review. 
They also facilitate investigations of the consistency of evidence across 
studies, and the exploration of differences across studies.’22 
 
To be more useful to decision makers, however, such reviews should assess the 
balance of benefits and adverse effects of an intervention.21, 24-26 A systematic 
review that assesses only benefits is likely to lead to unfair comparisons and one-
sided conclusions.27 However, the vast majority of systematic reviews focus on 
clinical effectiveness without addressing adverse effects.19, 20, 28-31 
 
The current emphasis on evidence of beneficial effects, and the relative lack of 
rigorous evaluations of adverse effects creates a challenging conundrum.13 Decision 
makers, prescribers and patients are obliged to struggle with a situation where they 
must evaluate quantitative effectiveness data from well-conducted systematic 
reviews against incomplete or inadequate adverse effects information of uncertain 
quality.13, 25 This imbalance in information may lead to interventions being 
prescribed inappropriately, or in patients being harmed by potentially avoidable 
adverse effects. 
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In order to redress the over-emphasis on benefits, the development and 
improvement of methods to quantify adverse effects should be made a key research 
priority. This will ensure that information on harms can be considered at the same 
time, and on an equal standing, with information concerning benefits.  
 
Although the methodology of conducting a systematic review of intended beneficial 
effects is well established and empirical research is available to support current 
recommendations, this is not the case for systematic reviews of adverse effects and 
many methodological issues remain unaddressed.  
 
The first step towards quantifying adverse effects is to retrieve good quality data on 
their association and frequency with particular interventions. This requires the 
development of optimal search techniques to retrieve information on adverse 
effects. Where and how such information is identified markedly affects the range 
and frequency of adverse effects found.14 A better understanding of the implications 
of using different sources and approaches to identifying data on adverse effects is 
urgently required.21 Development of these search techniques is the primary aim of 
the programme of research described in this thesis. 
 
 Aims and objectives of the thesis 1.3
1.3.1 Aim 
The aim of this research is to evaluate the most effective study designs, sources of 
information, and search strategies to retrieve information on adverse effects of 
pharmaceutical interventions. This will help to minimise any potential bias in the 
retrieval of information on adverse drug reactions and optimise the efficiency and 
utility of systematic reviews that incorporate adverse effects. 
 
1.3.2 Objectives 
1) To conduct a literature review of existing methodological studies that 
evaluate the impact of study design, sources searched, and search 
techniques used when adverse effects data are incorporated into systematic 
reviews. 
2) To describe and critique the retrieval methods used in systematic reviews of 
adverse effects. 
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3) To undertake a case study systematic review of adverse drug reactions in 
order to evaluate:  
a. the contribution of information on adverse drug reactions from 
different sources; 
b. the effectiveness of different searching methods for identifying 
information on adverse drug reactions. 
4) To evaluate the effectiveness of different searching methods using a series 
of systematic reviews of adverse drug reactions. 
5) To develop guidance and recommendations for retrieving information on 
adverse drug reactions to incorporate into a systematic review. 
 
 Research questions 1.4
This programme of research addresses the following important questions pertinent 
to systematic reviews of adverse effects data for healthcare decision making: 
A. Which study designs provide the best evidence on adverse effects in terms 
of availability, appropriate format, and being least prone to bias? 
B. Which sources of information provide the most efficient yield of relevant data 
on adverse drug reactions? 
C. Which search strategies are most effective in retrieving relevant data on 
adverse drug reactions from these sources in terms of sensitivity and 
precision? 
 
 Thesis structure 1.5
Chapter 2 discusses and clarifies the terminology surrounding adverse effects. It 
highlights the importance of adverse effects in healthcare. The value of systematic 
reviews of adverse effects is also discussed, as well as the challenges in identifying 
studies for inclusion in such reviews. 
 
Chapter 3 describes the methodology of a systematic review of the current 
methodological literature related to the retrieval of information on adverse effects. 
The results of this review are then divided into six sections and form Chapters 4 to 
9. 
 
Chapter 4 presents the results of first section of the methodological review relating 
to the contribution of different study designs in providing adverse effects data. 
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Chapter 5 presents on the second section of the methodological review relating to 
sources of information on adverse effects. 
 
Chapter 6 presents on the third section of the methodological review relating to 
database search strategies for information on adverse effects. 
 
Chapter 7 presents on the fourth section of the methodological review relating to the 
impact of publication status on the reporting of adverse effects. 
 
Chapter 8 presents on the fifth section of the methodological review relating to the 
impact of funding source on the reporting of adverse effects. 
 
Chapter 9 presents on the last section of the methodological review relating to other 
issues linked to the retrieval of information on adverse effects, such as background 
of the author of a study or country setting. 
 
Chapter 10 presents the results of a review of the retrieval methods used in 
published systematic reviews of adverse effects, highlighting areas where there are 
deficiencies in the methods used. In addition, this chapter presents comparisons 
with other types of reviews and an analysis of trends over time. 
 
Chapter 11 reports on the results of an information audit carried out on a case study 
of a systematic review with an adverse drug reaction as its primary outcome, 
namely fractures associated with thiazolidinediones. This section presents a 
comparative analysis of the sources of information for data on adverse effects for 
this case study. 
 
Chapter 12 evaluates the performance of using different search filters in MEDLINE 
and EMBASE for retrieving information for the case study systematic review of 
adverse drug reactions in Chapter 11. 
 
Chapter 13 reports on the presence or absence of adverse effects terms in the title, 
abstract or indexing of database records relating to articles which contain adverse 
effects data in the full-text. The articles are identified from a series of 26 published 
systematic reviews of adverse drug reactions. This chapter includes an evaluation 
of published search filters for information on adverse drug reactions and individual 
search terms. 
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Chapter 14 brings together the results of all sections of the current research 
including the methodological literature review, the review of systematic reviews of 
adverse effects, the case study systematic review, and search term exploration of 
26 reviews. A summary is included of the key findings, together with the implications 
of this research. 
 
In relation to the findings of the research, specific recommendations for the retrieval 
of information on adverse effects are given. A summary of areas for further research 
is then followed by conclusions to the research. 
 
Although public or patients were not directly involved in the planning, design, and 
execution of this project, (because of the methodological nature of the 
investigation), the output of this PhD will be of particular relevance to patients. 
Adverse effects and adverse reactions are important for health service users, their 
families, and their carers; unbiased, objectively derived, information on the harms as 
well as the benefits of an intervention is needed. Patients want to be sure that the 
treatments they receive are as safe and effective as possible. 
 
 Summary 1.6
There is an urgent need for accurate and complete information on adverse drug 
reactions. 
Systematic reviews could provide this information in an unbiased way. 
This programme of research evaluates the most appropriate study designs, data 
sources, and database search strategies for systematic reviews incorporating 
adverse drug reactions. 
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Chapter 2 Incorporating adverse effects into systematic reviews  
Before describing the challenges of incorporating adverse effects into systematic 
reviews, it is important to clarify what constitutes an adverse effect and why 
systematic reviews of adverse effects are required. 
 
 What are adverse effects? 2.1
There is considerable confusion in the nomenclature used for adverse effects. This 
confusion stems from a lack of consistent terminology32 and the plethora of terms 
available such as; ‘side effect’, ‘harm’, ‘adverse effect’, ‘adverse event’, 
‘complications’, ‘tolerability’, ‘toxicity’, ‘toxic effect’, ‘unintended effect’, ‘adverse drug 
reaction’, ‘adverse reaction’ and ‘adverse drug effect’.33 The use of a wide range of 
terms for adverse drug reactions has been reported as far back as 1881 by Louis 
Lewin; 
‘There is a large variety of names in medical publications for the 
untoward symptoms that follow the use of drugs… in England they 
are sometimes called ‘unpleasant symptoms’’34 
 
Trends in terminology have emerged over the years. ‘Side effect’ is a relatively old 
term and can be defined as any unintended effect that occurs during treatment 
which is related to or likely to be related to the treatment.35 Because, technically a 
‘side effect’ can be a positive or negative effect, whereas ‘adverse event’, ‘adverse 
effect’ and ‘adverse reaction’ are all negative,35 these latter terms are preferred in 
the medical literature and ‘side effect’ is generally restricted to patient information. 
 
An ‘adverse event’, ‘adverse effect’ or ‘adverse reaction’ are all unfavourable 
outcomes that occur after a patient has taken a medicinal product or undergone 
some procedure.34-36 However, an ‘adverse event’ differs from an ‘adverse effect’ or 
an ‘adverse reaction’ in that an ‘adverse event’ may or may not be attributed to the 
treatment.34 For instance, a patient may be involved in a road traffic accident whilst 
on drug X and whilst this is an ‘adverse event’ it may not be attributable to drug X 
and therefore not an ‘adverse effect’ or ‘adverse reaction’.34 ‘Adverse effects’ or 
‘adverse reactions’, on the other hand, are commonly used interchangeably, have 
similar meanings, and are ‘adverse events’ for which a causal relationship between 
the intervention and event is at least a reasonable possibility.34, 37 The subtle 
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difference between ‘adverse effect’ and ‘adverse reaction’ is that adverse effects are 
usually detected by laboratory tests or clinical investigations whereas ‘adverse 
reactions’ are detected by their clinical manifestations (signs and symptoms).38, 39 
 
A term that is used frequently in the current literature is ‘adverse drug reaction 
(ADR)’. The most widely accepted definition of this term is that of the World Health 
Organisation (WHO) and has been in existence for over 30 years. It states that an 
adverse drug reaction is: 
‘a response to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease, or 
for modification of physiological function’.35  
 
An adverse drug reaction is, therefore, an adverse effect or adverse reaction which 
results from and is related to a medication.10, 40 
 
Other terms sometimes used include ‘adverse drug event’ or ‘drug-related adverse 
event’. These terms have also caused further confusion as they have a wide 
spectrum of definitions.41 Whilst some have defined ‘adverse drug events’ as ‘any 
injury resulting from administration of a drug’,2 others disagree and state that the 
adverse event may or may not be related to the drug36, 40 in which case such terms 
should generally be discouraged as they imply a causal relationship.40 
 
Other related terms to ‘adverse effects’ include ‘harm’ (for damage or injury), 
‘complication’ (for adverse effects of surgical or other invasive treatments),37 
‘tolerability’ (for medically less important adverse effects, i.e. without serious or 
permanent sequelae),37 and ‘toxicity’ (degree to which a substance is poisonous). 
 
The study of adverse drug reactions comes under the umbrella of patient safety. 
Whereas adverse drug reactions are primarily concerned with the properties of the 
drug under normal use, the patient safety community is interested in harm resulting 
from a broader range of events, such as intentional and accidental poisoning (i.e. 
overdose), drug abuse, medication errors, or non-compliance.35 Systematic reviews 
strive to assess injuries incurred by drugs that were properly prescribed and 
administered. As the focus of this programme of research is adverse effects related 
to drugs and broader patient safety issues are excluded, the terms adverse drug 
reaction and adverse drug effects are adopted here, or where both drug and non-
drug adverse effects are discussed the term adverse effects will be used. 
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 Why are adverse drug reactions important?  2.2
2.2.1 Incidence and cost 
There are a number of factors which demonstrate the importance of adverse drug 
reactions, not least their incidence, severity and cost. Several studies have shown 
that adverse drug reactions are a major cause of ill health and death and result in 
substantial costs to healthcare systems.42 Estimates on the incidence and cost of 
adverse drug reactions, however, have varied widely, dependent, in the main, on 
the methodologies used to detect suspected reactions, the differences in the 
definitions of an adverse drug reaction,43 the nature of the patient group,44 and the 
range of costs included. For instance, some studies restrict their data collection to 
serious adverse drug reactions, others to hospital stay. 
 
2.2.2 Hospital admissions 
The majority of studies that have measured the incidence and/or cost of adverse 
drug reactions have tended to focus on the proportion of hospital visits, hospital 
admissions, or the incidence in hospitalised patients, and have been based in the 
US.45-59 However, a systematic review of the worldwide literature identified the rate 
of admissions to hospitals related to adverse drug reactions as 5.4%. This is lower 
than estimates from the UK.44 
 
A systematic review in 2002, of nine studies from the UK, estimated that the rate of 
hospital admissions directly attributable to adverse drug reactions (excluding errors, 
non-compliance and overdose) as 7.5%50 and that the burden of adverse drug 
reactions in hospital patients on the UK NHS is equivalent to 15 to 20 medium sized 
hospitals. This approximates to 4% of available bed days and a cost of £380 million 
per annum.50 Similar results were reported in a more recent observational study 
from the UK,60 which indicated that 6.5% of hospital admissions were due to 
adverse drug reactions. The median bed stay in patients with an adverse drug 
reaction is eight days, accounting for 4% of hospital bed capacity and at a cost to 
the UK NHS of around £466 million every year.60 
 
2.2.3 In-patient incidence 
As well as adverse drug reactions leading to admissions to hospitals, they can also 
occur during hospital stays.48 A UK based study in 2009 estimated that 14.7% of 
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patients experienced an adverse drug reaction in hospital.61 This study also 
estimated that an additional 1.9% of bed days were due to an adverse drug 
reaction, with an estimated cost to the NHS in England likely to exceed £171 million 
annually.61 
2.2.4 Overall cost 
The estimated cost of hospital admissions and adverse drug reactions in hospital to 
the NHS in England are in excess of £637 million per year.61 This is likely to be an 
underestimate of the total cost of adverse drug reactions, as it is restricted to 
hospital costs, does not take into account the large proportion of under-reporting of 
adverse effects, and does not incorporate indirect costs such as loss of productivity, 
outpatient treatment, disability and the social cost of adverse drug reactions. A 
report by Compass suggests that the true costs of adverse drug reactions to the 
NHS are as high as £2 billion per annum.62 
 
2.2.5 Incidence in the community 
Although the incidence of adverse drug reactions in the hospital setting may be 
difficult to calculate, measuring the incidence of adverse drug reactions in the 
community is even more problematic, as drug exposure in the population is 
unknown and under-reporting of adverse drug reactions is likely to be higher. Some 
studies in the 1970s attempted to estimate adverse drug reactions in the 
community, however, and figures ranged from 2.6% to 41%.36 The incidence of 
adverse effects is also likely to increase as the number of older people in the 
population, and hence the number of prescriptions for long-term diseases, 
increases.63 
 
2.2.6 Mortality 
While adverse drug reactions that result in hospitalisation or a prolonged stay in 
hospital are of serious concern, even more seriously, some adverse drug reactions 
result in death. Over 10,000 deaths per year in England and 106,000 deaths per 
year in the US have been estimated to be attributed to adverse drug reactions.48, 60 
This would suggest that, in the US adverse drug reactions rank from the fourth to 
sixth leading cause of death (after heart disease, cancer, stroke, pulmonary disease 
and accidents), even when used in proper doses for approved indications.48 Another 
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study based in Sweden implicated adverse drug reactions as the seventh most 
common cause of death.64 
 
2.2.7 Quality of life 
Although studies on the incidence and cost of adverse drug reactions have tended 
to focus on the very serious adverse effects which can lead to hospitalisation, long-
term disability, and even death, other adverse effects are also important. Less 
dangerous and less troublesome adverse effects are becoming of greater 
importance to patients, as interventions are increasingly being used for primary 
prevention (such as vaccines) in healthy patients or to treat self-limiting or relatively 
benign conditions.17, 31, 37, 65 Common adverse effects such as coughing, depression, 
incontinence, swollen ankles, drowsiness and headache may significantly impair the 
quality of life of drug recipients and their willingness to continue the treatment.37, 65, 66 
For example, patients with hypertension may be unwilling to endure symptoms such 
as cold limbs, tiredness, and sleepiness in return for the potential benefits,67 as 
patients may feel subjectively worse than before beginning their treatment.66 
Similarly healthy women taking oral contraceptives may be particularly concerned 
about relatively minor adverse effects, such as acne, weight gain, and disrupted 
menstrual pattern.68 Consequently, from a public health perspective common but 
seemingly minor adverse effects may be more important than the stories of more 
severe adverse effects that reach the media headlines.65 
 
2.2.8 Balancing efficacy with harms 
As treatments are used for less serious conditions, they may have less pronounced 
benefits, and as more treatment options become available, rare events may assume 
more importance. A rare event may be sufficient to inhibit use of the drug for a self-
limiting condition.17 For example, an increased risk of dying, even if small, may be 
unacceptable to relieve the pain of a simple headache.69 Where a treatment has 
small beneficial effects with a number needed to treat to achieve one beneficial 
outcome in the hundreds,31 or where there are a number of competing alternatives 
with similar beneficial outcomes, the adverse effects of an intervention may assume 
more importance to patients and decision makers.70 In addition, adverse drug 
reactions may lead to further treatments (and further costs) and cause patients to 
lose confidence in their doctors, and generate mistrust.25  
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In summary, all types of adverse effects are important, and although actual 
estimates may vary they all concur that the incidence and cost of adverse drug 
reactions is high. 
 
 What is known about adverse drug reactions pre-licensing? 2.3
When a new drug is licensed, not all its adverse effects are known because at this 
time only a limited number of healthy volunteers and highly selected patients are 
likely to have undergone exposure.3, 19, 25, 69, 71-79 It has been estimated that on 
average only about 1500 patients (ranging between 340 and 5000) have been 
exposed to a new drug when a product license is granted.11, 36, 80 In addition, pre-
licensing clinical trials often lack the follow-up necessary to detect delayed 
consequences or long term adverse effects.11, 71, 73, 74, 81, 82 The importance of 
quantifying adverse drug reactions post licensing is also particularly apparent in the 
case of drug treatment for patients with multiple disease states, and for children, 
women of childbearing age, and the elderly, because these population groups are 
rarely exposed to medication during its development.11, 19, 71, 73 Approval of a new 
drug through licensing, therefore, does not exclude the possibility of adverse effects, 
particularly effects that are rare or delayed,73 or which are differentially associated 
with particular sub-groups.71 
 
Many adverse effects are recognised, therefore, during the post-marketing phase of 
the life of a drug, once it is in widespread clinical use.75, 76, 83-87 Well known 
examples include fenfluramine and the risk of pulmonary hypertension, vigabatrine 
and visual field defects, and tolcapone and the risk of liver toxicity.87 It is estimated 
that 51% of approved drugs have serious adverse drug reactions that are not 
detected until after marketing,11 and in the UK, 4% of all licensed products are later 
withdrawn because of safety problems.88 Surveillance and 
pharmacoepidemiological studies form an important part of the post-marketing 
phase. 
 
 Why are systematic reviews incorporating adverse effects needed? 2.4
Many of the benefits of conducting a systematic review of effectiveness also apply 
to systematic reviews of adverse effects.18, 19, 65 For instance, systematic reviews of 
adverse effects have the potential to provide the most reliable evidence for decision-
making, can demonstrate the need for further research, provide more timely results, 
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help decision-makers cope with large amounts of evidence, increase the 
generalisability of the results of research, enable explanatory analysis regarding, for 
example, subgroups of patients, and, if appropriate, can use meta-analyses to 
increase the precision of estimates and so reduce the relative width of the 
confidence intervals of summary effect measures.71, 89 
 
2.4.1 More reliable evidence 
The most important aspect of a systematic review is its transparent and objective 
approach. By systematically identifying, appraising and summarising the evidence, 
systematic reviews, whether of effectiveness studies or adverse effects studies, 
allow a more objective appraisal of the evidence. This makes systematic reviews 
less prone to bias and error than traditional narrative reviews and a more reliable 
form of evidence for decision-making.90 
 
2.4.2 Cumulative approach  
The cumulative nature of systematic reviews, in which pre-existing available 
evidence is synthesised, not only enables the identification of gaps in the research 
but also enables health professionals to base decisions on all the appropriate 
evidence already available.6 In fact, ignoring previous research on adverse effects 
can lead to fatal results. For example, in 2001 a 24 year old healthy volunteer died 
from lung failure after researchers failed to uncover published research indicating 
the potentially lethal side effects associated with the inhalation of the drug 
hexamtheonium.91, 92 If systematic searches on the adverse effects of 
hexamethonium had been carried out before the trial, the pulmonary complications 
of the drug would easily have been identified.93 
 
2.4.3 More timely results 
A cumulative approach to research not only encourages researchers to learn from 
past experience but can also result in more timely results. It has been reported that 
there can be long delays in getting adverse effects information from research into 
practice.77 Systematic reviews of adverse effects may be a way to reduce such 
delays.94-96 For example, a systematic review would have revealed the 
cardiovascular risks associated with hormone replacement therapy (HRT) much 
earlier than 1997,97, 98 and a meta-analysis of rofecoxib (vioxx) would have revealed 
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a statistically significant excess risk of cardiovascular effects four years before the 
drug was withdrawn.95, 99 
 
2.4.4 Information overload 
The large volume of information on adverse effects in a range of formats from a 
diverse range of sources2, 100 also increases the need for systematic reviews of 
adverse effects. Each year about 9000 articles on adverse drug reactions are 
published in the scientific literature.101 In 2002, Meyler’s Side Effects of Drugs (an 
international encyclopaedia of adverse drug reactions and interactions) alone 
contained approximately 17,000 references and 6,000 cross-references to the Side 
Effects of Drugs Annual (a world-wide yearly survey of adverse drug reactions).31 By 
2006, the latest edition of Meyler’s Side Effects of Drugs contained over 40,000 
references.102 Systematic reviews of adverse effects are an invaluable tool for 
coping with this large amount of information and a possible solution to the problem 
of ‘information overload’.31 
 
2.4.5 Generalisability 
Another advantage of systematic reviews is their potential to allow greater 
generalisability of results and to enable subgroup analysis. The adverse effects 
found in one particular study with one set of patients might not be valid for other 
patients with different characteristics. If the same adverse effects are seen in many 
studies, however, and in different types of patients, then it may be concluded that 
the adverse effects have some generality.90 
 
Subgroup analysis is particularly useful for adverse effects data, as rates of adverse 
effects are highly environment dependent.103 By combining data across studies, 
systematic reviews can be used to view and investigate variations and to assess 
whether the differences are likely to be plausible or chance findings.103 For example, 
comparisons may be made of adverse drug reactions between different classes of 
drugs, different doses, and different subgroups of patients, such as older or younger 
patients, different ethnic groups, and men or women.21, 65, 71, 73 Systematic reviews 
may also be able to make sense of conflicting results by investigating differences 
between studies.71 
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2.4.6 Sample size 
Lastly, systematic reviews increase the sample size investigated. Although a single 
trial can be sufficiently well powered to detect differences in effectiveness, these 
usually tend to be seriously under-powered in order to detect differences in adverse 
effect rates.18, 96, 104-106 A large number of patients need to be treated before a rare 
adverse effect is identified. With serious adverse effects even a low level risk of 
harm may produce a major public health problem if the medication is widely used. 
For example, although the increase in absolute risk of a cardiovascular event may 
be small with rofecoxib (Vioxx), when a medication is used by 80 million patients, 
the numbers of affected patients can be substantial.80 While single trials may not 
have sufficient power to distinguish between adverse effects rates between drugs, a 
systematic review may be able to show small but significant differences.13, 70, 73, 105 
 
 Do systematic reviews incorporate adverse effects? 2.5
Although including adverse effects in systematic reviews may be as important as 
including intended beneficial effects,19 the vast majority of systematic reviews focus 
on clinical effectiveness without addressing adverse effects.19, 20, 28-31 
 
Ernst and Pittler 2001 categorised systematic reviews published on MEDLINE and 
the Cochrane Library as either reviews of effectiveness, reviews that included safety 
as a secondary outcome, or reviews with a primary focus on safety. They found that 
only 27% reviewed any harms data, with 4% assessing safety as their primary 
outcome.29, 30 
 
More recent research indicates that the proportion of reviews that include any harms 
data may have increased since Ernst and Pittler’s 2001 study. Moseley et al 2009107 
found that 22% of non-Cochrane physiotherapy reviews reported adverse effects 
whereas Hopewell et al 2007108 found that 48% of reviews from the Database of 
Abstracts of Reviews of Effects (DARE) provided some mention of adverse effects 
as an outcome measure, and Moher et al 2007 found that 57% of non-Cochrane 
reviews from MEDLINE reported on some aspect of harm.109 However, the 
proportion of reviews from DARE or non-Cochrane reviews (reviews not produced 
by the Cochrane Collaboration and not published in the Cochrane Database of 
Systematic Reviews) which have adverse effects as their primary outcome or 
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contained a meta-analysis of safety data has remained low since Ernst and Pittler’s 
2001 study ranging from 2% to 9%.108, 110, 111 
 
Other studies have focused on the reporting of adverse effects in subsets of 
Cochrane Reviews and have found that between 18% and 86% of such reviews 
included specific adverse effects data,20, 107-109, 111, 112 and that 10% of Cochrane 
Reviews had adverse effects as their primary outcome.108 
 
Aronson et al 2002 examined the number of systematic reviews of adverse effects 
from a different perspective, by categorising all publications cited in the Side Effects 
Drug Annual (SEDA) 2000. The proportion of all publications of adverse effects that 
were systematic reviews was very low, at 1.25% (45/3604).31 
 
Although it is difficult to compare these studies, as they used different sampling 
techniques to identify cohorts of systematic reviews, and different definitions of 
adverse effects, the literature indicates that the proportion of systematic reviews 
incorporating adverse effects is low but may be increasing, particularly in Cochrane 
reviews.  
 
 What are the challenges of retrieving information on adverse effects? 2.6
One of the main reasons for the relative lack of systematic reviews of adverse 
effects may be the difficulty in conducting these reviews and the lack of evidence-
based guidance available.113, 114 Although the same basic principles may be applied 
to systematic reviews of adverse effects as for reviews of effectiveness, there are 
also many specific procedures that need to be adapted to respond to the 
methodological challenges of identifying and incorporating adverse effects.113, 115 
The retrieval of information on adverse effects poses particular challenges,14, 15, 19, 37, 
116 and there are a number of factors contributing to this.  
 
2.6.1 Searching beyond randomised controlled trials 
Firstly, identifying information on adverse effects is particularly challenging because 
there is a diversity of study designs that might contain information of interest.2, 21 For 
instance, although RCTs may be the most appropriate source for information on 
effectiveness, other study designs, such as cohort studies, case-control studies and 
case reports, may also be appropriate for adverse effects data.2 Searching for non-
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RCTs can be problematic, owing to inconsistent terminology, variable indexing and 
a lack of research into appropriate search filters (pre-set combinations of search 
terms to retrieve articles of a particular study design or topic area). 
 
2.6.2 Sources of data 
Secondly, the resources that contain data on clinical effectiveness may not be the 
most appropriate resources for retrieving information on adverse effects.2 The 
identification of information on adverse effects often requires a much broader range 
of data sources.21, 27, 100, 117 There are many specialist databases for adverse effects, 
toxicity and drug information, as well as post-marketing surveillance data and 
tertiary sources (such as Meyler’s Side Effects of Drugs102 or Reactions bulletin) 
which may provide adverse effect information. 
 
2.6.3 Search strategies 
Lastly, compared with reviews of effectiveness, developing efficient search 
strategies (combinations of search terms) for use in databases (such as MEDLINE 
and EMBASE) which capture all the relevant literature on adverse effects, is much 
more difficult.2, 118 Specific difficulties arise when adverse effects terms are added to 
the search strategy. This is because adverse effects are poorly reported, 
inadequately indexed, inconsistently described, may not be limited to a particular 
condition, and specific named adverse effects may not be known at the time of 
searching.  
 
The most prominent difficulty in developing efficient search strategies for adverse 
effects is that of poor reporting of adverse effects. Reviews that assess the 
beneficial effects of an intervention usually have the relatively straightforward task of 
searching for outcomes that were also primary outcomes in the included studies and 
therefore appear prominently in the title, abstract, or indexing terms of a database 
record.119, 120 In contrast, systematic reviews which seek to examine adverse 
outcomes are likely to include studies where harms were only of secondary 
interest,118, 121 and few authors of trials devote substantial amounts of space to 
safety data.122 Adverse effects are, therefore, often not reported in the title, abstract 
or indexing of a database record, making the creation of search strategies to 
capture adverse effects difficult.19, 70, 118, 121, 123 
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Another issue in developing search strategies for retrieving adverse effects is the 
range of adverse effects searched for and the inconsistent terminology used. In 
contrast to the evaluation of effectiveness (where an intervention is likely to have 
only one or two beneficial outcomes), there is often a diverse range of potential 
adverse outcomes and for each outcome there can be a wide range of terms (such 
as lethargy, tiredness, malaise).70  
 
It is not always appropriate to limit search strategies for adverse effects to a 
particular disease or condition, for instance, when the adverse effects are suspected 
to occur in any population taking the drug irrespective of the disease or condition it 
is intended to treat, or where there is limited data for the drug with a particular 
disease or condition. This means that very broad searches may be conducted which 
may retrieve an unmanageable number of records. 
 
In many instances, the adverse effects of an intervention may be unknown or not 
predictable at the beginning of the systematic review process when the searches 
are conducted. Reliance on generic terms for adverse effect (such as side effects, 
adverse drug reactions, complications, toxicity) is unlikely to retrieve a large 
proportion of the available relevant studies,118 and in many data sources the 
indexing of safety terms has been found to be inconsistent or non-existent.19, 117 
 
In summary, although searching for information on adverse effects is problematic, it 
is also a fundamental part of the systematic review process. Difficult decisions need 
to be made on the study designs to search for (for example, RCTs, cohort studies or 
case series), the sources to search (for example, MEDLINE, EMBASE, TOXLINE), 
the concepts to include in any search strategies developed (for example, 
disease/condition, adverse outcomes, study design) and then the search terms to 
use to capture those concepts. It is these decisions which will be the focus of this 
programme of research.  
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 Summary 2.7
The costs of adverse drug reactions to the NHS are estimated to be as high as £2 
billion per annum. 
Adverse drug reactions cause over 10,000 deaths in the UK per year and can lead 
to hospitalization and disability as well as affect patients’ quality of life and 
compliance. 
Systematic reviews can provide timely reliable evidence on adverse effects, yet the 
vast majority of systematic reviews focus on effectiveness without addressing 
adverse effects. 
Research is urgently required into the most appropriate search techniques to 
identify information on adverse effects for systematic reviews. 
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Chapter 3 Methodological overview of the literature relating to the 
retrieval of information on adverse effects  
 Introduction 3.1
The preceding chapters demonstrated the need for systematic reviews incorporating 
adverse effects and presented many of the methodological challenges in the 
process of retrieving information on such effects. In particular, there is a lack of 
empirical evidence and guidance as to how and where to search for appropriate 
studies for inclusion in systematic reviews incorporating adverse effects, and a lack 
of clarity on how using different sources for retrieval may affect the clinical utility of 
the results of a review. It is, therefore, useful to conduct a review of the 
methodological research on the retrieval of information on adverse effects. 
 
This will help to consolidate what is already known about the methodology of 
searching for studies for inclusion in systematic reviews that incorporate adverse 
effects, as well as highlighting gaps in the evidence. 
 
3.1.1 Aim 
The aim of this research was to review the methodological literature pertinent to the 
retrieval of information on adverse effects for inclusion in systematic reviews. 
Particular emphasis was placed on studies evaluating the impact of incorporating 
different study designs, searching different sources of information (including 
databases, industry submissions, and unpublished data sources) and using different 
electronic database search strategies (combinations of search terms). 
3.1.2 Objectives 
 To provide access to evidence on which to base decisions on the methods 
used in the retrieval of information on adverse effects for systematic reviews 
of healthcare interventions. This includes study design selection, sources of 
information searched and database search strategies used. 
 To identity any gaps in this research area and to propose further research in 
order to fill these gaps.  
 To identify potentially useful data sources and search strategies for testing in 
systematic review case studies. 
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  Methods 3.2
3.2.1 Data sources 
It was anticipated that much of the literature in this newly developing area would be 
identified by searching beyond MEDLINE and EMBASE, and that much of the 
relevant research would not be published as peer-reviewed journal articles. For 
example, a previous systematic review on a similar methodological topic only 
identified 13 out of 30 of the included papers through searching MEDLINE and 
EMBASE.124 Therefore, a range of bibliographic databases were searched for this 
review. These databases were carefully chosen to allow the identification of reports, 
dissertations, and grey literature, in addition to journal articles. Handsearching of 
key journals in research methodology, drug safety, and librarianship was carried out 
to identify articles either not indexed, or not easily identifiable in electronic 
databases. Unpublished material was also sought by handsearching conference 
proceedings, scanning evidence-based websites, and from contacting experts in the 
field identified via the Cochrane Adverse Effects Methods Group and the East 
Anglia Research Synthesis Group. Conference proceedings and web sources were 
selected on the basis of their coverage of systematic review methodology. In 
addition, the bibliographies of any eligible articles identified were checked for 
additional references, and citation searches were carried out on all the included 
references using ISI Web of Knowledge. A list of the databases and other sources 
searched is given in Table 3.1. 
 
3.2.2 Search strategies 
Search strategies were devised to retrieve papers that evaluated any of the 
methodological aspects of searching for information on adverse effects for inclusion 
in a systematic review (Appendix A). Methodological aspects included study design 
selection, sources of evidence and literature searching.  
 
Although searches of The Cochrane Methodology Register (CMR) and the Centre 
for Reviews and Dissemination (CRD) administration version of the Database of 
Abstracts of Reviews of Effects (DARE) can be easily limited to methodology 
papers, searching for methodology papers in other databases can prove very 
difficult. Most databases, such as MEDLINE and EMBASE, do not index 
methodology papers well nor use consistent terminology to describe them.  
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Table 3.1 Sources searched for included studies 
 
Databases  
Original searches were carried out on 26th or 27th September 2007 with the most 
recent update searches carried out between 22nd October and 6th November 2009. 
Cochrane Database of Systematic Reviews (CDSR): methodology reviews only: 
2009 Issue 4 
Cochrane Methodology Register (CMR): 2009 Issue 4 
Database of Abstracts of Reviews of Effects (DARE): November 2009 
EMBASE: 1980 to 2009 Week 42 
Health Technology Assessment (HTA) Database: November 2009  
Health Management Information Consortium (HMIC): September 2009 
Index to Theses: November 2009 
Library, Information Science & Technology Abstracts (LISTA): Mid1960s-October 
2009 
MEDLINE: 1950 to October Week 3 2009 
MEDLINE in process: 22 October 2009 
 
Handsearching of Journals 
BMC Clinical Pharmacology - 2001;1(1) to 2009;9(17) 
BMC Medical Research Methodology - 2001;1 to 2009;9(69) 
Drug Safety - 1998;18(1) to 2009;32(11) 
Health Information and Libraries Journal (formally Health Libraries Review) - 
1994;11(1) to 2009;26(3) 
Journal of Clinical Epidemiology - 1998 to 2009;62(12) 
Journal of Information Science - 1979;1(1) to 2009;35(5)  
Journal of Librarianship and Information Science - 1969;1(1) to 2009;41(3)  
Journal of the Medical Library Association (formally the Bulletin of the Medical 
Library Association) - 2000;88(2) to 2009;97(4) 
Pharmacoepidemiology & Drug Safety - 1992;1(1) to 2009;18(11) 
 
Handsearching of Conference Proceedings 
Cochrane Colloquia 1994-2009 
HTAi 2004-2009 
Pharma-Bio-Med Conference and Exposition 2006-2008 
Symposium on Systematic Reviews 1998-2002 
 
Web Sources 
Agency for Healthcare Research and Quality (AHRQ) via http://www.ahrq.gov/ 
Searched: 28/10/09 
Health Technology Assessment Programme (HTA) via http://www.hta.ac.uk 
/index.shtml Searched: 28/10/09 
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A pragmatic approach was, therefore, required in the development of the search 
strategies in databases such as MEDLINE and EMBASE. This meant that search 
terms (such as, ‘search’, ‘safety’ or ‘trials’ terms) were often limited to the title field 
only and some potentially relevant text words and indexing terms (such as, ‘risk’) 
which retrieved thousands or tens of thousands of irrelevant records were omitted. 
All the search strategies were checked by a second experienced information 
scientist. 
 
No date or language restrictions were applied to the searches. Although logistical 
constraints meant that non-English publications were not included in the review, an 
estimation of the size of the non-English literature was thought useful.  
 
In addition to the search strategies for methodological papers (Appendix A), the full 
papers of systematic reviews with the primary outcome of an adverse effect indexed 
in either CDSR, (via The Cochrane Library, Issue 1:2010) and DARE (via the Centre 
for Reviews and Dissemination (CRD) website, March 2010) were checked to 
assess whether any methodological analysis of the retrieval of adverse effects data 
had been conducted within the review. 
 
3.2.3 Inclusion/exclusion criteria 
Any reports of empirical studies of the methods used in searching for information on 
adverse effects were eligible for inclusion. A research study was considered eligible 
for inclusion in this review if it used a standardised outcome measure to compare 
the identification and/or quantification of adverse effects from either different 
sources of information on adverse effects, different methods of identifying such 
information or the inclusion of different study designs. 
 
Studies were excluded if they were: 
A. examples of systematic reviews without a comparative evaluation of the 
different methodologies used to retrieve information on adverse effects 
B. limited to drug-interactions, toxicology or poisoning  
C. comparisons of animal or laboratory studies 
D. studies of causation/etiology (for example, studies on environmental factors, 
such as pesticides and pollution or studies on risk factors, such as cigarette 
smoking and drug abuse) 
E. studies that did not include a healthcare intervention 
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F. in a non-English language with no translation available at the British Library 
Studies that did not meet the criteria were excluded and their bibliographic details 
listed with reasons for exclusion. 
 
3.2.4 Identifying studies 
Firstly, the author screened the titles and abstracts of all the retrieved records to 
identify obvious exclusions (i.e. articles that had been retrieved by the searches 
which were unrelated to adverse effects, for example, articles on self-harm, or 
safety in the workplace). The remaining articles were then assessed independently 
by both the author and a second reviewer for potential included studies. Full copies 
of the articles deemed potentially relevant by either the author or the second 
reviewer were obtained. These articles were then assessed by the author and at 
least one other reviewer to determine if they met the inclusion criteria. 
 
3.2.5 Data extraction 
Data extraction was performed by the author and then double checked by another 
reviewer. Data from studies with multiple publications were extracted and reported 
as a single study. Where there were discrepancies between conference abstracts 
and journal articles, data were extracted from the journal article.  
 
3.2.6 Assessment of methodological quality 
The methodological quality of the included articles was assessed by the author and 
then double checked by a second reviewer using pre-set criteria. The included 
studies were categorised according to their objectives. The quality criteria were then 
adapted for each category of article and presented in the proceeding chapters. Any 
disagreements were resolved through discussion. 
 
 Results 3.3
Searches were originally undertaken in September 2007 and 4609 records were 
retrieved. Update searches were subsequently performed in August 2008 and again 
in November 2009 retrieving an additional 704 records and 905 records 
respectively. A total of 347 full papers were ordered for more detailed examination 
from the results of the database searches and a further 92 from sifting reviews on 
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DARE, reference checking, handsearching, and contacting experts. A flow diagram 
detailing the decision process is presented in Figure 3.1. 
 
There were 92 studies (from 95 publications) eligible for inclusion in the review. 
These studies were divided into six categories and form the next six chapters:  
 
Chapter 4: Includes 51 studies which assessed the impact of study design selection 
(such as, RCTs, cohort studies and case reports) on the identification and/or 
quantification of adverse effects  
 
Chapter 5: Includes 19 studies which compared the use of different sources of 
information on adverse effects (such as, MEDLINE, EMBASE and reference 
checking)  
 
Chapter 6: Includes 3 studies which evaluated the search terms or search strategies 
used to retrieve information on adverse effects in electronic databases 
 
Chapter 7: Includes 10 studies which assessed the impact of publication status 
(such as published peer review journal articles versus unpublished studies) on the 
identification and/or quantification of adverse effects  
 
Chapter 8: Includes 6 studies which assessed the impact of funding source (such as 
industry funded studies and government funded studies) on the identification and/or 
quantification of adverse effects 
 
Chapter 9: Includes 3 studies which assessed the impact of other factors related to 
the retrieval of information on adverse effects. 
 
In order to ascertain whether any substantive publications had been published since 
the last update searches in 2009, the methodological searches in Appendix A were 
repeated in February 2013. Additional papers on unpublished data and industry 
funded data were identified and incorporated in the main findings section 14.2 in 
Chapter 14. No potentially relevant articles were identified on study design, search 
strategies or data sources of adverse effects or adverse reactions. 
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Figure 3.1 Flow chart for included studies 
 
 
 
6218 unique records 
retrieved from electronic 
database searches 
347 full papers 
retrieved 
5871 articles that did not 
look at adverse effects of 
interventions were 
removed after checking 
title and abstract. For 
example, self-harm, 
patient safety, and 
health risks of smoking 
211 background 
papers 
228 potentially relevant 
studies 
136 papers potentially 
meeting the inclusion criteria 
92 papers potentially 
meeting the 
inclusion criteria: 72 
from DARE, 18 from 
reference checking 
and 2 from 
contacting experts  
95 included publications (92 
studies): 
52 on study designs (51 studies) 
19 on data sources 
3 on search strategies 
11 on unpublished data (10 studies) 
7 on industry data (6 studies) 
3 on other factors 
133 excluded publications 
(reasons given in each 
chapter) 
67 on study designs 
37 on data sources 
17 on search strategies 
9 on unpublished data 
3 on industry data (2 studies) 
0 for any other factors 
48 
 Summary 3.4
A review of the methodological literature relating to the retrieval of information on 
adverse effects was carried out. 
The included studies were categorized as related to the following; 
a) study design 
b) source of information 
c) database search strategy 
d) publication status 
e) funding status 
f) other 
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Chapter 4 Section A of the methodological overview: different study 
designs for information on adverse effects 
 Introduction 4.1
When devising a search strategy and selecting sources to search for a systematic 
review, it is important to know which study designs are specified in the inclusion 
criteria. Reviews may focus on particular types of study design, and the search 
strategies used and the sources searched should reflect this focus. Search terms or 
search filters (combination of search terms) may be used to restrict the search to 
specific study designs. For example, search filters are commonly used to restrict 
searches to randomised controlled trials (RCTs) in MEDLINE and EMBASE.125, 126 
The sources selected can also be dependent upon which study designs are sought. 
For example, the Cochrane CENTRAL database is an excellent source of RCTs, 
whereas Food and Drug Administration (FDA) surveillance data and specialist 
bulletins (such as the Adverse Drug Reaction Bulletin or Drug and Therapy 
Perspectives) provide access to case reports.  
 
There is considerable debate regarding the relative utility of different study designs 
in generating reliable quantitative estimates of risk of adverse effects. A diverse 
range of study designs, encompassing RCTs and non-randomised studies (such as 
cohort or case-control studies) may potentially record adverse effects of 
interventions and provide useful data for systematic reviews and meta-analyses.21, 
127 However, there are strengths and weaknesses inherent to each study design, 
and different estimates and inferences about adverse effects may arise, depending 
on study type.14  
 
4.1.1 Randomised controlled trials (RCTs) 
In principle, RCTs are the most appropriate study design for evaluating adverse 
effects. This is because, when properly conducted, they limit the risk of bias, control 
for confounding factors, and form the most reliable source of evidence for treatment 
effects.128 This makes RCTs the best study design for obtaining evidence on 
causation.3 Furthermore, RCTs facilitate the calculation of Numbers Needed to 
Harm (NNH) (from the incidence with and without the exposure) and a benefit:harm 
ratio.70 The process of randomisation within RCTs overcomes the potential problem 
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of confounding by indication, by controlling for unknown or not documented factors 
that could influence the risk of an adverse effect.65, 73, 129-132 This may be particularly 
important for suspected adverse effects, where patients at perceived high risk may 
avoid potentially harmful interventions.  
 
The presence of a control group is particularly important in studies of adverse 
effects as, it may be difficult to distinguish between an adverse effect and the 
symptoms of the disease being treated.82, 132-134 For example, patients with severe 
chronic rheumatoid arthritis have an increased mortality risk from malignancy, 
infections and cardiovascular disease and these same patients are likely to receive 
new biological therapies.133 Similarly, illnesses that require non-steroidal anti-
inflammatory drugs (NSAIDs), rather than NSAIDs themselves, may be responsible 
for an increased risk in haemorrhage.130 In the case of selective serotonin reuptake 
inhibitors (SSRIs) for depression, it may be difficult to decipher the number of 
suicides and suicide attempts that are due to the underlying illness rather than an 
adverse effect of the treatment. A control group, however, makes it possible to 
calculate the true or attributable rate in cases where the background incidence of 
such adverse events in untreated populations is reported.14, 31, 132  
 
The lack of availability of RCT data on adverse effects is the most important 
disadvantage to this study design.15, 114, 127, 131, 135, 136 It is often impractical, too 
expensive, or ethically difficult to investigate rare, long-term adverse effects with 
RCTs.3, 15, 71, 73, 129, 131, 137-141 Empirical studies have shown that many RCTs fail to 
provide detailed adverse effects data, that the quality of those that do report 
adverse effects is poor,20, 27, 81, 85, 122, 136, 142-156, 157 , 158-166 and that the reporting may 
be strongly influenced by expectations of investigators and patients.167 One study 
found that if systematic reviews of the 11 products withdrawn because of safety 
reasons from the UK and US markets in 1999-2001 had been limited to RCTs of 
patient relevant outcomes, then evidence of harm would have been identified for 
only one of the products.168  
 
In general, RCTs are designed and powered to explore efficacy.14, 21, 32, 65, 85, 129 As 
the intended effects of treatment are more likely to occur than adverse effects and 
more likely to occur within the time frame, RCTs may not be large enough or have 
sufficient follow-up to identify rare, long-term adverse effects, or adverse effects that 
occur after the drug has been discontinued.14, 19-21, 27, 42, 65, 76, 77, 85, 87, 89, 116, 127, 129, 132, 
133, 139-141, 143, 144, 168-178 How far the size of RCTs limits their usefulness for information 
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on adverse effects is debatable. On the one hand, the number of trials with 
thousands of participants is increasing and with the use of meta-analysis the 
numbers of participants is increased further. However, on the other side, the 
extremely large numbers of participants that may be required (up to two million)179 
and the statistical power106 required for rare events may mean that size of RCTs is 
still a major issue.31, 69, 83, 115, 173, 179 
 
Another problem with RCTs is their generalisability. RCT data may be limited if, as 
is often the case, trials specifically exclude patients at high risk of adverse effects, 
such as children, the elderly, pregnant women, patients with multiple diseases, and 
those with potential drug interactions.14, 21, 42, 76, 80, 114, 116, 127, 133, 140, 171, 180, 181 
 
Although RCTs may have limitations, particularly for rare, long-term or unexpected 
adverse effects, they are still cited as the best source of data for common or specific 
well recognised anticipated adverse effects which occur within a short-time frame of 
taking the intervention.13, 14, 31, 182 For instance, the relationship between anti-
arrhythmic drugs and an increased risk in sudden death was established through 
RCTs.65, 130 
 
Given the limitations of RCTs, it may be important to evaluate the use of data from 
non-randomised studies in systematic reviews of adverse effects. 
 
4.1.2 Observational studies 
In observational studies, interventions tend to be allocated according to usual 
practice as opposed to being actively allocated as with an RCT. The term 
‘observational study’ is used to describe any study in which individuals receive 
treatment based on usual practice or ‘real-world’ choices. The can be confusing, as 
it implies that the researcher observes an effect or behaviour (which is the case in 
all studies), without distinguishing design of the study, the level of investigator 
involvement in the design or the inherent rigour of the approach.  
 
Whereas the term ‘observational study’ is generally used to describe 
epidemiological studies such as cohort studies or case-control studies, in other 
instances, a broader definition of observational study is accepted and case series 
and case reports are also included. This differing inclusion of studies may stem from 
the fact that case reports and case series can be generated from observational 
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studies or from investigator lead experiments, such as randomized comparisons 
with placebo or other interventions. 
 
In either case there is a distinction between, for example, cohort studies and case-
control studies on the one hand, and case series and case reports on the other. 
Cohort studies and case-control studies are analytical studies: they tend to be used 
to assess causal relationships and are thus ‘hypothesis testing’. Case reports and 
case series, on the other hand, are descriptive studies and can be considered, in all 
but a few cases, ‘hypothesis generating. In pharmacovigilance terms, the latter are 
useful in signal detection, the former in signal testing or verification. 
 
For the purposes of this thesis the broader definition of observational studies is 
used.  
 
Owing to the lack of randomisation, all types of observational studies are potentially 
afflicted by an increased risk of bias (particularly from confounding)71, 183 and so may 
be a much weaker study design for establishing causation.3 Nevertheless, 
observational study designs may sometimes be the only available source of data for 
a particular adverse effect and are commonly used in evaluating adverse effects.21, 
114, 129, 139, 178, 184, 185  
 
Observational studies can have an advantage over RCTs in terms of their feasibility 
and statistical power,3, 65, 75, 132 and are assisted by the use of large databases within 
hospitals and primary care, such as the UK General Practice Research Database 
(GPRD) (now Clinical Practice Research Datalink (CPRD)), which allow researchers 
to conduct population based studies.3, 132, 133, 186  
 
The biggest challenge in observational studies is to find an appropriate comparison 
group with similar baseline characteristics, so that expected event rates can be 
accurately determined.129, 131, 133  
 
4.1.2.1  Cohort studies 
In a cohort study, a defined group of individuals who receive a particular intervention 
are followed up over time and compared to another group of individuals who did not 
receive the intervention. Because of a lack of randomisation, and the way in which 
patients are selected in cohort studies, the groups being compared are likely to be 
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unequal with respect to known and unknown variables. However, the importance of 
controlling for confounding by indication for unanticipated adverse effects is 
debatable. Authors have argued that confounding is less likely to occur when an 
outcome is unintended or unanticipated than when the outcome is an intended 
effect of the exposure. This is because the potential for that adverse effect is not 
usually associated with the reasons for choosing a particular treatment, and does 
not influence the prescribing decision.82, 178, 185, 187, 188 For instance, in considering 
the risk of venous thrombosis from different oral contraceptives in healthy young 
women, the choice of contraceptive may not be linked to risk factors for deep 
venous thrombosis (an adverse effect that is not anticipated). Thus, any difference 
in rates of venous thrombosis may be due to a difference in the risk of harm 
between contraceptives.178, 188 However, care should be taken, as cohort studies 
may suffer from diagnostic suspicion bias whereby those taking the intervention are 
more likely to be monitored and more likely to receive a diagnosis.3 In the case of 
deep venous thrombosis, for instance, this may be more frequently diagnosed in 
users of oral contraceptives, even if there was no causal link with the drugs.3  
 
A particular disadvantage of cohort studies is that they, like RCTs, may take a long 
time to complete and may not be large enough to identify very rare adverse 
effects.70, 73  
 
4.1.2.2 Case-control studies 
Another, probably less reliable, study design for the identification of adverse effects 
is the case-control study. Case-control studies start with selecting people who have 
already developed the adverse effect of interest (cases). Controls are then identified 
who do not have the adverse effect, but who are similar to the cases with respect to 
important determinants (such as age, sex and concurrent medical conditions).135 A 
particular problem with case-control studies is their susceptibility to recall bias.189 
The retrospective nature of this design means that sources such as medical records 
and interviews with patients about past behaviour are required. However, medical 
records are often incomplete and patients with an adverse effect may try harder to 
recall a potential culprit (recall bias) and interviewers may probe them more 
vigorously (interview bias).96, 129, 135, 137, 190, 191 
 
Case-control studies, however, may be most useful for adverse effects that are 
either very rare, take a long time after exposure to develop, or are catastrophic.3, 14, 
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81, 129, 131, 132, 135, 139, 141, 175, 192 For example, case-control studies have identified the 
association between NSAIDs or SSRIs and upper gastrointestinal bleeding, the 
increased risk of venous thromboembolism with oral contraceptives,135, 192-194 and 
the association between diethylstilboestrol (DES) ingestion by pregnant women and 
the development of vaginal adenocarcinoma in their daughters many years later.21, 
135, 194 If a prospective study had been undertaken to investigate the relationship 
between diethylstilboestrol and vaginal adenocarcinoma it would have taken at least 
20 years and would have required hundreds of thousands of women.135, 195 
 
4.1.2.3 Cross-sectional Studies 
Another study design sometimes used to investigate the relationship between an 
intervention and potential adverse effects is the cross-sectional study. In cross-
sectional studies the exposure and the potential adverse effect are measured at the 
same time, using for example a questionnaire or survey. Measuring the exposure 
and outcome simultaneously is a major problem with this study design, as it will not 
be known which came first,114, 141 and it will be impossible to distinguish between 
cause and effect. 
 
4.1.2.4 Ecological Studies 
An ecological study in which at least one variable is measured at the group (not 
individual) level. The occurrence of disease is compared between groups that have 
different levels of exposure. An example would be fracture rates in people living in 
areas of water fluoridation compared to those living in areas without water 
fluoridation. 
 
4.1.2.5 Case reports/case series 
Many adverse drug reactions are first reported as case reports or small case 
series.77, 87, 139, 196-200 Case reports are the mainstay of pharmacovigilance, whereby 
reports are submitted by health professionals and the public to national 
pharmacovigilance centres such as the Medicines and Healthcare products 
Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) 
in the US. Another system employed to monitor the safety of selected drugs is 
Prescription Event Monitoring (PEM). Doctors prescribing the selected drug are 
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provided with a special reporting form to record any adverse effects experienced by 
the patient.175, 201 
 
In addition to pharmacovigilance reporting, case reports represent a substantial 
amount of the published literature on adverse effects31 and are the main source of 
information used to withdraw a drug from the market for safety reasons.86, 168, 186, 192 
Indeed, many adverse effects have been successfully discovered through case 
reports, including the birth defects associated with thalidomide.202  
 
Case reports may be especially useful for unusual serious adverse effects that 
occur early on in the treatment and are unrelated to the indication of the drug,21, 73, 76, 
129, 133, 139, 182, 192, 197 are extremely rare,13, 77, 80, 82, 133, 137, 174, 203 or are typical of drug 
reactions (e.g. agranulocytosis, liver necrosis, Stevens-Johnson syndrome).103 
Some adverse drug reactions may be so convincing or dramatic that only one case 
report or at most a handful of reports are necessary to provide evidence of an 
association.131, 141, 196, 204-206 However, adverse effects with a long latency period, that 
are unexpected, have a modest increase, or are common in non-exposed patients, 
are much harder to detect with case reports.73, 80, 103 
 
There is always the danger of false positive signals when using case reports73, 82, 200 
and it should be noted that raising alarm about potential adverse effects can do 
more harm than good. For instance, the uptake of beneficial treatments were 
reduced or restricted in the case of the alleged associations between the measles, 
mumps and rubella (MMR) vaccine and autism,207 between sertindole (an 
antipsychotic drug) and sudden death,208 and between bendectin (used to treat 
nausea and vomiting) and birth defects.129, 130, 200 
 
A particular problem with case reports is that they lack a numerator (as the total 
number of cases is unknown)73, 209 and a denominator (as the number of exposed 
cases is unknown)42, 133, 209-212 and with no comparator group, they cannot be used 
to determine the risks or incidence of adverse reactions, causal relationships,14, 129, 
131, 133, 212, 213 or even to compare different drugs.175, 198, 212, 214  
 
Case reports are also likely to be more susceptible to publication bias than other 
study designs. Case reports that are new, interesting, unusual, unexpected, 
extreme, or associated with a useful teaching point, are more likely to be submitted 
by the author and accepted by the journal editor,131, 198 and a published case report 
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may then stimulate further reports.139, 209, 215 It is, therefore, not possible to know how 
representative the occasional case report is of overall medical experience.212, 216  
 
Poor reporting is also a problem in published case reports, as they often do not 
contain sufficient information or detail,204, 209-211, 217 and even when using case 
reports submitted to regulatory authorities, reporting of patient and drug information 
is often incomplete,31, 139, 210, 212, 218 and many cases are not submitted, with 
estimates of under-reporting as high as 98%213 and 99%.219 Under-reporting is 
particularly apparent for older drugs, less serious adverse effects, predictable 
adverse drug reactions, or with less interesting adverse effects.175 In addition, it has 
been found that few case reports are subsequently investigated or confirmed to be 
valid.220 
 
Nevertheless case reports may alert health professionals to potential adverse 
effects and may be a useful tool for hypothesis generating.31, 42, 114, 129, 141, 175, 177, 178, 
188, 209 With the use of data mining techniques of case reports submitted as part of 
spontaneous reporting systems, this information also has a predictive value in 
identifying early signals of new adverse drug reactions.221 These potential links 
between an adverse event and a particular drug can then, if necessary, be 
investigated further using other study designs. 
 
With so many potentially useful study designs for identifying adverse effects, with 
varying advantages and disadvantages, a major question is whether findings from 
different types of study designs agree. The extent of any discrepancy between the 
pooled risk estimates from different study designs is a key concern for systematic 
reviewers. Previous research has tended to focus on differences in treatment effect 
between RCTs and observational studies.222-228 However, estimates of beneficial 
effects may be prone to different biases to estimates of adverse effects amongst the 
different study designs. Bearing in mind the possibility of bias, increased workload, 
and difficulty in combining the data from diverse study designs, it is not clear 
whether the inclusion of all types of study designs results is most appropriate for 
systematic reviews incorporating adverse effects. This uncertainty has not been fully 
addressed in current methodological guidance on systematic reviews of harms,116 
probably because the existing research has so far been inconclusive, with examples 
of both agreement and disagreement in the reported risk of adverse effects between 
RCTs and observational studies.17, 21, 77, 98, 134, 138, 140, 177, 229-234 It may be hypothesized 
that RCTs might provide more accurate results and that including observational 
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studies may simply increase bias in a systematic review. On the other hand 
observational studies may primarily be devoted to assessing specific adverse 
effects and provide more complete data.  
 
This research aimed to systematically review meta-analyses or methodological 
studies comparing estimates of harm (for specific adverse effects) reported in one 
study design with those reported in another study design for the same adverse 
effect. 
 
 Methods 4.2
4.2.1 Inclusion criteria 
A meta-analysis or methodological evaluation was considered eligible for inclusion 
in this review if it evaluated studies of more than one type of design (for example, 
RCTs versus cohort, or RCTs versus case-control studies) in the identification 
and/or quantification of adverse effects of healthcare interventions. The main 
outcome measure was an estimate of the impact of different study designs on the 
combined estimates of the risk of adverse effects in terms of risk ratio (RR), odds 
ratios (OR), or weighted means difference (WMD). Other outcome measures were 
incidence rate of adverse effects, or ranking of adverse effects from different study 
designs. 
 
4.2.2 Data extraction 
Information was collected on the primary objective of the meta-analysis or 
methodological evaluation, study designs, and the adverse effects and interventions 
evaluated. The number of primary studies included in the analysis and number of 
patients by study design; the number of adverse effects in the treatment and control 
arm or comparator group were also recorded as were the types of summary 
statistics used in assessing differences between studies, such as risk ratio, odds 
ratio, or weighted means difference. In each instance, the categorisation of study 
design as specified by the author of the meta-analysis or methodological evaluation 
was relied upon. For example, if the author stated that he/she compared RCTs with 
cohort studies, it was assumed that the studies were indeed RCTs and cohort 
studies. 
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4.2.3 Assessment of methodological quality 
The following criteria were used to consider the validity of comparing risk estimates 
across different study designs: 
1. Presence of confounding factors 
Discrepancies between the results from different study designs may arise 
because of factors other than study design (such as differences in 
population or age group, delivery of intervention, drug dosage or outcome 
measurement). A record was made of whether the authors of the meta-
analysis or methodological evaluation reported checking whether the groups 
of different studies shared similar features in terms of population, 
interventions, comparators, and measurement of outcomes to improve the 
comparability of the risk estimates arising from different study designs. 
2. Heterogeneity by study design 
A record was made of whether the authors of the meta-analysis or 
methodological evaluation explored heterogeneity by study design, using 
measures such as Chi2 or I2 statistic. An indication of heterogeneity of each 
set of pooled results by study design was assessed using a cut-off point of 
P<0.10 for Chi2 test results and 50% for I2 results. In the few instances 
where both statistics were presented, the results of the I2 test were given 
precedence.235 
3. Statistical analysis comparing study designs 
A record was made of whether the authors of the meta-analysis or 
methodological evaluation described the statistical methods by which the 
magnitude of the difference between study designs was assessed.  
 
4.2.4 Analysis  
Duplicate data were excluded from the analysis. Any relevant missing statistical 
data, such as confidence intervals, were calculated from the raw data presented 
wherever possible. 
 
Potential discrepancies between the pooled odds (OR) from meta-analyses of 
different study designs were checked by (i) comparing the separate point estimates 
and overlap in confidence intervals, and (ii) making a quantitative and graphical 
comparison of the ratio of the pooled odds ratios from each study design. 
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A descriptive summary of the data in terms of confidence interval (CI) overlap 
between pooled sets of results by study design, and any differences in the direction 
of effect between study designs were presented. In order to be able to compare any 
disagreements in the results, each type of study design was compared to the others 
in turn. For instance, if a methodological evaluation included RCTs, cohort studies 
and case-control studies, RCTs were compared to cohort studies, then RCTs were 
compared to case-control studies, and lastly cohort studies were compared to case-
control studies. The results were said to agree if both study designs identified a 
statistically significant increase, a statistically significant decrease, or no statistically 
significant difference in the adverse effects under investigation. 
 
Potential quantitative differences or discrepancies between the pooled estimates 
from the respective studies designs for each adverse effect were illustrated by 
taking the ratio of odds ratios (ROR) from meta-analysis of one study design versus 
meta-analysis of another study design. The ROR was calculated using the pooled 
odds ratio for the adverse outcome from one study design divided by the pooled 
odds ratio for the adverse outcome from another study design. If the meta-analysis 
of one study design for a particular adverse effect yielded exactly the same OR as 
the meta-analysis of another study design (i.e. complete agreement, or no 
discrepancy between study designs), then the ROR would be 1.0 (and Ln ROR 
would be zero). Because adverse effects are rare, odds ratios and risk ratios were 
treated as equivalent.236 
 
The estimated RORs from each study design comparison were then used in a meta-
analysis (random effects inverse variance method - RevMan 5.1) to summarize the 
overall RORs between study designs across all the included reviews. The standard 
error (SE) of ROR was estimated using the standard errors for each type of study 
design respectively. For instance, in the case of comparing RCTs and observational 
study estimates, the SE was calculated as follows: 
 
SE(ROR) = square root of [SE Ln OR(RCT)2 + SE Ln OR(Observ)2] 
 
Standard errors pertaining to each pooled OR(RCT) and OR(Observ) were 
calculated from the published 95% confidence interval (CI). Statistical heterogeneity 
was assessed using I2 statistic with I2 values of 30-60% representing a moderate 
level of heterogeneity.237 
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Funnel plots were constructed to evaluate the distribution of the ROR against 
estimates of precision (1/SE). If there were no systematic differences or 
discrepancies between the pooled OR from the various study designs, then the 
ROR data points would be expected to be symmetrically distributed within the funnel 
shape. Conversely, if one set of study designs consistently generated either lower 
or higher estimates, then the RORs would be skewed to one side, with an 
asymmetrical funnel plot. 
 
 Results 4.3
4.3.1 Included studies 
In total, 51 meta-analysis or methodological evaluations met the inclusion criteria 
(Appendix B: Table 15.1).28, 136, 183, 238-286 Six were methodological evaluations with 
the main aim of assessing the influence of study characteristics (including study 
design) on the measurement of adverse effects,136, 183, 242, 247, 248, 264, 269 whereas the 
remaining 45 were systematic reviews within which subgroup analysis by study 
design was embedded.28, 238-241, 243-246, 249-263, 265-268, 270-286  
 
4.3.1.1  Adverse effects 
Nearly two-thirds of the meta-analyses or methodological evaluations compared the 
results from different study designs using only one specific named adverse effect 
(31/51, 61%),28, 238-241, 244-246, 249, 252-255, 257-262, 265, 266, 272, 274-281, 285 whilst six included 
one type of adverse effect (such as cancer, gastrointestinal complications, or 
cardiovascular events).242, 243, 256, 268, 269, 271 Fourteen included a number of specified 
adverse effects (ranging from two to nine effects) or any adverse effects.136, 183, 247, 
248, 250, 251, 263, 264, 267, 270, 273, 282-284, 286 
 
The most commonly included adverse effect was cancer (nine methodological 
evaluations), followed by cardiovascular events (eight methodological evaluations), 
venous thromboembolism (six methodological evaluations) and then haemorrhage, 
falls, fractures, and gastrointestinal complications (each in three methodological 
evaluations). 
 
The absolute numbers of adverse effects per type of study design were presented in 
only 18 methodological evaluations28, 183 Vohra, 2007 #11306, 244, 245, 251, 256, 257, 263, 267, 269, 273, 
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274, 277-279, 283, 285 and in eight of these the data were incomplete.183, 244, 269, 274, 277, 279, 
283, 285 The number of adverse effects reported in the pooled treatment arms ranged 
from 0 to 4615. However, most studies included rare adverse effects. 
 
4.3.1.2 Interventions 
The majority (44/51, 86%) of the meta-analysis or methodological evaluations 
included only one intervention (such as hormone replacement therapy (HRT) or 
nonsteroidal anti-inflammatory drugs (NSAIDs)),28, 183, 238-251, 253, 254, 256-260, 263-280, 282-285 
whilst seven methodological evaluations included more than one intervention, with a 
range of two to nine interventions.136, 252, 255, 261, 262, 281, 286  
 
Most of the methodological evaluations (43/51, 84%) focused on adverse effects of 
pharmacological interventions.28, 136, 183, 238, 239, 241-246, 249, 251-258, 260-266, 268, 269, 271-281, 283, 
285, 286 Other topics assessed were surgical interventions (such as bone marrow 
transplantation and hernia operations),136, 240, 247, 248, 250, 270 a public health 
intervention (water fluoridation),259 blood transfusion,267 diagnostic test 
(ultrasonography),282and a physical intervention (spinal manipulation).284 
 
The most commonly studied intervention was hormone replacement therapy (HRT) 
(nine methodological evaluations),238, 244, 249, 252, 253, 255, 266, 272, 280 followed by NSAIDs 
(eight methodological evaluations)242, 245, 256, 263, 268, 269, 271, 277 and oral contraceptives 
(eight methodological evaluations).183, 241, 246, 252, 254, 258, 260, 276  
 
4.3.1.3  Outcome measures 
The majority of the methodological evaluations (39/51, 76%) compared pooled risk 
ratios and/or odds ratios from different types of study design.136, 238, 240-246, 249-256, 258-
263, 265-269, 271, 272, 274-277, 279-282, 286 Although risk ratio was sometimes used for case-
control studies instead of odds ratios, most adverse effects are rare so this was 
assumed not to impede the results.  
 
Seven methodological evaluations measured the incidence of adverse effects,183, 247, 
248, 257, 270, 273, 278, 283 three methodological evaluations reported the number of cases 
of an adverse effect (with no denominator),28, 284, 285 one methodological evaluation 
measured weighted means difference (WMD) (in addition to risk ratios),239 and 
another measured relative frequencies of adverse effects.264 
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4.3.1.4  Sample size 
The number of included studies in each comparison set of pooled results ranged 
between two and 1885 primary studies. Those methodological evaluations with the 
highest number of primary studies tended to include case reports. 
 
4.3.1.5 Study designs 
Eleven methodological evaluations did not distinguish between cohort and case-
control studies, and these study types were grouped by the authors under the 
umbrella term ‘observational studies’ and compared to RCTs.  
 
4.3.2 Excluded studies 
Sixty-seven studies were excluded from this section of the systematic review 
(Appendix B: Table 15.2). Nearly a third of these studies (20/67) did not compare a 
formally recognized study design (such as RCTs, cohort studies or case-control 
studies) but compared study designs using a categorisation such as, prospective 
versus retrospective studies, phase two versus phase three RCTs, nested versus 
non-nested case-control studies, case-controlled versus case-crossover studies, or 
studies divided by data collection methods.287-306 Although these studies are 
methodologically interesting, it would not be possible to relate any differences 
identified to the retrieval of information on adverse effects. For example, it is very 
difficult to develop a search strategy to identify only nested case-control studies. 
 
Twelve studies were excluded because their hypothesis stated that the intervention 
had a protective effect.307-318 For example, in one study oral contraceptives were 
thought to provide a protective effect against ovarian cancer.307 Fourteen studies 
discussed the differences between the results of study designs without all of the 
pooled results or estimates,134, 319-331 and eight studies presented the results of each 
of the individual studies grouped by study design but did not present the pooled 
results.171, 332-338 Five studies did not compare similar data, for example, similar 
adverse effects,339, 340 similar comparators,140 or similar outcome measures.341, 342 
For three studies only the abstract was available and not enough information could 
be ascertained.230, 343, 344 Two studies contained duplicate data from studies already 
included,345, 346 one study did not separate the pooled results of cohort studies and 
RCTs,347 one study did not include a healthcare intervention,348 and lastly, one study 
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did not measure the magnitude or direction of any adverse effects but looked at the 
decline in risk.349 
 
4.3.3 Summary of methodological quality 
1. Role of confounding factors 
Although many of the methodological evaluations acknowledged the potential for 
confounding factors that might yield discrepant findings between study designs, no 
adjustment for confounding factors was reported in most instances.28, 136, 183, 238-241, 
243-246, 248-253, 256-262, 264-268, 270-286 However, a few authors did carry out subgroup 
analysis stratified for factors such as population characteristics, drug dose, or 
duration of drug exposure. 
 
There were five instances where the authors of the methodological evaluations 
performed some adjustment for potential confounding factors.242, 254, 255, 263, 269 Three 
carried out meta-regression,242, 254, 263 one measured differences in heterogeneity 
when stratified by dose or duration,255 and in the other methodological evaluation 
the adjustment method carried out was unclear.269 In three of the methodological 
evaluations, other factors (such as drug dose and duration) were thought to be 
potentially responsible for any discrepancies between the results from different 
study designs.254, 255, 269  
 
2. Heterogeneity by study design 
Twenty-two meta-analyses or methodological evaluations measured the 
heterogeneity of at least one set of the included studies grouped by study design 
using statistical analysis such as Chi2 or I2.136, 239, 242-244, 246, 249, 251, 252, 256, 258, 259, 263, 265, 
266, 269, 272, 277, 279-281  
 
The pooled sets of RCTs were least likely to exhibit any strong indication of 
heterogeneity; only five (15%)136, 244, 279, 282 of the 33136, 239, 243, 244, 249, 252, 263, 277, 279 sets 
of pooled RCTs were significantly heterogeneous (Figure 4.1) and in two of these 
sets of RCTs the heterogeneity was only moderate with I2=58.9%244 and I2=58.8% 
(Appendix B: Table 15.1).279 
 
In terms of least heterogeneity, RCTs were followed by cohort studies (7/21, 33%), 
‘observational’ studies (as described by the authors) (14/25, 56%), then case-
control studies (16/19, 84%), cross-sectional studies (1/1, 100%) and ecological 
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studies (1/1, 100%) (Figure 4.1). This reflects the traditional hierarchy of evidence 
for clinical effectiveness. 
Figure 4.1 Significant heterogeneity between studies of the same design 
 
 
3. Statistical analysis comparing study designs 
Authors of eight methodological evaluations136, 183, 240, 246, 248, 254, 258, 270 explicitly 
tested for a difference between the results by study design, seven reported p-
values136, 240, 246, 248, 254, 258, 270 and one presented risk ratio estimates.183 
 
Six methodological evaluations239, 246, 249, 258, 259, 280 reported on the heterogeneity of 
the pooled studies of one design, the pooled studies of another design, and the 
heterogeneity of all the studies combined. This can indicate statistical differences 
where the pooled study designs combined are significantly heterogeneous but no 
significant heterogeneity is seen when the study designs are pooled separately. One 
meta-analysis (breast cancer with hormone replacement therapy)249 identified that 
although significant heterogeneity was observed with all studies, there was no 
significant heterogeneity when the studies were grouped by study design. 
 
4.3.4 Preparation of data 
4.3.4.1 Duplicate data 
A major problem with the methodological evaluations was the issue of duplicate 
data. For instance, some methodological evaluations presented both fixed and 
15% 
33% 
56% 
84% 
100% 100% 
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random effects models,238, 246, 276, 281 some presented both grouped data (for 
example, all cancers, all NSAIDs, all diuretics or all doses of a drug) and discrete 
sets of data (for example, by type of cancer, by type of NSAID, by type of diuretic or 
by drug dose),243, 262, 268, 276 one carried out analysis from adjusted and unadjusted 
data,275 and lastly, one presented multiple data from systematic reviews of the same 
intervention and adverse effect. It is likely that the primary studies included in these 
systematic reviews overlapped considerably, again introducing duplicate data 
analysis.269 
 
Some authors also carried out analysis on secondary outcomes which were related 
to or surrogates of the primary outcome. Examples include blood transfusion rates 
as well as total blood loss, bone mineral density as well as fractures, cancer 
recurrence as well as mortality, preterm birth as well as low birth weight, delayed 
speech as well as dyslexia, 30 day mortality, stroke and myocardial infarction as 
well as mortality, death as well as new infections, asystole as well as bradycardia, 
and ulcer bleeding/perforation and death attributable to ulcer bleeding/perforation as 
well as symptomatic ulcer.183, 239, 265, 267, 270, 273, 283 
 
Using the same data set more than once or multiple related outcomes in any 
analysis may make the data appear inappropriately homogenous and may present 
relationships which do not exist. The following decisions were, therefore, 
implemented before data entry into the statistical software package STATA (version 
12.0).  
1) Where both random effects models and fixed effects models were 
presented,238, 246, 276, 281 the random effects models were selected over the 
fixed effects models as they represented a more conservative approach, and 
studies were often heterogeneous (where measured).  
2) The separate analysis for each named NSAID,276 each named cancer,243 
each named diuretic,262 and the two separate analysis by rofecoxib drug 
dose268 were selected in preference to the grouped set of results of all 
NSAIDs, all cancers, all diuretics and all drug doses of rofecoxib. 
3) Pooled adjusted data were selected in preference to unadjusted data where 
both were presented.275 
4) The systematic reviews with the largest number of included studies were 
selected from McGettigan and Henry 2008.269 
5) Primary outcomes of symptomatic ulcer,183 fractures,265 mortality,267, 270 
infections,273 low birth weight,247 dyslexia,247 and bradycardia283 were 
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selected in preference to the secondary outcomes of ulcer bleeding or 
perforation and death attributable to ulcer bleeding or perforation,183 bone 
mineral density,265 cancer recurrence,267 30 day mortality, stroke and 
myocardial infarction,270 death,273 preterm birth and other perinatal 
outcomes,247 delayed speech,247 and asystole.283 
6) Where outcomes were reported as risk ratios and weighted means 
difference, risk ratios were selected in preference to weighted means 
difference. Re-exploration was therefore selected in preference to total blood 
loss or blood transfusions.239 
 
4.3.4.2 Unreported data 
Another problem in comparing the results of the methodological evaluations was 
that of unreported data. In two methodological evaluations, risk ratios were not 
presented for all the results by study design but were divided by specific study 
characteristics. In Bollini et al 1992242 the case-control studies were pooled 
according to whether they were hospital-based or community-based case-control 
studies and in Douketis et al 1997252 the cohort studies were pooled according to 
whether they were prospective or retrospective cohort studies. In order for all case-
control studies in Bollini et al 1992242 and all cohort studies in Douketis et al 1997252 
to be compared to the other study designs, these results were weighted 
appropriately and amalgamated to estimate risk ratios and confidence intervals of 
the studies combined.  
 
Confidence intervals were not presented for nine of the methodological 
evaluations.28, 183, 257, 264, 273, 274, 283, 284,266 Confidence intervals could be estimated 
from the information given in five of these methodological evaluations, four of which 
presented the number of adverse effects183, 257, 273, 283 and numbers of participants 
and one presented risk ratio estimates with p-values.274 In the case of the 
methodological evaluations that presented incidence data,183, 257, 273, 283 confidence 
intervals were estimated for the incidence of adverse effects only in the treatment 
arms, as in many cases no information on a control group was given or there was 
no control group - for example, with case series. Confidence intervals could not be 
calculated for four methodological evaluations: three presented only the number of 
adverse effects (with no denominator)28, 284, 285 and the other presented relative 
frequencies of adverse effects.264 
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4.3.5 Size of studies 
In 19 methodological evaluations the total number of participants was reported in 
each set of pooled studies by study design238, 239, 241, 243, 245, 249-251, 256, 257, 263, 266, 267, 270, 
273, 279, 282, 283 and in another 13 methodological evaluations the pooled number of 
participants was reported for at least one type of study design.28, 136, 246, 254, 258, 264, 265, 
269, 271, 274, 276, 277, 284 
 
Cohort studies contained the highest number of participants per study with a mean 
of 26,699 (4,966,061/186), followed by studies classified as observational with a 
mean of 11,953 (3,824,807/320) participants per study, and case control studies 
which had a mean of 8,717 (1,447,084/166) participants. RCTs had the lowest 
mean number of participants at 1,671 (840,354/503) (Figure 4.2). 
Figure 4.2 Mean number of participants per study according to study design 
 
 
4.3.6 Confidence interval overlap 
4.3.6.1 Risk ratios or odds ratios 
In almost all instances, the confidence intervals (CIs) for the risk ratios or odds 
ratios for the pooled results from the different study designs overlapped (94%, 
151/160). However, there were nine pooled sets of results (in six methodological 
evaluations) where the confidence intervals did not overlap.136, 249, 252, 255, 261, 280  
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Six of the nine pooled sets of results where confidence intervals did not overlap 
investigated hormone replacement therapy (HRT) with a named adverse effect of 
either a named cancer, (such as breast cancer,249 endometrial cancer255 or cervical 
cancer280) or venous thromboembolism.252 The other pooled sets of results were 
very specific, looking at psychotropic drugs and falls,261 symptomatic intracranial 
bleed with anticoagulant versus antiplatelet,136 and visceral or vascular injury with 
laparoscopy versus open surgery for inguinal hernia.136 
 
The nine pooled sets of results without confidence overlap compared a range of 
different study designs with no consistent pattern. Four compared RCTs with 
observational studies, either ‘observational’ studies in general,136, 249, 257 or case-
control studies.252 The five other pooled sets of results compared either cohort 
studies with case-control studies,255, 280 or cohort studies and cross-sectional 
studies.261 
 
4.3.6.2 Incidence rates of adverse effects 
In just over three-quarters of instances (76%, 13/17) the confidence intervals for the 
incidence rates of adverse effects from the different studies overlapped (Table 4.1). 
There were only four instances where the confidence intervals did not overlap: 
general anesthesia and urinary retention;257 regional anesthesia and urinary 
retention;257 propofol and bradycardia;283 and symptomatic ulcer and NSAIDSs.183 
Again, the pooled sets of results without overlapping confidence intervals compared 
a range of study designs with no consistent pattern. They compared RCTs with 
either ‘observational’ studies in general,136, 249, 257 cohort studies,183 or case series.283 
 
Table 4.1 Confidence interval overlap between study designs in studies 
measuring incidence 
Study design comparisons Confidence interval overlap 
RCTs versus ‘observational’ studies (N=4) 2 (50%) 
RCTs versus cohort studies (N=7) 6 (86%) 
RCTs versus case series (N=5) 4 (80%) 
Cohort versus case series (N=1) 1 (100%) 
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Table 4.2 Confidence interval overlap and agreement between study designs in studies measuring risk ratios or odds ratios 
Study design 
comparisons 
Confidence 
interval overlap 
Agreement in findings between the study designs Discrepancy in findings between the study designs 
Both showed a 
significant increase 
Both did not identify 
any significant 
difference 
Both showed a 
significant 
decrease 
Significant risk increase in one 
versus significant risk 
decrease in the other 
Significant increase in one 
versus no significant 
difference in the other 
Significant decrease in 
one versus no difference 
in the other 
RCTs versus all 
‘observational’ studies 
(N=58) 
54 (93%) 11 (19%) 23 (40%) 3 (5%) 1 (2%) 19 (33%) 1 (2%) 
Subgroup analysis based on specific observational designs against RCTs 
RCTs versus 
‘observational’ studies 
(N=32) 
29 (91%) 6 (19%) 13 (41%) 3 (9%) 1 (3%) 8 (25%) 1 (3%) 
RCTs versus cohort 
studies (N=16) 
16 (100%)  3 (19%) 8 (50%)  0 0 5 (31%) 0 
RCTs versus case-control 
studies (N=10) 
9 (90%)  2 (20%) 2 (20%)  0 0  6 (60%) 0 
Analysis of non-RCTs studies 
Cohort versus case-control 
studies (N=64) 
60 (94%) 19 (27%) 23 (38%) 0 1 (2%) 20 (31%) 1 (2%) 
Cohort versus cross-
sectional studies (N=18) 
17 (94%) 4 (22%) 11 (61%) 0 0 3 (2%) 0 
Cohort versus ecological 
studies (N=1) 
1 (100%) 0 1 (100%) 0 0 0 0 
Case-control versus cross 
sectional studies (N=18) 
18 (100%) 4 (22%) 11 (61%) 0 0 3 (2%) 0 
Cross-sectional versus 
ecological studies (N=1) 
1 (100%) 0 1 (100%) 0 0 0 0 
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4.3.1 Agreement and disagreement of results 
4.3.1.1 Agreement 
In the majority (111/160, 69%) of the methodological evaluations, the results of the 
treatment effect agreed between types of study design in terms of identifying a 
significant increase, significant decrease or no significant difference in the adverse 
effects under investigation.136, 238, 241-243, 245, 250, 252, 254-256, 259-263, 265-269, 271, 272, 274-277, 279-
282, 286 Most studies that demonstrated an agreement between study designs did not 
find a significant increase or significant decrease in adverse effects (70/111, 63%) 
(Table 4.2).  
 
4.3.1.2 Disagreement 
There were other instances136, 238-240, 243, 246, 250-253, 258, 260-263, 265, 268, 269, 271, 276-278, 280-282 
(29%, 47/160) where although the direction of the effects were not opposing, 
apparently different conclusions may have been reached had a review been 
restricted to just one type of study design and undue emphasis was placed on 
statistical significance tests. Table 4.2 shows that the most common discrepancy 
between study types occurred when one set of studies identified a significant 
increase whilst another study design found no statistically significant difference. For 
instance, a significant increase in an adverse effect could be identified in an 
analysis of RCT data, yet pooling the observational studies may have identified no 
significant difference in adverse effects between the treatment and control group.  
 
Disagreements between RCTs and observational studies were fairly evenly 
balanced. There were eight instances where a significantly elevated risk with RCTs 
was demonstrated but no significant difference with observational studies and 11 
instances where observational studies demonstrated a significantly elevated risk 
with no significant difference identified by RCTs. 
 
There was a tendency for case-control studies to show a greater degree of harm 
than cohort studies. There were 14 adverse effects where meta-analyses of case-
control studies found significant elevated risk, but meta-analyses of cohort studies 
did not confirm this risk. Conversely, there were six adverse effects where meta-
analyses of cohort studies demonstrated significantly elevated risk, but the meta-
analyses of case-control studies did not show significant risk. 
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Given the imprecision in deriving estimates of rare events, this may not reflect any 
real difference between the estimates from different study designs, and it would be 
more sensible to concentrate on the overlap of confidence intervals (CIs) rather than 
the variation in size of the p-values from significance testing. 
 
Where possible, the sample sizes of the studies which disagreed were compared. It 
was hypothesized that those study designs which disagreed because one type of 
study design identified an increase or decrease in an adverse effect and another 
study design identified no significant difference, might be due to differences in 
sample size. Large sample sizes might be required to identify a significant 
difference in rare adverse effects. Nineteen of the 49 pooled sets of results which 
disagreed reported on the number of participants by study design. However, in only 
seven of the 19 sets of results, a smaller number of participants were reported for 
those studies which identified a non-significant difference when the larger set of 
pooled results identified a significant increase or decrease.  
 
There were major discrepancies in only two pooled sets of results.249, 255 In these 
instances, whilst one study design identified a protective effect another type of study 
design identified an increased risk of the outcome. Col et al 2005249 found an 
increase in breast cancer with menopausal hormone therapy in RCTs (RR 3.41 
(1.59-7.33)) but a decrease in observational studies (RR 0.64 (0.50-0.82)). Grady et 
al 1995255 found that whilst cohort studies demonstrated a decrease in endometrial 
cancer with estrogen plus progestin (RR 0.4 (0.2-0.6)), case-control studies 
demonstrated an increase (RR 1.8 (1.1-3.1)). 
 
4.3.2 Ratio of risk ratio or odd ratios estimates 
Risk ratios or odd ratios from the different study designs were compared to other 
study designs by meta-analysis of the respective ratio of risk ratios or odds ratios 
(RORs) for each adverse effect. In instances where risk ratios or odds ratios were 
unavailable, the incidence or number of cases of adverse effects was compared 
from different study designs.  
 
The RORs from the different study design comparisons are presented in Table 4.3 
and the corresponding forest plots in Figure 4.3 and Appendix B: Figure 15.1 to 
Figure 15.6. The overall RORs from meta-analysis using the data from all studies 
that compared RCTs with cohort studies or case control studies or that grouped 
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studies under the umbrella of ‘observational’ studies was estimated to be 1.03 (95% 
CI 0.93-1.15) with moderate heterogeneity (I2=56%, 95% CI of I2=38-67%) (Table 
4.3 and Figure 4.3). 
 
Generally, the pooled RORs from the study design comparisons show no significant 
difference between the results from different study designs with either low or 
moderate heterogeneity (Table 4.3 and Appendix B: Figure 15.1 to Figure 15.6). 
However, it was interesting to note that, on average, meta-analyses of cohort 
studies gave odds ratios that were a relative 6% lower than those of meta-analyses 
of case-control studies. Although this difference between cohort and case-control 
studies did not reach conventional threshold of statistical significance, the low to 
moderate heterogeneity seen overall is an indicator that there may be a consistent 
pattern of variation between these study designs. 
Table 4.3 Ratio of odds ratios (RORs) of adverse effects in study design 
comparisons 
Study design 
comparison 
Pooled ratio of odds ratios (RORs) 
and 95% confidence intervals (CIs) 
Heterogeneity 
(I2) 
RCTs versus all 
observational studies (N=58) 
1.03 (0.93-1.15) 56% 
RCTs versus cohort studies 
(N=16) 
1.02 (0.82-1.28) 43% 
RCTs versus case-control 
studies (N=10) 
0.84 (0.57-1.23) 54% 
RCTs versus ‘observational’ 
studies (N=32) 
1.08 (0.94-1.22) 60% 
Cohort versus case-control 
studies (N=64) 
0.94 (0.87-1.01) 55% 
Cohort versus cross-sectional 
studies (N=18) 
0.97 (0.89-1.07) 10% 
Case-control versus cross-
sectional studies (N=18) 
1.07 (0.95-1.21) 26% 
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Figure 4.3 Meta-analysis of RORs from RCTs versus all observational studies 
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NB: Studies are listed by first author’s last name and year of publication. In some 
studies more than one outcome or intervention was assessed. In these instances, 
indicated by lowercase letters after the study year, the data were entered in the 
meta-analysis separately. Other studies compared RCTs to cohort studies and 
case-control studies separately and therefore are listed twice (with no lowercase 
letter after the study year). 
 
4.3.3 Incidence of adverse effects 
The pooled ratio of incidence from different study designs are presented in Table 
4.4. These results suggest a higher risk of adverse effects in RCTs than cohort 
studies (1.75 (1.5-2.04)). However, there is a high level of heterogeneity in the 
pooled studies and these results are highly influenced by one study, Tramer et al 
2000 (Appendix B: Figure 15.7 to Figure 15.9). The pooled ratio of incidence of 
adverse effects was greater in case series than cohort studies (0.24 (0.07-0.84)); 
these figures are based on only one study in which the number of cases of adverse 
effects was very small (seven and four).278 
 
Table 4.4 Pooled ratio of incidence of adverse effects in study design 
comparisons 
Study design comparison Pooled ratio of incidence and 
95% confidence intervals (CIs) 
Heterogeneity 
(I
2
) 
RCTs versus cohort studies 
(N=7) 
1.75 (1.50-2.04) 94% 
RCTs versus studies described 
as ‘observational’ (N=4) 
2.37 (0.70-8.05) 60% 
RCTs versus case series (N=3) 1.98 (0.59-6.64) 85% 
Cohort studies versus case 
series (N=1) 
0.24 (0.07-0.84) NA 
 
4.3.4 Number of adverse effects 
One methodological evaluation identified a higher number of adverse effects in 
RCTs (164 serious adverse effects, 4615 non-serious) than ‘observational’ studies 
(39 serious adverse effects, 3553 non-serious),285 and another a higher number of 
adverse effects in the ‘observational studies’ (nine) than RCTs (zero).28 However, 
the sample size of the studies was not reported. 
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Two methodological evaluations28, 284 compared the number of adverse effects from 
RCTs and case series, or RCTs and case reports. One, however, did not separate 
the results from case reports and case series,28 and the other reported small 
numbers of adverse effects (RCTs - four cases, case series - three cases and case 
reports - seven cases).284 
 
4.3.5 Relative frequencies of adverse effects 
One methodological evaluation compared the relative frequencies of adverse effects 
of amiodarone from trials and case reports.264 The rank order of adverse effects 
from this methodological evaluation suggests that the frequencies of adverse effects 
may be different in clinical trials when compared to case reports. 
 
4.3.6 Sensitivity analysis 
There are no adverse effects where two or more separate meta-analyses have used 
exactly the same primary studies (i.e. had complete overlap of the included studies) 
to generate the pooled estimates. This reflects the different time periods, varying 
search strategies, and inclusion and exclusion criteria that have been used by 
authors of these meta-analyses, such that, even though they were looking at the 
same adverse effect, they used data from different studies in generating pooled 
overall estimates.  
 
There were three adverse effects that were evaluated in more than one review; 
venous thromboembolism (VTE), gastrointestinal complications, and stroke. There 
was some, but not complete overlap of primary studies in: four separate reviews of 
venous thromboembolism (VTE) with hormone replacement therapy (involving three 
overlapping case-control studies from total of 31 observational studies analysed);238, 
244, 252, 272 three reviews of venous thromboembolism (VTE) with oral contraceptives 
(one overlapping RCT, six of 14 cohort studies, and two of 24 case-control 
studies);241, 252, 260 three reviews of gastrointestinal complications with NSAIDs 
(involving six of 24 cohort studies and eight of 75 case-control studies);242, 256, 271 and 
two reviews of stroke with oral contraceptives (involving one of seven cohort 
studies, and nine of 30 case-control studies).246, 254 
 
For the sensitivity analysis, the older meta-analyses pertaining to venous 
thromboembolism (VTE), gastrointestinal complications and stroke were removed 
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so that the modest overlap could be further reduced, with only one review per 
specific adverse effect for the sensitivity analysis. The most recent meta-analyses 
for the RCTs comparisons with ‘observational’ studies (Canonico et al 2008 for 
venous thromboembolism (VTE) with hormone replacement therapy (HRT), 
Douketis et al 1997 for venous thromboembolism (VTE) with oral contraceptives) 
and for the comparisons of cohort and case-control studies (Agency for Healthcare 
Research and Quality 2002 for venous thromboembolism (VTE) with hormone 
replacement therapy (HRT), Bergendal et al 2009 for venous thromboembolism 
(VTE) with oral contraceptives, Henry et al 2003 for gastrointestinal complications 
with NSAIDs, and Chan et al 2004 for stroke with oral contraceptives) were used for 
analysis, yielding RORs that are very similar to the original estimates: 
 1.06 (95% CI 0.96-1.18) for the overall analysis of RCTs versus all 
observational studies 
 1.00 (95%CI 0.71-1.42) for RCTs versus case control studies 
 1.07 (95% CI 0.86-1.34) for RCTs versus cohort studies 
 0.94 (95% CI 0.87-1.02) for cohort versus case-control studies  
 
4.3.7 Funnel plots 
4.3.7.1 RCTs versus all observational studies 
In Figure 4.4 the magnitude of discrepancy in the RORs from each meta-analysis 
that compared RCTs with observational studies (cohort studies, case-control studies 
or studies grouped under the umbrella term ‘observational studies) was plotted 
against the precision of its estimates (1/SE). Values on the x-axis show the 
magnitude of discrepancy, with the central Ln ROR of zero indicating no 
discrepancy or complete agreement between the pooled odds ratio estimated from 
RCTs and observational studies. The y-axis illustrates the precision of the 
estimates, with the data points at the top end having greater precision. This 
symmetrical distribution of the RORs of the various meta-analyses around the 
central Ln ROR value of zero illustrates that random variation may be an important 
factor accounting for discrepant findings between meta-analyses of RCTs as 
compared to observational studies. If there had been any systematic and consistent 
bias that drove the results in a particular direction for certain study designs, the plot 
of RORs would likely be asymmetrical. The vertically tapering shape of the funnel 
also suggests that the discrepancies between RCTs and observational studies are 
less apparent when the estimates have greater precision. This may support the 
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need for larger studies to assess adverse effects, be they RCTs or observational 
studies. 
Figure 4.4 Funnel plot: Discrepancy between RCTs and observational studies 
in relation to precision of estimates 
 
 
The forest plot in Figure 4.3 of RCTs and observational studies also demonstrates 
that there is no consistent systematic variation in pooled risk estimates of adverse 
effects from RCTs compared to observational studies.  
 
4.3.7.2 Cohort studies versus case-control studies 
Visual inspection of the Funnel Plot (Figure 4.5) and the results from the Egger test 
(p=0.02) suggests that there is an asymmetrical distribution of the discrepancy 
between cohort studies and case-control studies and that this asymmetry is 
statistically significant. There seem to be fewer instances where the meta-analyses 
of case-control studies gave lower estimates of harm and a relative predominance 
of studies on the left side of the plot showing that case-control studies frequently 
tended to give higher estimates of risk than those from cohort studies. The shape of 
this funnel plot would be consistent with the overall ROR estimate (0.94 (95% CI 
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0.87-1.01) described in Table 4.3 and Appendix B: Figure 15.4. In studies with 
greater precision at the top of the funnel plot, there did not appear to be as much 
discrepancy between study designs. Again, this may support the view that larger 
studies are needed to assess adverse effects. 
 
Figure 4.5 Funnel plot: Discrepancy between cohort studies and case-control 
studies in relation to precision of estimates 
 
 
 Discussion 4.4
Most of the pooled results from the different study designs concurred in terms of 
identifying a significant increase or decrease, or no significant difference in risk of 
adverse effects. On the occasions where a discrepancy was found, the difference 
usually arose from a finding of no significant risk of adverse effects with one study 
design, in contrast to a significant risk of adverse effects from the other study 
design. This may reflect the limited size of the included studies to identify significant 
differences in rare adverse effects. 
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These analyses found little evidence of systematic differences in adverse effect 
estimates obtained from meta-analysis of RCTs and observational studies. The 
RORs did not suggest any consistent differences from meta-analysis of RCTs and 
observational studies. This interpretation is supported by the funnel plot, which 
shows that differences between the results of different study designs are equally 
distributed across the range. Some discrepancies may arise by chance, or through 
lack of precision from limited sample size for detecting rare adverse effects. The 
funnel plot shows that discrepancies may arise not just from differences in study 
design or systematic bias, but possibly because of the random variation, fluctuations 
or noise, and imprecision in attempting to derive estimates of rare events. There 
was less discrepancy between the study designs in meta-analyses that generated 
more precise estimates from larger studies, either because of better quality, or 
because the populations are more similar (perhaps because large RCTs capture a 
broad population similar to observational studies). Indeed, the adverse effects with 
discrepant results between different study designs were distributed symmetrically to 
the right and left of the line of no difference, meaning that RCTs and observational 
studies do not consistently over or under-estimate risk of harm as compared to 
another. It is likely that differences are attributable to other important factors, such 
as population and delivery of intervention. While there are a few instances of 
sizeable discrepancies, the pooled estimates indicate that overall (particularly where 
larger, more precise primary studies are available), meta-analysis of RCTs should 
yield adverse effects estimates that broadly match meta-analysis of observational 
studies. 
 
Different types of observational studies may not obtain similar results. It was found 
that on average, meta-analysis of case-control studies tended to give slightly higher 
estimates of harm as compared to cohort studies. This finding was reflected in the 
asymmetrical shape of the funnel plot, showing that the direction of the 
discrepancies (as estimated by the RORs) was more frequently due to relatively 
higher estimates of harm from case-control studies than cohort studies. 
Alternatively, this could be interpreted as cohort studies being more susceptible to 
underestimating the extent of harm. 
 
Although reasons for the few apparent discrepancies are unclear, specific factors 
that may have led to differences in adverse effects were discussed by the 
respective authors. The differences between observational studies and RCTs in 
McGettigan and Henry 2008’s meta-analysis of cardiovascular risk were thought to 
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be attributable to different dosages of the anti-inflammatory drugs used.269 
Differences in Papanikolaou et al 2006136 and Col et al 2005249 were attributed to 
differences in exact definitions and study populations. The major discrepancy 
identified in Col et al 2005 on HRT and breast cancer is already well documented.77, 
98, 138, 177, 229-233 This discrepancy has also been explained by the timing of the start of 
treatment relative to menopause which was different between trials and 
observational studies. After adjustment, it has been found that the results from the 
different study designs no longer differ.350, 351 Other methodological evaluations 
suggested that the nature of the study designs themselves were a factor that may 
have led to differences in estimates. For example, some stated that RCTs may 
record a higher incidence of adverse effects due to closer monitoring of patients, 
more sensitive and aggressive detection methods270 and more thorough recording, 
resulting from regulatory requirements.136, 271 Where RCTs had a lower incidence, it 
was suggested that this could be attributed to the exclusion of high-risk patients249, 
270 and possibly linked to support by manufacturers.136  
 
Other well-known biases were discussed by the authors in relation to case-control 
studies. For instance it was suggested that case-control studies might overestimate 
risk because a more vigorous search for a drug history is likely in cases than 
controls (recall bias)251 and doctors may be more likely to undertake diagnostic 
investigations in patients taking medications (diagnostic suspicion bias).246 Lower 
estimates of risk in observational studies were often attributed to a healthy cohort 
bias,183, 243, 249 the use of prescription drug databases with the limitation of leaving 
out over the counter drugs such as aspirin,242, 277 and publication bias.271, 346 
 
An explanation for the tendency towards slightly higher estimates of harm from 
case-control studies than cohort studies in this research is difficult to ascertain. 
However, there are a number of possible reasons. Firstly, this could be a spurious 
result as the values for the ROR do not reach statistical significance. Nevertheless, 
the asymmetrical funnel plot does demonstrate a fairly consistent discrepancy 
between cohort studies compared to case-control studies. One important factor here 
may be the greater statistical power of case-control studies to detect small, but 
significant risk of harm from rare adverse events. Another reason could be related to 
differences in susceptibility to bias amongst study designs, where bias in case-
control studies may arise if cases and controls do not have equal opportunity for 
past exposure (or if there is bias in ascertaining exposure).251 Nevertheless, case-
control studies based on pharmacoepidemiological databases with pharmacy and 
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medical record linkage may not be susceptible to such recall bias. Conversely, bias 
in cohort studies can develop if the exposed and unexposed groups do not have 
equal opportunity for the adverse event happening (or being measured) and doctors 
may be more likely to undertake diagnostic investigations or recommend more 
frequent follow-up in patients taking certain types of medications.246 
 
Equally, discrepancies between study designs could have stemmed from 
confounding, as a result of variation in characteristics of participants, timing and site 
of study, and definitions of exposure and outcomes. For instance, if one set of 
studies is carried out on a younger cohort of patients, with a lower drug dosage or 
with shorter duration of use, or is reliant on passively ascertaining adverse effects 
data,136, 146, 178, 296 it might be expected that the magnitude of any adverse effects 
recorded would be lower. Nevertheless, the asymmetrical pattern of the funnel plot 
would tend to suggest a more systematic cause of discrepancy between study 
designs, rather than just chance variation in participants and definitions of exposure 
and outcome. The design of case-control studies may involve a greater extent of 
selection of risk factors for analysis and reporting, and significant findings may be 
more likely to be selectively published (and thus subsequently included in 
systematic reviews). 
 
Finally, differences in observed and unobserved patient characteristics may have 
accounted for discrepancies between designs. The extent of statistical adjustment 
for potential confounders in observational studies is somewhat dependent on the 
variables measured in the primary dataset. Given the different starting points in data 
collection between case-control and cohort studies, the effect of unmeasured 
confounders may afflict either design to dissimilar extents. 
 
 Limitations 4.5
This systematic review of meta-analyses and methodological evaluations has a 
number of limitations. When comparing the pooled results from different study 
designs it is important to consider any confounding factors that may account for any 
differences identified. However, most of the methodological evaluations were not 
conducted with the primary aim of assessing differences in study design but were 
systematic reviews with some secondary comparative evaluation of study design 
embedded within them. It is not surprising, therefore, that many did not consider 
confounding factors. In many instances, it may also not have been possible to 
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control for numerous potential confounding factors as the primary studies may not 
have contained the required information. The small number of studies included 
(sometimes as low as one) may have not enabled statistical analysis such as meta-
regression to be undertaken.  
 
Another limitation of this overview is that it was constrained by information 
contained in the included evaluations, as it was not feasible to source and evaluate 
the thousands of primary studies contained in the meta-analyses. In each instance, 
the author’s categorisation of the study design was used. However, the authors may 
not all have used the same definitions for each study design. This is a particular 
problem with the observational studies, where it is often difficult to decipher the 
methodology used in the primary study and categorise it appropriately. However, it 
was noted that most of the included reviews had passed DARE criteria or were from 
peer-reviewed sources i.e. both the primary study and systematic review had 
undergone peer review. Moreover, any misclassification is likely to be non-
differential in impact, which should not lead to elevated risk estimates from any 
particular study designs. As an added precaution to help overcome this limitation, 
an analysis was carried out of RCTs compared to all ‘observational’ studies (either 
cohort studies, case-control studies or ‘observational’ studies), with a subgroup 
analysis based on different types of observational designs. 
 
Another important limitation to this review is the potentially unrepresentative sample 
used. Systematic reviews with embedded data comparing different study designs 
may have been missed. The search strategy used was limited to a literature search 
to identify methodological papers whose primary aim was to assess the influence of 
study design on adverse effects and to a sift of systematic reviews of adverse 
effects (as a primary outcome) from the Cochrane Database of Systematic Reviews 
(CDSR) and Database of Abstracts of Reviews of Effects (DARE). Nevertheless, it 
should be noted that the CDSR and DARE databases cover a large proportion of all 
systematic reviews and that systematic reviews in which adverse effects are 
included as a secondary aim are unlikely to present subgroup analysis by study 
design for the adverse effects data. 
 
There was considerable heterogeneity between the comparisons of different 
studies, suggesting that any differences may be specific to particular types of 
interventions or adverse effects. It may be that particular types of adverse effects 
can be identified more easily via particular types of study designs.2, 14, 73, 115 
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However, it was difficult to assess the methodological evaluations by type of 
adverse effects. This would be of interest, given that the literature suggests that 
RCTs may be better at identifying some types of adverse effects (such as common, 
anticipated and short-term) more effectively than observational studies.  
 
 Conclusions 4.6
These findings have important implications for the conduct of systematic reviews of 
harm, particularly with regards to selection of a broad range of relevant studies. 
Although there are strengths and weaknesses to each study design, empirical 
evidence from this overview indicates that there is, on average, no difference 
between estimates on the risk of adverse effects from meta-analyses of RCTs and 
other study designs and slight differences (on average) between estimates on the 
risk of adverse effects obtained from meta-analyses of cohort and case-control 
studies. The differences between study designs are most apparent when the meta-
analysis only has a few studies, suggesting that we should be particularly cautious 
in trusting single studies of rare harms. Instead of restricting the analysis to RCTs or 
certain study designs (which might lead to a potentially one-sided view), it might be 
preferable for systematic reviewers of adverse effects to evaluate a broad range of 
studies that could help build a complete picture of any potential harm and improve 
the generalisability of the review without loss of validity. 
 
 Summary 4.7
This review explores the concordance between estimates of the risk of adverse 
effects from different study designs. 
51 meta-analyses or methodological evaluations were included. 
Overall meta-analyses of RCTs tend to agree with meta-analyses of observational 
studies. However, there is a tendency for meta-analyses of case-control studies to 
give slightly higher estimates of harm compared to meta-analyses of cohort studies. 
  
 84 
Chapter 5 Section B of the methodological overview: sources of 
information on adverse effects 
  Introduction 5.1
One aim of the systematic review process is to identify as many relevant studies 
addressing the question posed as possible. This process usually entails searching a 
range of different data sources, of which the selection is an important consideration 
for any systematic reviewer. The sources searched are likely to influence the 
amount and type of data retrieved.14  
 
There are many potentially useful sources for information on adverse effects. In 
addition to those traditionally searched for effectiveness data, information on 
adverse effects can be identified from: specialist journals; bulletins and databases; 
drug monographs or summaries; trial registries; spontaneous reporting 
systems/post-marketing surveillance systems; or prescription-event monitoring 
(PEM) data. A summary of the types of sources for information on adverse effects 
with selected examples is contained in Appendix B: Table 15.3. 
 
Despite the large number of potentially useful sources for information on adverse 
effects, a recent survey showed that most systematic reviews of adverse effects rely 
only on MEDLINE.110, 352 This is probably due to familiarity, widespread availability, 
and a lack of knowledge of other sources. However, MEDLINE is unlikely to be the 
most definitive source of information on adverse effects.31, 353 
 
Although MEDLINE may not be the most comprehensive source of information on 
adverse effects it is not known which data sources are most fruitful. A comparative 
evaluation of the different sources of information in identifying adverse effect data 
would, therefore, be useful for authors of systematic reviews. This chapter aims to 
systematically review existing methodological research studies that have 
investigated the impact of using different sources to identify information on adverse 
effects of healthcare interventions. 
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 Methods 5.2
5.2.1 Inclusion criteria 
A research study was considered eligible for inclusion if it compared the 
effectiveness of two or more data sources in identifying information on adverse 
effects of a healthcare intervention.  
 
5.2.2 Data extraction 
Information was collected on: the intervention and adverse effects search for; the 
data sources evaluated; the outcome measures used to compare data sources; and 
the results. The primary outcome was measures of the contribution from the 
sources tested, such as the number of relevant references retrieved and overlap 
with other sources. Secondary outcome measures included the cost of searching 
the data sources and the ease with which the records were retrieved. 
 
5.2.3 Assessment of methodological quality  
The included studies were assessed using the following questions: 
1. Generalisability: Did the search queries cover a range of interventions and 
adverse effects? Was a large enough sample of relevant references used to 
compare the sources of information to make inferences about the results? 
(evaluated using 95% confidence intervals) 
2. Database overlap: Were the number of unique relevant references and the 
total number of relevant references recorded for each data source? 
3. Limitations of the search strategies: Were any of the limitations of the search 
strategies used to identify the relevant references taken into consideration? 
For example, relevant references may have been available on a particular 
database but limitations of the search strategy meant these references were 
not retrieved 
4. Comparative outcomes: Were adequate comparisons made between the 
included sources of information?  
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5.2.4 Analysis 
It was envisaged that the nature of the outcomes used here would not enable any 
formal statistical analysis to be carried out, although, the rank orders of the sources 
from the different studies were compared where possible. 
 
 Results 5.3
5.3.1 Included studies  
Nineteen methodological evaluations met the inclusion criteria for this review 
(Appendix B: Table 15.4).354-372 Seventeen of the methodological evaluations were 
published as full papers354, 356-361, 363-372 and two were presentations.355, 362  
 
5.3.1.1 Search strategies 
The majority of the methodological evaluations (11/19) included more than one 
search for adverse effects data.354, 356-358, 361, 364, 367, 369-372 Ninety-four separate 
searches were conducted for information on adverse effects, though four 
methodological evaluations (representing 36 searches) did not present the results of 
each search separately.356-358, 372 In order to be able to compare the results of all 19 
methodological evaluations, the combined results of the searches within each 
methodological evaluation were used wherever possible. In two instances, 
combining the results within a methodological evaluation was deemed 
inappropriate. One methodological evaluation contained searches for two different 
types of intervention - tooth extraction and a drug intervention - succinlycholine371 
and another included searches of different data sources.369  
 
5.3.1.2 Types of interventions 
Most of the methodological evaluations (16/19, 84%) included searches for named 
drug interventions.354-362, 364-366, 368-371 Three methodological evaluations searched for 
natural products, such as herbal medicines363, 372 or aromatherapy,367 and one 
methodological evaluation included a search on tooth extraction (in addition to 
searches for a drug intervention).371  
  
 87 
5.3.1.3 Types of adverse effects 
Twelve methodological evaluations included searches for a wide range of adverse 
effects.354, 355, 357, 360, 362, 364, 366-370, 372 Five methodological evaluations included 
searches for either named adverse effects,359, 361, 365, 369, 371 such as pancreatitis,365 
hepatitis,369 or hypoglycaemic coma,361 or a group of adverse effects, such as 
gastrointestinal side effects,359 or effects on the heart.371 The other methodological 
evaluations did not specify the adverse effects included.356, 358, 363  
 
5.3.1.4 Data sources included 
The total number of data sources used to identify information on adverse effects 
was 61 (Table 5.1). The majority of the sources evaluated were bibliographic 
databases (25) or textbooks/drug monographs (17). The number of sources 
compared in each methodological evaluation varied widely between two and 24. 
 
5.3.2 Excluded studies 
Thirty-seven studies were excluded from this review (Appendix B: Table 15.5).373-409 
Eighteen compared data sources for drug information, such as drug interactions or 
chemical toxicology, but did not include adverse effects,374, 377-381, 385, 386, 390, 393, 400, 401, 
403, 405-409 eight included comparisons of sources of drug information, including 
adverse drug reactions, but did not present the results for identifying the information 
on adverse drug reactions separately.373, 375, 376, 388, 389, 395, 399, 402 Eight were 
descriptive studies which contained no formal comparative evaluation of the source 
or sources discussed,382, 383, 387, 392, 394, 397, 398, 404 two studies were conference 
abstracts with insufficient information to assess whether they met the inclusion 
criteria,391, 396 and one study included only consumer health information sources.384 
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Table 5.1 Sources compared in the 19 included methodological evaluations 
 
Source Number of Methodological 
Evaluations 
Internet Search Engines 
AltaVista  1 
Full-text Databases  
Iowa Drug Information Service (IDIS)  5 
Bibliographic Databases  
Adverse effects databases 
SEDBASE: Side Effects of Drugs* 1 
TOXLINE (Toxicology Literature Online) 4 
Pharmaceutical databases 
ADIS Inpharma 1 
ADIS LMS Drug Alerts Online/ADIS 2 
De Haen’s Drugs in Research* 1 
De Haen’s Drugs in Use* 3 
Derwent Drug File (previously RingDoc) 4 
International Pharmaceutical Abstracts (IPA) 6 
Pharma marketing  1 
Pharmline 2 
Generic databases 
BIOSIS Previews 3 
CAB HEALTH 1 
CINAHL 1 
Core MEDLINE 1 
EMBASE 9 
ExtraMED  1 
Health Reference Center (includes some full-text)  1 
JICST-EPlus  1 
MEDLINE 12 
Mental Health Abstracts 1 
National Technology Information Service (NTIS) 1 
PASCAL 3 
PsycINFO 1 
Science Citation Index (SCI) 1 
Uncover  1 
Conference Databases 
British Library Inside Conferences  1 
Conference Papers Index (CPI)  1 
Referenced Summary Databases 
AltMedDex  1  
Drug Information Fulltext  1 
RUGDEX  1 
Lexi-Comp Database  3 
Micromedex  3 
Micromedex Computerized Clinical Information 
Service (CCIS)  
1 
Natural Standard  1 
Spontaneous Reporting Systems/Post-marketing Monitoring Data  
Internet 
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Table 5.1 Sources compared in the 19 included methodological evaluations 
 
Source Number of Methodological 
Evaluations 
Food and Drug Administration (FDA) website 1 
Original Texts  
Bulletins/Newsletters  
Clin Alert  1 
Reactions  1 
Journals  
Handsearching  1 
Textbooks/Monograph Collections 
Clinical Pharmacology  2 
Epocrates Online Free 1 
Epocrates Online Premium  1 
Facts and Comparisons  2 
Martindale The Extra Pharmacopoeia  1 
Meyler’s Side Effects of Drugs  1 
Physician’s Desk Reference (PDR) 1 
Physician’s GenRx  1 
RxList.com  1 
Side Effects of Drugs Annuals (SEDA) 1 
Textbook of Adverse Reactions  1 
Specialist Textbooks (electronic or paper) 
Natural Medicines Comprehensive Database  2 
Physicians’ Desk Reference for Herbal Medicines  1 
The Complete German Commission E Monograph  1 
The Lawrence Review of Natural Products  2 
The Natural Pharmacist  1 
Tyler’s Honest Herbal  1 
Other Sources of Published and Unpublished Information  
Authors/Experts 1 
Industry  
Industry Submissions  3 
In-house database  1 
Reference Checking 1 
 
Key * - database now closed 
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5.3.1 Summary of methodological quality 
The methodological quality of the individual studies is summarized in Appendix B: 
Table 15.4. 
1. Generalisability 
The generalisability of many of the methodological evaluations was limited by the 
low number of relevant references studied and in some cases the limits on the type 
of interventions and adverse effects included. 
2. Database overlap 
Whilst most methodological evaluations compared data sources by the number of 
relevant references retrieved, only four fully described both the total number of 
relevant references and the unique relevant references,359-361, 370 and five partially 
took account of total and unique relevant references.357, 364, 366, 368, 371 This creates 
difficulty with the assessment of the overlap between sources and the value of their 
combinations. 
3. Limitations of the search strategies 
The majority of the studies did not take into account any limitations of the search 
strategies used to identify the relevant references. However, the precision of 
searches could be calculated for three methodological evaluations.357, 370, 371 The 
precision in these studies was relatively high, suggesting that focused searches 
were undertaken. Three methodological evaluations359, 360, 371 recorded the number 
of relevant references available in each database that were not retrieved by 
searching. The types of search strategies used varied considerably, as in some 
studies they were designed as part of a systematic review (using broad searches to 
maximise sensitivity) and in other methodological evaluations they were designed to 
answer specific questions and a more focused approach was adopted. 
4. Comparative outcomes 
Twelve methodological evaluations compared data sources by the number of 
relevant references. The other evaluations compared the number of case reports of 
adverse events,365 the unique relevant publications,366 or gave scores to the sources 
of information for ability to answer specific queries on adverse effects.356, 358, 362, 363, 
372  
 
The search functionality and cost of searching the databases was rarely considered. 
However, three methodological evaluations356, 357, 369 mentioned cost implications, 
with one carrying out a cost analysis.357 Three methodological evaluations recorded 
a score for the ease of use356, 358, 362 and two recorded the time spent searching.362, 
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369 Results of these cost and ease of use elements will now be outdated as the cost 
and search interfaces for data sources change rapidly over time. 
 
5.3.2 Database comparisons 
5.3.2.1 MEDLINE 
In four of the 12 methodological evaluations355, 357, 359-361, 364-368, 370, 371 that included 
searches of MEDLINE, MEDLINE provided the highest number of relevant records. 
However, these evaluations either compared MEDLINE with International 
Pharmaceutical Abstracts (IPA) database only,359 compared MEDLINE together with 
PASCAL against reference books,361 or searched for non-pharmaceutical drugs.367, 
371 
 
The sources which retrieved more relevant references than MEDLINE were 
EMBASE (eight out of nine methodological evaluations),355, 357, 360, 364, 366-368, 370, 371 
Derwent Drug File (previously RingDoc) (three out of four methodological 
evaluations),355, 366, 368, 370 TOXLINE (one out of four methodological evaluations),355, 
357, 360, 364 an internal database (one out of one methodological evaluation),366 or 
industry submissions (one out of three methodological evaluations).355, 360, 365 
 
5.3.2.2 EMBASE 
Nine methodological evaluations (representing 10 case study searches) included 
EMBASE in their assessment,355, 357, 360, 364, 366-368, 370, 371 and in eight of these 
searching EMBASE retrieved more relevant references than searching 
MEDLINE.355, 357, 360, 364, 366, 368, 370, 371 In five methodological evaluations searching 
EMBASE retrieved the highest number of relevant references.355, 357, 360, 364, 371  
 
The only databases which retrieved more relevant references than EMBASE in any 
search were Derwent Drug File (three out of four methodological evaluations),366, 368, 
370 MEDLINE (two out of nine methodological evaluations both of non-
pharmaceutical drugs),367, 371 and an in-house company database (one of one 
methodological evaluations).366 
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5.3.2.3 International Pharmaceutical Abstracts (IPA) 
Six evaluations included International Pharmaceutical Abstracts (IPA),354, 355, 357, 359, 
367, 369 and in all but one369 IPA retrieved either the lowest or joint lowest number of 
relevant records.  
 
5.3.2.4 Iowa Drug Information Service (IDIS) 
Five methodological evaluations included searches of Iowa Drug Information 
Service (IDIS).354, 355, 357, 364, 369 In the three methodological evaluations that also 
included MEDLINE, EMBASE and TOXLINE – these databases retrieved more 
relevant references than IDIS. In three of the four methodological evaluations that 
compared IDIS with IPA, searching IDIS retrieved more relevant references than 
IPA.354, 355, 357, 369 
 
5.3.2.5 Derwent Drug File 
Three of the four methodological evaluations indicated Derwent Drug File’s potential 
value over both EMBASE and MEDLINE.366, 368, 370 The other methodological 
evaluation only carried out a search on Derwent Drug File for effectiveness studies 
and may have missed relevant references on adverse effects.355  
 
In two of the four methodological evaluations that included searches of Derwent 
Drug File, Derwent Drug File retrieved the highest number of relevant references.368, 
370 In the other two methodological evaluations, one found that searching an in-
house company database retrieved more references than Derwent Drug File,366 and 
in another the searches on Derwent Drug File were for effectiveness studies only 
and not specifically for adverse effects data.355  
 
5.3.2.6 TOXLINE 
TOXLINE did not retrieve the highest number of relevant references in any of the 
methodological evaluations. However, in all searches TOXLINE provided at least 
one relevant reference and in at least two searches provided more relevant 
references than IDIS, PHARMLINE, PASCAL and IPA.  
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Although TOXLINE retrieved more relevant references than MEDLINE in one 
methodological evaluation,357 this was not the case in the three other 
methodological evaluations, which included both MEDLINE and TOXLINE.355, 360, 364  
 
5.3.2.7 BIOSIS Previews 
In the three methodological evaluations that included BIOSIS Previews, it was found 
that MEDLINE and EMBASE retrieved more relevant records than BIOSIS 
Previews.355, 357, 370 However, BIOSIS Previews retrieved more relevant records than 
IDIS, IPA, PASCAL and PHARMLINE in the two methodological evaluations that 
also searched these databases.355, 357 
 
5.3.2.8 Other databases 
Many of the databases were only searched in one or two methodological 
evaluations making any comparison between studies difficult. However, it is notable 
that these databases did not tend to retrieve a high number of relevant references, 
with the exception of an in-house industry database.366 
 
5.3.2.9 Unique references 
Seven methodological evaluations357, 359-361, 366, 370, 371 recorded the number of unique 
relevant references from each data source for at least one search. However, all the 
databases within these evaluations produced unique records and there was little 
change in the comparative value of different databases when unique references 
were considered. 
5.3.3  
5.3.4 Comparisons of non-database sources 
The majority of the methodological evaluations focused on bibliographic databases 
as sources of information. Other sources reviewed were: drug monographs from key 
textbooks (print and electronic); industry submissions; Internet sites (AltaVista, 
Health Reference Centre and Uncover); bulletins; reference checking; 
handsearching; personal communication; the Food and Drug Administration (FDA) 
website; and an in-house company database. All these sources retrieved relevant 
references, except for the website - Health Reference Centre,367 and the tertiary 
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sources Physician’s Desk Reference for Herbal Medicines and Tyler’s Honest 
Herbal.372  
5.3.4.1 Data from industry 
The four methodological evaluations which included industry submissions or a 
company database also demonstrated the value of their inclusion. In two 
methodological evaluations, industry data retrieved the greatest number of adverse 
effects365 or references on adverse effects.366 In one methodological evaluation all of 
the data from industry were unique,360 and in the other methodological evaluation 
industry submissions only retrieved less relevant records than MEDLINE and 
EMBASE out of the 23 sources evaluated.355 
 
5.3.4.2 Micromedex versus Lexi-comp 
Few of the non-database resources were included in more than one methodological 
evaluation and in some circumstances the numbers of relevant references or case 
reports retrieved were not recorded. This was particularly the case when drug 
monographs were evaluated. These sources tend to provide summary information 
and were more likely to be given a ‘score’ (such as on a scale of A to D or a points 
scale) or assessed in terms of answering specific questions regarding adverse drug 
reactions.356, 358, 362, 363, 372 Although the overlap between sources included in the 
methodological evaluations was generally low, three methodological evaluations 
included both Micromedex and Lexi-comp and in each evaluation Micromedex 
scored higher than Lexi-comp.356, 358, 362 
 
5.3.5 Comparisons of the data retrieved 
As well as measuring the number of relevant references retrieved, other attributes of 
the references are important in terms of their impact on the identification and 
quantification of adverse effects. One methodological evaluation compared the 
number of different adverse effects identified from the included databases and the 
number of relevant references retrieved with an abstract.368 However, this did not 
substantially alter the results. 
 
One methodological evaluation366 found that although a search of an in-house 
company database retrieved the most number of records, the majority of these were 
conference abstracts and that unique records identified in EMBASE tended to be 
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from non-English language sources. Conference abstracts often do not contain 
enough information to be included in a systematic review and non-English studies 
may be difficult or costly to translate. 
 
 Discussion 5.4
The lack of consistency of outcome measures and the use of different information 
sources in each methodological evaluation makes direct comparisons difficult. 
Some patterns in retrieval from the different sources did emerge, such as the 
relative value of EMBASE for adverse drug reactions and the potential value of 
Derwent Drug File over either MEDLINE or EMBASE. 
 
It is not that surprising that searches in EMBASE tended to retrieve more relevant 
references for adverse drug reactions than MEDLINE, as EMBASE is a large 
pharmacological and biomedical bibliographic database renowned for its drug-
related literature. However, it would be interesting to assess the value of this 
database and others in retrieving non-drug related adverse effects, especially as the 
only methodological evaluations to include non-pharmaceutical interventions found 
that MEDLINE retrieved more relevant references than EMBASE.367, 371 
 
The relative value of Derwent Drug File over EMBASE and MEDLINE merits further 
analysis. Derwent Drug File covers aspects of drug development, synthesis, 
evaluation, manufacture, and use, including adverse effects. The one 
methodological evaluation that did not identify more records on Derwent Drug File 
than on MEDLINE and EMBASE only searched Derwent Drug File for effectiveness 
data, despite searching MEDLINE and EMBASE for both effectiveness data and 
adverse effects data.355 Of the three methodological evaluations which indicated 
that searching Derwent Drug File retrieves more relevant records than other 
sources, one was produced by the providers of Derwent Drug File,368 one only 
recorded unique records,366 and two are over 15 years old.366, 370 
 
 Limitations 5.5
A major limitation of this review is the dearth of recent research identified in this 
area. This review did not incorporate a cut-off date, although it is realised that any 
papers regarding the value of different sources of information (such as databases) 
will quickly become out dated as electronic and paper sources are susceptible to 
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content change, closure/out-of-print, or the emergence of new information sources. 
For instance, the size of electronic databases (including the number and range of 
journals indexed) has increased dramatically since many of these methodological 
evaluations were published. 
 
There are many other potentially useful sources of data not covered in these 
studies, particularly, Science Citation Index (SCI), database gateways (such as 
TOXICOLOGY http://library.dialog.com/bluesheets/html/bloT.html which searches 
40 different databases), sources of conference proceedings, sources of post-
marketing surveillance data (such as Vigibase),410 industry clinical trial registries, 
specialist bulletins, textbooks and journals, discussion web sites,397, 411, 412 
contacting authors and citation searching. Nevertheless, review authors have 
highlighted concerns with the heterogeneous nature of information from Vigibase 
(the database of individual reports collected by the WHO Uppsala Monitoring 
Centre) as data are collected from many different National Centres with different 
criteria for reporting and acceptance. More recent studies have also identified 
problems with textbooks - for instance, only half of newly discovered adverse effects 
are documented in The Physicians' Desk Reference.86 Variation in drug information 
from tertiary sources, such as reference books, has also been recorded405 and 
many textbooks do not describe their methods for retrieving data on adverse effects 
or do not purport to be systematic or comprehensive and have been criticized for 
delays in incorporating adverse effects.221  
 
Full-text searching was also rarely explored but may be useful for searching for 
adverse effects which are often addressed as secondary outcomes and not 
contained in the title, abstract or keywords of an article.  
 
Although one methodological evaluation indicated the value of searching 
AltaVista,367 other search engines such as Google or Google Scholar may be worth 
exploring. However, the majority of web pages (68%, 354/519) have been found to 
inadequately cover safety warnings,404 and any evaluation of Internet search 
engines is problematic due to the inconsistency of repeating searches on the 
Internet and the fast pace of change in Internet search engines.  
 
The majority of the methodological evaluations in this review used the number of 
relevant references from each database for comparison. However, this is not a 
sufficient criterion to evaluate the quality of a database. Other aspects such as 
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number of unique references, search interface, the size and accuracy of the 
database thesaurus, precision (or number needed to read (NNR)), overlap, updating 
time, cost of access, coverage (breadth of type of publications, years etc.), type of 
data retrieved, and the range and frequency of adverse effects information identified 
are also important. For instance, the completeness and currency of sources will 
affect their appropriateness for more recently developed healthcare interventions.  
 
An analysis of precision may prove particularly useful as an indicator of the relative 
value of searching EMBASE. This database is notorious for over-indexing, which 
can lead to an unmanageable number of records retrieved.413, 414 For instance, 
although searching EMBASE may retrieve the largest number of relevant records, it 
may also retrieve the most irrelevant records. 
 
An assessment of the use of different data sources for information on adverse 
effects is complicated by database search functionality, updating time, and the 
reporting and indexing of adverse effects in database records. For example, it is 
difficult to standardise search strategies on all databases studied in a comparative 
analysis, as different keywords/indexing are used in each database. In addition, a 
database may cover a large proportion of the relevant literature on adverse effects, 
yet if this literature cannot be easily retrieved than the database may be of limited 
value. For example, Derry et al 2001 demonstrated that even searches of both 
MEDLINE and EMBASE could not feasibly retrieve all those RCTs on adverse 
effects contained in these databases due to a lack of appropriate terms in the title, 
abstract or indexing.118 Only 66 of 107 RCTs which reported on adverse effects 
mentioned this in the title or abstract.118 It has been suggested that the indexing 
problems found by Derry et al 2001 in RCTs in MEDLINE and EMBASE may also 
extend to non-randomised studies.15 
 
Furthermore, when conducting literature searches the resource implications may 
need to be balanced against the potential yield of relevant information. This is 
particularly true when searching for adverse effects where data may be sparse and 
of limited quality and firm conclusions are difficult to reach. Comparing the cost of 
searching different data sources is difficult. One study compared the cost from 
different online databases of retrieving one relevant reference.357 However, this 
study is relatively old and in recent years there has been a decline in users of online 
dial-up databases (such as those provided by DIALOG, Datastar or STN) and a 
sharp increase in users of databases through the Internet either freely or via 
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subscriptions. Other methodological evaluations simply listed subscription rates for 
the electronic information resources included.356, 369 However, subscription rates 
vary depending on provider (e.g. OVID, EBSCO), licensing agreements (e.g. large 
site license), type of access (e.g. concurrent users), type of institution (e.g. private 
sector, charity), and format of access (e.g. CD-ROM, network) and are difficult to 
compare. 
 
 Conclusions 5.6
This review suggests that EMBASE, Derwent Drug File, MEDLINE and industry 
submissions may potentially provide the greatest number of relevant references for 
adverse effects information and that a range of sources may be useful in conducting 
a thorough search for information on adverse effects. 
 
However, many of the methodological evaluations included in this review are over 
10 years old and/or include a small set of relevant references for comparison with 
little consideration of the effectiveness of the search strategies used. A systematic 
evaluation of the value of an extensive range of different sources using a number of 
outcome measures with a large reference set of records is urgently required in order 
to provide guidance on the current sources available for information on adverse 
effects.  
 
 Summary 5.7
This review explores the relative contribution of different sources of information on 
adverse effects using 19 methodological evaluations. 
Unfortunately many evaluations are outdated but evidence indicates that EMBASE, 
Derwent Drug File and industry data may be particularly valuable for adverse drug 
reactions. Although MEDLINE is also useful it rarely contributed the most number of 
relevant references. 
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Chapter 6 Section C of the methodological overview: database 
search strategies for information on adverse effects 
 Introduction 6.1
To identify as complete and unbiased a set of studies as possible and to strengthen 
the validity of the results of a systematic review, a methodical, reproducible, and 
thorough search for relevant research evidence is required.22, 23, 415 Electronic 
bibliographic databases are the most commonly used source of information 
searched for systematic reviews of either effectiveness or adverse effects as they 
are a relatively efficient and accessible source of healthcare literature.22, 23 
 
Searching bibliographic databases can be a difficult and time-consuming process 
and usually requires the skills of an information specialist or experienced 
searcher.416-418 In order to search a database, a combination of text words (words in 
the title or abstract) and/or indexing terms (keywords assigned to bibliographic 
references) are usually selected. The choice of text words and indexing terms and 
how they are combined will affect the studies retrieved. The combined set of terms 
used in database searching is known as a search strategy. Search strategies need 
to be devised which balance sensitivity (the ability to identify as many relevant 
articles as possible) with precision (the ability to exclude as many irrelevant articles 
as possible). There is often a marked trade-off between sensitivity and precision, 
and a compromise between the two is needed. Although it is important not to miss 
relevant studies, retrieving a large number of irrelevant records is likely to increase 
the overall time and cost of doing a systematic review.419, 420 
 
In recent years, research has been undertaken to improve search strategies to 
retrieve particular types of information, for example, to retrieve specified study 
designs (such as RCTs), or subject areas (such as public health), or specific 
populations (such as the elderly).421 This research has led to the development of 
predefined search strategies, known as search filters or search hedges.125, 421-423 A 
search filter is a predefined combination of search terms designed to retrieve 
information on a particular topic. The filter may be created and evaluated in various 
ways. For example, search terms in a filter may be subjectively derived by 
contacting experts in literature searching or the topic area. Alternatively, search 
terms may be objectively derived using word frequency analysis or statistical 
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analysis on a set of relevant records. The best combination of search terms can 
then be identified by running proposed search combinations and measuring how 
many relevant and irrelevant records are retrieved. Alternatively, word frequency or 
statistical analysis, such as logistic regression, can be used to suggest the best 
combination of search terms. Once a search filter has been developed, it may or 
may not then be tested against a different set of relevant records (a validation 
set).421  
 
Methodological search filters have been developed for various study designs and 
have proved to be particularly useful for identifying effectiveness studies.22, 23, 125, 126, 
421, 424 Within The Cochrane Collaboration, for example, a highly sensitive search 
strategy is widely used for identifying reports of RCTs and has recently been 
updated.22, 125 In PubMed the 'Clinical Queries' feature allows searchers to filter 
articles according to aetiology, diagnosis, prognosis, therapy or clinical prediction 
guides.425 These filters have been developed using objective statistical analysis at 
McMaster University423 and are revised periodically. 
 
Although systematic reviews incorporating adverse effects have become 
increasingly important, there is little guidance on what constitutes the best search 
strategy.116 The development of a search filter to identify information on adverse 
effects would be particularly useful given the problems of searching specifically for 
studies on adverse effects. This chapter aims to systematically review 
methodological studies that report on the development and evaluation of search 
filters to identify articles with information on adverse effects resulting from any 
healthcare intervention. 
 
 Methods 6.2
6.2.1 Inclusion criteria  
Methodological evaluations were considered eligible for inclusion in this review if 
one of the main objectives was the evaluation of a search filter or search filters that 
could be used for retrieving articles with adverse effects data of a healthcare 
intervention from an electronic database. To be eligible, these methodological 
evaluations were also required to give at least one measure of the performance of 
the filters, such as, sensitivity/recall (proportion of relevant articles retrieved by the 
filter), precision (the number of relevant articles divided by the total number of 
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studies retrieved with that filter), accuracy (proportion of all articles that are correctly 
classified by the filter), numbers needed to screen/read (the inverse of precision), or 
specificity (proportion of irrelevant articles that were not identified by the filter).  
 
6.2.2 Data extraction 
Information was extracted on the databases and interface for which the search filter 
was devised, the type of intervention(s), the type of adverse effect(s) and the 
methods used to create/test the search filter, such as the source and size of the 
reference set of relevant records and validation set of relevant records. In addition, 
the outcome measures were recorded. Primary outcomes of interest were measures 
of sensitivity/recall, precision, accuracy, numbers needed to screen/read or 
specificity. 
 
6.2.3 Assessment of methodological quality  
The methodological quality of the included studies was assessed using published 
criteria adapted specifically for this review.
426
 The included methodological 
evaluations were assessed using the following questions; 
1. Were the tested and recommended search strategies/search filters 
described in sufficient detail to allow reproducibility? (i.e. were the exact 
search terms with relevant truncation, field limits and combinations 
presented and the search interface stated). 
2. Were the tested search terms objectively derived? For example, by 
statistical analysis using word frequency counts comparing relevant and 
non-relevant records. 
3. Was an adequate reference set of relevant records obtained? For example, 
did the set of relevant records used to develop the search filters cover a 
range of interventions and adverse effects, and was the set of records 
obtained from a range of resources (such as databases and handsearching) 
or a broad enough search strategy to capture a relatively comprehensive set 
of relevant records. 
4. Did two or more researchers screen the retrieved records for relevant 
studies? 
5. Were clear inclusion criteria for the reference set given? (i.e., in particular 
were details presented on the types of outcomes (adverse effects) included 
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and any exclusion criteria that may have implications for the search strategy, 
such as study design). 
6. Were confidence intervals calculated for the performance estimates? 
Confidence intervals will enable the reader to assess the precise accuracy of 
the performance estimates, such as sensitivity and precision. 
7. Were the results tested on a validation set of relevant records? (i.e. was the 
performance of the developed search strategy/filter tested on a different set 
of relevant records from those used to derive the search filter). 
 
 Results 6.3
6.3.1 Included studies 
Three methodological evaluations met the inclusion criteria for this review (Appendix 
B: Table 15.6),121, 360, 427-430 two were published as full papers and one was a 
conference presentation.427, 428 Although this review was not limited by type of 
healthcare intervention all three methodological evaluations aimed to maximise the 
sensitivity of search strategies to identify papers on adverse effects of drug 
interventions. 
 
The methodological evaluation by Wieland et al 2005 evaluated search strategies 
for a named specific adverse effect (breast cancer with oral contraceptives),121, 429, 
430 whereas the other two methodological evaluations by Badgett et al 1999 and 
Golder et al 2006 aimed to develop search strategies to capture all adverse effects 
or all serious adverse effects for a particular class of drugs.360, 427, 428 All three 
methodological evaluations developed search strategies for use in MEDLINE and 
the methodological evaluation by Golder et al 2006 also included search strategies 
for use in EMBASE.360 
 
6.3.2 Excluded studies 
Seventeen studies were excluded from this review (Appendix B: Table 15.7). Eight 
contained no evaluation of the search strategies for adverse effects data that they 
proposed,431-439 three were designed to identify sensitive search strategies for 
causation or aetiological studies, which although they might include adverse effects 
papers would also include papers on genes and environmental exposures,440-442 two 
did not suggest any search filters but undertook co-word analysis (analysis of the 
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co-occurrence of words illustrated in a matrix),443, 444 three were in a non-English 
language,445-447 and one evaluated search strategies to retrieve systematic reviews 
of adverse effects, rather than primary data.448 
 
6.3.3 Summary of methodological quality 
The number of relevant records in the reference sets varied considerably (Appendix 
B: Table 15.8). The largest study was by Badgett et al 1999 and was based on 
several hundred records with a validation set of records. However, the precision of 
the searches could not be measured with this particular study design.427, 428 The 
other two studies by Golder et al 2006 and Wieland et al 2005 tested their search 
strategies on only 84 and 58 records relevant records,121, 360, 429, 430 and did not test 
the search strategies on a validation set of records (another set of relevant records) 
(Appendix B: Table 15.8Error! Reference source not found.).121, 360, 429, 430 
 
Although each methodological evaluation used a number of sources to identify its 
reference set of records, it is possible that the original search strategies (despite 
searching a range of sources) failed to retrieve a substantial number of relevant 
records. The original search strategies might then have biased the results obtained. 
For instance, if the reference set is obtained using the term ‘adverse’ (among 
others) then this term is more likely to retrieve articles in the reference set and so 
more likely to have a higher sensitivity when tested on that reference set. In this 
way, evaluation of search filters is often in danger of becoming self-fulfilling. In order 
to overcome the potential bias of search strategies, handsearching can be used to 
identify a relevant reference set.423 
 
Each methodological study was limited to a particular class of drugs, limiting the 
generalisability of their results. The derivation of search terms was not described in 
Badgett el al 1999,427, 428 whilst Golder et al 2006 and Wieland et al 2005 used 
either terms derived from relevant records from a systematic review or terms used 
in previous studies.121, 360, 429, 430 
 
Although none of the studies presented confidence intervals around their 
performance estimates, these could be calculated using the data reported 
(Appendix B: Table 15.6). 
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6.3.4 Comparison of recommended search strategies 
All three methodological evaluations were able to create highly sensitive search 
strategies that had between 97% and 100% sensitivity. However, the results of the 
two methodological evaluations that also measured precision indicate that this can 
only be achieved with very poor precision (between 0.9% and 2.8%).121, 360, 429, 430 
This low precision indicates that in order to retrieve one additional article on adverse 
effects, between 36 and 125 records will need to be screened, which may be 
potentially unmanageable, given that full-text checking is often necessary. 
 
The search strategy with the highest sensitivity in Wieland et al 2005121, 429, 430 did 
not contain any text words for the intervention (oral contraceptives) and relied only 
on the adverse effect terms (breast cancer). Searching with terms for this 
intervention would have missed nine of the relevant references, as these records 
did not contain any terms for oral contraceptives in the title, abstract or indexing, 
despite being in the full paper. However, as the authors acknowledge, any search 
strategy that excludes terms for the intervention is likely to lead to unmanageable 
numbers of records for reviewers to sift.  
 
The methodological evaluations by Badgett et al 1999427, 428 and Golder et al 2006360 
both indicate the value of using floating subheadings (subject headings not attached 
to any indexing terms) for highly sensitive searches in MEDLINE. Badgett et al 
1999427, 428 suggests the use of the subheadings ‘adverse effects’, ‘complications’, 
‘poisoning’ and ‘drug effects’, whereas Golder et al 2006360 recommend the use of 
‘adverse effects’, ‘complications’, and ‘drug effects’.  
 
Golder et al 2006360 was the only methodological evaluation to attempt to develop a 
search filter for EMBASE. The suggested search strategy in Golder et al 2006360 for 
EMBASE did not differ substantially from the suggested search strategy in 
MEDLINE, other than in the use of subheadings. While the MEDLINE search filter 
indicated the value of floating subheadings, the EMBASE search filter suggested 
that using subheadings attached to the named drug intervention (for example, 
vigabatrin/adverse drug reaction or vigabatrin/drug toxicity) performed better.  
 
Badgett et al 1999427, 428 and Wieland et al 2005121, 429, 430 both included study 
designs in their filter, and Golder et al 2006360 and Wieland et al 2005121, 429, 430 both 
included specified known adverse effects. Text words (words in the title or abstract) 
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such as ‘adverse effects’, ‘side effect’ and ‘adverse reaction’ were only included in 
the filter by Golder et al 2006.360  
 
 Discussion 6.4
The complete search strategy for identifying papers in a systematic review on 
adverse effects is likely to depend on the inclusion criteria for the review. For 
example, if the inclusion criteria are limited to particular study designs then the 
search strategy may need to reflect this. Two of the included studies in this review 
recommend search strategies for adverse effects using not only adverse effects 
terms but also study design terms. Similarly, search strategies may need to be 
adapted in reviews designed to establish whether an association exists between an 
intervention and a suspected adverse effect, to assess the frequency of a known 
adverse effect, or to review the safety profile of an intervention. Depending on the 
question to be addressed, searches can be restricted to specific adverse effects as 
in the case of Wieland et al 2005121, 429, 430 or searched using a generic search filter 
for all adverse effects, as in the case of Golder et al 2006360 or Badgett et al 
1999.427, 428 The results here indicate that creating a highly sensitive search strategy 
with an acceptable level of precision is difficult, irrespective of whether the focus is 
on a specific named adverse effect, or a broad search for any (unspecified) potential 
adverse effects.  
 
6.4.1 Use of adverse effects terms 
The use of adverse effects terms alone may not be sufficient to identify papers with 
information on adverse effects, as adverse effects terms may not be in the title, 
abstract or indexing of some relevant papers. A study by Derry et al 2001118 has 
also indicated that creating highly sensitive search strategies for information on 
adverse effects is problematic. They studied 107 trials that reported adverse effects 
data and assessed the number of papers that were indexed with relevant terms for 
adverse effects in MEDLINE and EMBASE, and how many titles or abstracts 
contained ‘adverse effects’ or related terms. They found that a combined search 
covering the two databases using both index and text word terms for adverse 
effects would have retrieved only 82 of 107 (77%) trials.118 Other studies have also 
indicated the problems of searching on terms for adverse effects in the title and 
abstract.119, 148, 449 One study found that of the adverse effects literature from one 
database, 64% (of 3,040 studies) contained adverse effects terms in the title,119 
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whilst two more recent studies found that adverse effects were mentioned in only 
53% (130/243) and 63% (328/521) of abstracts of journal articles.148, 449 A much 
smaller study on RCTs of drug therapy for dementia found that 94% (31/33) referred 
to harm in the title or abstract.149 This may suggest that reporting varies depending 
on topic or study design. 
 
6.4.2 Use of intervention terms 
It is often assumed that search strategies should contain terms for the intervention 
under investigation. While this is probably true for clinical trials, the situation is 
different for observational studies that are focused on identifying the etiology or 
multiple risk factors behind a particular adverse outcome e.g. the risk factors for 
breast cancer. Wieland et al 2005121, 429, 430 found that not all studies of adverse 
effects contained terms for one of the suspected drugs (oral contraceptives) in the 
bibliographic details. However, another study indicated that searching on drug terms 
in the title might be an effective method for searching for adverse effects, identifying 
99% of papers.119 It should be noted that this study was carried out in FDA Clinical 
Experience Abstracts and is now over 30 years old. 
 
6.4.3 Use of subheadings 
Some guidance on search strategies for adverse effects is currently available,431-438 
though the degree to which this is evidence-based is difficult to ascertain. Much of 
the guidance has tended to emphasize the usefulness of subheadings (such as 
‘adverse effects’ or ‘drug toxicity’) in MEDLINE and EMBASE.431, 432, 434-439 The 
results from Golder et al 2006360 and Badgett et al 1999427, 428 suggest that 
subheadings are useful.  
 
 Limitations  6.5
It is difficult to produce guidance on searching for information on adverse effects 
from the three studies meeting the inclusion criteria here. All three studies included 
a relatively limited set of studies on a specific class of drug and did not thoroughly 
test objectively derived search terms, although they do indicate the difficulties of 
searching for adverse effects and provide useful suggestions for structuring 
searches. 
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 Conclusions 6.6
This review highlights the problems of achieving a balance between sensitivity and 
precision when searching for information on adverse drug reactions, and the lack of 
research in this area. Although high sensitivity can be achieved, this is likely to be 
associated with poor precision. Authors of systematic reviews may, therefore, need 
to take pragmatic decisions when creating search strategies for adverse effects and 
sacrifice sensitivity for precision. In order to compensate for this loss in sensitivity, 
searches of electronic databases could then be supplemented with other means of 
identifying papers, such as reference checking, contacting industry, and citation 
searches.  
 
The limitations of the case studies identified by this review, and the large number of 
other search strategies that have been proposed but not yet empirically tested,431-439 
suggest that further research is needed to develop clear evidence-based guidance 
as to the most efficient means of creating search strategies for information on 
adverse effects. 
 
 Summary 6.7
This review presents on the results of three evaluations of published search filters 
for adverse drug reactions. 
Current evidence suggests that search filters for specific named adverse drug 
reactions and unknown adverse drug reactions tend to record low precision and 
may miss relevant papers.  
There is a dearth of research on search filters for adverse effects or adverse 
reactions: particularly useful areas for future research would include an analysis of 
subheadings (which is included in Chapter 13). 
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Chapter 7 Section D of the methodological overview:  impact of 
publication status on the reporting of adverse effects 
 Introduction 7.1
A major issue in systematic reviews is the problem of publication bias.22, 23 
Potentially important data could be missing from a systematic review because of 
selective reporting and inadequate dissemination of results. If the missing data or 
unpublished results differ systematically from the published data, a systematic 
review may become biased, with an inaccurate assessment of the intervention’s 
effects.96 For instance, positive significant outcomes are more likely to be published 
than non-significant findings, and a systematic review based mainly on published 
literature might over-estimate the efficacy of the intervention.450, 451 The impact of 
unreported or unpublished adverse effects data has not been fully clarified.15, 89, 115 
 
Poor reporting of adverse effects is well-recognized. Published trials usually provide 
only brief descriptions of adverse effects, or report only statistically significant and 
life-threatening adverse effects.452-457 Unpublished data might potentially have an 
important role in ascertaining information on adverse effects.197 Company clinical 
trial reports and drug approval information (such as that prepared by the US Food 
and Drug Administration (FDA)) have been found to contain much more information 
on adverse effects than published papers.21, 458-462 For example, although six pages 
were devoted to cardiovascular risk in an FDA statistical review on rofecoxib, only 
three lines were available in the New England Journal of Medicine article of the 
same trial,21 and some adverse effects in an industry funded unpublished FDA data 
were not included in a peer-review journal publication of the same study.459, 460, 463-465  
 
Given the considerable difficulties involved in retrieving unpublished data, and the 
uncertain yield, the impact of including unpublished safety data in safety reviews 
needs critical examination. This chapter aims to systematically review the 
methodological literature that has compared or analysed published versus 
unpublished adverse effects data. 
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 Methods  7.2
7.2.1 Inclusion criteria 
A methodological evaluation was considered eligible for inclusion in this review if it 
compared adverse effects of healthcare interventions according to publication status 
(i.e. published versus unpublished literature). Eligible articles were those that 
reviewed cohorts of published and unpublished studies and compared the 
quantitative reporting of adverse effects, in particular the frequency, rate, or risk of 
adverse effects. ‘Published’ articles were generally considered to be manuscripts 
that were found within peer-reviewed journals. 
 
7.2.2 Data extraction 
Information was collected on the interventions and adverse effects studied, the 
sources of published and unpublished data, and the outcome measures (such as 
effect size or number of cases) used to compare the information on adverse effects 
from studies with differing publication status.  
 
7.2.3 Assessment of methodological quality 
The following criteria were used to assess the validity of the included evaluations: 
1) Confounding factors by study design: The results of published studies may 
differ from those of unpublished studies due to factors other than publication 
status, such as study design, type of participant, characteristics of the 
intervention, and methodological quality. Did the researchers select 
comparison groups that were equally matched – for instance, did the 
unpublished studies share similar aims, designs and sample sizes as the 
published ones? If not, were suitable adjustments made for potentially 
confounding factors?  
2) Definition of publication status: Were explicit criteria used to categorise or 
define unpublished studies, and how did the investigators verify that a 
particular dataset was genuinely unpublished? For example, unpublished 
data may consist of information obtained from the manufacturers or 
regulatory agencies. Conversely, a broader definition of ‘grey literature’ may 
include information from websites, dissertations, policy documents, research 
reports, and conference abstracts. 
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3) External Validity and Representativeness: Did the researchers select a 
broad-ranging sample of studies (in terms of size, diversity of topics and 
spectrum of adverse effects) which were reasonably reflective of current 
literature? 
 
7.2.4 Analysis 
For methodological evaluations that measured incidence rates or number of cases 
of adverse effects only a descriptive comparison was presented. If the reviews 
presented risk ratios or odds ratio, a comparison of the magnitude of treatment 
effect was sought from unpublished studies versus that of published studies. The 
unpublished: published ratio was calculated simply by using: 
The pooled risk ratio for the adverse outcome from unpublished 
data, divided by the pooled risk ratio for the adverse outcome from 
published studies. 
 
The estimated ratios of unpublished versus published treatment effects generated 
from each methodological evaluation were then used in a meta-analysis to 
summarize the overall difference in risk ratios between unpublished and published 
studies. The 95% confidence interval for the combined effect was estimated using a 
random effects model. The ratios for individual studies were weighted by the square 
of the standard error plus the variance between studies, using a least squares 
Normal approximation. Because adverse events are rare, odds ratios and relative 
risks could be treated as equivalent.236 
 
In studies where the risk ratios for the unpublished data were not presented, these 
values were extrapolated from the risk ratio values of the published data and the 
combined (published and unpublished) risk ratio values using data analysis and 
statistical software (STATA). It was assumed that a fixed effects model had been 
used, as there was not enough information to do this assuming a random effects 
model so an estimate of the variance between studies could not be calculated. This 
was tested for the studies where the unpublished data were given. 
 
If the methodological evaluation looked at more than one adverse outcome, 
‘serious’ or ‘major’ adverse effects were selected. Alternatively, for studies looking 
at specific named adverse effects, the main analysis on the risk ratios was based on 
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the primary outcome of interest. A sensitivity analysis was conducted based on risk 
ratios of any secondary outcomes that were reported. 
 
 Results 7.3
7.3.1 Included studies 
Ten methodological evaluations met the inclusion criteria (Appendix B: Table 
15.9).28, 264, 283, 458, 466-471 Published data tended to be retrieved from sources 
commonly used in systematic reviews, such as electronic databases and reference 
checking. However, one methodological evaluation used licensing applications to 
identify published trials.458 Unpublished data was mostly obtained from regulatory 
authorities, although one methodological evaluation also solicited information from 
health professionals and the public as well as obtaining data from medical 
records466 and one methodological evaluation contacted the manufacturer only.469 
 
7.3.2 Excluded studies 
Nine methodological evaluations were excluded from this review (Appendix B: Table 
15.10).197, 455, 472-478 Three compared published data and reported data for the same 
study, using either a primary reporting database,455 Food and Drug Administration 
(FDA) submissions,473 or data collected for Individual Participant Data (IPD) 
analysis,478 three did not contain sufficient information,472, 476, 477 one compared 
agreement of count rates of adverse effects from published studies and the FDA but 
did not present any numerical rates or frequencies,474 one was a descriptive timeline 
review of published and unpublished studies,197 and one reported preliminary 
findings of an included methodological evaluation.475 
 
7.3.3 Summary of methodological quality 
The methodological quality of the individual studies is summarized in Appendix B: 
Table 15.9. 
1. Effect of Confounding factors 
Only one methodological evaluation controlled for confounding factors.468 Although 
this found differences between the results of published and unpublished trials, this 
was not the case after controlling for differences between the studies, such as 
quality and industry sponsorship (p=0.728). Here the differences in rates of adverse 
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effects were potentially due to variations in dose of the intervention, with high dose 
being associated with more than twice the rate of adverse effects as low or medium 
dose.468 
 
2. Accuracy in classification of ‘unpublished’ data 
Although all the methodological evaluations indicated where published and 
unpublished data were sought, only two studies provided clear details of the steps 
used in defining data as being ‘unpublished’.468, 469, 475 Researchers tended to 
classify unpublished data as that originating from regulatory agencies, but there is a 
risk of misclassification here if the data had been published in a journal that the 
researchers failed to identify. Overall, there was a potential risk of misclassification 
in most of the methodological evaluations. 
 
3. External validity 
All 10 methodological evaluations reviewed drug interventions but only two reviewed 
a broad range of drugs.458, 466 Most of the methodological evaluations included a 
range of adverse effects. However, three were restricted to a specific adverse effect 
(dyspepsia,468 thrombotic thrombocytopenic purpura (TTP),28 or bradycardia,283) and 
one was restricted to a particular type of adverse effect (cardiovascular and 
thrombolytic events).467 The number of included studies in each methodological 
evaluation varied between 11 and 1698. However, four methodological evaluations 
included less than 30 studies. Overall, the generalizability of the data would be 
rather limited due to the small range of interventions and adverse effects 
considered. 
 
7.3.4 Completeness of reporting: published versus unpublished 
Hemminki 1980458 compared the percentage of trials that reported on adverse 
effects, and found that when compared to published trials, adverse effects data was 
found in a significantly greater proportion of unpublished trials submitted to the 
Finland regulatory authority.  
 
7.3.5 Frequencies of case reports: published versus unpublished 
Four methodological evaluations compared published case reports with unpublished 
reports.28, 264, 283, 466 As part of a pharmacovigilance programme evaluating new 
safety alerts, Bennett et al 2005466 looked at serious adverse reactions of 16 drug 
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interventions and found that the vast proportion of cases were from spontaneous 
unpublished reports in the FDA or the Centers for Disease Control and Prevention 
(CDC) database. Published case reports and cases from clinical trials made up only 
a small proportion of the total number of cases and in four instances there were no 
published cases of an adverse reaction despite unpublished data being available. 
 
Similarly in Tramer et al 1997, which reported on case reports of bradycardia with 
propofol, more case reports were identified through national drug monitoring centres 
than from published case reports.283 Cosmi et al 2000 was the only methodological 
evaluation that identified more cases from the published literature than the 
unpublished data, however, this study compared both published case reports and 
case series with unpublished case reports.28 
 
Loke et al 2004264 looked at the rank order for the relative frequencies of particular 
adverse reactions with amiodarone from published case reports as compared to the 
unpublished World Health Organisation (WHO) database. Published cases 
consisted most frequently of respiratory and nervous system adverse reactions, 
whereas thyroid and skin disorders were ranked as the more frequent adverse 
reactions in the unpublished data. According to Loke et al 2004264 these differences 
may potentially arise from the publication process where authors and journal editors 
have a preference for manuscripts with interesting features. 
 
7.3.6 Risk ratio estimates: published versus unpublished 
Five methodological evaluations used meta-analytic techniques to combine the data 
from the published and unpublished studies.467-471  
 
Three methodological evaluations presented risk ratios and confidence intervals for 
published studies and unpublished studies separately, as well as for the combined 
studies.468, 469, 471 In each instance, to avoid the potential problem of duplicate data, 
only one set of results was included in the meta-analysis. In Hemminki 2000467 the 
results for cardiovascular and thrombolytic combined were selected, as opposed to 
cardiovascular events alone. In Ross et al 1997469 and Whittington et al 2004471 the 
results for major/serious adverse effects were selected in preference to the more 
specific adverse effects of angina and suicide attempt or ideation. 
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Two methodological evaluations presented risk ratios and confidence intervals for 
published studies and for the combined studies, but not for unpublished studies.467, 
470 For these two methodological evaluations the risk ratio and confidence interval 
for unpublished studies which would be required to give the combined values was 
estimated (Table 7.1).  
 
Table 7.1 Observed and estimated estimates of risk ratios with confidence 
intervals 
Study Observed risk ratio and 95% 
confidence intervals (CIs) 
Estimated risk ratio and 95% 
confidence intervals (CIs) 
MacLean et al 2003
468
 1.07 (0.70-1.63) 1.07 (0.69-1.64) 
Ross et al 1997
469
 1.04 (0.64-1.71)  1.04 (0.63-1.70) 
Whittington et al 2004
471
 1.87 (0.79-4.46)  2.00 (0.87-4.64) 
 
When this method of extrapolation was checked for consistency against the three 
studies that had unpublished data available, the extrapolation yielded a good 
approximation to the actual figures. Two of these estimates were very close, with 
extrapolated values of 1.07 (95% CI 0.69-1.64) compared with actual values of 1.07 
(95% CI 0.70-1.63)468 and extrapolated values of 1.04 (95% CI 0.63-1.70) compared 
with actual values of 1.04 (95% CI 0.64-1.71).469 However, there was a slight 
overestimate for the other study471 where the extrapolated values were 2.00 (95% 
CI 0.87-4.64) compared with the actual values of 1.87 (95% CI 0.79-4.46). This may 
be due to the very large risk ratio and wide confidence interval for the published 
studies in this study (Figure 7.1). In these three instances where risk ratios were 
available, the actual reported data were used for the analysis rather than the 
extrapolated figures. 
 
In Figure 7.1, the largest methodological evaluations gave a close approximation to 
a ratio of risk ratios of 1.0 whilst two smaller methodological evaluations gave 
estimates either side of the line of no effect (at 1.0) but with wide confidence 
intervals. There was no evidence of heterogeneity amongst the results of the 
methodological evaluations (p=0.7, I2=0).  
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Figure 7.1 Meta-analysis of results from unpublished versus published 
studies 
 
 
A ratio of risk ratios of 1.0 would imply that the estimates of effect from published 
and unpublished studies are the same. When pooled, the ratio of risk ratios, 
unpublished over published is estimated to be 0.95 (95% CI 0.65 to 1.37) (Figure 
7.1). This suggests that there is no major systematic variation in risk estimates of 
adverse effects when studies were published or unpublished. A sensitivity analysis 
based on the use of risk ratios for secondary adverse effect outcomes from three 
studies yielded a pooled ratio of risk ratios of 0.94 (95% CI 0.64 – 1.40) similar to 
the main analysis. 
 
Although the availability of unpublished adverse effects data did not change the 
direction or statistical significance of the risk, it is worth noting that owing to 
inclusion of a greater number of events the precision of the pooled estimate was 
increased, with narrower 95% confidence intervals (Table 7.2). 
  
Study or Subgroup
Hemminski 2000
Maclean 2003
Ross 1997
Wallace 2006
Whittington 2004
Total (95% CI)
Heterogeneity: Chi² = 2.39, df = 4 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.29 (P = 0.77)
Weight
2.8%
40.7%
21.9%
29.9%
4.7%
100.0%
IV, Fixed, 95% CI
2.84 [0.31, 26.32]
0.88 [0.49, 1.58]
1.13 [0.51, 2.51]
0.96 [0.49, 1.90]
0.36 [0.06, 2.02]
0.95 [0.65, 1.37]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Published has higher RR Published has lower RR
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Table 7.2 Relative risks/odds ratios and confidence intervals for unpublished 
studies, published studies, and published and unpublished studies combined 
 
* extrapolated values based on data given on published studies and combined 
studies 
 
7.3.7 Quality of unpublished data compared to published studies  
Although some methodological evaluations reported on the quality of the included 
studies, only three evaluations looked for differences in quality between the 
published and unpublished studies.458, 466, 468 One methodological evaluation 
Study Unpublished 
studies relative 
risk/odds ratio 
and 95% 
confidence 
intervals (CIs) 
Published 
studies, 
relative 
risk/odds ratio 
and 95% 
confidence 
intervals (CIs) 
Published and 
unpublished 
studies 
combined 
relative 
risk/odds ratio 
and 95% 
confidence 
intervals (CIs) 
Ratio of risk 
ratios/odds 
ratios, 
unpublished 
over published 
and 95% 
confidence 
intervals (CIs) 
Hemminki and 
McPherson, 
2000
467
 
Cardiovascular 
and Thrombotic  
OR 4.65  
(0.62– 35.15)* 
OR 1.64  
(0.65-4.21) 
OR 1.97  
(0.84-4.58) 
OR 2.84 
(0.31 – 26.32) 
Hemminki and 
McPherson, 
2000
467
 
Cardiovascular 
only 
OR 4.35  
(0.59 -32.21)* 
OR 1.39  
(0.48-3.95) 
OR 1.78  
(0.70-4.52). 
OR 3.13  
(0.33 – 30.06) 
MacLean et al 
2003
468
 
RR 1.07  
(0.70 – 1.63) 
RR 1.21  
(0.81-1.81) 
RR 1.14  
(0.85-1.53) 
RR 0.88  
(0.49 – 1.58) 
Ross et al 
1997
469
 Major 
adverse effects 
OR 1.04  
(0.64-1.71) 
OR 0.92  
(0.49-1.72) 
OR 0.99  
(0.67-1.46) 
OR 1.13  
(0.51 – 2.51) 
Ross et al 
1997
469
 
Angina 
OR 0.99  
(0.50-1.97) 
OR 0.92  
(0.49-1.72) 
OR 0.95  
(0.60-1.51) 
OR 1.08  
(0.42 – 2.73) 
Wallace 2006
470
 RR 1.92  
(1.12 – 3.29)* 
RR 2.0  
(1.3-3.0) 
RR 1.97  
(1.42-2.75) 
RR 0.96  
(0.49 – 1.90) 
Whittington 
2004
471
 
Serious adverse 
effects 
RR 1.87  
(0.79 – 4.46) 
RR 5.15  
(1.17-22.56) 
RR 2.55 
(1.23-5.3) 
RR 0.36  
(0.06 – 2.02) 
Whittington 
2004
471
 
Suicide attempt 
or ideation 
RR 1.23  
(0.48 – 3.15) 
RR 10.30 (0.58 
-183.53) 
RR 1.51 
(0.62 – 3.69) 
RR 0.12 
(0.01 – 2.47) 
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compared the quality of the reporting of case reports and found that completeness 
of individual case reports of adverse effects varied depending on the source of data, 
with published case reports and reports from clinical trials being the most complete 
and MEDWATCH reports being the least complete.466 
 
Three evaluations looked to see if methodological characteristics of study design 
were adequately reported.458,468, 469 One found that the aspects of trial methodology 
were less well reported in FDA reviews as compared to published studies. Detailed 
descriptions of randomisation, allocation concealment and blinding were more 
frequent in the published studies.468 
 
The methodological evaluation by Ross et al 1997 measured the mean quality score 
of studies on the Jadad scale.469 Unfortunately the scores were not reported by 
publication status, however, the authors did note that the availability of far greater 
detail in the unpublished trials meant that these studies were rated as either of 
equal or higher quality than the published trials.469 
 
The other methodological evaluation found no significant differences between 
published and unpublished trials of psychotropic drugs, in terms of numbers that are 
controlled, ‘good’ or the mean number of patients. However, in the same 
methodological evaluation some differences were reported among the small number 
of trials of non-psychotropic drugs. Published trials of non-psychotropic drugs were 
more likely to include a control group and more likely to include a larger mean 
number of patients.458 
 
 Discussion 7.4
This overview provides important information for systematic reviewers who are 
considering the inclusion of unpublished adverse effects data. The key finding is 
that unpublished studies do provide additional adverse effects data that is not 
otherwise covered in the published studies. However, there was insufficient data to 
conclude whether the inclusion of unpublished studies has a major impact on the 
results of meta-analyses. One methodological evaluation looked at proportion of 
trials with information on adverse effects, and found that a higher percentage of 
unpublished trials contained information on adverse effects compared to published 
trials.458 This may reflect either that trials with information on adverse effects are 
less likely to be published, or selective reporting where information on adverse 
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effects is excluded from journal manuscripts. However, this may equally indicate 
that regulatory authorities require more detailed reports of adverse effects data than 
journal editors.  
 
In this set of methodological evaluations, the addition of unpublished data did not 
lead to significant alterations in the risk ratio estimates for adverse effects. While the 
addition of unpublished data may not alter the effect estimates for adverse effects, 
the inclusion of unpublished data may enable reviewers to establish adverse effects 
estimates earlier,470 and increase the precision of adverse effect estimates.476 
Improvements in precision may be particularly useful in situations where adverse 
effects are rare, such as the possible risk of suicide in patients taking 
antidepressants. Four methodological evaluations indicated that unpublished case 
reports can yield different information on the relative frequencies of potential 
adverse events.28, 264, 283, 466 For those interested in case reports, limiting a review to 
published cases only could yield a very different picture of the safety profile. 
 
However, concerns have been raised around the methodological and reporting 
quality of adverse effects data in unpublished studies, particularly as unpublished 
data are not peer-reviewed.458, 467, 468, 479, 480 Although some evidence was identified 
that certain aspects of trial design or quality may be better reported in published 
studies458, 468 evidence to the contrary was also identified.469 The results of one 
methodological evaluation also suggest that published case reports have more 
complete reporting than unpublished studies, presumably because some peer 
reviewing and editing process has occurred during submission of the report466 or 
that the authors took a different approach when preparing a regulatory notification to 
submitting a paper for publication. Other studies have also indicated problems in 
using unpublished data from regulatory agencies.481 Problems include inconsistent 
terminology,482 misspellings,482 duplicate entries,483 errors,468 incomplete 
information,482, 483 and discrepancies in the data.473 
 
One potential problem related to publication bias but not covered in any of the 
methodological evaluations is that of multiple, or duplicate publications.484 Repetitive 
publications could falsely elevate the number of case reports of a specific adverse 
effect.485 There can be major difficulties in determining whether the ‘unpublished’ 
data had or had not already been reported in a journal article, and this issue was not 
fully addressed in most of the methodological evaluations.  
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The difficulties in identifying and accessing unpublished data should also be 
considered.392, 454, 467, 468, 471, 480 Manufacturers have been unresponsive to requests 
for information on adverse effects,471 or simply refused to give any data.454 It took 
researchers 1.3 years and an appeal at the High Court in Finland to gain access to 
unpublished studies submitted with drug licensing documents,467 and even when 
unpublished data is retrieved it can be difficult to decipher.468 Information from 
authors may, however, be easier to obtain than from manufacturers.486 Studies have 
indicated variable response rates of 24% (9/38),392 69% (356/519)486 and 80% 
(12/15)454 when authors are requested for unpublished safety data, although in the 
study by Chan et al 2005,486 the contacted authors had recently published and the 
response rate could have been higher than in a systematic review.  
 
The sources used in each methodological evaluation to retrieve published and 
unpublished data could possibly have influenced the results. In one methodological 
evaluation466 unpublished case reports were sought from a wide range of sources 
including health professionals and the public. The sources used for unpublished 
data in all the other methodological evaluations were from drug regulatory 
authorities such as the Food and Drug Administration (FDA) and Committee on 
Safety of Medicines (CSM) or directly from industry. (In October 2005, the CSM was 
merged with the Medicines Commission, to form the Commission on Human 
Medicines (CHM). The Medicines and Healthcare products Regulatory Agency 
(MHRA) and the European Medicines Agency (EMA) have an increasing profile 
within this organisation). Difficulties in differentiating between funding bias and 
publication bias are bought about as a result. Despite the potential for differences 
between studies (her than publication status) influencing the adverse effects 
estimates, only one of the methodological evaluations controlled for confounding 
factors, such as sponsorship.468 
 
 Limitations 7.5
There are a number of limitations to this review. Methodological evaluations are 
difficult to retrieve from electronic searches, and it is possible that review articles 
were missed where published and unpublished data were evaluated as secondary 
or tertiary outcomes. The diverse range of data sources in the methodological 
evaluations are a potential limiting factor when pooling the risk ratios of unpublished 
versus published, and this meta-analysis should be interpreted with caution, even 
though statistical heterogeneity was not detected.  
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From this review it is difficult to draw conclusions on the impact of other categories 
of literature that are distinct from peer-reviewed journals (for example, regulatory 
reports, websites, and conference proceedings). The methodological evaluations in 
this review did not focus on these sources, despite the increasing amount of 
evidence available in these forms. A comparative assessment of the association 
between such literature and the reporting of adverse effects would also be useful, 
particularly as this type of literature is difficult to search for in a systematic and 
reproducible way (for example, the Internet) and can be more difficult and expensive 
to retrieve (for example, reports and conference proceedings). Finally, there is a 
concern about the possibility of reporting or publication bias with respect to 
methodological evaluations, where investigators may have chosen not to write up 
their findings if they did not find any significant differences between published and 
unpublished studies.487 
 
Given the above limitations, future methodological research should focus on 
checking the nature, quality and accessibility of adverse effects data from non-peer 
reviewed sources, such as regulatory authorities and pharmaceutical companies. 
This should clarify whether or not the yield is worth the additional efforts required to 
obtain such data. Finally, the impact of unpublished data on pooled risk ratio 
estimates could be more thoroughly assessed if the intention to compare data 
sources according to publication status was built in at the protocol stage of 
systematic reviews of adverse effects. 
 
 Conclusions 7.6
Although no clear evidence was found that data on adverse effects from published 
and unpublished data sources differ, there is some evidence that inclusion of 
unpublished data can provide more precise risk ratio estimates in a meta-analysis of 
adverse effects. Evaluation of unpublished case reports may also generate a 
different picture of the relative frequencies of specific adverse effects. However, the 
strength of these conclusions is limited by the lack of adjustment of confounding 
factors, particularly of study quality and industry funding.  
 
Authors of systematic reviews who plan to include unpublished adverse effects data 
should take extra care in assessing the quality of the data, and in minimizing the 
possibility of data duplication. 
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 Summary 7.7
This review includes 10 studies which compare published and unpublished data on 
adverse drug reactions.  
Unpublished trial data may contain more complete adverse drug reaction data. 
Frequencies of adverse drug reaction case reports may differ in published and 
unpublished sources. 
Estimates of the risk of adverse drug reactions using ratio of risk ratios suggest that 
published and unpublished data do not differ. 
It is unclear whether the quality of published adverse drug reaction information is 
better than unpublished data. 
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Chapter 8 Section E of the methodological overview: impact of 
funding source on the reporting of adverse effects  
 Introduction 8.1
In many countries manufacturers have a regulatory requirement to monitor the 
adverse effects of their drugs and may, therefore, be a useful source of additional 
information on adverse effects. A review of celecoxib concluded that clinical trial 
reports produced by or for manufacturers were an ‘ideal source of information for 
systematic reviews and meta-analyses’.462 Much of the data on adverse effects is 
contained in industry funded studies and this is likely to escalate as the percentage 
of studies funded by industry sources is increasing.488 
 
Data from manufacturers is not always readily available12 and may be classed as 
‘commercial in confidence’ by the company owning the data. Furthermore, 
documents produced by manufacturers can be extremely long and difficult to 
navigate. In addition, studies produced by or for manufacturers may be subject to 
publication and selective reporting bias,452, 489, 490 as adverse effects may be 
suppressed or omitted from published studies, particularly when they are not 
statistically significant,452, 459, 460, 486 or results from only selected stages of the trial 
are presented.490 Studies that find an increased risk of an adverse effect may never 
be published.491  
 
There is a large body of literature that has identified an association between 
industry funding and better study outcomes.489 These studies have tended to focus 
on effectiveness outcomes, with the primary aim of comparing the beneficial effects 
reported and the source of funding for a study. Better study outcomes, however, can 
be as a result of a more effective intervention or a lower adverse effects profile or a 
combination of the two. Research has indicated that industry sponsored meta-
analyses yielded lower odds ratios for adverse effects than those reported by 
academic based meta-analyses.21, 492, 493 However, this reporting of lower rates of 
adverse effects may not appear in primary studies. In palliative care and cancer 
care it has been suggested that pharmaceutical companies may report adverse 
effects more comprehensively than non-industry funded studies,494 although the 
suppression of trial data on suicide with seroxat suggests that industry may withhold 
adverse effects data.495 This research aims to systematically review the 
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methodological literature concerning the reporting of adverse effects and any 
potential association with source of funding (such as industry or non-profit 
organisations). 
 
 Methods 8.2
8.2.1 Inclusion criteria 
A methodological evaluation was considered eligible for inclusion in this review if it 
compared the results or interpretation of reported adverse effects data according to 
funding source (for example, adverse effects data in pharmaceutical industry 
research versus data from non-profit organisations, or from one manufacturer 
versus another).  
 
8.2.2 Data extraction 
Information was collected on the selection criteria, interventions and adverse 
effects, the number, study design and funding sources of studies included in the 
methodological evaluation, and the outcomes used in assessing differences 
between studies. 
 
8.2.3 Assessment of methodological quality 
The following criteria were used to assess the quality of the existing methodological 
evaluations; 
1. Confounding factors by study design: Did the researchers select comparison 
groups (i.e. data from different funding sources) that were equally matched? 
For instance, did the industry funded studies share similar aims, designs and 
sample sizes as those that were non-industry funded? If not, were there 
adjustments for potentially confounding factors that could affect the 
association between funding and the nature of the adverse effects data? The 
following confounding factors were looked for to see if they had been 
considered: study design; methodological quality; type of intervention and 
control intervention; sample size; disease area; type of adverse effects. 
2. Missing data or misclassification: How often were the researchers able to 
reliably establish the source of funding for the reported data? 
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3. Blinding: Were the researchers aware of the funding source when they were 
judging the nature of the adverse effects data? 
4. Validity and Representativeness: Did the researchers select an adequate 
sample of studies (in terms of size, diversity of topics and range of adverse 
effects) that were reasonably reflective of current literature? 
 
 Results 8.3
8.3.1 Included studies 
Six methodological evaluations met the inclusion criteria (Appendix B: Table 
15.11).99, 496-501 All six were concerned with drug interventions, with five of the six 
evaluations limited to the adverse effects of a single agent or single class of 
drugs.99, 498-501 Two methodological evaluations were limited to specific adverse 
effects,99, 498 whereas the other methodological evaluations included any adverse 
effects. Only one methodological evaluation assessed funding source and reporting 
of safety data across a wide range of diseases and drugs.496, 497 The number of 
studies included in the methodological evaluations ranged between 10 and 504 with 
only two methodological evaluations including more than 100 studies.496, 497, 499 
 
Half of the methodological evaluations focused on adverse effects data within 
clinical trials496, 497, 499, 500 and two included observational data.99, 498 One had a 
mixture of reports of original research, reviews and letters.501 Most methodological 
evaluations compared manufacturer funding with non-manufacturer funding, though 
one evaluation looked for differences in adverse effects data in research funded by 
competing manufacturers.500 
 
8.3.2 Excluded studies 
There were two methodological evaluations excluded from this review (Appendix B: 
Table 15.12).247, 248, 502 One502 contained duplicate data from an included 
methodological evaluation,498 whereas another was excluded as the categories of 
funding source were unclear, but were unlikely to include industry funded studies.247, 
248  
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8.3.3 Summary of methodological quality 
Four of the methodological evaluations used some form of adjustment for potentially 
confounding factors, although the comprehensiveness of those factors varied 
(Appendix B: Table 15.11).99, 496-499 A major constraint in assessing an association 
between source of funding and the reporting of adverse effects was the lack of 
information on funding source. Only two methodological evaluations described the 
number of studies not reporting any funding source, both these evaluations included 
only trial data and reported that 17.3% and 28.6% of studies did not disclose any 
funding source.496, 497, 499 Blinding was reported in only two evaluations, one which 
tested the effect of blinding on a subsample of included studies and found that 
blinding did not impact on the results.496, 497 Overall, the assessment of quality and 
validity showed that the Als-Nielsen et al 2003 evaluation, which included both 
studies not reporting funding source and considered blinding, was probably the 
most robust (Appendix B: Table 15.11).496, 497  
 
Definitions of manufacturer associated funding varied, as did the methods and 
outcome measures used to assess the association between funding and adverse 
effects reporting, making it difficult to pool the results of the methodological 
evaluations identified. 
 
8.3.4 Selective reporting  
Als-Nielsen et al 2003 looked at a diverse range of RCTs and noted that trials 
funded by for-profit organizations were more likely to report adverse events 
(128/146, 88%) than trials funded by non-profit organisations (32/67, 48%).496, 497 
 
8.3.5 Magnitude of risk of harm 
It may be hypothesized that the risk of harm from the sponsor's product might be 
downplayed in industry funded studies. Three of the four methodological evaluations 
which measured the magnitude of the risk of adverse effects support this 
hypothesis.99, 498, 499 
 
A subgroup evaluation from Kemmeren et al 2001's meta-analysis showed that the 
pooled data from industry funded studies yielded a weaker association between 
third generation oral contraceptives and venous thrombosis.498 Similarly, Juni et al 
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2004's meta-analysis of cardiovascular events and rofecoxib showed that studies 
funded by Merck were associated with greater cardioprotective effects of naproxen 
(a comparator for rofecoxib), implying a lesser risk of harm from Merck's product 
(rofecoxib).99 However, the weakness of this evidence is that they were post-hoc 
subgroup analyses, involving only a small number of studies (11 studies in Juni et al 
200499 and 10 studies in Kemmeren et al 2001498) and subject to confounding, as no 
adjustments were made for any study design or patient characteristics. 
 
Nieto et al 2007's evaluation of inhaled corticosteroids reported that statistically 
significant results for adverse effects were found less frequently in pharmaceutical 
industry funded studies, whereas non-industry funded studies were more likely to 
report significant harm.499  
 
Conversely Als-Nielsen et al 2003 noted that a higher frequency of adverse effects 
tended to be found in the experimental arm of industry funded trials than trials 
funded by non-profit organisations.496, 497  
 
8.3.6 Confounding factors 
The differences between the results or conclusions of studies funded by industry 
and non-profit organisations could reflect other factors such as the chosen 
interventions and disease area, different study designs, methodological quality, and 
study size.  
 
Nieto et al 2007 found that studies funded by industry differed from those not funded 
by industry and were more likely RCTs; multicentre; to use a parallel design in 
prospective comparative studies; to state that their primary objective was studying 
efficacy, to use lower dosages of the medication; and to have a larger sample size 
and shorter follow-up times. The studies also differed in the methods used to 
investigate adverse effects. Industry funded studies were more likely to limit the 
assessment to only non-specific clinical data (such as medical history) and/or 
laboratory data (such as blood count) or cortisol metabolism (such as plasma or 
urinary cortisol level), and less likely to assess other specific adverse effects such 
as growth (height) or bone metabolism (densitometry). An adjusted prevalence ratio 
as reported by Nieto et al 2007499 0.94 (95% CI 0.77 to 1.15) suggested that the 
difference associated with funding might be mediated by other variables in the 
analysis.  
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8.3.7 Interpretation of adverse effects data 
The included studies revealed some interesting potential associations between 
funding source and the subjective interpretation or conclusions regarding adverse 
effects data. For example, Nieto et al 2007 found that authors of pharmaceutical 
company funded studies were more likely than authors of non-pharmaceutical 
studies to conclude that a drug was safe, even among studies that found a 
statistically significant increase in adverse effects.499 Similarly, Rochon et al 1994 
found that a manufacturer associated drug was often judged to be less toxic, even 
though this interpretation was not always supported by a test of statistical 
significance.500 Finally, Als-Nielsen et al 2003 noted an association between 
favourable recommendations for a product and the manufacturer's sponsorship, 
irrespective of the actual magnitude of treatment benefit or safety results seen in the 
trial.496, 497 
 
The study by Juni et al 200499 also indicated that conclusions might differ with 
studies funded by industry indicating larger protective effects of an adverse effect in 
the drug comparator. This enabled authors to conclude that the difference in 
adverse effects between the experimental group and the comparator was a result of 
a protective effect in the comparator group rather than an increased risk of adverse 
effects in the experimental group.  
 
There is possible potential for error and bias when trying to judge whether the data 
interpretation and conclusions of a study are excessively favourable or not. Stelfox 
et al 1998501 and Als-Nielsen et al 2003496, 497 attempted some degree of blinding of 
the reviewers but none of the remaining four methodological evaluations used any 
blinding.  
 
8.3.8 Competing manufacturers 
Just as it may be hypothesized that studies by manufacturers with a financial 
interest in the intervention are more likely to have favourable conclusions, it may 
also be hypothesized that competing manufacturers are more likely to emphasize 
concern over safety of a rival intervention.503 One methodological evaluation looked 
at this possible association,501 finding that the reverse might be true and that 
authors who are neutral or supportive of the safety of an invention were more likely 
to have a financial interest with competing manufacturers. It would appear that 
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neutral or supportive authors are more likely to have a financial relationship with any 
manufacturer of the intervention or competing product. This study had some 
limitations, including a lack of a temporal analysis (it is not known whether support 
of the intervention preceded funding from the manufacturer), loose definitions of an 
association with industry funding, and failure in checking the appropriateness of the 
conclusions of the authors against the actual adverse effects data of the studies. 
 
 Discussion 8.4
This systematic review has identified somewhat mixed evidence surrounding the 
postulated link between industry funding and more favourable reporting of adverse 
effects data. Bearing in mind the limitations of this review (see below), it is only 
possible to draw tentative conclusions. Firstly, there is no strong evidence that 
funding source leads to selective reporting of adverse effects outcomes that 
favoured the sponsor’s product. Indeed, Als-Nielsen et al 2003, probably the 
methodological evaluation with the strongest quality criterion, found that the 
opposite was true, with industry funded studies providing more complete reporting 
and higher rate of adverse effects for the experimental arm.496, 497 Unlike non-profit 
organization funded studies, pharmaceutical companies hoping to submit a 
licensing application could be more focused on providing an accurate depiction of 
adverse events, as the data might be subjected to rigorous regulatory scrutiny. 
Indeed, it is possible that the information submitted to the regulatory authorities is 
less positive than that seen in the published articles.504 
 
There is also no strong evidence that industry funded studies present a lower 
magnitude of risk of harm from the sponsor’s product, although pharmaceutical trials 
have been accused of using design modifications to ascertain lower adverse effects. 
Such methods might potentially include: using lower doses of the intervention and 
higher doses for the controls; monitoring for adverse effects using open-ended or 
non-specific questions; the use of eligibility criteria and run-in periods to exclude 
patients prone to adverse effects; a focus on a single adverse effect or a narrow 
range of related adverse effects to obscure harms of the drug; repeated analysis of 
data until any extra risk of adverse effects disappears; and the choice of 
inappropriate comparators or interventions known to have few adverse effects.27, 124, 
146, 452, 490, 499, 500, 502, 505, 506  
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This systematic review indicates that funding source may impact on the nature of 
the authors’ interpretation and conclusions regarding the safety profile. However, 
the interpretation of adverse effects data relies not only on statistical significance, 
but also on subjective judgements on clinical relevance, preventability, and absolute 
risk.  
 
 Limitations 8.5
There were a number of methodological issues of concern with the evaluations 
included in this review. First of all, all the methodological evaluations were 
‘observational’ in nature. While some of them had pre-defined objectives496, 497, 501 
others were post hoc or subgroup analyses. Confounding was a major problem in 
most of the methodological evaluations, where the baseline features (e.g. study 
design, patient population, primary objectives) of the industry funded studies might 
have differed from those of the non-industry funded studies. This is particularly 
apparent in Nieto et al 2007 where the observed differences became non-significant 
after adjustment for confounding factors.499 
 
There is also the possibility of reporting or publication bias with respect to 
methodological evaluations.487 Journal editors may look more favourably upon 
articles that show biased reporting of adverse effects in industry funded studies, or 
researchers who do not find any industry-related bias might choose not to submit 
their articles for publication. Equally, researchers finding evidence of industry 
funded bias may avoid publicizing the results so as not to jeopardize any industry 
funding ties that they might have. 
 
The generalizability of the data is also contentious. It would be unfair to draw broad 
conclusions about bias in all industry funded studies when the data are limited to a 
few studies or to only a specific class of drugs. Moreover, reporting 
recommendations have changed over time, with tightening of regulatory 
requirements, and the publication of the Consolidated Standards of Reporting Trials 
(CONSORT) statement on harms.32 Existing methodological evaluations have not 
taken into account temporal changes, or the availability of complete adverse effects 
data from unpublished company trial reports available from trials registries such as 
the GlaxoSmithKline Clinical Trials Registry (http://ctr.gsk.co.uk/welcome.asp) and 
ClinicalStudyResults.org (www.clinicalstudyresults.org). 
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Failure to accurately classify funding source is the most prominent weakness in the 
methodological evaluations. In Nieto et al 2007’s evaluation, 87 studies (17.3%) 
were categorised as non-industry funded, despite there being no information on 
funding source.499 Misclassification of such a large number of studies could have a 
major influence on the direction and magnitude of any link between funding and 
adverse effects data. The largest methodological problem though, lies with the 
difficulty in verifying authorship and the reliability of financial declarations in 
published papers. Two recent papers have highlighted problems with ghost 
authorship and inaccurate financial disclosures (e.g. not disclosing a financial 
interest in one article, but declaring industry funding in another publication).507, 508 If 
studies categorized under non-industry funding were misclassified and were actually 
industry funded, this would dilute the strength of any argument that non-industry 
funded studies provided less-biased reports of adverse effects. 
 
A considerable amount of subjectivity was involved in trying to determine whether 
the interpretation and conclusions of a study were biased towards the sponsor’s 
product. Reviewers who were critical of the pharmaceutical industry might have 
taken a harsher view in finding fault with industry funded studies, while those 
supportive of the industry might have been less likely to judge the presence of bias. 
Unfortunately, blinding and inter-rater reliability were key parameters that were 
seldom specified by the methodological researchers. 
 
 Conclusions 8.6
Industry funding may not be a major threat to bias in the reporting of the raw 
adverse effects data, though bias might be introduced in the interpretation and 
conclusions of the industry funded studies. 
 
The limitations of the included methodological evaluations in this review suggests 
that further research is required in this area in order to draw any firm conclusions on 
the impact of including or excluding industry sponsored studies in systematic 
reviews of adverse effects. In the meantime efforts should be made where possible 
to include all relevant studies and be explicit about the sources of funding of 
included studies. 
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 Summary 8.7
This review of six methodological studies in the literature comparing reporting of 
adverse effects and funding source indicates that there is no strong evidence that 
funding source leads to selective reporting of adverse effects. However, funding 
source may impact on the author’s interpretation and conclusions. 
Additional information to that in the published literature can be obtained from 
industry funded data. 
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Chapter 9 Section F of the methodological overview: other issues 
related to the retrieval of information on adverse effects 
 Introduction 9.1
As well as the potential for publication bias and industry funding bias, there are 
other potential sources of bias that may impact on the reporting of adverse effects, 
including that from the author or journal editor, or by language, country setting or 
publication year. The potential bias from these sources may have an impact on the 
methods used to retrieve information on adverse effects. For example, limiting to 
core MEDLINE will help identify only those articles from high-impact factor journals, 
contacting clinicians in the field is more likely to retrieve articles by the clinicians 
themselves, and searches can be limited by country settings, language or date 
ranges. 
 
This section of the review aims to systematically identify research studies that has 
investigated the impact of different sources of information on adverse effects and 
has not been covered elsewhere in this review (Chapters 4 to 8). 
 
 Methods 9.2
9.2.1 Inclusion criteria 
A research study was considered eligible for inclusion in this review if it compared 
the impact of different sources of information on adverse effects and was not 
covered in the other sections of this review (Chapters 4 to 8). 
 
9.2.2 Data extraction 
Information was collected on the interventions and adverse effects studied, and the 
number and type of included studies. The main outcome measure was an estimate 
of the impact on the pooled estimates of adverse effects. 
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9.2.3 Assessment of methodological quality 
The following criteria were used to assess the quality of the existing methodological 
evaluations; 
1. Confounding factors by study design: Did the researchers select comparison 
groups (i.e. similar characteristics of the populations and interventions studied) 
that were equally matched? For instance, did the researchers select comparable 
studies in terms of study design, dose of drugs, and patient age structure? Did 
they use similar methods for ascertaining adverse effects data from 
participants? If not, were there adjustments for potentially confounding factors 
that could affect the association between the selected factors and the nature of 
the adverse effects data? The following confounding factors were looked for to 
see if they had been considered: type of study, characteristics of participants, 
methodological quality, type of intervention and control intervention, sample 
size, disease area, type of adverse effects and funding source. 
2. Blinding: Were the researchers aware of the potential influencing factors when 
they were judging the nature of the adverse effects data? 
3. Validity and Representativeness: Did the researchers select an adequate 
sample of studies (in terms of size, diversity of topics and range of adverse 
effects) which were reasonably reflective of current literature? 
 
 Results 9.3
9.3.1 Included studies 
Only three methodological evaluations met the inclusion criteria,247, 248, 301, 509, 510 two 
investigated the reporting of adverse effects of surgical interventions,247, 248, 301 and 
one of these also carried out an analysis of a drug intervention (Appendix B: Table 
15.13).247, 248 The other methodological evaluation looked at diagnostic screening.509, 
510 All recorded the impact of author affiliation on the reporting of adverse effects, 
while two recorded the impact of year of publication247, 248, 301 and one looked at 
country setting, and impact factor of journal publication.247, 248 
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9.3.2 Excluded studies 
There were no excluded studies for this section of the review. 
 
9.3.3 Summary of methodological quality  
1. Confounding factors by study design: All the methodological evaluations 
reported on the influence of at least one other factor (such as study design) in 
addition to the factors (such as author affiliation) included in this review. Chou et 
al 2007 looked at a large number of factors including quality criteria, study 
design factors, severity of adverse effects and demographic or risk factor 
variables.247, 248 Jorgensen et al 2007 only looked at one other factor, type of 
article (such as original research or editorial),509, 510 and Rothwell et al 1996 
looked at author affiliation, year of publication and whether studies were 
performed prospectively or retrospectively, and carried out a multiple regression 
analysis of these factors along with author affiliation.301 
2. Blinding: Blinding was only reported by Jorgensen et al 2007. In this study, 
blinding would have been particularly important given the subjective nature of 
the outcomes measured.509, 510 
3. Validity and Representativeness: The generalisability of all three methodological 
evaluations was poor. All were limited to a named intervention and two limited to 
named adverse effects.247, 248, 301 In addition, the methodological evaluation 
which included a drug intervention was limited to only 16 RCTs.247, 248 
 
9.3.4 Authorship 
The two methodological evaluations which looked at the association between 
authorship and the reporting of adverse effects in surgical papers both identified 
significantly lower risks of complications in those studies with a single surgeon as 
the author,247, 248, 301 against studies with neurologist or physician as an author301 or 
at least one non surgeon as an author.247, 248 In addition, Chou et al 2007 reported 
significantly lower risks in studies with multiple surgeon authors than those with at 
least one non surgeon.247, 248 The methodological evaluation that looked at the 
reporting of adverse effects in diagnostic studies found similar results, with authors 
working in screening reporting less adverse effects and being less likely to 
acknowledge over-diagnosis.509, 510  
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9.3.5 Other factors 
The study by Chou et al 2007 found that journals with a high impact factor reported 
higher rates of adverse effects for both surgical and drug interventions and that the 
rates of adverse effects were not significantly different by publication year or country 
setting.247, 248 Rothwell et al 1996 also found no difference in the reporting of 
adverse effects by publication year once they had controlled for differences in study 
methodology and authorship.301 
 
 Discussion 9.4
The difference between reporting of adverse effects by surgeons and non-surgeons 
could be attributable to a number of factors, such as scientific fraud, differential 
diagnosis by surgeons and non-surgeons, a bias towards surgeons with a better 
success rate undertaking research, or publication bias by surgeon authors.301 
Similarly, the difference in the reporting of harm by authors working in screening 
could also be attributed to scientific fraud, better ascertainment of adverse effects 
by authors not working in screening, or publication bias. 
 
If studies by surgeons and studies by authors working in screening were more likely 
to report lower risks of adverse effects this would lead to systematic reviewers 
relying heavily on contacting surgeons or clinicians in diagnosis for relevant studies 
to identify a lower risk of adverse effects. 
 
The lack of difference in the reporting of adverse effects by publication year and 
country setting is reassuring to those reviewers who have restricted their searches 
with date limits or country of origin. Limits or emphasis on studies from particular 
countries can occur at the search stage of a systematic review, either directly by 
limiting search strategies, or indirectly by using language restrictions or databases 
with a particular country or regional bias. For example, MEDLINE originates in 
America and has a higher proportion of American studies than EMBASE, which 
originates in Europe. Even more obviously, LILACS is restricted to Latin American 
and Caribbean literature. 
 
Higher reporting rates in journals with a high impact factor merits further 
investigation, as this may be indicative of a form of publication bias. Articles with 
more significant results might be more likely to be accepted in high impact journals, 
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or authors might perceive their results to be of greater interest and send them to 
high impact journals. These results suggest that systematic reviewers that rely 
heavily on handsearching high impact journals or limiting their searches to 
databases such as core MEDLINE might obtain higher rates of adverse effects than 
those systematic reviews with wider search criteria. 
 
 Limitations 9.5
The main limitations of this review are the lack of blinding and generalisability within 
the included studies. The low number of included studies in this chapter limits the 
generalisability of these findings even further. 
 
 Conclusions 9.6
Author affiliation and journal impact factor may be important predictors of the 
reporting of adverse effects. Authors of systematic reviews need to be cautious in 
over-reliance on contacting clinical experts in the area, such as surgeons or those 
involved in screening, or limiting their review to particular journal titles (through 
handsearching or databases such as core MEDLINE). 
 
 Summary 9.7
This review included three studies investigating the impact of author affiliation on 
the reporting of adverse effects, two studies recording the impact of year of 
publication, one recording the impact of country setting and one the impact of 
journal publication impact factor.  
Surgeons and those working in screening reported fewer adverse effects than other 
authors, journals with a high impact factor reported higher rates of adverse effects, 
and there was no difference in the reporting rates of adverse effects by country 
setting or publication year. 
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Chapter 10 Methods used to search for adverse effects data in 
systematic reviews: 1994 to 2011 
 Introduction 10.1
Chapters 4 to 9 highlight the methodological challenges in conducting systematic 
reviews of adverse effects. For instance, the complexities of using search filters to 
retrieve adverse effects data are apparent in Chapter 6. The relative value of a 
range of different databases and other sources for information on adverse effects is 
shown in Chapter 5. The research from Chapters 4, 7, and 8 demonstrate the 
potential value of non-RCTs, industry data, and unpublished data. Given the 
empirical evidence from Chapters 4 to 9 on where and how to search, which study 
designs and types of data to include, and the value of searching for unpublished 
and industry funded data, it is interesting to assess how authors of systematic 
reviews of adverse effects currently undertake the search process. Any gaps 
between what methodological research indicates should be done and current 
practice in systematic reviews of adverse effects can then be identified. 
 
Previous research has indicated deficiencies in the search quality and reporting of 
search strategies in systematic reviews,511-537 including systematic reviews of 
adverse effects.110, 352, 538, 539 It may be hypothesized that the research developments 
in search methodology identified in Chapter 5, on sources of information for adverse 
effects, and Chapter 6, on electronic search strategies, could have led to 
improvements in the search techniques used within systematic reviews. Research 
has indicated improvements over time in the overall quality of effectiveness 
reviews,107, 540 and in the search methodology in dental systematic reviews,541 but 
research on systematic reviews of adverse effects has not examined any time 
trends with respect to search quality and reporting.110, 352, 538, 539 The research in this 
chapter aims to describe current practice in retrieving information on adverse effects 
for inclusion in systematic reviews and to summarize trends over the time period 
1994 to 2011. This will give an indication as to whether methods used are becoming 
more in line with the research available in Chapters 4 to 9, give an indication of the 
breadth of methods used, and identify potentially useful techniques that can then be 
tested in future research on the retrieval of information on adverse effects. 
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 Methods 10.2
10.2.1 Search strategy  
Systematic reviews of adverse effects were identified by screening all records 
published since 1994 in the Cochrane Database of Systematic Reviews (CDSR) 
(via The Cochrane Library, Issue 6:2011) and the Database of Abstracts of Reviews 
of Effects (DARE) (via the Centre for Reviews and Dissemination (CRD) website, 
June 2011). No search strategy was implemented, as previous research has 
indicated that even very broad search strings would miss relevant records.448 These 
databases were chosen because they are the most accessible major collections of 
systematic reviews of healthcare interventions. DARE is compiled through rigorous 
monthly searches of bibliographic databases, including MEDLINE and EMBASE, as 
well as handsearching of key journals, grey literature, and regular searches of the 
Internet.542, 543 CDSR contains all Cochrane reviews, including new and updated 
reviews. 
 
10.2.2 Inclusion/exclusion criteria 
A review was included if the primary aim was to evaluate an adverse effect or 
effects, known to be, or suspected to be, associated with an intervention, regardless 
of whether the review author's hypothesis or conclusions stated that the intervention 
increased or reduced the outcome. Articles that investigated the complete safety 
profile of an intervention were included if this was their primary aim. The author and 
another researcher independently screened titles and abstracts and selected full 
articles for inclusion. Any discrepancies between the researchers were resolved by 
discussion and consensus. 
 
10.2.3  Data extraction 
Pre-defined descriptive data on review methodology were abstracted using a 
standardised form created in Microsoft Access 2007. For each review, baseline data 
were collected on: the year of publication; the types of intervention (for example, 
drug intervention, diagnostic procedure or surgical technique); the type of adverse 
effects evaluated (for example, pre-specified named adverse effects or generic 
adverse effects); and the types of study design included (for example, randomised 
controlled trials (RCTs) or cohort studies).  
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Details were extracted on how information on adverse effects was retrieved by the 
authors of the reviews, namely:  
 which databases were searched, for example, MEDLINE or EMBASE 
 which interfaces (software) were used, for example, PubMed, OVID, or 
SilverPlatter 
 any other sources of information consulted or additional approaches to 
information gathering employed, for example, reference checking, 
handsearching, or contacting experts. 
 
Details of search strategies were also extracted: 
 on the category of search terms used from the standard categories of patient 
group, disease or condition, intervention, comparator and outcome (PICO) 
used for clinical effectiveness search strategies22, 23 
 in which database fields such as title, abstract, or indexing the terms were 
searched 
 whether any synonyms were used for text word searches and whether or not 
truncation was used 
 whether a search filter was applied, for example, to identify a particular study 
design such as RCTs  
 whether any language or date restrictions were applied  
 whether the search strategy was reproducible. 
 
Searches were judged to be reproducible if the review authors provided details of 
the combinations of search terms used, including Boolean logic, field restrictions, 
truncation, and search filters, as well as any date or language restrictions applied. 
 
Finally, the qualifications of the searcher (for example, information scientist/librarian 
or other), the number of records identified by the searches, and the number of 
studies included in each review were recorded. 
 
10.2.4 Analysis 
Data were categorized and a descriptive summary presented. A record was made of 
changes in: the number and proportion of systematic reviews of adverse effects 
published; the study designs included in the reviews; the number and type of 
sources searched; the breadth or quality of the search strategies employed; date or 
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language restrictions applied to the searches, reproducibility of the search strategies 
employed; and any relationship between the quality of the searches and the 
qualifications of the searcher. Trends across time were investigated using a linear 
regression model, where applicable, and statistical significance was calculated.544 
 
The results were then compared, where possible, with other surveys on the retrieval 
of information for systematic reviews. In order to facilitate meaningful comparisons 
with this survey, surveys were selected that evaluated similar parameters, such as 
similar databases and sources searched in the sample of reviews, details of 
reproducibility of search strategies, and presence or absence of language and date 
restrictions. Comparisons could not be made with surveys that simply reported on 
whether ‘adequate searches’ were undertaken with no further details. 
 
 Results 10.3
From 4656 Cochrane reviews and 11062 DARE abstracts screened, 918 full reports 
were retrieved and 849 reviews met the inclusion criteria (799 from DARE, 50 from 
CDSR). The reviews were dated from 1994 to 2011. Overall 5% (849/15812) of 
reviews in both databases focused on adverse effects, 1% (50/4656) of Cochrane 
reviews and 7% (799/11062) of DARE reviews. The number of reviews focusing on 
adverse effects has increased over time (trend P<0.001) (Figure 10.1 and Appendix 
C: Table 15.14) in line with the overall trend of increasing numbers of systematic 
reviews being published, such that the proportion of total reviews of adverse effects 
from CDSR or DARE has remained relatively stable.  
 
10.3.1 Characteristics of the included studies 
10.3.1.1 Types of interventions studied 
Throughout the time period studied, the included reviews are dominated by those 
evaluating the adverse effects of drugs (73%). Only a few studies examined surgical 
or dental procedures (13%), physical interventions such as acupuncture (7%), or 
diagnostic or screening interventions (1%) (Appendix C: Table 15.14). The most 
common interventions studied were, Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) (59 reviews), Hormone Replacement Therapy (HRT) or contraceptives 
(mostly hormonal) (51 reviews each), corticosteroids (26 reviews), and 
antidepressants (25 reviews).  
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Figure 10.1 Number of systematic reviews of adverse effects 1994-2011 
 
*2011 is incomplete as searches were carried out in July 2011 and it takes time for 
all reviews published in a year to appear in bibliographic databases and 
subsequently be identified and included in DARE. For the same reason data from 
the year 2010 may be incomplete. 
 
10.3.1.2 Scope of adverse effects evaluation 
Some of the reviews (473/849, 56%) concentrated on pre-specified adverse effect 
outcomes (such as thrombosis or stroke) or a pre-specified class of effects (such as 
gastrointestinal or cardiovascular) (190/849, 22%), rather than analysing all 
potential adverse effects for a given intervention (186/849, 22%). This pattern 
remains consistent throughout the time period studied. 
 
10.3.1.3 Study designs included 
The reporting of study design appears to be improving as the proportion of reviews 
including unclear study designs (such as ‘epidemiological studies’, ‘prospective and 
retrospective studies’, or ‘empirical studies’) or with no study design reported has 
decreased (Appendix C: Table 15.15). Overall, about 3% (25/849) of reviews did not 
report on the types of studies included in their analysis and 19% (165/849) were 
unclear in their description of some of the included studies (Appendix C: Table 
15.15). 
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There has been a slight increase in reviews limited to data from RCTs since 1994 
with an overall average of 33% (280/849) (Figure 10.2 and Appendix C: Table 
15.15). 
Figure 10.2 Percentage of systematic reviews of adverse effects with included 
studies limited to RCTs only 1994-2011 
 
 
The proportion of reviews that include randomised controlled trials (RCTs) or cohort 
studies has seen a general increase since 1994, with an overall average of 61% 
(517/849), and 37% (310/849) respectively (Figure 10.3 and Appendix C: Table 
15.15). However, the proportion of reviews including case-control studies has not 
increased, with an overall average of 25% (216/849). Case series and case reports 
were not included in many reviews, 8% (68/849) and 6% (55/849) respectively. 
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Figure 10.3 Percentage of systematic reviews of adverse effects including 
RCTs, cohort studies and case-control studies 1994-2011 
 
 
10.3.2 Conduct of the review 
10.3.2.1 Resources searched 
Nearly all of the reviews (837/849, 99%) listed the resources used to identify the 
primary studies for the review. Eight reviews did not report on the search methods 
used, and in four reviews it was not possible to accurately determine the data 
sources because of incomplete reporting or vague statements, such as ‘we used 
computer based searches and bibliographies of published articles’ or ‘studies were 
identified from review articles, computer aided literature searches and from 
discussion with colleagues’.  
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10.3.2.2 Databases and other sources searched 
Twelve reviews did not specify the number of databases searched. Of those that 
did, the median number of databases searched was three (range 0 to 25). Four 
reviews stated that they did not search any bibliographic databases. One hundred 
and seventy one reviews (171/837, 20%) searched one database and in 164 cases 
this was MEDLINE. Less than half of the reviews searched two or fewer databases 
(359/837, 43%) and nearly a quarter (192/837, 23%) searched more than four 
databases (Figure 10.4).  
Figure 10.4 Number of databases searched within each systematic review 
 
The number of databases searched per systematic review appears to have 
increased since 1994, with a median of one or two databases in each year from 
1994 to 2001 and three or four databases in each year from 2002 to 2011 
(Appendix C: Table 15.16). The median number of non-database sources searched 
throughout the time period studied remained constant, at one or two each year 
(Appendix C: Table 15.16).  
 
The most frequently searched database was MEDLINE (817/849, 96%), followed by 
EMBASE (462/849, 54%) (Table 10.1). Many reviews (88%, 743/849) reported 
searching at least one source other than databases. Reference lists were by far the 
most popular non-database resource (642/849, 76%) (Table 10.1). In addition, 
some more recent reviews are looking at manufacturers package inserts (13 
reviews) and related articles feature in PubMed (10 reviews). 
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Table 10.1 Sources searched in order of frequency 
Data Source Reviews that searched each 
source, N=849  
MEDLINE 817 (96%) 
Reference lists of published studies 642 (76%) 
EMBASE 462 (54%) 
CENTRAL* 205 (24%) 
Cochrane Library* 176 (21%) 
Contacting experts 156 (18%) 
Scanned conference reports 142 (17%) 
Industry data 110 (13%) 
CINAHL 107 (13%) 
Cochrane Database of Systematic Reviews (CDSR)*  69 (8%) 
Handsearching  65 (8%) 
BIOSIS Previews/Biological Abstracts  64 (8%) 
Current Contents**  56 (7%) 
PsycINFO/PsycLit  52 (6%) 
Web of Science***  52 (6%) 
Database of Abstracts of Reviews of Effects (DARE)*  48 (6%) 
FDA website  47 (6%) 
Science Citation Index (SCI)**  45 (5%) 
Cochrane Registers (e.g. Cochrane Schizophrenia Group')  38 (4%) 
Textbooks  38 (4%) 
Internet  34 (4%) 
Personal files  31 (4%) 
Citation searches  27 (3%) 
HealthStar (no longer available)  29 (3%) 
ClinicalTrials.gov  25 (3%) 
International Pharmaceutical Abstracts (IPA)  25 (3%) 
LILACS  25 (3%) 
Surveillance data  22 (3%) 
Scopus  21 (2%) 
CancerLit (no longer available)  20 (2%) 
Allied and Complementary Medicine Database (AMED)  19 (2%) 
ACP Journal Club  17 (2%) 
TOXLINE  17 (2%) 
Dissertation Abstracts (now Dissertations and Theses: 
Abstract and Index (ProQuest)) 
 16 (2%) 
Google Scholar  15 (2%) 
POPLINE  15 (2%) 
Manufacturers Package Insert  13 (2%) 
Current controlled trials.gov  12 (1%) 
Centralised Information Service for Complementary 
Medicine (CISCOM) 
 11 (1%) 
Health Technology Assessment (HTA) Database  11 (1%) 
ISI Proceedings  10 (1%) 
National Research Register (NRR)  10 (1%) 
Related Articles in PubMed  10 (1%) 
NHS Economic Evaluation Database (NHS EED)   9 (1%) 
National Institutes of Health website   8 (1%) 
OVID***   8 (1%) 
Reprotox   9 (1%) 
Web of Knowledge***   6 (1%) 
Australian New Zealand Clinical Trials Registry (ANZCTR)   5 (1%) 
Iowa Drug Information Service (IDIS)   5 (1%) 
PASCAL   5 (1%) 
SIGLE (now open sigle)   5 (1%) 
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Sources searched in four reviews or less are excluded. 
*Searches of The Cochrane Library may have included CDSR, CENTRAL, DARE, 
NHS EED, and/or the HTA Database.  
**Overlap exists between Current Contents and Science Citation Index (SCI). 
*** Interface described as source in the review 
 
10.3.2.3 Trends in databases searched 
Almost all the reviews after 1998 searched MEDLINE and the proportion of reviews 
searching EMBASE, CENTRAL and ‘The Cochrane Library’ (which might also 
include CENTRAL) increased dramatically after the late 1990s (Figure 10.5 and 
Appendix C: Table 15.17).  
Figure 10.5 Percentage of systematic reviews searching the top four 
databases 1994-2011 
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Figure 10.6 Percentage of systematic reviews searching only MEDLINE 1994-
2011 
 
 
The percentage of reviews that included searches of MEDLINE with no other 
databases has decreased over the time period studied (Figure 10.6). 
 
10.3.2.4 Trends in use of non-database sources 
Reference lists remained the most popular non-database source throughout the 
time period studied (overall 76%), although scanning conference reports has seen 
an upsurge since 1999 (overall 17%) (Figure 10.7 and Appendix C: Table 15.18). 
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Figure 10.7 Percentage of systematic reviews searching the top four non-
databases 1994-2011 
 
 
10.3.2.5 Grey literature and unpublished data 
Few attempts to retrieve grey literature or unpublished data via specialist database 
searches were reported. Sixteen reviews searched Dissertation Abstracts (now 
Dissertations and Theses: Abstract and Index (ProQuest)), 10 searched ISI 
Proceedings, five reviews reported searching SIGLE (now OpenSIGLE - System for 
Information on Grey Literature in Europe), and one review searched Conference 
Papers Index (CPI) (Table 10.1) 
 
Non-database sources of unpublished data or grey literature included contacting 
experts (156/849, 18%), scanning conference reports (142/849, 17%), seeking 
pharmaceutical company data (110/849, 13%), searching the FDA website (47/849, 
6%), and using surveillance data (22/849, 3%) (Table 10.1).  
 
Fifty-five reviews (6%) sought ongoing studies by either searching ClinicalTrials.gov 
(25 reviews), Current controlled trials.gov (12 reviews), the National Research 
Register (NRR) (now discontinued) (10 reviews), the National Institutes of Health 
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website (eight reviews), Australian New Zealand Clinical Trials Registry (ANZCTR) 
(five reviews), the International Standard Randomised Controlled Trial Number 
(ISRCTN) Register (three reviews), the WHO International Clinical Trials Registry 
Platform (ICTPR) (three reviews), Ongoing Skins Trials Register (two reviews), 
Netherlands Trials Registry (NTR) (one review), University Hospital Medical 
Information Network (UMIN) Clinical Trial Registry (one review), or by searching a 
unspecified clinical trials register (10 reviews). 
 
10.3.2.6 Dedicated adverse effects sources 
Seventy-two reviews reported that they had searched at least one specialist 
resource for adverse effects. Many of these reviews had searched more than one 
source. Thirty-eight reviews consulted textbooks and although many did not specify 
the textbooks searched, of those that did the most popular were: Drugs in 
Pregnancy and Lactation and the Physicians’ Desk Reference. Another 22 reviews 
attempted to retrieve surveillance data while others used specialist adverse effects 
databases, the most popular being TOXLINE (17 reviews). Other specialist sources 
consulted were Reprotox (nine reviews), DART (three reviews), Reactions (three 
reviews), Teris (three reviews), and Motherisk (one review). 
 
Although few reviews searched specialist databases of adverse drug reactions, 
some reviews did search drug information databases such as International 
Pharmaceutical Abstracts (IPA) (25 reviews), Iowa Drug Information Service (IDIS) 
(five reviews), Derwent Drug File (three reviews) and Pharmline (two reviews). In 
addition, 47 consulted the U.S. Food and Drug Administration (FDA) website and 
eight consulted the European Medicines Agency (EMA) (previously EMEA) website. 
 
10.3.2.7 Database interfaces/software 
The use of different software for interrogating databases can impact on the results. 
For instance, MEDLINE via PubMed rather than OVID offers more records and 
automatic modification of search terms to enhance retrieval. The majority of the 
reviews did not give any indication of the database interfaces used (574/849, 68%). 
The most common interfaces stated were PubMed (184 reviews, 22%), OVID (67 
reviews, 8%), and Web of Science (50 reviews, 6%). 
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10.3.2.8 Reporting of search strategies 
The proportion of reviews (725/849, 85%) providing some information on search 
strategies has increased over time, as has the proportion of reviews giving sufficient 
detail to allow the search to be reproduced according to the criteria stated earlier in 
this chapter. Overall, only 9% (74/849) of the reviews reported reproducible 
searches (even when web appendices and supplementary materials were 
considered) (Figure 10.8 and Appendix C: Table 15.19).  
 
Those searches that were not reproducible typically used unclear terminology (such 
as ‘the following terms were searched’ or ‘the keywords … were used’ or simply 
‘we searched for XYZ’) and gave no indication of the following: 
 whether the terms were entered as text words, indexing terms, or 
subheadings 
 if indexing terms had been exploded (for example, exploding the term 
‘neoplasms’ will retrieve narrower terms such as breast neoplasm etc.) 
 whether text words had been truncated (for example, smok* to retrieve 
smoking, smoke, smokers etc.) 
 how the terms had been combined together (for example, using the Boolean 
operators, OR, AND or NOT) 
 
Those reviews that contained reproducible search strategies tended to have either 
an appendix or table with the complete search strategy listed (65/74, 89%). 
Cochrane reviews were also more likely to contain reproducible search strategies 
(14 of the 74 reviews with reproducible search strategies were published in CDSR). 
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Figure 10.8 Percentage of systematic reviews with reproducible search 
strategies 1994-2011 
 
 
10.3.2.9 Quality of search strategies 
Research has indicated that the sensitive searches required for systematic reviews 
should generally incorporate a mixture of text words and indexing terms, a range of 
synonyms and truncation where appropriate.22, 23 The search strategies reported in 
this survey were of variable quality. Of those reviews that provided information on 
their search strategies, few (152/725, 21%) reported the fields (such as title, 
abstract or indexing) to which the search terms were restricted. Over a third 
(60/152, 39%) used no text words for at least one category of terms (for example, 
intervention) relying solely on indexing terms. Nearly a fifth (28/152, 18%) used no 
indexing terms for at least one category of terms and relied solely on text words.  
 
Of the 92 reviews that used text words, 26 did not use any synonyms for at least 
one of the facets and 12 of the 92 reviews that used text words did not use any 
truncation where it may have been appropriate. 
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10.3.2.10 Search terms used 
Most reviews (725/849, 85%) indicated the actual terms used or the category of 
terms used, such as the population, disease, intervention, comparator, outcome 
(Table 10.2).  
Table 10.2 Categories of search terms used in database search strategies 
Category 
Reviews using terms in 
category, N=849 
Population (e.g. elderly)  97 (11%) 
Disease 179 (21%) 
Intervention 702 (83%) 
Comparison  10 (1%) 
Outcome: named adverse effect (e.g. headache) 393 (46%) 
Outcome: generic adverse effect (e.g. adverse 
effects, side effects or complications) 
 39 (5%) 
Outcome: named adverse effect and generic adverse 
effect 
 90 (11%) 
Methodological filters (e.g. randomized controlled 
trials) 
199 (23%) 
Search strategy not stated 124 (15%) 
 
Those search strategies that incorporated terms for the outcomes/adverse effects 
(in 522 reviews) tended to search on specific adverse effects (such as ‘thrombosis’ 
or ‘headache’) (393 reviews) rather than using a combination of specific adverse 
effects and generic adverse effects (such as adverse effects, side effects or 
complications) (90 reviews) or solely generic outcome terms (39 reviews). Five 
reviews relied on adverse effects terms alone, such as liver damage, root sensitivity, 
thrombocytopenia or ectopic pregnancy with no other category of terms used. 
 
It was difficult to ascertain how many reviews used generic adverse effects indexing 
terms or subheadings, as only 32 reviews using generic outcome terms stated the 
fields searched. Fourteen reviews stated that they used generic adverse effects 
indexing terms (such as Medical Subject Headings (MeSH)) and 16 stated that they 
had used generic adverse effects subheadings/qualifiers such as ‘adverse effects’, 
‘complications’, ‘toxicity’ or ‘poisoning’. Only two reviews reported using ‘floating’ 
subheadings, that is, subheadings not attached to any indexing terms. One review 
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reported using the floating subheading ‘adverse events’ in MEDLINE (although the 
authors probably meant ‘adverse effects’, as this is the subheading available in 
MEDLINE) and the other review reported using the subheadings ‘adverse effects’ 
and ‘complications’. 
 
10.3.2.11 Search restrictions 
Of the 661 reviews that gave a date range for the searches, 219 (219/661, 33%) 
applied date restrictions later than the year of inception of the databases searched. 
Only 61 (61/219, 29%) of the reviews that restricted by date gave a reason for this 
restriction. such as the review was an update of an existing review, the drug was 
only available since that date, or a change in medical practice meant that research 
before that date was not applicable.  
 
In around half of the reviews (50%, 421/849) it was unclear whether the searches 
had been restricted by language; 17% (146/849) explicitly restricted by language 
and 33% (282/849) explicitly did not. 
 
Using data from those reviews stating whether or not date restrictions or language 
restrictions were applied, there is some evidence that fewer reviews may be 
restricting their searches by date (other than the year of inception of the databases) 
or by language (Figure 10.9 and Appendix C: Table 15.20). 
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Figure 10.9 Percentage of systematic reviews with date or language 
restrictions 1994-2011 
 
 
10.3.2.12 Conducting the searches 
Only 109 (109/849, 13%) of the reviews gave any indication as to the qualifications 
of the person who conducted the searches. Of those that did, 73 were conducted by 
qualified librarians or information professionals and 36 by researchers. The 
literature searches performed by information professionals tended to be carried out 
in more databases (median 4) than those performed by non-information 
professionals (median 2) or where the searcher was not reported (median 3) (Table 
10.3). 
  
0%
20%
40%
60%
80%
100%
120%
P
e
rc
e
n
ta
ge
 o
f 
sy
st
e
m
at
ic
 r
e
vi
e
w
s 
date restriction language restriction
 155 
Table 10.3 Profession of searcher and number of sources searched 
Searches 
conducted by 
Median and range 
of databases 
searched 
Median and range 
of other sources 
searched 
Median and range 
of total sources 
searched 
Information 
professional 
(N=73) 
4 (1–25) 2 (0–48) 6 (1–58) 
Non-information 
professional 
(N=36) 
2 (0–10) 1 (0–6) 4 (1–10) 
Unclear or not 
reported (N=740) 
3 (0–17) 1 (0–37) 4 (1–50) 
 
Reviews from this survey that list reproducible strategies were much more likely 
(25/73, 34%) to have been conducted by an information specialist than reviews 
which did not report reproducible searches – only 6% (48/775) of these were carried 
out by an information specialist. This was despite the fact that those searches 
produced by information specialists tended to include more search terms and were 
therefore more complex to report. 
 
10.3.2.13 Precision of searches 
Precision could be calculated in those reviews stating both the number of included 
studies and the total number of studies identified by the searches. Only 53% 
(449/849) of reviews stated the number of records retrieved by their literature 
searches. The median number of records retrieved was 631 (range 13 to 76,977) 
with 31 reviews reporting 5,000 records or more. The number of included studies 
was reported in all the reviews and ranged from one to 561 with a median of 18. 
The precision of the searches varied widely from 0.0026% (number needed to read, 
NNR, 380) to 63% (NNR, 2) with a median of 3% (NNR, 32). 
 
Although some reviews included a flow diagram, the starting point was not always 
the number of records identified by the searches and the starting point was unclear. 
In some instances, it might have been the number of potentially relevant records 
(after a first sift) or the number of full-text papers examined. The arduous and 
impractical nature of repeating searches meant that this information was not 
gathered. 
 
 156 
 Discussion 10.4
In this survey, only 5% of systematic reviews on CDSR and DARE were systematic 
reviews of adverse effects. This finding is consistent with earlier surveys.29, 108, 111 
Although the number of reviews of adverse effects appears to have increased over 
time, this exponential increase is in line with an increase in all systematic reviews of 
healthcare interventions and has been identified in other surveys.545 It would be 
interesting to assess the trend in the proportion of systematic reviews that primarily 
study effectiveness but also include adverse effects, as these might be increasing in 
line with Cochrane guidance, particularly in Cochrane reviews.  
 
There are several findings from this survey regarding the nature and methodology of 
the retrieval of information on adverse effects in systematic reviews that merit 
further discussion and, where possible, comparison to other surveys of the conduct 
and reporting of retrieval in systematic reviews.  
 
10.4.1 Characteristics of the included studies 
10.4.1.1 Types of interventions studied 
One area of concern is that systematic reviews identified in this survey have mainly 
been directed towards the adverse effects of pharmacological interventions 
throughout the time period studied. The disproportionate number of systematic 
reviews of pharmacological interventions is demonstrated when the results of this 
survey are compared to other surveys of systematic reviews.109 This might occur as 
a result of licensing requirements, leading to more primary studies reporting adverse 
drug reactions, or a perception that medications can have more unwanted side 
effects than other types of healthcare intervention. This emphasis on drug therapy 
has already been identified as a key issue, given that surgical and other physical 
interventions are widely used in healthcare, and can have equally important or 
serious adverse effects.110 In Chapters 4 to 9 the majority of the empirical evidence 
conducted in the retrieval of adverse effects data was also concerned with drug 
interventions. The lack of evidence for non-pharmaceutical research could also be a 
hindrance for authors of systematic reviews. 
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10.4.1.2 Scope of adverse effects evaluation 
Throughout the time period studied, the proportion of systematic reviews that 
focused on pre-specified adverse outcomes of interest was high (78%). The 
possible indication is that many reviewers continued to have an a priori hypothesis 
when conducting a review and the detection of new, unrecognised adverse effects 
was of lesser interest. Indeed they might think that a systematic review is not a good 
way to identify new adverse effects. Similarly, a recent survey of drug safety reviews 
also found that 80% of reviews evaluated pre-specified adverse outcomes of 
interest.546 It was interesting to note that the proportion of reviews attempting to 
conduct a complete safety profile had not declined over the years, given the relative 
ease of concentrating on a few major outcomes. Conversely, some researchers 
argue that the focused approach is more immediately able to yield clinically relevant 
results than broader reviews, which might not aim to prove or disprove specific 
hypotheses (but could help to identify important signals for further evaluation).113 
 
10.4.1.3 Study designs included 
Although reporting of study designs appears to be improving, many reviews still use 
unclear terminology to describe their included studies. However, it can often be 
difficult to decipher the type of observational study from the original full-text 
publication, as many primary studies either do not state the study type (e.g. cohort 
study or case-control study), do not report the methods used in enough detail or use 
methods that do not fit a predefined study design. 
 
Compared to other non-Cochrane systematic reviews, fewer reviews in the current 
study were restricted to RCTs.109, 140, 539 This probably stems from the widely held 
view that short-term trials in selected populations are not the best study design for 
the evaluation of rare or long-term adverse effects, and that reviewers might find it 
necessary to utilize other study designs.14, 19-21, 27, 42, 65, 76, 77, 85, 89, 116, 127, 129, 132, 133, 139-
141, 143, 144, 168-178 However, it was interesting to note that contrary to current evidence 
(Chapter 4),22, 23, 547 the proportion of reviews limiting their included studies to RCTs 
does not appear to be decreasing, but may even be increasing in systematic 
reviews of adverse effects. 
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Cochrane reviews included in this survey were all limited to RCTs, in line with other 
studies that have found Cochrane reviews assessing adverse effects are generally 
restricted to RCTs meeting the effectiveness review eligibility criteria.27, 29, 30, 539, 548 
 
10.4.2 Conduct of the review 
10.4.2.1 Resources searched 
In line with recommendations in the literature,549-552 the majority of reviews in the 
current study explicitly reported on the databases and information sources 
searched. Possibly this reflects the source of the systematic reviews in this survey, 
as Cochrane reviews are expected to adhere to strict reporting guidelines22 and 
have been found to be more rigorous than reviews published in peer reviewed 
journals107, 109, 518, 540, 553, 554 and reviews included in DARE have met a basic quality 
threshold.542, 543 
 
10.4.2.2  Databases and other sources searched 
The number of sources searched (median 3, range 0 to 25) was similar to that 
reported in systematic reviews of cancer (median 3, range 1 to 25),545 but lower than 
that reported in systematic reviews of qualitative data (median 5, range 1 to 23),527 
and higher than in systematic reviews of adverse drug reactions (median 2, range 1-
13).555 This might reflect the nature of searching for qualitative data and drug data. 
Specialist databases for qualitative data are sadly lacking, necessitating a wide 
selection of databases, and few affordable databases are restricted to drug 
information. 
 
Many reviews in the current study (88%) reported searching at least one source 
other than databases. A survey of Cochrane and non-Cochrane reviews also 
identified a high proportion of reviews using non-database sources (91%).533 
 
A number of other surveys of systematic reviews also indicated the sources 
searched in their individual reviews.107, 516-518, 520, 521, 523, 531, 537, 546, 555 Table 10.4 gives 
a comparison of the database and non-database sources searched in this survey of 
systematic reviews of adverse effects with sources searched in other surveys of 
reviews. Comparisons could only be made with those surveys of other reviews 
publishing data on the number or percentage of individual sources searched.  
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Table 10.4 Sources searched in systematic reviews of adverse effects compared to 
other reviews 
Data Source Percentage of reviews, topic area and publication year 
MEDLINE 100% Adverse drug effects 2009
555
 
100% Medical education 2011
537
 
 99% Pediatric oncology 2009
545
 
 97% Dentistry 2003
523
 
 96% Adverse effects (current study) 
 93% Complementary medicine and safety 2012
556
 
 93% Effectiveness 1998
516, 517
 
 91% Physiotherapy 2009
107
 
 89+% Drug safety 2012
546
 
 79% Emergency medicine 2001
520
 
 68% Qualitative data 2006
527
 
 68% Paediatric complementary and alternative medicine 2002
521
 
 66% Asthma interventions 2000
518
 
Reference lists of 
published studies 
 87% Physiotherapy 2009
107
 
 76% Adverse effects (current study) 
 72% Complementary medicine and safety 2012
556
 
 72% Pediatric oncology 2009
545
 
 72% Paediatric complementary and alternative medicine 2002
521
 
 70+% Drug safety 2012
546
 
 62% Emergency medicine 2001
520
 
 54% Asthma interventions 2000
518
 
EMBASE  66% Complementary medicine and safety 2012
556
 
 65% Drug safety 2012
546
 
 59% Physiotherapy 2009
107
 
 54% Adverse effects (current study) 
 49% Pediatric oncology 2009
545
 
 47% Adverse drug effects 2009
555
 
 28% Paediatric complementary and alternative medicine 2002
521
 
 26% Dentistry 2003
523
 
 24%
 
Effectiveness 1998
516, 517
 
 3% Emergency medicine 2001
520
 
CENTRAL  32% Pediatric oncology 2009
545
 
 24% Adverse effects (current study) 
 15% Dentistry 2003
523
 
Cochrane Library  82% Drug safety 2012
546
 
 68% Complementary medicine and safety 2012
556
 
 55% Physiotherapy 2009
107
  
 44% Adverse drug effects 2009
555
 
 36% Paediatric complementary and alternative medicine 2002
521
 
 21% Adverse effects (current study) 
 12% Effectiveness 1998
516, 517
 
Contacting 
experts 
 43% Physiotherapy 2009
107
 
 34% Paediatric complementary and alternative medicine 2002
521
 
 28% Asthma interventions 2000
518
 
 28% Pediatric oncology 2009
545
 
 24+% Drug safety 2012
546
 
 18% Adverse effects (current study) 
 14% Emergency Medicine 2001
520
 
Scanned 
conference 
reports 
 35% Drug safety 2012
546
 
 22% Pediatric oncology 2009
545
 
 17% Adverse effects (current study) 
 17% Paediatric complementary and alternative medicine 2002
521
 
Industry data  43% Drug safety 2012
546
 
 13% Adverse effects (current study) 
 13% Paediatric complementary and alternative medicine 2002
521
 
CINAHL  70% Qualitative data 2006
527
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Table 10.4 Sources searched in systematic reviews of adverse effects compared to 
other reviews 
Data Source Percentage of reviews, topic area and publication year 
 52% Physiotherapy 2009
107
 
 42% Medical education 2011
537
 
 24% Complementary medicine and safety 2012
556
 
 21% Paediatric complementary and alternative medicine 2002
521
 
 15% Pediatric oncology 2009
545
 
 13% Adverse effects (current study) 
  7% Effectiveness 1998
516, 517
 
  5% Drug safety 2012
546
 
Handsearching  79% Medical education 2011
537
 
 26% Dentistry 2003
523
 
 24% Asthma interventions 2000
518
 
 23% Paediatric complementary and alternative medicine 2002
521
 
 10% Emergency medicine 2001
520
 
  8% Adverse effects (current study) 
  6% Drug safety 2012
546
 
BIOSIS 
Previews/Biologic
al Abstracts 
 13% Paediatric complementary and alternative medicine 2002
521
 
  8% Adverse effects (current study) 
  4% Physiotherapy 2009
107
 
Current Contents  10% Effectiveness 1998
516, 517
 
  7% Adverse effects (current study) 
  7% Physiotherapy 2009
107
 
  6% Paediatric complementary and alternative medicine 2002
521
 
PsycINFO/ 
PsycLit 
 57% Qualitative data 2006
527
 
 34% Paediatric complementary and alternative medicine 2002
521
 
 18% Physiotherapy 2009
107
 
  6% Adverse effects (current study) 
  4% Drug safety 2012
546
 
Web of Science**  11% Drug safety 2012
546
 
  5% Adverse effects (current study) 
Science Citation 
Index (SCI) 
 14% Physiotherapy 2009
107
 
 11% Paediatric complementary and alternative medicine 2002
521
 
  5% Adverse effects (current study) 
Textbooks/ 
bulletins 
 12% Pediatric oncology 2009
545
 
  4% Adverse effects (current study) 
  4% Drug safety 2012
546
 
Personal files   6% Paediatric complementary and alternative medicine 2002
521
 
  4% Adverse effects (current study) 
HealthStar (no 
longer available) 
  8% Physiotherapy 2009
107
 
  4% Paediatric complementary and alternative medicine 2002
521
 
  3% Adverse effects (current study) 
  2% Drug safety 2012
546
 
International 
Pharmaceutical 
Abstracts (IPA) 
  3% Adverse effects (current study) 
  2% Drug safety 2012
546
 
AMED   2% Adverse effects (current study) 
 49% Complementary medicine and safety 2012
556
 
CancerLit  25% Pediatric oncology 2009
545
 
  2% Adverse effects (current study) 
Dissertations and 
Theses: Abstract 
and Index 
(ProQuest)  
 15% Paediatric complementary and alternative medicine 2002
521
 
  7% Physiotherapy 2009
107
 
  2% Adverse effects (current study) 
Google Scholar   2% Adverse effects (current study) 
  2% Drug safety 2012
546
 
Manufacturers   2% Adverse effects (current study) 
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Table 10.4 Sources searched in systematic reviews of adverse effects compared to 
other reviews 
Data Source Percentage of reviews, topic area and publication year 
Package Insert   2% Drug safety 2012
546
 
CISCOM   1% Adverse effects (current study) 
 32% Complementary medicine and safety 2012
556
 
OVID**   4% Drug safety 2012
546
 
  1% Adverse effects (current study) 
OPEN SIGLE    2% Drug safety 2012
546
 
  1% Adverse effects (current study) 
 
*In the current survey the terminology used by the authors of the systematic reviews 
was accepted. For example, where authors stated that they searched CDSR this 
was categorized as CDSR and where they stated that they had searched ‘The 
Cochrane Library’, this was categorized separately as ‘The Cochrane Library’. Other 
surveys may have accepted statements such as ‘we searched CDSR’ to mean that 
‘The Cochrane Library’ was searched. 
**In some reviews the interface was described as if it was a database 
 
The current survey demonstrates many similarities with other surveys of systematic 
reviews, in terms of the percentage of reviews that search particular sources. Table 
10.4 illustrates the popularity of MEDLINE and reference checking among all types 
of reviews. Although the current survey is not limited to any particular type of 
intervention, the majority of the reviews evaluate adverse drug effects (621/849, 
73%). In this survey, the percentage that search each resource is very similar to 
other studies of reviews of adverse drug reactions, with the exception of The 
Cochrane Library (Table 10.4).546, 555 For example, MEDLINE is searched in 96% of 
the reviews in this survey, compared with 100% in the survey by Cornelius et al 
2009555 and over 89% in the survey by Alves et al 2012.546 EMBASE is searched in 
54% of reviews in the current survey, compared with 47% in the survey by Cornelius 
et al 2009.555 The difference with respect to searching The Cochrane Library may 
arise from the different categorizations used, as searches of The Cochrane Library 
databases may be listed individually (such as CDSR, CENTRAL or DARE) or 
collectively as ‘The Cochrane Library’. The present study distinguishes between 
reviews stating that they searched named databases in The Cochrane Library (such 
as CENTRAL) and reviews stating that they searched ‘The Cochrane Library’. 
 
Many of the differences between reviews as to the sources searched can largely be 
explained in terms of topic area or date. For example, CINAHL, which specializes in 
nursing and allied health, is searched more often in reviews of qualitative 
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research,527 physiotherapy,107 medical education,537 and paediatric complementary 
and alternative medicine.521 EMBASE, which is a well-known source for drug and 
general medical information, is searched more often in drug and physiotherapy 
reviews or more recent reviews. PsycINFO/PsycLit is searched more often in 
reviews of qualitative data527 and reviews of paediatric complementary and 
alternative medicine.521 In this survey, fewer reviews were restricted to MEDLINE 
(20%) than a previous survey of systematic reviews of orthodontics 2000-2004 (in 
which 56% searched only MEDLINE)528 or in a survey of pediatric oncology reviews 
1998-2007 (in which 31% searched only MEDLINE).545 This may reflect the more 
diverse databases required for searching for adverse effects data, or the time period 
studied. There is also a general trend for more recent reviews to include more 
databases, particularly, with EMBASE and The Cochrane Library.  
 
10.4.2.3 Trends in databases searched 
The number of databases searched overall appears to be increasing over the time 
period 1994-2011, with a decline in the number of reviews of adverse effects 
searching only MEDLINE or only one database. This may be due to previous 
studies that demonstrated the usefulness of searching beyond MEDLINE or 
searching more than one source for clinical effectiveness information,557-560 and 
other studies, such as those included in Chapter 5, which have indicated that 
MEDLINE is not the most useful source of information on adverse drug reactions.355, 
357, 360, 364-366, 368, 370, 561 Another factor could be the increasing number of databases 
available to researchers, either through institutional subscriptions, or free of charge 
via the Internet. Another survey also identified an increase in the searching of 
MEDLINE, EMBASE, CINAHL, The Cochrane Library, and reference checking. 562  
 
10.4.2.4 Trends in use of non-database sources 
The number of other sources searched remains low, with a median of one or two 
sources searched per review for each publication year. The popularity of reference 
checking throughout the period studied is unsurprising given its low cost and relative 
ease. 
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10.4.2.5 Grey literature and unpublished data 
The research in Chapters 7 and 8 demonstrate that data on adverse effects from 
industry and unpublished sources can make a major contribution to reviews of 
adverse effects. In this survey, relatively few reviews (110/849, 13%) reported an 
attempt to source information from pharmaceutical companies and attempts to 
source unpublished data and grey literature were lacking. 
 
10.4.2.6 Dedicated adverse effects sources 
The evidence reported in Chapter 5 also demonstrates the value of searching 
Derwent Drug File, yet only three of the 849 reviews searched this database. Other 
dedicated sources of adverse effects might also be useful but have rarely been 
searched.  
 
10.4.2.7 Database interfaces/software 
The majority of the reviews in this survey give no indication of the database 
interface used (68%). This is consistent with a survey of Cochrane reviews535 in 
which 83% did not mention the database platform and a survey of Cochrane and 
non-Cochrane reviews533 in which 64% failed to mention the database platform. 
 
10.4.2.8 Reporting of search strategies 
Detailed reporting of the full literature search process for systematic reviews is 
recommended and can impact on reader confidence in the results and 
conclusions.22, 23, 563, 564,550 For nearly 25 years, guidelines on the reporting of 
systematic reviews have included recommendations that reviews should give a 
clear description of the methods of the literature search, including specifying the 
sources searched, search terms used and any language or date restrictions, in 
order that the search might be repeated.5, 549-552, 564-567 As with other surveys109, 528, 
531, 533, 535, 537 a high proportion of reviews in this study (725/849, 85%) provide some 
information on their search strategy, though, few have given sufficient detail to allow 
the search to be reproduced according to the criteria stated earlier (74/849, 9%). 
This lack of detail causes difficulty with determining search adequacy, making it 
impossible for other researchers to replicate searches. The absence of a detailed 
search strategy creates obvious difficulties for future researchers who may need to 
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update a particular systematic review as well as for readers trying to assess its 
quality. Other studies have highlighted the failure of systematic reviews to report 
whether a comprehensive search strategy was undertaken,511-532 with reproducibility 
of search strategies between 0% and 8.2%.516, 517, 534, 537, 556 
 
It was reassuring to note an increase in the number of reproducible search 
strategies. The advent of electronic publishing and the potential for detailed search 
strategies to be published online as supplementary material might have been a 
contributing factor, as many of the reviews that reported reproducible search 
strategies published the full search strategy in an appendix or table.  
 
Although other studies have highlighted the failure of systematic reviews to report 
on the undertaking of a comprehensive search strategy,511-532 few studies have 
detailed analyses on the aspects of search methods that are poorly reported. 
However, two recent surveys of systematic reviews, one of 129 Cochrane Reviews 
and 168 non-Cochrane Reviews,533 and another of 65 Cochrane reviews,535 
assessed the reporting of a number of different attributes of the search process that 
were similar to attributes assessed in the current survey (Table 10.5). Comparison 
suggests that reporting of searches in systematic reviews of adverse effects is as 
complete or incomplete as that for other systematic reviews. Similar results have 
also been found in other types of systematic review for the reporting of language 
restrictions,109, 531, 533, 535, 537, 545, 556, 568 dates covered by searches,521, 533, 568 and 
search terms used.109, 531 
 
10.4.2.1 Quality of search strategies 
Many of the reported literature searches relied solely on indexing or text word 
searches, with little use of synonyms and truncation, which are often crucial aspects 
for the type of sensitive search strategy required by systematic reviews.22, 23 This 
may be particularly true in identifying information on adverse effects, given the 
inconsistent terminology and poor indexing in this area.19, 70, 118, 121, 123 
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Table 10.5 Reporting of items in systematic reviews 
Reported Item Current survey 
of systematic 
reviews of 
adverse effects 
(N=849) 
Survey of 
Cochrane 
reviews by 
Yoshii et al 
2009535 (N=65) 
Survey of 
systematic reviews 
identified on 
MEDLINE by 
Sampson and 
McGowan 2008533 
(N=297) 
Databases used 837 (99%) 100% 293 (99%) 
Database Platform  275 (32%) 17% 107 (36%) 
Dates covered by 
search 
661 (78%)  207 (70%) 
Search terms used 
stated 
725 (85%) 88% 254 (86%) 
Other sources used 743 (88%)  271 (91%) 
Language 
restrictions 
428 (50%) 69% 166 (56%) 
Qualifications of 
searcher 
109 (13%)  34 (11%) 
 
10.4.2.2 Search terms used 
Of the 725 reported search strategies, the majority (702/725, 97%) searched on 
terms for the intervention, such as aspirin or acupuncture. It would be also expected 
that the vast majority of reviews of effectiveness would include intervention terms. 
 
However, unlike searches for systematic reviews of clinical effectiveness the 
searches for systematic reviews of adverse effects in this survey tended to search 
for ‘outcome’ terms (in this case adverse effects terms) (72%). Difficulties exist with 
searching either generic adverse effects terms or specified adverse effects, with 
research indicating that the use of both generic adverse effects terms and specific 
adverse effects terms retrieves only 77% of the available literature in MEDLINE and 
EMBASE and that handsearching of journals may be the only way to identify some 
articles.118  
 
For reviews that use databases to search for all adverse effects for a given 
intervention, a search using floating subheadings (such as ‘adverse effects’, or 
‘complications’) is recommended.360, 427, 428, 439 In this survey, only two of the 849 
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reviews reported using floating subheadings for adverse effects, although this could, 
in part, reflect the poor reporting of the search strategies.  
 
Even when a search is carried out for named adverse effects, searching can be 
problematic. Wieland et al 2005121, 429 demonstrated the difficulty of searching for a 
specific adverse effect (breast cancer) associated with a particular intervention (oral 
contraceptives) and showed that to achieve 100% sensitivity, a search on only the 
adverse effect outcome (in this case breast cancer) might be required, without any 
terms for the intervention.121, 429 The majority of reviews in this survey searched on 
intervention and only four reviews searched for adverse effects terms alone. This 
probably reflects the impractical nature of searching on only adverse effects terms 
(due to the high number of records retrieved) but may also indicate that relevant 
studies were missed in many reviews. 
 
10.4.2.3 Search restrictions 
In line with current guidance, it was reassuring to see a decline in the use of date 
and language restrictions in systematic review search strategies, particularly as the 
dramatic increase in the literature available could make such restrictions more 
tempting. 
 
10.4.2.4 Conducting the searches 
Although good practice guidelines on the reporting of meta-analysis such as the 
MOOSE (Meta-analysis of Observational Studies in Epidemiology) statement550 
require the authors to provide details on the qualifications of the searcher, the 
majority of the reviews in this survey did not comply with this requirement (87%). 
The finding is similar to a survey of Cochrane and non-Cochrane reviews in which 
only 11% gave some indication of the qualifications of the searcher.533 Overall, 9% 
(73/849) of the searches were reported to have been conducted by a qualified 
librarian or information professional. Low numbers of medical education reviews 
also reported the involvement of an information professional (15%).537 
 
In this survey, literature searches carried out by information professionals were 
more likely to be reproducible, to include more search terms, and to search more 
databases. Booth 2006 also found that more databases were searched in reviews 
involving an information professional,527 and Sampson and McGowan 2008 found 
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the reporting of the role of the searcher to be associated with greater reproducibility 
of searches.569  
 
10.4.2.5 Precision of searches 
The precision of the searches in the current survey (median of 3%, range 0.0026% 
to 63%) was similar to a study by Sampson et al 2011 (median of 3%, range 0.7% 
to 36%),570 demonstrating that although searching for adverse effects may be 
difficult, searches tend to retrieve a similar proportion of relevant studies to other 
types of review. Decisions by searchers of adverse effects to be pragmatic and risk 
missing relevant studies, by for example including adverse effects/outcome terms, 
might account for this. 
 
The problems identified with flow charts in this survey have been identified in 
previous research,536 and few reviews have been found to include a flow diagram.104 
 
 Limitations  10.5
This survey is based on what authors of the included systematic reviews reported. 
Reporting was often unclear. For example, study design descriptions such as 
‘prospective’ or ‘retrospective studies’ were used, databases were described only by 
their provider, such as, OVID, EBSCO and Web of Science, and searching 
descriptions such as ‘handsearching’ were used without stating the sources 
handsearched. 
 
In the absence of better reporting, it is impossible make a more detailed judgement 
of the quality of the search strategies in systematic reviews of adverse effects. For 
the majority of the data collected for this survey it is also difficult to identify any 
trends over the time period covered, as information on search methodology reported 
by the review authors is lacking. However, the present study does indicate an 
increase in the number of sources searched and a reduction in search date limits 
over time, in line with other surveys that have also indicated improvements in the 
search process adopted.107, 540, 541 
 
The reported numbers of sources searched by the 50 Cochrane reviews in this case 
study are also likely to be an underestimate, as most Cochrane reviews use 
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specialist registers that typically include extensive searches of bibliographic 
databases, such as MEDLINE, and handsearches of journals. 
 
The results from this survey may not be representative of all systematic reviews of 
adverse effects. The study examined systematic reviews of adverse effects 
identified from CDSR and DARE, both of which have detailed criteria for considering 
the conduct of searches in systematic reviews. For instance, DARE requires one 
database plus at least one other source to have been searched, for example, 
another database, a handsearch, reference lists, or contact with authors. (This can 
be reported in the published review or the information obtained from elsewhere, 
such as a website, another publication, or the authors). Equally, the Cochrane 
Handbook provides explicit recommendations on the nature of the databases (such 
as CENTRAL, MEDLINE, and EMBASE) that should be included in searches. 
Hence, these findings may not be generalizable to wider situations, where 
“systematic” reviews are more loosely defined, and the quality of the searches might 
be less apparent.  
 
This review also gives no indication of the reporting or search techniques used in 
systematic reviews where adverse effects are a secondary objective. At present, it 
is unclear how systematic reviews directed at effectiveness build in a component of 
adverse effects analysis as a secondary endpoint and further research is required. 
 
 Conclusions 10.6
Positive trends were seen in the conduct of searches with regard to the number of 
databases searched, including increased use of EMBASE and The Cochrane 
Library. Other improvements have included the decreasing proportion of systematic 
reviews limiting their search strategies by date or language, as well as more 
comprehensive reporting, by which reproducibility of search strategies is enhanced. 
However, these changes are not dramatic and few other improvements in search 
techniques were apparent throughout the time period studied. 
 
Despite efforts to improve the reporting of search methodology in systematic 
reviews, comprehensive and transparent reporting of search strategies still poses a 
problem. 
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 Summary 10.7
A survey was carried out of the search methodology in 849 systematic reviews of 
adverse effects published from 1994 to 2011.  
Comparisons were made to other types of reviews and trends over the time 
reported. 
Poor reporting of search strategies in systematic reviews of adverse effects made 
detailed analysis difficult. However, small improvements in search methodology 
were identified particularly in terms of the increasing number of databases searched 
and the decline in search restrictions applied. 
 
  
 170 
Chapter 11  The contribution of different sources for information on 
adverse drug reactions: a case study of fractures with thiazolinediones 
 Introduction 11.1
The survey of reviews in Chapter 10 indicates that, as with reviews of effectiveness, 
authors of systematic reviews of adverse effects tend to focus on searching 
MEDLINE and reference checking to identify relevant studies. However, empirical 
evidence collected in Chapter 5 suggests that MEDLINE may not yield the most 
data on adverse effects, particularly when searches are made for drug-related 
adverse reactions. Derwent Drug File, EMBASE and industry submissions may 
provide the highest number of relevant references or unique relevant references 
with information on adverse effects. Findings in Chapter 5 are limited, particularly in 
light of the age of the methodological evaluations included in the review, the 
restricted range of sources compared in each single evaluation, and the failure to 
take into account the effect of search strategies employed in each source. There are 
major time and cost implications of searching beyond MEDLINE, so the yield and 
contribution of other sources merits careful consideration.  
 
The results from the survey of reviews in Chapter 10 also indicate the varying 
methods used in systematic reviews of adverse effects. This variation may, in part, 
reflect the different questions posed in each review but also may reflect the lack of 
guidance on search methodology in this area. Further research should aim to clarify 
the value of specialist adverse effect databases, drug information databases, and 
other sources such as manufacturer’s data, in order that the benefits of information 
available from such sources, and the most efficient combinations can be 
determined.  
 
The objective of this stage of the research programme was to determine the 
contribution of searching a diverse range of sources to identify information on 
adverse drug reactions for a systematic review, taking into account any limitations of 
the search strategies.  
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 Methods 11.2
11.2.1  Case study 
A case study systematic review was carried out in order to be able to assess the 
contribution of different data sources. The following criteria were used to select the 
subject area for the case study systematic review: 
a) the intervention was a named drug  
b) the adverse drug reaction was a named discrete adverse effect, non-
subjective in diagnosis and for which search terms were easily defined 
c) there needed to be a large enough number of relevant studies with data on 
the adverse drug reaction to compare the retrieval rates from different 
sources 
d) relevant RCTs and observational studies with data on the adverse drug 
reaction were available. 
 
After discussion with clinicians and undertaking scoping searches on a number of 
potential topics, a case study systematic review of thiazolidinedione-related 
fractures in patients with type 2 diabetes mellitus was selected. This review was an 
update of a previous systematic review, with an increased number of sources 
searched.265 The protocol for this review update is contained in Appendix D. 
 
11.2.2 Search strategy 
In order to be able to assess the efficiency of using different sources to identify 
information on adverse drug reactions, a wide range of sources was searched for 
relevant studies for this case study review. Bibliographic databases, such as 
MEDLINE and EMBASE, were included, as well as specialist drug databases, such 
as Derwent Drug file and Iowa Drug Information Service (IDIS), sources with grey 
literature, such as Google and Medscape DrugInfo, the Manufacturer’s website, and 
databases of conference proceedings, such as Conference Papers Index (CPI) and 
Conference Proceedings Citation Index – Science. In addition to databases, other 
sources were searched, such as newsletters, bulletins, and referenced texts. A full 
list of sources searched is contained in the protocol in Appendix D. 
 
The search strategy used in each database contained just two components, namely 
the interventions; thiazolidinediones (rosiglitazone and pioglitazone) and the 
outcomes; fractures or bone mineral density. Indexing terms and terms in the title 
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and abstract (including multiple synonyms) were used for each component, where 
available. The strategy was translated for each database and kept as consistent as 
possible across databases in order that a fair comparison between database results 
could be made. In order to be able to assess the effectiveness of searching Internet 
search engines such as AltaVista, Google and Google Scholar only the first three 
pages of results of Internet searches were screened for relevant articles. The first 
three pages were selected, in order to reflect common practice in searching the 
Internet571-573 and due to the impractical nature of reviewing all the results from 
Internet searches, which can often be millions of pages. The full electronic search 
strategies used are contained in Appendix E. 
 
11.2.3 Analysis 
The included references from this case study systematic review formed the basis of 
the analysis. For the primary analysis, all publications with sufficient outcome data 
for meta-analysis (by either presenting enough data to calculate the odds ratio, 
relative risk, or weighted means difference, or by presenting the odds ratio, relative 
risk, or weighted means difference themselves) were included.  
 
11.2.3.1 Individual assessment of sources 
A record was made of the availability of each of the included references and where 
they were identified. For each reference available on a database but not identified 
by the search strategy, the bibliographic record was then examined to determine 
why it had not been identified. A record was also made of any relevant references 
identified or available from only one data source. 
 
The sensitivity, precision, and numbers needed to read (NNR) for the searches in 
each of the databases was calculated using the following definitions; 
 
Sensitivity (%) = number of included records retrieved x 100 
          total number of included records  
 
Precision (%) = number of included records retrieved x 100 
        total number of records retrieved 
 
 
 173 
Number Needed to Read (NNR) = total number of records retrieved OR 1/precision  
      number of included records retrieved  
 
In addition, sensitivity*precision was calculated to allow equilibrium between 
sensitivity and precision to be assessed.574 
 
11.2.3.2 Minimum combination of sources 
The minimum combination of sources required to identify all included publications 
using the search strategies employed in this case study was recorded. In addition, a 
record was made of the minimum number of sources from which all the included 
publications were available, independent of the search strategy used. 
 
11.2.3.3 Individual study identification 
In order to allow for multiple publications for the same study, the analysis was 
repeated with all relevant individual studies, as opposed to all relevant publications.  
 
11.2.3.4 Randomised controlled trials (RCTs) and observational 
studies 
The analysis was then repeated with the included RCTs and observational studies 
separately, because certain databases may provide better access to specific study 
types, for example, CENTRAL focuses on clinical trials. 
 
11.2.3.5 Marginal sensitivity and marginal precision 
Although the sensitivity and precision of searching each individual source 
independently may be important to any potential searcher, the overlap in content 
between the sources in terms of relevant and non-relevant records is also important. 
Both the additional relevant records and non-relevant records retrieved from 
searching the sources in two particular orders were assessed. From the numbers of 
additional records retrieved, the marginal sensitivity, marginal precision, and 
additional numbers needed to read (NNR) for each additional resource could be 
calculated. Two different orders of sources chosen were selected on the basis that 
they reflected a theoretical order of sources and current practice:  
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a) Theoretical order: Beginning with the source from which the highest number 
of relevant records was retrieved, followed by the source from which the 
highest number of additional relevant records were retrieved and so forth, 
until all the relevant records were retrieved. In instances where the same 
number of additional relevant records would be retrieved from more than one 
source, then the source with the least number of irrelevant records was 
selected. 
b) Order of Current Practice: An order of sources that reflects common practice 
in systematic reviews. The top ten most frequent sources were selected (in 
order of popularity) from the review of systematic reviews in Chapter 10.  
 
 Results 11.3
11.3.1  Records retrieved 
From the database searches, 3591 unique records were retrieved (5663 before de-
duplication). An additional 680 records (before de-duplication) were retrieved from 
searches for ongoing studies, 629 spontaneous case reports, 90 monographs or 
chapters from databases or texts, and 10 entries in databases or texts that listed 
adverse effects. Although the search strategies remained fairly consistent in all the 
databases, the searches in Scirus, EMBASE and BIOSIS retrieved particularly high 
numbers of records, 1928, 1017 and 880 respectively (Table 11.1) 
 
11.3.2  Included studies 
Fifty-eight references (representing 41 studies) were included in the case study 
systematic review; 29 references (representing 19 studies) were for RCTs and 29 
references (representing 22 studies) were for observational studies. Most of the 
included references (31) were published as journal articles, 17 were conference 
abstracts and 10 were unpublished reports. A list of the included and excluded 
references is contained in Appendix F. 
 
Two publications (DeFonzo 2008 and Seufert et al 2008) included in the previous 
systematic review by Loke et al 2008265 were excluded from the analysis as they did 
not contain any fracture data. The data were identified by Loke et al 2008265 from 
contacting the authors. 
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11.3.3  Where the references were identified 
11.3.3.1 Bibliographic Databases 
Using the search strategies with the drug and fracture terms retrieved at least one 
included reference in all the databases, except Inside Conferences (Table 11.1). 
The highest sensitivity was achieved from searching Science Citation Index (SCI) 
(60.34%), followed by BIOSIS Previews (46.55%), EMBASE (41.38%), and then 
MEDLINE (32.76%).  
 
In the majority of the databases, precision was relatively high in the context of 
systematic review literature searches (Table 11.1). The highest precision was 
achieved in CENTRAL at 41.67%, followed by International Pharmaceutical 
Abstracts (IPA) and PASCAL at 25.00%. The lowest precision was achieved from 
searching Scirus at 0.88%, EMBASE at 2.36%, and BIOSIS Previews 3.01% (Table 
11.1). 
 
The database searches with the best combination of sensitivity and precision were 
PASCAL (sensitivity*precision 6.90%), Science Citation Index (SCI) (6.77%), and 
ADIS Clinical Trials (4.16%) (Table 11.1). 
 
Other sources 
Five references were not identified in any of the bibliographic databases. Two were 
identified through handsearching, one from reference checking, one from: Google 
Scholar, Litt’s Drug Eruption Global Database, or AHFS Drug Information, and lastly 
one from either: Lexi-Comp, AHFS Drug Information, Clinical Pharmacology, 
Martindale: the complete drug reference, Merck, Side Effects of Drugs annual 
(SEDA), Medicine Safety Update, or Drugs and Therapy Perspectives (Table 11.2). 
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Table 11.1: References retrieved by databases, in order of sensitivity 
Database Records 
retrieved 
Relevant 
records 
retrieved 
Unique 
relevant 
records 
retrieved 
Sensitivity 
(N=58) 
Precision  NNR Sensitivity* 
Precision 
Relevant 
studies 
retrieved 
Relevant 
records 
available 
Missed 
references 
Science Citation Index (SCI) 312 35  3 60.34% 11.22% 9 6.77% 24  42  7 
BIOSIS Previews 880 27  1 46.55% 3.01% 34 1.40% 21  31  4 
EMBASE 1017 24 2 41.38% 2.36% 42 0.98% 23  27  3 
MEDLINE 251 19  0 32.76% 7.57% 13 2.48% 18 26  7 
Scirus (journal sources) 1928 17  0 29.31% 0.88% 114 0.26% 17  23  6 
Derwent Drug File 141 16  0 27.59% 11.35% 9 3.13% 15  21  5 
PASCAL 64 16  0 27.59% 25.00% 4 6.90% 15  22  6 
British Library Direct 117 15  1 25.86% 12.82% 8 3.31% 15  27  12 
Thomson Reuters Integrity 96 15  0 25.86% 15.63% 6 4.04% 11  21  6 
TOXLINE 141 14  0 24.14% 9.93% 10 2.40% 13 19 5 
ADIS Clinical Trials Insight 70 13  0 22.41% 18.57% 5 4.16% 12 21 8 
Iowa Drug Information Service (IDIS) 60 12  0 20.69% 20.00% 5 4.14% 11  16  4 
GlaxoSmithKline Clinical Trials Registry 186 10 10 17.24% 5.38% 19 0.93% 10 10  0 
International Pharmaceutical Abstracts (IPA) 28 7  0 12.07% 25.00% 4 3.02% 7  14  7 
CINAHL 70 6  0 10.34% 8.57% 12 0.89% 6  10  4 
Conference Proceedings Citation Index- Sci  45 6  0 10.34% 13.33% 8 1.38% 6  6  0 
CENTRAL 12 5  0 8.62% 41.67% 2 3.59% 5  10  5 
Medscape DrugInfo 115 4  1 6.90% 3.48% 29 0.24% 3  6  2 
Conference Papers Index (CPI) 31 2  0 3.45%% 6.45% 10 0.50% 2 2 0 
Inside Conferences 7 0  0 0% NA NA NA 0 0  0 
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Table 11.2 References (RCTs and observational studies) retrieved by non-
bibliographic databases 
Source Relevant 
references 
identified 
Relevant 
RCTs 
identified 
Relevant 
observational 
studies 
identified 
Relevant 
references 
available 
Unique 
relevant 
references 
Relevant 
studies 
Internet Search Engines 
Google Scholar* 3 2 1 33 0 3 
Google* 2 1 1 45 0 2 
AltaVista* 1 0 1 40 0 1 
Intute 0 0 0 0 0 0 
Internet Reference Collections 
The Drug Safety 
Research Unit 
(DSRU) Scientific 
Publications 
0 0 0 0 0 0 
MedWatch FDA 
website 
0 0 0 0 0 0 
Bulletins and Newsletters 
Reactions Weekly 5 2 3 5 0 5 
Reactions 
PharmacoVigilance 
Insight (includes 
Reactions Weekly) 
5 2 3 5 0 5 
Drugs and Therapy 
Perspectives 
4 2 2 4 0 4 
Medicines Safety 
Update 
2 2 0 2 0 2 
Clin-Alert 1 0 1 1 0 1 
Drug Safety Update 0 0 0 0 0 0 
Adverse Drug 
Reactions Bulletin 
0 0 0 0 0 0 
Canadian Adverse 
Reaction Newsletter 
(CARN) 
0 0 0 0 0 0 
Referenced or Partially Referenced Sources 
Lexi-Comp database 7 3 4 7 0 7 
AHFS Drug 
Information 
5 3 2 5 0 5 
Side Effects of 
Drugs annual 
(SEDA) 
5 4 1 5 0 5 
The Merck Manual 5 3 2 5 0 5 
Martindale: the 
complete drug 
reference 
4 3 1 4 0 4 
Litt’s Drug Eruption 
Global Database 
2 1 1 2 0 2 
Medical Evidence 
Matters 
1 1 0 1 0 1 
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Table 11.2 References (RCTs and observational studies) retrieved by non-
bibliographic databases 
Source Relevant 
references 
identified 
Relevant 
RCTs 
identified 
Relevant 
observational 
studies 
identified 
Relevant 
references 
available 
Unique 
relevant 
references 
Relevant 
studies 
Clinical 
Pharmacology 
1 1 0 1 0 1 
DRUGDEX 1 1 0 1 0 1 
ADIS R&D Insight** 0 0 0 0 0 0 
Drug Safety Portal** 0 0 0 0 0 0 
eMedicine** 0 0 0 0 0 0 
General Practice 
Notebook** 
0 0 0 0 0 0 
Adverse Drug 
Reactions (Lee)*** 
0 0 0 0 0 0 
Davies Textbook of 
Adverse Drug 
Reactions*** 
0 0 0 0 0 0 
Meylers’s Side 
Effects Of Drugs*** 
0 0 0 0 0 0 
ToxEd*** 0 0 0 0 0 0 
XPharm*** 0 0 0 0 0 0 
 
*search limited to the first three pages of results, as per current practice.571-573 
**referenced monograph gave information on fractures with rosiglitazone or 
pioglitazone but did not reference any of the relevant references  
***referenced monograph did not contain information on fractures with rosiglitazone 
or pioglitazone  
 
11.3.3.2 Non-Referenced Sources 
ABPI electronic Medicines Compendium (eMC), British National Formulary (BNF), 
Davis’s Drug Guide, Drugs.com, Epocrates Online, Physicians’ Desk Reference 
(PDR) and RxList listed or discussed fractures as an adverse effect but did not 
contain any citations.  
 
Mosby's Medical Drug Reference and Rxmed Modell’s Drugs in current use and 
new drugs did not include any information on fractures with glitazones. 
 
11.3.3.3 Unique references identified by search strategies 
The highest number of unique references (i.e. those that were found only in one 
particular source) were identified from the GlaxoSmithKline (GSK) Clinical Trials 
Registry (10 references), followed by Science Citation Index (SCI) (3 references), 
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EMBASE (2 references), and BIOSIS Previews, British Library Direct and Medscape 
DrugInfo (one reference each). In addition to unique references from databases, 
handsearching identified two unique references, and reference checking one unique 
reference. 
11.3.4 Minimum combination of sources to identify all relevant 
references 
The minimum combination of sources to retrieve all the relevant references with the 
search strategies used in this case study was: GlaxoSmithKline (GSK) Clinical 
Trials Registry; Science Citation Index (SCI); EMBASE; BIOSIS Previews; British 
Library Direct; Medscape DrugInfo; handsearching; reference checking; AHFS Drug 
Information; and Thomson Reuters Integrity or Conference Papers Index (CPI). 
 
11.3.5 Where the individual studies were identified 
11.3.5.1 Bibliographic Databases and other sources 
A similar pattern emerged when limiting the evaluation of identified records to 
individual studies, as opposed to the individual publications. Science Citation Index 
(SCI) identified the greatest number of studies (24), followed by EMBASE (23 
studies), BIOSIS (21 studies), and MEDLINE (18 studies) (Table 11.1).  
 
11.3.5.2 Unique studies identified by search strategies 
The highest number of unique studies were identified from the GlaxoSmithKline 
(GSK) Clinical Trials Registry (seven studies), followed by Science Citation Index 
(SCI) (two studies), EMBASE (two studies), BIOSIS Previews, British Library Direct, 
and Medscape DrugInfo (one study). In addition to unique studies from databases, 
handsearching identified one unique study. 
 
11.3.5.3 Minimum combination of sources to identify all studies 
The minimum combination of sources to retrieve all the studies with the search 
strategies used in this case study was GlaxoSmithKline (GSK) Clinical Trials 
Registry, Science Citation Index (SCI), EMBASE, BIOSIS Previews, British Library 
Direct, Medscape DrugInfo, and handsearching. 
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11.3.6  Where the references were available 
11.3.6.1 Bibliographic Databases 
The greatest number of relevant references available were on Science Citation 
Index (SCI) (42), followed by BIOSIS (31), British Library Direct (27) and EMBASE 
(27), and then MEDLINE (26). 
 
The majority of the searches (using fracture and drug terms) did not retrieve all the 
relevant references available on each database (Table 11.1). The only databases in 
which all the relevant references available were identified were either conference 
proceedings databases or the drug company database. Due to the limitations of the 
interface for the drug company database, this database was searched with the drug 
terms only and all records sifted for the adverse effect. British Library Direct missed 
the highest number of relevant references (12 references), followed by ADIS Clinical 
Trials Insight at eight references, and then International Pharmaceutical Abstracts 
(IPA), MEDLINE and Science Citation Index (SCI), with seven missed references 
each.  
 
Almost all the records missed did not contain any ‘bone’ or ‘fracture’ in the 
bibliographic details. However, in British Library Direct (which only allows searching 
of the title), two references were not retrieved as they contained no ‘drug’ terms and 
no ‘bone’ or ‘fracture’ terms in the title. One reference was not retrieved because it 
contained no ‘drug’ terms in the title, and another contained the phrase 
‘rosiglitazone-associated fractures’ and was not identified owing to the use of the 
hyphen. In both PASCAL and Thomson Reuters Integrity one reference did not 
contain any relevant terms for the thiazolidinediones. 
 
11.3.6.2 Other sources 
The majority of the references were available on the Internet by a search on the 
specific reference using search terms from its citation (Table 11.2). Those articles 
that were not available on the Internet tended to be conference proceedings. The 
bulletins, newsletters, and referenced or partially referenced sources were all 
handsearched, and the number of relevant references identified from these sources 
matches the number of relevant references available (Table 11.2). 
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11.3.6.3 Unique references available 
Seven references were unique in relation to their availability. Three references were 
only available from Science Citation Index (SCI), one from Medscape DrugInfo, one 
from BIOSIS Previews, one from British Library Direct and one from handsearching. 
The unique references identified from the GlaxoSmithKline (GSK) Clinical Trials 
Registry were also available from AltaVista, Google, or Google Scholar. 
 
11.3.6.4 Minimum combination of sources with relevant 
references 
The minimum number of sources that contained all the included references was 
Science Citation Index (SCI), Medscape DrugInfo, BIOSIS Previews, British Library 
Direct, and handsearching. 
 
11.3.7  Where the randomised controlled trials (RCTs) were identified 
When the analysis was restricted to RCTs only, the highest sensitivity was achieved 
from searching BIOSIS Previews (37.93%) followed by EMBASE (34.48%) and 
Science Citation Index (SCI) (34.48%) (Table 11.3). The databases which achieved 
a higher sensitivity when searching was limited to RCTs as opposed to all studies 
were CENTRAL, GlaxoSmithKline (GSK) Clinical Trials Registry, Thomson Reuters 
Integrity, and Medscape DrugInfo (Table 11.3).  
 
The highest precision when searching for RCTs was achieved in CENTRAL at 
41.67%, followed by PASCAL at 10.94%, and International Pharmaceutical 
Abstracts (IPA) at 10.71%. (Table 11.3). 
 
The database searches with the best combination of sensitivity and precision were 
CENTRAL (sensitivity*precision 3.59%) followed by Thomson Reuters Integrity 
(2.91%), and PASCAL (2.64%) (Table 11.3). 
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Table 11.3 RCTs retrieved by databases, in order of sensitivity 
Database Relevant 
records 
retrieved 
Unique 
relevant 
records 
retrieved 
Sensitivity 
(N=28) 
Precision Number 
needed to 
read (NNR) 
Sensitivity* 
Precision 
Relevant 
studies 
retrieved 
(N=19) 
Relevant 
records 
available 
Missed 
relevant 
records 
BIOSIS Previews 11 1 37.93% 1.25% 80 0.47% 8 14 3 
Science Citation Index (SCI) 10 0 34.48% 3.21% 31 1.11% 6 16 6 
EMBASE 10 1 34.48% 0.98% 102 0.34% 9 13 3 
GlaxoSmithKline Clinical Trials Registry 9 9 31.03% 4.84% 21 1.50% 9 9 0 
Thomson Reuters Integrity 9 0 31.03% 9.38% 11 2.91% 5 14 5 
MEDLINE 7 0 24.14% 2.79% 36 0.67% 6 13 6 
PASCAL 7 0 24.14% 10.94% 9 2.64% 6 11 4 
Derwent Drug File 6  0 20.69% 4.26% 23 0.88% 6 11 5 
Iowa Drug Information Service (IDIS) 6 0 20.69% 10.00% 10 2.07% 5 10 4 
Scirus (journal sources) 6 0 20.69% 0.31% 323 0.06% 6 11 5 
ADIS Clinical Trials Insight 5 0 17.24% 7.14% 14 1.23% 4 12 7 
CENTRAL 5  0 17.24% 41.67% 2 3.59% 5  10 5 
British Library Direct 4 1 13.79% 3.42% 29 0.47% 4 13 9 
TOXLINE 4  0 13.79% 2.84% 35 0.39% 3 9 5 
International Pharmaceutical Abstracts (IPA) 3 0 10.34% 10.71% 9 1.11% 3 9 6 
Medscape DrugInfo 3 0 10.34% 2.61% 38 0.27% 2 4 1 
CINAHL 2 0 6.90% 2.86% 35 0.20% 2  6 4 
Conference Proceedings Citation Index- Sci 2 0 6.90% 4.44% 23 0.31% 2 2 0 
Conference Papers Index (CPI) 1 0 3.45% 3.23% 31 0.11% 1 1 0 
Inside Conferences 0  0 0 NA NA NA 0 0  0 
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11.3.8  Where the observational studies were identified 
When the analysis was restricted to the observational studies, the highest sensitivity 
was achieved from searching Science Citation Index (SCI) at 86.21%, followed by 
BIOSIS Previews at 55.17%, and EMBASE at 44.83% (Table 11.4). The most 
notable difference in sensitivity for observational studies as opposed to all types of 
studies was for Science Citation Index (SCI) which increased from 60.34% to 
86.21% (Table 11.4). 
 
The highest precision, when the analysis was restricted to observational studies, 
was achieved in International Pharmaceutical Abstracts (IPA) (14.29%), followed by 
PASCAL (14.06%), and ADIS Clinical Trials Insight (11.43%) (Table 11.4).  
 
The database searches with the best combination of sensitivity and precision were 
Science Citation Index (SCI) (sensitivity*precision 6.91%), followed by PASCAL 
(4.36%), and British Library Direct (3.56%) (Table 11.4). 
 
The number of missed references in almost all the databases was notably higher 
when searching for RCTs than observational studies (Table 11.3 and Table 11.4). 
 184 
Table 11.4 Observational studies retrieved by databases, in order of sensitivity 
Database Relevant 
records 
retrieved 
Unique 
relevant 
records 
retrieved 
Sensitivity 
(N=29) 
Precision NNR Sensitivity* 
Precision 
Relevant 
studies 
retrieved 
(N=22) 
Relevant 
records 
available 
Missed 
relevant 
references 
Science Citation Index (SCI) 25 3 86.21% 8.01% 12 6.91% 18 26 1 
BIOSIS Previews 16 0 55.17% 1.82% 55 1.00% 13 17 1 
EMBASE 14 1 48.28% 1.38% 72 0.67% 14 14 0 
MEDLINE 12 0 41.38% 4.78% 21 1.98% 12 13 1 
British Library Direct 11 0 37.93% 9.40% 11 3.56% 11 14 3 
Scirus (journal sources) 11 0 37.93% 0.57% 175 0.22% 11 12 1 
Derwent Drug File 10 0 34.48% 7.09% 14 2.44% 9 10 0 
TOXLINE 10 0 34.48% 7.09% 14 2.44% 10 10 0 
PASCAL 9 0 31.03% 14.06% 7 4.36% 9 11 2 
ADIS Clinical Trials Insight 8 0 27.59% 11.43% 9 3.15% 8 9 1 
Iowa Drug Information Service (IDIS) 6 0 20.69% 10.00% 10 2.07% 6 6 0 
Thomson Reuters Integrity 6 0 20.69% 6.25% 16 1.29% 6 7 1 
CINAHL 4 0 13.79% 5.7% 18 0.79% 4 4 0 
Conference Proceedings Citation Index- Sci 4 0 13.79% 8.89% 11 1.23% 4 4 0 
International Pharmaceutical Abstracts (IPA) 4 0 13.79% 14.29% 7 1.97% 4 5 1 
Conference Papers Index (CPI) 1 0 3.45% 3.23% 31 0.11% 1 1 0 
GlaxoSmithKline Clinical Trials Registry 1 1 3.45% 0.54% 186 0.02% 1 1 0 
Medscape DrugInfo 1 1 3.45% 0.87% 115 3.00% 1 2 1 
CENTRAL 0 0 0 NA NA NA 0 0 0 
Inside Conferences 0  0 0 NA NA NA 0 0  0 
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11.3.9  Marginal sensitivity and marginal precision 
11.3.9.1 Order 1: Theoretical order 
When the sources are searched in order of retrieval of the highest number of 
relevant records until all the relevant references are identified, the order for 
searching is as in Table 11.5. 
 
The number needed to read is high in Medscape DrugInfo (110) and BIOSIS 
Previews (680). Although searching this combination of sources identifies all the 
relevant references (100% sensitivity), overall precision was low at 2.75%. 
 
Table 11.5 Marginal sensitivity, marginal precision and additional number 
needed to read using the source with the highest number of relevant 
records first 
 
Source Additional 
records to 
sift 
Additional 
relevant 
references 
Marginal 
sensitivity 
(N=58) 
Marginal 
precision 
Additional 
number 
needed to 
read (NNR) 
Science Citation Index 
(SCI) 
312 35 60.34% 11.22% 9 
GlaxoSmithKline 
Clinical Trials Registry 
186 10 17.24% 5.38% 19 
EMBASE 819 4 6.90% 2.81% 36 
AHFS Drug 
Information* 
2 2 3.45% 100% 1 
Handsearching N/A 2 3.45% N/A N/A 
Conference Papers 
Index (CPI) 
24 1 1.72% 4.17% 24 
British Library Direct 46 1 1.72% 2.17% 46 
Medscape DrugInfo 110 1 1.72% 0.91% 110 
BIOSIS Previews 608 1 1.72% 0.16% 608 
Reference checking N/A 1 1.72% N/A N/A 
TOTAL 2107 58 100% 2.75% 36 
 
*AHFS Drug Information or a combination of Litt’s Drug Eruption Global 
Database and either - Lexi-Comp Database, Clinical Pharmacology, Martindale: 
the complete drug reference, The Merck Manual or Side Effects of Drugs annual 
(SEDA), Medicines Safety Update or Drugs and Therapy Perspectives. 
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11.3.9.2 Order 2: Current practice in systematic reviews 
Three references would not have been identified had the search been restricted 
to the top ten most popular sources of data used in systematic reviews of 
adverse effects (Table 11.6). These references could have been identified from 
Medscape DrugInfo (one reference), British Library Direct (one reference), and 
from Conference Papers Index (CPI) or Thomson Reuters Integrity (one 
reference). Only one review of the 849 systematic reviews of adverse effects 
from Chapter 10 included Conference Papers Index (CPI). Medscape DrugInfo, 
British Library Direct, and Thomson Reuters Integrity were not included in any of 
these reviews. If MEDLINE alone had been searched, along with reference 
checking, then only 34% (20/58) of the relevant references would have been 
identified. Even a search of MEDLINE, EMBASE, and CENTRAL along with 
reference checking, would have retrieved less than half (43%, 25/58) of the 
relevant references (Table 11.6). 
Table 11.6 Marginal sensitivity, marginal precision and additional number 
needed to read using order of sources in current practice  
Source Additional 
records to 
sift 
Additional 
relevant 
references 
Marginal 
sensitivity 
(N=58) 
Marginal 
precision 
Additional 
number 
needed to 
read (NNR) 
MEDLINE 251 19 32.76% 7.57% 13 
Reference 
Checking 
NA 1 1.72% NA NA 
EMBASE 808 5 8.62% 0.62% 161 
CENTRAL 0 0 0% 0% 0 
GlaxoSmithKline 
Clinical Trials 
Registry 
186 10 17.24% 5.38% 19 
CINAHL 30 0 0% 0% 0 
Handsearching NA 2 3.45% NA NA 
BIOSIS Previews 706 10 17.24% 1.67% 60 
Science Citation 
Index (SCI) 
58 6 10.34% 17.14% 6 
Textbooks/ 
bulletins 
NA 2* 3.45% NA NA 
TOTAL 2039 55 94.83% 2.85% 35 
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 Discussion 11.4
This case study demonstrates the value of searching multiple sources in order to 
identify data on adverse drug reactions for a systematic review. The minimum 
number of sources needing to be searched in order to identify all the relevant 
references with the proposed search strategy was ten. Even were it possible to 
devise a ‘perfect’ search strategy that could retrieve all the relevant references 
available on each source, a minimum of five sources would still need to be 
searched. The most common practice of searching just MEDLINE and reference 
checking would have failed to retrieve two-thirds of the relevant references 
(38/58, 66%). Even a search of MEDLINE, EMBASE, and CENTRAL along with 
checking of reference lists would have failed to retrieve over half the relevant 
references (33/58, 57%). 
 
The results from searching each source varied enormously in terms of sensitivity 
and precision, with a general trade-off between the two. The high sensitivity 
achieved in Science Citation Index (SCI), BIOSIS Previews, and Scirus, in 
particular, warrant further investigation. As this is only one case study, it would 
be difficult to generalise the findings from this case study review to other 
systematic reviews without further research. Science Citation Index (SCI) has 
only been included in one previous evaluation and proved useful despite only 
being searched for effectiveness studies (Chapter 5). Scirus has not been 
included in other evaluations (Chapter 5) and although in previous case studies 
BIOSIS Previews provided a substantial number of relevant references and 
unique references, more relevant records tended to be identified from MEDLINE 
or EMBASE (Chapter 5). However, in the present case study, BIOSIS Previews 
identified more relevant records than either MEDLINE or EMBASE.  
 
Other differences have been observed when the present case study was 
compared to previous case studies in Chapter 5. Whereas previous case studies 
indicated a higher yield from Derwent Drug File than MEDLINE or EMBASE, in 
this case study both MEDLINE and EMBASE retrieved a higher number of 
relevant references than Derwent Drug File. In addition, PASCAL also ranked 
better in this case study than in previous case studies identifying more relevant 
references than TOXLINE. 
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There are, however, many similarities between this case study and the previous 
case studies described in Chapter 5. For instance, all the case studies have 
indicated the value of BIOSIS Previews over Iowa Drug Information Service 
(IDIS), International Pharmaceutical Abstracts (IPA) and PASCAL. For drug 
interventions, EMBASE yielded more relevant references than MEDLINE. And 
MEDLINE, EMBASE and TOXLINE retrieved more relevant references than 
Iowa Drug Information Service (IDIS), and lastly Iowa Drug Information Service 
(IDIS) retrieved more relevant references than International Pharmaceutical 
Abstracts (IPA).  
 
Although most case studies in Chapter 5 focused on comparative evaluations of 
databases, in some instances the value of non-database sources such as 
reference checking, handsearching, and textbooks was demonstrated. In this 
case study review, contacting manufacturers or searching manufacturer 
websites was particularly useful for identifying unique studies. However, the 
ease of retrieving industry funded studies will vary greatly depending on the drug 
company. 
 
The low sensitivity achieved by some of the databases is not surprising. For 
instance, specialist conference databases such as Conference Papers Index 
(CPI) and Inside Conferences contain only conference abstracts, CINAHL 
specialises in nursing and allied health, the GlaxoSmithKline (GSK) Clinical 
Trials Registry contains only industry funded studies, and CENTRAL focuses on 
clinical trials.  
 
Non-bibliographic databases do not tend to identify a high proportion of relevant 
references. Most of these sources are typically aimed at providing information 
for drug development, or for prescribers, or contain added value (such as 
synthesized data from studies in Medical Evidence Matters) and do not intend to 
be comprehensive. Such sources may be more useful at the developmental 
stage of a systematic review when the decision is made of which adverse effects 
to include in the search strategy. 
 
In searching terms, this systematic review was relatively straightforward in that 
the adverse effect was known in advance and well defined. However, in most of 
the databases, relevant references were missed with the search strategy used, 
which included terms for both the drug (thiazolidinediones) and outcome (fracture) 
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only. Those sources in which references were not missed were either browsed 
(such as bulletins, newsletters and referenced texts or databases), searched with a 
simplified search strategy due to interface restrictions (such as the 
GlaxoSmithKline (GSK) Clinical Trials Registry), or were databases of conference 
proceedings (such as Conference Proceedings Citation Index- Science, 
Conference Papers Index (CPI), and Inside Conferences).  
 
The large discrepancy between the number of references available on the Internet 
and the number retrieved can be partially explained by the fact that only the first 
three pages were viewed, that a more lateral or iterative searching approach was 
not applied (such as following links from search results or repetitive search 
attempts), and that the references of articles retrieved were not checked (many of 
the press articles identified on the Internet had references to the included studies). 
Of the bibliographic databases, British Library Direct missed the highest number 
of relevant references. This is likely to be a result of the search interface for this 
database, which does not allow searching of terms in the abstract. With the other 
databases, the variation in the references missed was mostly attributable to 
differences in indexing practices or the assignment of keywords for the adverse 
effect (fracture). 
 
In all the databases, the number of missed references with the search strategies 
used was higher for RCTs than for observational studies. Adverse effects are 
more likely to be a secondary outcome in RCTs than in observational studies 
and, such that adverse effects terms are less likely to appear in the title, abstract 
or indexing/keywords of bibliographic records of RCTs than observational 
studies.  
 
Interestingly, the minimum combination of sources required to identify all the 
relevant references did not include MEDLINE, and neither did the combination of 
sources identified through the selection of the sources with the highest 
sensitivity first. This is partially due to the fact that searching MEDLINE did not 
identify any unique references or have the highest sensitivity. 
 
 Limitations 11.5
The main limitation of this study is that it is based on only one case study, 
creating difficulty with the generalisability of the results to other systematic 
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reviews of other interventions or other adverse effects. Moreover, most of the 
trial reports with fractures came from the GlaxoSmithKline (GSK) Clinical Trials 
Registry, and other pharmaceutical company reports may not provide as much 
detail. 
 
It was difficult to maintain consistency in the search strategy among the different 
interfaces for the different databases in order to make fair comparisons. In 
addition, it was not possible to conduct any type of cost analysis of searching 
each source, due to the complex pricing mechanisms employed by database 
providers, which can be dependent on the type of organisation, size of network, 
number of concurrent users, and the provider from which the database is 
purchased. Another limitation of this case study is that the searches using the 
Internet search engines do not necessarily reflect current practice as searches 
tend to be more idiosyncratic and opportunistic and may, therefore, have 
retrieved more relevant references.  
 
 Conclusions 11.6
This case study demonstrates the potential value of searching a number of 
sources to identify data on adverse drug reactions. In this instance, a 
combination of searching the GlaxoSmithKline (GSK) Clinical Trials Registry, 
Science Citation Index (SCI), EMBASE, BIOSIS Previews, British Library Direct, 
Medscape DrugInfo, handsearching, reference checking, AHFS Drug Information, 
and Thomson Reuters Integrity or Conference Papers Index (CPI) retrieved all the 
relevant references. 
 
The case study here also demonstrates the failure of a broad search strategy with 
numerous synonyms, text words, and indexing terms to identify all the relevant 
references available on each database. Primarily, this was because of a lack of 
fracture terms in the title, abstract, or indexing/keywords of bibliographic records, 
again emphasising the need for authors of systematic reviews of adverse drug 
reactions to search a wide range of sources and authors of studies to ensure 
adverse effects terms appear in the title or abstracts.  
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 Summary 11.7
______________________________________________________________________ 
A wide range of sources were searched in a case study systematic review of 
thiazolidinedione-related fractures.58 included references were analysed as to 
the sources from which they were identified, the availability of each reference, 
and whether each reference was unique to each source. 
Using the search strategy employed in this case study, a minimum of 10 sources 
needed to be searched to identify all 58 included references. 
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Chapter 12 Search filters in MEDLINE and EMBASE: a case study 
of fractures with thiazolidinediones 
 Introduction 12.1
Developing efficient search strategies (combinations of search terms) for use in 
databases (such as MEDLINE and EMBASE) which capture all the relevant 
literature on adverse effects is challenging.2, 118 Specific difficulties arise when 
adverse effects terms are added to the search strategy, because adverse effects 
are poorly reported, inadequately indexed, inconsistently described, and can be 
new or unexpected at the time of searching.19, 117 
 
To avoid omitting any relevant studies, Derry et al 2001 proposed an arduous 
and highly resource intensive approach based on a broad search without 
adverse effects terms, where a large number of potentially irrelevant full-text 
articles would need to be manually screened. However, other methods of 
electronic searching have since been developed and tested to try and ease the 
process of identifying and retrieving studies of specific interest.  
 
Attempts have been made to develop search filters for retrieving papers on 
adverse effects (Chapter 6). There are currently 12 published search filters for 
MEDLINE121, 360, 427, 428, 430, 432, 434 and three for EMBASE (Appendix G).360, 432 All 
these filters, with the exception of the filters by Buckingham et al 2005,434 were 
developed to maximise sensitivity, that is, to retrieve a high proportion of all 
available relevant records. The search filters by Wieland et al 2005121, 430 aimed 
to identify as many of the relevant records as possible for a named specific 
adverse effect (breast cancer with oral contraceptives), whereas the other filters 
aimed to capture all or all serious adverse effects for particular interventions. 
The search filters by Badgettt et al 1999, Golder et al 2006 and Wieland et al 
2005 were developed using research techniques and tested.121, 360, 427, 428, 430 
However, the precision of the search filters is not recorded in Badgett et al 1999 
and the search filters by Golder et al 2006 and Wieland et al 2005 are not 
validated with other case studies.121, 360, 427, 428, 430  The other search filters 
available432, 434 are based solely on expert opinion and have not yet been 
evaluated. 
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The aim of this case study was to explore the sensitivity (the ability to identify as 
many relevant articles as possible), precision (the ability to exclude as many 
irrelevant articles as possible), and number needed to read (NNR) (the number 
of records requiring sifting in order to identify one relevant article) with adverse 
effects search filters. 
 Methods 12.2
As with Chapter 11, the included references from an update of a previously 
published systematic review265 on fracture related adverse effects associated 
with the use of thiazolidinediones (rosiglitazone and pioglitazone) formed the 
basis of analysis for this case study (Appendix D). The original search strategy 
used for this case study systematic review contained just two facets, the 
intervention; thiazolidinediones (rosiglitazone and pioglitazone) and the 
outcomes; fractures and bone mineral density. Indexing terms and terms in the 
title and abstract (including multiple synonyms) were used for each facet. No 
generic adverse effects terms (such as ‘safety’, ‘side effect’ or ‘adverse event’) 
were included in the search strategy, making it possible to assess the effect of 
the addition of adverse effects terms. The searches were carried out in 
MEDLINE and EMBASE, as well as numerous other sources (Appendix E). 
 
The adverse effects search filters available for MEDLINE and EMBASE were 
then run to assess the number of relevant references that would have been 
retrieved had these filters been applied, and also the total number of records 
retrieved (Appendix G). Each search filter was run in turn, and a separate 
Endnote library created for the results from each strategy. This enabled 
calculation of the sensitivity, precision, and the number needed to read (NNR) of 
the searches to be carried out. These, and the sensitivity*precision574 for the 
searches in each of the databases was calculated using the definitions described 
in Chapter 11. 
 
As the adverse effect used in this investigation (fractures) was known before the 
searches were conducted, some adaptations were made to the generic adverse 
effects search strategies by Badgett et al 1999427, 428 and Golder et al 2006360 
(Appendix H). Generic search filters are designed to identify any adverse effects 
of an intervention and contain only generic adverse effects related terms, such 
as ‘side effects’ and ‘adverse events’. In this instance, the generic search 
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strategies proposed by Badgett et al 1999 and Golder et al 2006 were combined 
(ANDed) with the fracture terms. 
 
The search strategies by Wieland et al 2005121, 430 were translated from the 
PubMed interface to OVID MEDLINE. Two of the search strategies in Wieland et 
al 2005121, 430 did not contain any intervention terms. These search strategies 
were not tested in this case study owing to the large volume of records (over 
8,000 records with MeSH terms and over 40,000 records with text words) that 
running a search for ‘fracture’ and ‘risk’ terms alone generates, and thus the 
impractical nature of employing such a search strategy for this type of 
systematic review.  
 
 Results 12.3
Fifty-eight references (representing 41 studies) contained sufficient data to allow 
meta-analysis for the relevant outcomes of interest and were included in the 
systematic review. Of these 58 references, 19 were identified in MEDLINE (12 
observational studies and seven RCTs) and 24 in EMBASE (14 observational 
studies and 10 RCTs).  
 
12.3.1  MEDLINE 
The original search strategy using only the drug terms for thiazolidinediones and 
the named adverse effect (fractures) retrieved 251 records of which 19 
contained relevant adverse effects data (representing 18 studies) (Table 12.1). If 
the Golder et al 2006a/2006b search filter had been applied, in addition to the 
thiazolidinediones and fracture terms, then the same number of relevant 
references (19) would have been identified with 50 fewer records to sift (Table 
12.1). The search filters by Badgett et al 1999,427, 428 BMJ Clinical Evidence 
2006,432 and Wieland et al 2005f,121, 430 each missed only one relevant reference 
(each filter missed a different reference). In the case of the Badgett et al 1999427, 
428 filter, the missed reference would have been identified had the text word 
‘safety’ been included in the search strategy. The paper missed by the BMJ 
Clinical Evidence 2006432 filter would have been retrieved had the subheading 
‘drug effect’ been included (de.fs), and in the case of the Wieland et al 2005f121, 
430 filter the missed reference would have been identified had the MeSH term 
‘Fracture, bone/ci’ been included (ci is the subheading ‘chemically induced’). 
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High precision was achieved by the Buckingham et al 2005b,434 Wieland et al 
2005a,121, 430 Wieland et al 2005b,121, 430 and Wieland et al 2005c121, 430 filters 
(Table 12.1). These search strategies all rely only on MeSH terms. The 
Buckingham et al 2005b,434 Wieland et al 2005a,121, 430 and Wieland et al 
2005c121, 430 filters also achieved the best combination of sensitivity and 
precision (Table 12.1). 
 
12.3.2  EMBASE  
The original search strategy using only the drug terms for thiazolidinediones and 
the named adverse effect (fractures) retrieved 1017 records of which 24 
contained relevant adverse effects data (representing 23 studies) (Table 12.1). 
Although fewer records required sifting with the addition of the search filters (328 
less with the BMJ Clinical Evidence 2006432 filter, 546 less with the Golder et al 
2006b360 filter, and 621 less with Golder et al 2006a360 filter), if any of the filters 
had been applied then not all the relevant records would have been identified. 
Three of the four references missed by all the search filters included the text 
word ‘risk’ but did not include any other terms related to ‘adverse effects’ in the 
title, abstract or indexing. The other reference missed by all the search filters did 
not contain any generic adverse effects terms (but did include fracture terms).  
 
The additional reference missed by the Golder et al 2006b360 filter was identified 
by the BMJ Clinical Evidence 2006432search strategy by the text word 
‘complications’. The additional five references missed by the Golder et al 
2006a360 filter were identified by the BMJ Clinical Evidence 2006432 filter with the 
subheading ‘Adverse Drug Reaction’ (/ae) (four references) or the text word 
‘complications’ (one reference).  
 
Although the addition of the search filters improved the precision of the 
searches, this still remained low at below 5% (Table 12.1). The best combination 
of sensitivity and precision was achieved by the Golder et al 2006b*360 filter, 
although none of the filters achieved a good balance due to low precision. 
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Table 12.1 Sensitivity, precision, and number needed to read (NNR) using 
search filters in MEDLINE and EMBASE 
 Number 
of records 
retrieved 
Number of 
relevant 
records 
(sensitivity 
N=19) 
Precision Number 
needed 
to read 
(NNR) 
Sensitivity* 
precision 
MEDLINE 
Original search 
with no filter 
251 19 (100%) 7.57% 13 7.57% 
Badgett 1999*
427, 
428
 
148 18 (94.74%) 12.16% 8 11.52% 
BMJ Clinical 
Evidence 2006
432
 
118 18 (94.74%) 15.25% 7 14.45% 
Buckingham 
2005a
434
 
49 10 (52.63%) 20.41% 5 10.74% 
Buckingham 
2005b
434
 
11 6 (31.58%) 54.55% 2 17.23% 
Golder 
2006a/2006b*
360
  
201 19 (100%) 9.45% 8 9.45% 
Wieland 
2005a
121, 430
 
22 10 (52.63%) 45.45% 2 23.92% 
Wieland 
2005b
121, 430
  
10 4 (21.05%) 40.00% 3 8.42% 
Wieland 
2005c
121, 430
  
28 11 (57.89%) 39.29% 2 22.74% 
Wieland 
2005d
121, 430
  
45 8 (42.11%) 17.78% 6 7.49% 
Wieland 
2005e
121, 430
  
58 11 (57.89%) 18.97% 5 10.98% 
Wieland 2005f
121, 
430
 
120 18 (94.74%) 15.00% 7 14.21% 
EMBASE 
 Number 
of records 
retrieved 
Number of 
relevant 
records 
(sensitivity 
N=24) 
Precision Number 
needed 
to read 
(NNR) 
Sensitivity* 
precision 
Original search 
with no filter 
1017 24 (100%) 2.36% 42 2.36% 
BMJ Clinical 
Evidence 2006
432
 
689 20 (83.33%) 2.90% 34 2.42% 
Golder 2006a*
360
  396 15 (62.50%) 3.79% 26 2.37% 
Golder 2006b*
360
  471 19 (79.17%) 4.03% 25 3.19% 
*adapted search strategy 
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 Discussion 12.4
In MEDLINE, the search filters by Badgett et al 1999,427, 428 BMJ Clinical 
Evidence.432 Golder et al 2006a/2006b,360 and Wieland et al 2005f121, 430 
achieved a high level of sensitivity (95% or 100%) with an improved level of 
precision from the original search strategies. This would indicate that these 
MEDLINE search filters could have been a useful addition to the search 
strategies. 
 
The highest precision in MEDLINE was achieved from those search filters that 
relied on Medical Subject Headings (MeSH). The search strategies by 
Buckingham et al 2005434 were designed to achieve high precision (whereas the 
other filters were designed with systematic reviews in mind) so it is not that 
surprising that the Buckingham et al 2005b filter achieved the highest precision. 
However, as with all searching there was a trade-off between sensitivity and 
precision.  
 
In EMBASE, the BMJ Clinical Evidence 2006432 and Golder et al 2006b360 
search filters achieved a level of sensitivity that might be considered acceptable 
by some authors of systematic reviews, with a reduction in the number of 
records to sift. None of the search filters achieved 100% sensitivity and precision 
was low using any of the filters. Although precision remained low with the 
addition of adverse effects filters in EMBASE, in practical terms, hundreds less 
records required sifting. Therefore, depending on the level of sensitivity judged 
to be acceptable, these filters could be of use in situations where unmanageable 
numbers of records would otherwise be retrieved. 
 
In terms of precision, the results from searching MEDLINE and EMBASE 
differed remarkably. Searches in MEDLINE achieved a much higher precision 
(or lower number needed to read, NNR) than similar searches in EMBASE. This 
could be due to differences in the practice of indexing in the two databases. 
Other studies have indicated that searches of EMBASE result in lower precision 
than MEDLINE.413, 414 
 
This research indicates the potential value of adverse effects search filters, 
although as 100% sensitivity was not achieved by the majority of the filters, they 
should be applied with caution. Authors of systematic reviews may, therefore, 
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need to take pragmatic decisions when creating search strategies for adverse 
effects and sacrifice sensitivity for precision. In order to compensate for this loss 
in sensitivity, searches of electronic databases could then be supplemented with 
other means of identifying papers, such as reference checking, contacting 
industry, and citation searches.  
 
The complete search strategy for identifying papers in a systematic review on 
adverse effects is also likely to depend on the inclusion criteria for the review. 
For example, if the inclusion criteria are limited to particular study designs, then 
the search strategy may need to reflect this. These search filters could be 
adapted for the review in question, so need not be used prescriptively but more 
as a basis for ideas for terms. 
 
 Limitations 12.5
The main limitation to the present study is that only one case study systematic 
review was used, limiting the generalisability of the results. In addition this case 
study was of a named adverse effect, while a case study of a safety profile 
systematic review, in which all adverse effects are searched, might have given 
different results.  
 
A further limitation is the adaptation of the search strategies by Badgett et al 
1999427, 428 and Golder et al 2006.360 These filters were originally created and 
tested for use in searches where the adverse effects were not known in advance 
of searching. In the present study, these search filters were used in addition to 
fracture terms, though use of the filters without the fracture terms would be 
impractical, given the vast number of irrelevant records that would have been 
retrieved (over 4000 with the filter by Badgett et al 1999,427, 428 and over 6000 
with the Golder et al 2006360 filters).  
 
 Conclusions 12.6
Adverse effects search filters in MEDLINE, when combined with specific 
adverse effects terms, can achieve a high level of sensitivity with an improved 
level of precision. In addition, a high level of precision can be achieved in 
MEDLINE with adverse effects indexing terms. It appears difficult to achieve 
similar high levels of sensitivity and precision with search filters in EMBASE.  
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Further research is required, with more case study systematic reviews, for a 
range of interventions (pharmacological and non-pharmacological) and a diverse 
variety of adverse effects to test the generalisability of these findings. A broad 
range of reviews where no adverse effects terms were used in the search 
process could be assessed to determine whether the addition of an adverse 
effect filter would have improved precision of the searches without loss of 
sensitivity. This should include not just systematic reviews for specific named 
adverse effects (such as fractures) but also reviews that aim to provide a broad 
evaluation of the safety profile of an intervention, thereby capturing all adverse 
effects.  
 
Similarly, as adverse effects data are available from different study designs 
(often non-randomized designs), it would help to design and evaluate the value 
of specific filters for particular types of study, such as, case-control study 
designs. 
 
 Summary 12.7
The 58 included references from the case study systematic review of 
thiazolidinedione-related fractures in Chapter 11 were used to test the 
performance of published search filters in MEDLINE and EMBASE. 
Sensitivity, precision, number needed to read (NNR) and sensitivityXprecision 
were all measured. 
A high level of sensitivity with an improved level of precision could be achieved 
in MEDLINE. 
Precision remained low in EMBASE, even with a decrease in sensitivity. 
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Chapter 13 Adverse effects terms in database records: an analysis 
of the included papers from 26 systematic reviews 
 Introduction 13.1
One of the key difficulties in conducting specific searches for adverse effects 
stems from the absence of adverse effects terms in the title, abstract or indexing 
of relevant articles. In 2001, Derry et al118 evaluated trials that reported data on 
adverse effects and found that about 23% of such trials had no adverse effects 
terms (either generic, such as ‘adverse effect’ or ‘side effect’, or specific, such 
as ‘headache’ or ‘rash’) in the title, abstract or indexing of records in either 
MEDLINE or EMBASE. Hence, electronic searches based on specific adverse 
effect related terms could miss nearly a quarter of the relevant papers. The lack 
of adverse effects terms in the title, abstract or indexing of papers that contain 
adverse effects data is a major problem for the creation of adverse effects 
search filters (combinations of search terms to retrieve references on adverse 
effects). Any combination of search terms that needs to designate adverse 
effects (either as terms in the tile, abstract or indexing) has a high potential to 
miss relevant papers. The lack of confidence in adverse effects search filters 
has led current guidance to emphasize the use of non-specific searches (without 
relying on adverse effects search filters) as well as the need to check full-text 
versions of retrieved articles.22 Unfortunately, implementation of such guidance 
in systematic reviews is onerous and time-consuming compared to running more 
specific adverse effects based searches.  
 
Methodological developments in the past decade might have changed the 
situation since Derry et al 2001’s study.118 At the time of Derry et al 2001’s118 
study there was no specific requirement for authors to mention adverse effects 
in the title and abstract, even where adverse effects data are described in detail 
in the full paper. In 2003, 10 new recommendations about the reporting of harms 
were added to the Consolidated Standards of Reporting Trials (CONSORT) 
including a recommendation that it should be stated in the title or abstract if the 
study collected data on harms.32 Additionally, the Cochrane Adverse Effects 
Methods group (http://aemg.cochrane.org/), which was formed in 2007, as well 
as many other authors, have called for improved reporting of adverse effects.85, 
122, 144, 145, 147, 148, 153, 575-596 However, it is unclear if these developments have had 
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a meaningful impact on the prevalence of adverse effects terms in the title, 
abstract or indexing of relevant adverse effects papers. 
 
The case study reported in Chapter 12 also suggests that some adverse effects 
search filters proposed for MEDLINE121, 360, 427, 428, 430, 432, 434 and EMBASE360, 432 
may be useful in increasing the precision of searches for adverse effects without 
a dramatic decline in sensitivity. This may be due to improvements in the 
reporting of adverse effects terms since the Derry et al 2001 study,118 although 
the findings from the case study in Chapter 12 may not be generalisable to other 
systematic reviews. 
 
The research in this Chapter aims to ascertain whether the reporting of adverse 
effects terms in the title, abstract, or indexing of papers that contain adverse 
effects data has improved since the study by Derry et al in 2001.118 This would 
enable searchers to make better use of terms for adverse effects in identifying 
papers with adverse effects data when searching electronic databases. In 
addition, this research aims to assess the ability of published search filters to 
identify papers with adverse effects data in MEDLINE and EMBASE, with a 
more detailed analysis of individual search terms within these filters. 
 
This research expands the study conducted by Derry et al 2001118 by including a 
larger sample of included papers from a wider range of systematic reviews (thus 
improving on the generalisability of the results), including Science Citation Index 
(SCI), taking account of non-RCTs, and evaluating published adverse effects 
search filters and individual adverse effects search terms. 
 
 Methods 13.2
13.2.1  Selection of systematic reviews with adverse effects data 
A collection of papers that reported data on the frequency of adverse effects 
was sought from the included studies from systematic reviews of adverse 
effects. The use of included papers from systematic reviews has been shown to 
be effective in identifying a reference standard set of records for use in studies 
evaluating search strategies.597 
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The included reviews may have evaluated adverse effects in different ways, for 
instance, by singling out specific named adverse clinical outcomes of interest 
(such as fractures or myocardial infarction), or by taking a broader look at the 
general safety or tolerability profile without any limits to particular adverse 
outcomes.  
 
The systematic reviews of adverse effects were identified through browsing the 
Database of Abstracts of Reviews of Effects (DARE). Systematic reviews 
published up to 2006 were thought unlikely to contain a large volume of studies 
published from 2002 onwards. A systematic review was, therefore, considered 
eligible for inclusion if it was published between 2007 and 2010 (when the 
search was conducted). This was deemed a long enough time period in which to 
generate a sufficient number of papers to compare with the Derry et al 2001 
study. In addition, a systematic review was considered eligible for inclusion if: 
a) An adverse drug reaction was the primary outcome. 
b) Generic adverse effects search terms or specified named adverse 
effects search terms had not been used by the review authors. This 
enabled an unselected cohort to be built, where relevant articles had not 
already been chosen because of the presence of adverse effects terms. 
Typically, such reviews would have relied on search terms for 
population/condition and intervention only, such as type 2 diabetes and 
rosiglitazone. 
c) The search included either handsearching or reference checking in 
addition to database searches. 
 
13.2.2 Selection of primary studies with adverse effects data 
The included references in each systematic review were checked for papers 
published in English after the year 2000, so that a contemporaneous study 
cohort could be obtained. Non-English language papers were excluded, as there 
was concern about obtaining valid matches for adverse effects terms in different 
languages. Full-text articles were checked to confirm the presence of adverse 
effects data that had been used in the systematic review. The papers were then 
de-duplicated, in order to remove copies of papers that had been included in 
more than one systematic review. 
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13.2.3 Data analysis 
13.2.3.1 Availability in selected databases 
The first stage of the analysis was to check whether each paper was contained 
in MEDLINE, EMBASE or Science Citation Index (SCI). MEDLINE and EMBASE 
were selected in order to compare the results with Derry et al 2001 and because 
they are the most frequently used databases in systematic reviews of adverse 
effects (Chapter 10). Science Citation Index (SCI) was selected, as this 
database contained the highest number of relevant references in a case study 
systematic review of fractures and rosiglitazone conducted by the authors 
(Chapter 11). In order to ascertain whether each paper was contained in the 
databases, several iterations using author names and words from the title were 
used.  
 
13.2.3.2 Adverse effects terms in the database records 
For each database the available papers were checked to ascertain if: 
1. The authors mentioned terms synonymous with ‘adverse effects’ in the 
title or abstract, potentially enabling the paper to be found in an 
electronic search. Adverse effects terms, such as ‘adverse events’, ‘side 
effects’, ‘tolerated’, and ‘unwanted effects’ were accepted. This is in line 
with terms accepted by Derry et al 2001.118 
2. The authors mentioned specific named adverse effects terms (such as 
‘headache’ or ‘cancer’) in the title or abstract. The terms were accepted 
based on the adverse effects included in the systematic review. For 
example, for a systematic review on cancer as an adverse effect, only 
cancer-related terms were accepted. This part of the analysis was only 
conducted on included studies from reviews for a specific named 
adverse effect.  
3. The papers had been indexed (using subject headings or subheadings) 
with relevant terms for adverse effects, potentially enabling the paper to 
be found in an electronic search. Adverse effects terms were accepted 
on the basis that they could be considered synonymous with ‘adverse 
effects’ and would have been accepted by Derry et al 2001.118 Examples 
of included indexing terms are drug toxicity/ and side effects/. Examples 
of included subheadings are ‘adverse effects (ae)’, or ‘adverse drug 
reaction (ae)’. 
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4. The papers had been indexed with specific named adverse effects 
terms. The terms were accepted based on the adverse effects included 
in the systematic review. For example, for a systematic review on cancer 
as an adverse effect, only cancer-related terms were accepted. This part 
of the analysis was only conducted on included studies from reviews for 
a specific named adverse effect. 
 
13.2.3.3 Published search filters 
The papers available on MEDLINE and EMBASE were checked to ascertain if 
they would have been identified if a published search filter had been applied to 
the search strategy. Each filter was tested in turn and the sensitivity of using 
each filter recorded. Due to the logistical constraints of repeating search 
strategies it was not possible to measure the precision of the search filters. It is 
reasonable to assume that precision will be higher with a search filter as 
opposed to without a filter, as fewer records would be retrieved with a filter. The 
MEDLINE search filters tested were Badgett et al 1999,427, 428 Golder et al 
2006,360 BMJ Clinical Evidence 2006,432 and Buckingham et al 2005,434 and the 
EMBASE filters were Golder et al 2006360 and BMJ Clinical Evidence 2006432 
(Appendix G). The PubMed filters by Wieland et al 2005121, 430 were not tested 
as these filters were designed specifically for a review on oral contraceptives 
and breast cancer (Appendix H). 
 
The search filters by Badgett et al 1999427, 428 and Golder et al 2006360 did not 
contain any specific named adverse effects terms and could therefore be tested 
on all the included papers. The other filters432,434 (including a second filter by 
Golder et al 2006)360 used specific named adverse effects terms and were, 
therefore, only tested on those included papers identified from systematic 
reviews of a specific named adverse effect and not those reviews that aimed to 
carry out a generalised broad evaluation of safety. 
 
In addition to the search combinations proposed in the published search filters, 
each term included in at least one search filter was tested individually and the 
sensitivity measured; this included terms from Wieland et al 2005.121, 430 The test 
was carried out to ascertain whether specific terms included in the search filters 
were particularly useful in retrieving papers containing adverse effects data. 
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 Results 13.3
13.3.1  Systematic reviews included 
Twenty-six systematic reviews met the inclusion criteria.239, 598-622 Half were 
concerned with the safety profile for an intervention,598, 599, 603, 606-611, 614-616, 619 
while the other half were limited to a named/specific adverse effect with an 
intervention.239, 600-602, 604, 605, 612, 613, 617, 618, 620-622 
 
13.3.2 Primary studies included 
A total of 474 papers were included in the systematic reviews; 232 papers were 
excluded from the analysis; 140 were published before 2001, 33 papers did not 
contain adverse effects data in the full-text relevant to the systematic review in 
which they were cited, 26 were not indexed on either MEDLINE, EMBASE or 
Science Citation Index (SCI), 25 were duplicate papers (contained in more than 
one systematic review) and eight were published in a non-English language. 
Those references not identified in any of the databases were 15 company 
reports, eight conference papers, two Food and Drug Administration (FDA) 
reports and one book. 
 
The remaining 242 papers were eligible for use in the analysis. The majority of 
the references (89%, 216/242) were for randomized controlled trials (RCTs), 
although, there were 13 case series, five chart reviews, three case reports, three 
cohort studies, one non-RCT study, and one uncontrolled study. 
 
13.3.3  Database records of primary studies 
There were 231 references indexed on MEDLINE, 119 papers from reviews on a 
specified adverse effect and 117 from safety profile reviews (five references 
were included in both types of review).  
 
On EMBASE there were 222 references indexed (two of which were not indexed 
on MEDLINE), 113 papers from reviews on a specified adverse effect and 114 
from safety profile reviews (5 references were included in both types of review).  
 
References indexed on Science Citation Index (SCI) numbered 238 (11 of which 
were not indexed on MEDLINE), 127 papers from reviews on a specified 
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adverse effect and 116 from safety profile reviews (five references were 
included in both types of review). 
 
13.3.4  Comparison with previous research 
In order to compare the results with Derry et al 2001,118 the adverse effects 
terms in the title, abstract and indexing of records on MEDLINE and EMBASE 
were recorded. A list of accepted terms identified in at least one paper is given 
in Appendix I: Table 15.23. 
 
The number of included studies with adverse effects terms in the title, abstract 
or indexing in each of the 26 systematic reviews is listed in Appendix I:Table 
15.24 summarises these results and compares them to the Derry et al 2001 
study.118 The  average percentage of papers per systematic review containing 
adverse effects terms in the title or abstract or indexing in MEDLINE or 
EMBASE is higher in the present study than in Derry et al 2001.118 The variation 
between reviews is greater in the present study than in Derry et al 2001.118 
 
Table 13.1 Average percentage of records with adverse effects terms in the 
title, abstract or indexing in the present study and in Derry et al 2001 
 Adverse effects 
terms in title or 
abstract (range) 
Adverse effect 
indexing terms in 
MEDLINE or 
EMBASE (range) 
Retrievable by a 
combined search 
(range) 
Present study  69% (21% to 100%) 90% (14% to 100%) 92% (43% to 100%) 
Derry 2001118  59% (49% to 69%) 64% (54% to 76%) 77% (69% to 83%) 
 
Overall, a combined search using terms in the title, abstract or indexing run in 
both MEDLINE and EMBASE would have failed to retrieve 19 papers (8%) of 
the 233 papers across all 26 systematic reviews. All of these were RCTs. This is 
much lower than the 23% of papers that would have been missed with a similar 
search approach in Derry et al 2001.118 
 
13.3.5  Variation between types of review 
Those papers included in reviews which aimed to identify a specific named 
adverse effect were more likely to contain an adverse effect term in the title or 
 207 
abstract (74% versus 65%), or in the indexing (97% versus 84%) in MEDLINE or 
EMBASE than the papers from a review which provided a safety profile for an 
intervention (Appendix I: Table 15.24). 
 
13.3.6  Performance of adverse effects terms 
13.3.6.1 Generic adverse effects terms 
Generic adverse effects terms (such as side effect or adverse event) may be 
used in either systematic reviews of a safety profile of an intervention or reviews 
of a specific named adverse effect. Although the use of generic adverse effects 
terms in the title and abstract is similar in MEDLINE, EMBASE and Science 
Citation Index (SCI) (at around two-thirds), the use of indexing terms and 
subheadings varies considerably (Table 13.2). EMBASE, in particular, assigns 
generic adverse effect indexing terms to records far more frequently (66%) than 
MEDLINE (0.4%) or the keywords in Science Citation Index (SCI) (7%). Adverse 
effects subheadings are also used more frequently in EMBASE (83%) than 
MEDLINE (53%) and are not available in Science Citation Index (SCI). 
 
13.3.6.2 Specific named adverse effects terms 
The use of specific named adverse effects search terms could only be assessed 
in systematic reviews of specific named adverse effects. Although the use of 
specific adverse effects terms in the title and abstract is similar in MEDLINE, 
EMBASE and Science Citation Index (SCI) at around 25%, again the use of 
indexing terms varies considerably (Table 13.2). EMBASE, in particular, assigns 
specific named adverse effect indexing terms to records far more frequently 
(56%) than MEDLINE (8%), or the keywords in Science Citation Index (SCI) 
(14%). 
 
13.3.6.3 Generic and specific adverse effects terms together 
Using any adverse effects terms in the title, abstract or indexing would have 
identified 89% of all relevant references in EMBASE, 80% in MEDLINE and 70% 
in Science Citation Index (SCI) (Table 13.2).  
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Table 13.2 Adverse effects terms in the title, abstract or indexing of 
records in MEDLINE, EMBASE or Science Citation Index (SCI) 
Database 
(number of 
records) 
 
Generic 
adverse 
effects in 
title, abstract  
Generic 
adverse 
effects in 
indexing or 
keywords  
Generic 
adverse effects 
in subheadings  
Any generic 
adverse 
effects  
MEDLINE 
(N=231) 
147 (64%)   1 (0.4%) 122 (53%) 179 (77%) 
EMBASE 
(N=222) 
147 (66%) 147 (66%) 185 (83%) 197 (89%) 
Science 
Citation 
Index (SCI) 
(N=238) 
153 (64%)  16 (7%) NA 155 (65%) 
Database 
(number of 
records) 
Specific 
adverse 
effects in 
title, abstract  
Specific 
adverse 
effects in 
indexing or 
keywords  
 Any 
specific 
adverse 
effects 
MEDLINE 
(N=119) 
28 (24%)  10 (8%)  31 (26%) 
EMBASE 
(N=114) 
29 (26%) 63 (56%)  66 (58%) 
Science 
Citation 
Index (SCI) 
(N=127) 
28 (22%) 18 (14%)  36 (28%) 
Database 
(number of 
records) 
Any adverse 
effects terms 
(generic or 
specific) in 
title or 
abstract 
Any adverse effects terms 
(generic or specific) in 
indexing, subheadings or 
keywords 
Any 
adverse 
effects 
terms 
(generic or 
specific) 
MEDLINE 
(N=231) 
164 (71%) 122 (53%) 185 (80%) 
EMBASE 
(N=222) 
156 (70%) 192 (86%) 198 (89%) 
Science 
Citation 
Index (SCI) 
(N=238) 
162 (68%)  32 (13%) 167 (70%) 
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13.3.6.4 Search filters which exclude specific named adverse 
effects 
Search filters based on generic adverse effects terms (such as ‘adverse effect’ 
or ‘side effect’ or ‘tolerability’ or ‘toxicity’) can potentially be used in any 
systematic review and were tested on all the included studies. In MEDLINE 28% 
(65/231) and 13% (29/231) of papers would have been missed respectively if 
the Badgett et al 1999427, 428 and Golder et al 2006360 search filters had been 
applied. In EMBASE 12% (26/222) of papers would have been missed if the 
Golder et al 2006360 search filter had been applied (Table 13.3).  
 
13.3.6.5 Search filters which include specific named adverse 
effects 
Those filters dictating the use of specific named adverse effects terms were 
tested with the included papers from systematic reviews of specific named 
adverse effects. In MEDLINE 77% (92/119), 93% (111/119), 97% (116/119) and 
7% (8/119) of papers would have been missed respectively if the BMJ Clinical 
Evidence 2006432, the Buckingham et al 2005 variants,434 and Golder et al 
2006360 search filters had been applied. In EMBASE 43% (49/113) and 4% 
(5/114) of papers would have been missed respectively if the BMJ Clinical 
Evidence 2006432and Golder et al 2006360 search filters had been applied (Table 
13.3).  
 
The sensitivity of the BMJ Clinical Evidence filter432 would have been improved if 
the specific named adverse effects terms had been ORed instead of ANDed 
with the generic adverse effects terms. In MEDLINE, 109 papers would have 
been retrieved with a sensitivity of 92% (109/119) and 109 in EMBASE with a 
sensitivity of 96% (109/113).  
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Table 13.3 Sensitivity of MEDLINE and EMBASE search strategies for 
adverse effects 
 Number of Relevant 
Records 
Sensitivity  
Search strategies excluding specified named adverse effects terms 
MEDLINE (N=231) 
Badgett427, 428 166 72% 
Golder360 202 87% 
EMBASE (N=222) 
Golder360 195 88% 
Search strategies including specified named adverse effects terms  
MEDLINE (N=119) 
BMJ Clinical Evidence432 27 23% 
Buckingham434 Without the quick filter 
(hedge) 
8 7% 
Buckingham434 With the quick filter 
(hedge) 
3 3% 
Golder360  111 93% 
EMBASE (N=114) 
BMJ Clinical Evidence432 65 57% 
Golder360  109 96% 
 
13.3.6.6 Retrieval of RCTs and observational studies 
Of the 24 non-RCT studies in MEDLINE, all were retrieved by either the BMJ 
Clinical Evidence 2006432 and the Golder et al 2006360 search strategies. The 
search strategy by Badgett et al 1999427, 428 retrieved all but three chart reviews 
and one non-RCT.  
 
Twenty-three non-RCT studies were available in EMBASE and all 23 were 
retrieved by the BMJ Clinical Evidence 2006432 and the Golder et al 2006360 
search strategies. 
 
13.3.6.7 Individual search terms 
Appendix I: Table 15.25 shows the number of relevant records retrieved using 
each individual generic search term contained in at least one published search 
filter. 
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In MEDLINE, terms which retrieved the highest number of relevant records were 
the subheadings ‘therapeutic use (tu)’ (77%, 177/231) and ‘adverse effects (ae)’ 
(51%, 117/231). This was followed by the terms ‘adverse adj3 event$’ (32%, 
75/231), ‘safety’ (31%, 71/231), ‘adverse adj2 events’ (29%, 67/231) and ‘risk’ 
(28%, 64/231) in the title or abstract, and the subheadings ‘drug effects (de)’ 
(27%, 62/231), and ‘complications (co)’ (18%, 41/231). None of the indexing 
terms retrieved a large proportion of the relevant records and searching the title 
and abstract or all fields made little difference to the results.  
 
In EMBASE, the highest number of relevant records were retrieved with the 
floating subheadings, ‘adverse drug reaction (ae)’ (83%, 185/222) and ‘side 
effect (si)’ (83%, 185/222). This was followed by the EMTREE indexing term exp 
drug safety/ (38%, 85/222), and then the terms ‘adverse adj3 event$’ (32%, 
71/222), ‘safety’ (28%, 63/222), ‘adverse adj2 events’ (28%, 63/222) and ‘risk’ 
(27%, 61/222) in the title or abstract. 
 
It should be noted that‘adj2’ and ‘adj3’ refer to the adjacency or proximity 
operator in OVID. A search for ‘adverse adj3 event$’ will retrieve records in 
which the word ‘adverse’ occurs within 3 words of the word ‘event$’. The $ 
symbol is the truncation symbol in OVID to search for multiple words with the 
same root. For example, ‘event’ and ‘events’ will be retrieved. 
 
 Discussion 13.4
It is reassuring to note that the use of adverse effects terms in the title, abstract 
or indexing, in MEDLINE and EMBASE for articles that are known to contain 
adverse effects data, has increased compared to previous findings.118 In the 
past, specific searches for studies that contained adverse effects data have 
been hindered by the frequent absence of adverse effects terms. However, 
these findings now indicate that reviewers can, with caution, choose to use more 
focused search filters, or specific named adverse effects terms, rather than face 
the arduous task of broad non-specific searches followed by evaluation of full-
text articles.  
 
The variation in adverse effects terms in the title, abstract or indexing in the 
current study is much greater than in the study by Derry et al 2001.118 This might 
reflect the greater number of systematic reviews included in the present study, 
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(26 as opposed to three in the study by Derry et al 2001),118 and the greater 
variation in topic coverage in the present study. However, this variation raises 
concerns for searchers who may wish to use adverse effects terms in their 
search strategies, as although for some systematic reviews 100% sensitivity 
was achieved, this was much lower for other reviews. 
 
The use of specific named adverse effects indexing terms and generic adverse 
effects indexing terms was much higher in EMBASE than MEDLINE or Science 
Citation Index (SCI), and reflects the general practice in EMBASE of assigning 
more indexing terms to records. The high sensitivity in EMBASE may be at the 
cost of low precision. Other studies have indicated that EMBASE gives more 
irrelevant material than MEDLINE.413, 414  
 
There was a lack of relevant keywords for adverse effects in the records from 
Science Citation Index (SCI). This is not surprising, given that these terms are 
assigned either by the author when the paper is submitted for publication, or 
from words or phrases that frequently appear in the titles of the references cited 
by the paper. This means that the adverse effect would need to be a key aspect 
of the paper or in the title of references for that paper to appear as keywords. In 
addition, not all records in Science Citation Index (SCI) contain keywords. For 
example, meeting abstracts tend not to include any keywords as the authors of 
abstracts generally do not have to provide keywords and abstracts generally do 
not include references. MEDLINE and EMBASE, on the other hand, have 
controlled vocabularies and indexing is a manual process based on the full text 
of the article.  
 
The search filters by Badgett et al 1999427, 428 and Golder et al 2006360 achieved 
fairly high sensitivity, and the filter by BMJ Clinical Evidence 2006432 would also 
have achieved high sensitivity had the specific named adverse effects been 
ORed instead of ANDed with the generic adverse effects terms. Whether this 
level of sensitivity is acceptable for a systematic review search will depend on 
the topic under evaluation, resources available, and anticipated gain in 
precision. For example, if the search filters reduced the numbers of records 
needed to sift from an unmanageable set of tens of thousands of records, these 
search filters may be worth using. High precision is often at the loss of 
sensitivity. For instance, the Buckingham filters434 aimed to achieve high 
precision and it is not surprising that these filters fared poorly with respect to 
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sensitivity. The inevitable trade-off between sensitivity and precision may or may 
not be problematic depending on the particular review. For example, in 
situations where the search filters reduced the numbers of records needed to sift 
by only a handful, then any loss in sensitivity might not be acceptable. Even in 
circumstances where search filters reduce the numbers needed to read by a 
significant amount, caution might be needed in the case of rare events, where 
any loss in sensitivity might impact on the results of a review. 
 
To limit things further, the analysis of the utility of particular search terms can 
help in the design of new filters, or in guiding the modification of existing ones 
for improved performance. The most useful individual search terms in both 
MEDLINE and EMBASE were adverse effects subheadings. These tended to 
retrieve more relevant records than either text words or indexing terms. In the 
common scenario where a customized search strategy for a particular topic 
needs to be built from scratch, it would be sensible to design the search with a 
greater emphasis on inclusion of relevant subheadings, rather than rely on 
picking up specific terms in the title or abstract. Subheadings are likely to be 
more useful, as there is a dearth of appropriate indexing terms available. In 
addition, adverse effects terms are less likely to appear in the title and abstract 
and when they do there is a lack of consistency in the terms used. 
 
Evaluation of adverse effects may involve the inclusion of a range of different 
study designs, such as non-randomized pharmacoepidemiological studies. The 
ability to accurately identify relevant observational studies would be a potentially 
useful feature of a search filter. It has been suggested that the problems 
identified by Derry et al 2001 may extend to non-RCTs.15 Although based on a 
small sample, the results here indicate that the BMJ Clinical Evidence 2006432 
and the Golder et al 2006360 search strategies might be particularly useful in 
retrieving non-randomized studies. Many observational studies are focused on 
adverse effects as primary, rather than secondary, outcomes and are therefore 
easier to retrieve. 
 
It was interesting to note that not all the references to included studies from 
each systematic review contained adverse effects data relevant to the 
systematic review. Some contained information on other adverse effects, some 
were letters or reviews referring to primary studies, and some were studies 
which simply reported on efficacy. In practical terms, this brings about debate on 
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whether it is best to spend time perfecting the search strategy for adverse 
effects or to write to all authors of studies which may have collected adverse 
effects data. 
 
 Limitations 13.5
The main limitation of this research is that the precision of the search terms and 
search filters could not be measured. Although this study indicates which search 
terms are most effective in retrieving papers with adverse effects data, these 
terms may also retrieve a high proportion of irrelevant records (but less so than 
similar searches with no adverse effects terms at all). In developing any search 
strategy it is important to obtain a balance between sensitivity and precision.  
 
Caution should be applied when using the results of this study, especially as 
some of the search terms appeared to have only a vague connection to adverse 
effects (such as ‘therapeutic use’, ‘pharmacology’ ‘follow-up’ or ‘risk’). Although 
systematic review searches aim to be as comprehensive as possible, such a 
search may yield several thousand articles and only a small fraction of them will 
be relevant. Search results should aim to be manageable in terms of the 
feasibility of screening all the potentially relevant studies, particularly as previous 
recommendations have suggested that checking full-text may be necessary. 
 
  Conclusions 13.6
There is increasing prevalence of adverse effects terms in the title, abstract and 
indexing terms on MEDLINE and EMBASE of articles that contain adverse 
effects data. However, there is considerable variation in the reporting between 
topic areas.  
 
With respect to individual search terms, subheadings, either free floating or with 
subject headings, appear to be most useful in identifying papers with adverse 
effects data in both MEDLINE and EMBASE. Few indexing terms exist for 
adverse effects, and the sensitivity of those is low, particularly in MEDLINE. 
Although some free text terms for adverse effects in the title and abstract may 
be useful, they should be applied in addition to other terms. 
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The adverse effects search filters available varied considerably in terms of 
sensitivity, and although high sensitivity could be achieved in both MEDLINE 
and EMBASE, 100% sensitivity was not achieved. Search filters for adverse 
effects could, therefore, be useful for capturing relevant records for systematic 
reviews of adverse effects; nonetheless, they should be applied with caution. 
 
Further research, which also measures precision of the search terms and filters 
is required to establish the full value of using adverse effects terms in search 
strategies. In the meantime, improvements in the allocation of subheadings to 
bibliographic records could ease the workload of the systematic reviewer. 
 
 Summary 13.7
Two hundred and forty-two articles with adverse effects data were selected from 
26 systematic reviews for analysis. The sensitivity of adverse effects search 
filters and individual search terms were calculated. 
The sensitivity of search filters for adverse effects varied but a high sensitivity 
could be achieved. Subheadings provided the highest sensitivity of the individual 
search terms assessed. 
There is an increasing prevalence of adverse effects terms in the title, abstract, 
and indexing of records in MEDLINE and EMBASE. Overall a search on both 
MEDLINE and EMBASE would have failed to identify 8% of relevant articles. 
However variation exists between topic areas. 
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Chapter 14 Discussion 
 Overall summary 14.1
Healthcare professionals, patients and policy makers need to make informed 
decisions about the drugs they administer or recommend. To do this they 
require evidence about the effectiveness of drugs and their adverse effects. New 
drugs do not usually add many ‘benefits’ in comparison to current treatments so 
a full investigation of adverse effects can be a ‘deciding factor’.  
 
Systematic reviews are generally regarded as providing the best evidence to 
inform decision making and should provide a reliable and objective source of 
information on both the effectiveness and adverse effects of an intervention. 
Considerable research and effort has been undertaken in establishing optimal 
information retrieval methods for identifying studies of effectiveness. The overall 
aim of this thesis was to identify and evaluate optimal methods for retrieving 
information on adverse drug effects within systematic reviews.  
 
The first stage was to identify and consolidate the existing research evidence in 
this area. A systematic review was undertaken, which summarised all aspects of 
the methodological literature to date on the retrieval of information on adverse 
effects and the impact of different sources of information (Chapters 3 to 9). 
Topic areas included: study design selection (such as RCTs versus cohort 
studies); the relative value of different sources of information (such as database 
and non-database sources) in identifying relevant information; the usefulness of 
adverse effects database search filters; the impact of the inclusion of 
unpublished material and industry funded studies; and potential bias by type of 
author (clinician or academic); journal impact factor; year of publication; and 
country setting.  
 
The second stage of this programme of research aimed to summarise current 
practice in the retrieval of information in systematic reviews of adverse effects 
and identify any apparent time trends in the methodologies employed. An 
evaluation was undertaken of the search methods in 849 systematic reviews 
published between 1994 and 2011 (Chapter 10). The search methods used in  
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these systematic reviews of adverse effects were also compared with those 
methods used in other types of systematic reviews. 
 
The final stage of this thesis was to carry out primary investigations into two 
major gaps in the research on the retrieval of information on adverse effects, 
namely the effectiveness of adverse effects database search filters and the 
relative value of searching different information sources for adverse effects data. 
These issues were addressed in a detailed analysis of a systematic review 
conducted by the author and an evaluation of a series of published systematic 
reviews.  
 
The papers included in a systematic review of thiazolidinedione related-fractures 
were used to assess the relative contribution of different information sources 
(including databases and non-database sources) in identifying relevant 
references or studies (Chapter 11). This case study was then used to measure 
the sensitivity and precision of published adverse drug reaction search filters in 
MEDLINE and EMBASE (Chapter 12).  
 
In addition, 242 included papers from 26 systematic reviews of adverse drug 
reactions were used to assess the sensitivity of individual adverse effects search 
terms in MEDLINE, EMBASE and Science Citation Index (SCI) and the 
sensitivity of adverse effects search filters in MEDLINE and EMBASE (Chapter 
13). 
 
As far as can be ascertained, this is the first attempt to amalgamate all the 
literature pertaining to the retrieval of information on adverse effects and the 
largest most comprehensive analysis of data sources and search strategies for 
adverse drug reactions. 
 
 Main Findings 14.2
There are a number of important findings from this research. On average, there 
is no difference in the risk estimates of adverse effects of an intervention derived 
from meta-analyses of RCTs and those from meta-analyses of observational 
studies. In almost all instances the confidence intervals from meta-analyses of 
RCTs and meta-analyses of observational studies overlap and there is 
agreement in terms of the conclusions reached. 
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The value of identifying unpublished data and industry funded studies is 
highlighted. This research found that unpublished studies and data from drug 
manufacturers can provide additional data that is not otherwise covered in 
published studies.There was mixed evidence surrounding the postulated link 
between industry funding and more favourable reporting of adverse drug 
reactions data. Industry funded studies contained more complete reporting of 
adverse drug reactions but tended to have more positive conclusions, 
irrespective of the raw adverse effects data. These findings are confirmed in 
more recent studies. For example, differences in the types of case reports in the 
published literature and unpublished pharmacovigilance systems have been 
identified,623 a comparison of conference abstracts and journal articles to full 
reports in the GlaxoSmithKline (GSK) Clinical Trials Registry suggested that 
87.9% of all adverse effects were not reported in publically available ‘published’ 
versions,624 published studies on insomnia medication have also been found to 
report much less safety information than unpublished studies,625 and industry 
sponsored trials have been found to be associated with better harm reporting.626 
 
Based on the research evidence from this thesis, it is clear that no single 
information source contains all of the data on adverse effects for a particular 
systematic review and that MEDLINE may not yield the highest number of 
relevant articles. The most efficient combination of sources to identify 
information on adverse effects is still unknown. Neither is agreement on a 
hierarchy of information sources (based on their relative value) likely to be 
reached in the near future. 
 
It was found that adverse effects search terms are increasingly prevalent in the 
title, abstract and indexing terms of records that contain adverse drug reactions 
data in MEDLINE and EMBASE. The value of using subheadings in MEDLINE 
and EMBASE (such as ‘adverse effects’ in MEDLINE and ‘adverse drug 
reaction’ in EMBASE) is also particularly apparent. It was interesting to note that 
61% of systematic reviews of adverse effects analysed in this thesis include 
some outcome (adverse effects) terms in their search strategy. 
 
Although there is a slight improvement in the reporting of search strategies in 
systematic reviews of adverse effects from 1994 to 2011, overall only 9% of 
such reviews report a reproducible search strategy. There is also some 
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improvement in the search methodology adopted in systematic reviews of 
adverse effects. The number of databases searched appears to be increasing, 
and the proportion of reviews limiting their searches to MEDLINE or using date 
or language restrictions to be decreasing. These changes are not dramatic, and 
few other improvements in search methods are apparent.  
 
Particular areas of concern in the methodology of systematic reviews of adverse 
effects are the increase in the proportion of reviews limited to RCTs only 
between 1994 and 2011, the lack of any attempts to identify unpublished data or 
data from pharmaceutical companies, and the potentially inappropriate selection 
of information sources. There were large discrepancies between the individual 
information sources contributing the most information on adverse effects and 
those sources currently searched in systematic reviews of adverse effects 
(Appendix J). For instance, the highest sensitivity in the case study review was 
achieved by searching Science Citation Index (SCI) followed by BIOSIS 
Previews, yet only 5% and 8% of reviews respectively search these databases. 
No reviews searched Scirus, Derwent Drug File, British Library Direct, Thomson 
Reuters Integrity, and ADIS Clinical Trials Insight, yet these databases retrieved 
29%, 28%, 26%, 22% and 21% of references respectively. Although MEDLINE 
is the most commonly used database and indeed is often the only database 
searched, only 33% of relevant references were retrieved with this database in 
the case study systematic review.  
 
The results of this programme of research have important implications for 
practice, guidance and the direction of further research. 
 
 Implications for practice 14.3
The findings from this thesis have several implications for the conduct of 
systematic reviews. In particular the results suggest that rather than limiting 
systematic reviews to certain study designs it might be better to evaluate a 
broad range of studies. In this way a more complete, generalizable picture of 
harms of an intervention might be built, without any loss of validity. This is 
particularly relevant in reviews in which there are few RCTs identifying or 
reporting adverse effects, or where the reporting in RCTs is poor. When few 
RCTs are identified that report harms, this can lead to a misconception that a 
given intervention is safe, when its safety is actually unknown. Reviews which 
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assess long-term, rare or unexpected adverse effects may not identify adverse 
effects if their analysis is limited to RCTs. RCTs rarely assess harms as their 
primary outcome, so typically lack the power to detect differences in harms 
between groups. Usually designed to evaluate treatment efficacy/effectiveness, 
RCTs are often conducted over a shorter period of time, with relatively smaller 
number of participants than observational studies.  
 
Evidence from this programme of research indicates that authors of systematic 
reviews incorporating adverse effects should consider including unpublished 
studies and industry funded data to enable adverse effects to be identified 
earlier and to obtain a more precise estimate of effect or incidence. However, 
including unpublished data and industry funded studies brings challenges. For 
example, particular care is required in assessing the quality of unpublished 
material that has not been through the rigorous peer review process many 
journal editors employ. Review authors also need to minimize the possibility of 
data duplication or double counting - as the same adverse effect may appear in 
the published and unpublished data. Authors may therefore need to reconcile 
the various adverse effects reports to establish which to use, especially if data 
differs between sources. In addition, extra vigilance could be required by 
systematic reviewers in assessing any author interpretation or conclusions in 
industry funded studies, as these might be unduly positive.  
 
A further challenge is in identifying industry funded studies and the unpublished 
literature.114 Searches might need to be extended beyond standard bibliographic 
databases to identify data from specialist websites, company and other 
study/trial registries, regulatory agencies (such as Health Canada and the FDA), 
conference abstracts, contacting experts, and reference lists. Contacting 
industry for information is notoriously slow and time consuming with low 
response rate. It would be helpful, therefore, if drug companies made all their 
data available publically, for example by making all study reports available on 
their websites or by depositing data in publicly accessible repositories such as 
clinicaltrials.gov. Improvements in the usability of websites, such as the FDA 
website and conference websites, and the accessibility (in terms of aspects such 
as cost and functionality) of databases of conference proceedings, could also 
help reviewers identify and/or obtain unpublished data. 
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The particular information sources that should be searched in any systematic 
review will vary depending on the topic area of the review and it is difficult to 
generalize the findings from this research to all reviews. However, it is clear from 
the research in this thesis, that authors of systematic reviews should not rely 
solely on MEDLINE for information on adverse effects but should attempt to 
identify data on adverse effects from multiple sources, and use additional 
techniques such as handsearching and reference checking. In light of these 
findings, searchers might need to rethink their current practice and choice of 
databases. 
 
Previous research indicated that adverse effect search terms cannot be relied 
upon, and that any search strategy that includes adverse effects terms could 
miss a high volume of relevant references. Although caution still needs to be 
exercised, the situation has improved and search strategies in MEDLINE and 
EMBASE can now include adverse effects terms or adverse effects search filters 
with reasonable sensitivity. The improved reporting of adverse effects in 
bibliographic records may, in part, be a result of the implementation of 
guidelines for trial reporting such as CONSORT (Consolidated Standards of 
Reporting Trials)626 , 627-631 and subsequent better indexing of adverse effects by 
database providers. If improvements continue, review authors will be able to use 
adverse effects search terms and search filters with more confidence. 
 
Authors of systematic reviews still need to improve the reporting of search 
strategies for adverse effects and report more reproducible search strategies in 
order for readers to be convinced by the methodology and for update searches 
to be undertaken. A number of guidelines on reporting standards of systematic 
reviews are now available to help authors, such as AMSTAR632 (Assessment of 
Multiple Systematic Reviews), RAMESES633 (Realist And MEta-narrative 
Evidence Syntheses: Evolving Standards), MOOSE550 (Meta-analysis of 
Observational Studies in Epidemiology), MECIR (Methodological standards for 
the conduct of Cochrane Intervention Reviews), PRISMA546, 547,550 (Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis) and PRISMA 
Harms Extension) and journal editors are encouraging adherence to these 
guidelines. These guidelines all include aspects on the reporting of search 
strategies (such as the search strategy itself) and on the information sources 
(database and non-database) searched. In addition to these guidelines more 
journals now allow the inclusion of web appendices and supplementary material, 
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enabling authors of systematic reviews to overcome restrictive word limits to 
journal articles and to report full search strategies for at least one of the 
databases searched.  
 
In summary, carrying out a systematic review of adverse effects (as a 
standalone review or in addition to an effectiveness review) is an arduous task in 
which an attempt should be made to search multiple data sources (including 
unpublished data sources and industry data) for a range of study designs. The 
inclusion of all study designs, as well as published and unpublished studies and 
studies funded by industry and non-profit organisations, is likely to create a large 
workload for any systematic reviewer, especially where a safety profile review is 
undertaken, including all possible adverse effects. However, improvements in 
assigning adverse effects search terms to bibliographic records in databases 
may lead to opportunities to use adverse effects search filters with more 
confidence and help ease the workload of the reviewer. In addition, 
systematically reviewing all of the evidence for all possible adverse effects might 
be impractical, with decisions needing to be made to assess only those adverse 
effects that are important to decision makers and patients or to make 
transparent decisions to limit by other factors which can be justified based on 
the individual review. 
 
 Dissemination and implications for guidance 14.4
Guidance on searching for information on adverse effects needs to be updated 
in the light of the findings in this programme of research, and should be 
disseminated to a targeted audience. A wide variation in the search 
methodology employed in systematic reviews of adverse effects is identified in 
this thesis. The need for further development of guidance and a consensus in 
standards for retrieving adverse effects data is also highlighted. Current main 
sources of guidance for systematic reviewers are: The Cochrane Handbook;22 
and CRD’s Guidance for undertaking reviews in healthcare.23 Both of these texts 
have relevant sections on searching and incorporating adverse effects data, 
which can now be based on much stronger evidence. 
 
Dissemination has been an integral part of this programme of research. Efforts 
have been made to present the research sections of this thesis as they are 
completed, to ensure the timeliness of the dissemination of the findings. 
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Dissemination has included publications in peer-review journals,352, 547, 561, 634-640 
presentations and workshops at international conferences, and seminars at 
national events. 
 
Where papers were submitted was carefully considered in order to reach the 
most appropriate audience while satisfying academic requirements of achieving 
high impact publications. For example, papers on advanced searching 
techniques are mainly of interest to information specialists, therefore journal 
titles, such as Health Information Libraries Journal and the Journal of Medical 
Library Association, were selected. Academics/researchers were targeted 
through journals such as the Journal of Clinical Epidemiology, International 
Journal of Technology Assessment in Health Care, and BMC Medical Research 
Methodology. Clinicians and other health professionals through journals such as 
Therapeutic Advances in Drug Safety, PLOS Medicine, PLOS One and the 
British Journal of Clinical Pharmacology. These audiences overlap and in 
addition, these publications may be viewed by people from other fields. As of 
November 2013, 15 journal articles have been published with the findings from 
this research, and these have already been cited in over 250 publications 
(Google Scholar), including other journals, and textbooks on methodological 
standards in systematic reviews641, 642 and clinical research.643, 644 A complete 
summary of the thesis, which summarises all the pertinent findings, is also to be 
published in Health Information Libraries Journal 
 
Presentations have also been targeted at a wide international and national 
audience with oral presentations at Cochrane Colloquia, Cochrane Entities 
meetings, a Cochrane Canada webinar, Pharma-Bio-Med conferences, National 
Institute for Health and Care Excellence (NICE) meetings, InterTASC 
Information Specialists' Sub-Group (ISSG) meetings and the School of Health 
and Related Research (ScHARR) symposium. Information on the dissemination 
products from this research are also listed on a CRD projects page645 and some 
of the presentations are available on YouTube, the Cochrane Adverse Effects 
Methods Group website and the Cochrane Collaboration training website. 
 
Positive critical summaries of this research are available in the safety section of 
the SuRe Info (Summarized Research in Information retrieval for HTA) resource 
on the HTAi (Health Technology Assessment international) Vortal646 and the 
search strategy elements are appraised on the InterTASC Information 
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Specialists' Sub-Group (ISSG) Search Filter Resource.
426
 A critical appraisal of 
this research has also been published in the Cochrane Newsletter.647 
 
The search strategy elements from this thesis have already been incorporated 
into search guidance provided by Elsevier on searching EMBASE648 and the 
author of this thesis has been approached to collaborate on an update of the 
adverse effects chapter in The Cochrane Handbook and to incorporate the 
findings from this thesis into the handbook.  
 
The support and advice for authors of reviews of adverse effects (through 
groups such as the Cochrane Adverse Effects Methods group) has been 
enhanced by the research from this thesis. Regular workshops targeted at this 
challenging area of systematic reviewing are now far more evidence based. This 
support needs to continue to grow. 
 
The provision of current evidence based guidance, support and training can lead 
to improvements in other people’s work, improving the evidence that endorses 
policy and practice and ultimately enhancing patient care. 
 
 Implications for research 14.5
Although the research from this thesis addresses many questions, there are still 
questions that remain unanswered. The results from the comparisons of 
different types of study design could be explored further. For example, it would 
be useful (based on a case-control type of design) to carry out an in-depth 
examination of the meta-analyses (and their included primary studies) with 
substantial discrepancy amongst the RCTs and observational studies, as 
compared to other meta-analyses where RCTs and observational studies had 
close agreement. Any future research in this area should consider the role of 
confounding factors (such as different population selection, duration of drug 
exposure, drug dosage etc.) between studies, and the lack of precision in point 
estimates of risk for rare events that could have accounted for discrepant 
findings amongst RCTs and observational studies.  
 
Different types of adverse effects may be identified by different study designs. 
This research compared study designs which reported on the same adverse 
effects for the same intervention and identified similar estimates. The types of 
 225 
adverse effects reported in RCTs and non-RCTs can differ substantially, given 
differences in populations, length of follow-up, sample size and ascertainment. 
For example, observational studies tend to include larger sample sizes with a 
longer follow-up period than RCTs and could be more likely to identify long-term 
rare events.  
 
The reason for the increase in the proportion of systematic reviews limiting their 
analysis to RCTs requires investigation. It might be due to the difficulties of 
including non-RCTs, in which case further support and guidance may be 
required for authors of reviews, or it may be inexperienced or under-resourced 
reviewers, or it may be a perception that RCTs are sufficient, or that 
observational studies are inferior or may introduce bias, or limiting to RCTs may 
be used to reduce large numbers of records. 
 
The research in this thesis which assessed the contribution of different sources 
of information and the performance of different search strategies in terms of 
sensitivity and precision was based on only one case study systematic review. 
More case studies are needed if the generalisability of these results is to be 
improved. 
 
Due to the retrospective nature of the analysis of the search strategies in the 26 
published systematic reviews, the precision of the adverse effects search filters 
and adverse effects search terms could not be calculated. Further research 
evaluating the sensitivity and precision of adverse effect search filters and 
individual search terms in multiple reviews is required, including assessment of 
the inevitable trade-off between the two and impact on the results of reviews. 
 
Research is needed into the development of adverse effects search filters in 
databases other than MEDLINE - in particular, filters with higher precision in 
EMBASE and filters in those databases providing a high yield of relevant 
records such as Science Citation Index (SCI), BIOSIS Previews, and Derwent 
Drug File. It was notable that search filters were predominately written for 
MEDLINE. 
 
This thesis focused on the retrieval of adverse effects of pharmaceutical 
interventions. It is apparent that much of the research on adverse effects has 
focused on drug information and few systematic reviews of adverse effects 
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include a non-pharmaceutical intervention. Although some of the same 
principles may apply to other types of interventions, such as surgical 
procedures, medical devices, or diagnostic procedures, there are many 
differences that require exploration. Retrieval of information on the adverse 
effects of non-drug interventions may be even more problematic than for drug 
interventions, particularly given the scarcity of specialist information sources, 
inconsistent terminology, poor reporting in primary studies and a lack of 
acknowledgement that non-drug interventions have adverse effects.  
 
Future research on information retrieval might benefit from sensitivity analysis of 
the results of systematic reviews, whereby meta-analyses are repeated with and 
without the inclusion of papers from different sources, as we need to answer the 
question of whether searching so widely actually makes a difference to the 
results and conclusions of systematic reviews and ultimately the decisions made 
by patients, health professionals and policy makers. However, with such 
research, caution needs to be applied as the generalisability of the results will 
always be questionable. In addition, if there is no bias or systematic difference in 
articles available from different sources (say MEDLINE versus EMBASE), any 
review that aims to be thorough and obtain a precise estimate of the results as 
possible may need to include as many studies as possible. This could be 
particularly the case with adverse effects, which, by their very nature, are rare.  
 
Future research should help inform guidance even further and enable more 
definitive recommendations in the complexities of creating search strategies and 
the selection of sources, particularly in areas not covered in this thesis, such as 
non-drug interventions. 
 
 Conclusions 14.6
Although there have been improvements in the search methods used in 
systematic reviews of adverse effects, there are still some major discrepancies 
between the methods advocated in the literature and current practice. These are 
particularly apparent in the selection of databases searched, the lack of 
searches for unpublished data and industry funded studies, and the increasing 
restriction of included studies to RCTs only. In addition, poor reporting of search 
strategies in systematic reviews of adverse effects remains a major obstacle to 
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those wishing to replicate or update the searchers or assess the quality of the 
review. 
 
The results of this programme of research support broad inclusion of sources in 
reviews of adverse drug reactions. Empirical studies suggest that including 
industry funded data, unpublished data and observational studies in a 
systematic review is unlikely to bias the results of a review but contribute extra 
data that might enable adverse effects to be identified earlier and more precise 
estimates of adverse effects to be obtained. 
 
In relation to where and how to search, it is apparent that a combination of 
sources are required to identify adverse drug reactions data for systematic 
reviews and that MEDLINE is unlikely to contribute the highest yield of relevant 
papers. Evidence also suggests that using adverse effects search filters for 
databases such as MEDLINE and EMBASE can be useful and the success of 
adverse effects search terms and filters to capture relevant papers has 
improved. 
 
The suggested recommendations for authors of systematic reviewers that have 
evolved from this research will hopefully lead to more systematic reviews 
incorporating adverse effects (either as a standalone review or in addition to an 
evaluation of effectiveness) and to improvements in the reporting and conduct of 
the literature searches in such reviews. 
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Chapter 15 Appendices 
 
 Search strategies for methodological overviews in Appendix A:
Chapters 3 to 9 
 
Cochrane Database of Systematic Reviews (CDSR): methodology reviews 
only 
Interface: http://www.thecochrane library.com 
Version: 2007 Issue 3 (original search), 2008 Issue 3 (first update search), 2009 
Issue 4 (second update search) 
Date Searched: 26/09/07 (original search), 17/08/09 (first update search), 
22/10/09 (second update search) 
In the original search 10 protocols and 12 systematic reviews were browsed for 
potentially relevant articles. None were deemed relevant. The first update 
search, only identified one new review and this was not deemed relevant. The 
second update search identified 3 new protocols and one new review and these 
were not deemed relevant. 
 
Cochrane Methodology Register (CMR) 
Interface: http://www.thecochrane library.com 
Version: 2007 Issue 3 (original search), 2008 Issue 3 (first update search), 2009 
Issue 4 (second update search) 
Date Searched: 26/09/07 (original search), 17/08/09 (first update search), 
22/10/09 (second update search) 
The following search strategy, using terms in the title, abstract and keywords, 
retrieved 1517 records in the original search and an extra 249 records in the first 
update search and 344 in the second update search; 
#1 adverse 
#2 side next effect* 
#3 unintended next effect* 
#4 unintended next event* 
#5 unintended next outcome* 
#6 unintended next reaction* 
#7 unintended next interaction* 
#8 unintended next response* 
#9 unintentional next effect* 
#10 unintentional next event* 
#11 unintentional next outcome* 
#12 unintentional next reaction* 
#13 unintentional next interaction* 
#14 unintentional next response* 
#15 unwanted next effect* 
#16 unwanted next event* 
#17 unwanted next outcome* 
#18 unwanted next reaction* 
#19 unwanted next interaction* 
#20 unwanted next response* 
#21 unexpected next effect* 
#22 unexpected next event* 
#23 unexpected next outcome* 
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#24 unexpected next reaction* 
#25 unexpected next interaction* 
#26 unexpected next response* 
#27 undesirable next effect* 
#28 undesirable next event* 
#29 undesirable next outcome* 
#30 undesirable next reaction* 
#31 undesirable next interaction* 
#32 undesirable next response* 
#33 adrs or ades or adr 
#34 drug next surveillance 
#35 post next marketing next surveillance 
#36 postmarketing next surveillance 
#37 treatment next emergent  
#38 complication*  
#39 tolerability  
#40 toxicity  
#41 harm or harms or harmful  
#42 safety  
#43 safe  
#44 tolerance 
#45 tolerate 
#46 toxic 
#47 risk or risks 
#48 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 
OR #21 OR #22 OR #23 OR #24 OR #25 or #26 or #27 or #28 or #29 or #30 or 
#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or 
#42 or #43 or #44 or #45 or #46 or #47) 
 
Database of Abstracts of Reviews of Effects (DARE) 
Interface: Administration CRD in-house database  
Date Range: 1994 - Present 
Date Searched: 26/09/07 (original search), 13/08/08 (first update search), 
27/10/09 (second update search) 
The search strategy was composed of two search facets, adverse effects and 
methodology papers. Searching for m in the st1 field enable the search to be 
limited to methodology papers and to exclude example systematic reviews. The 
following search strategy retrieved 341 records in the original search and 13 
new records were identified in the first update search and 40 in the second 
update search; 
The original and first update search were carried out in the old CAIRS interface 
as follows 
S adverse or side(w)effect$ or unintended(w)effect$ or unintended(w)event$ or 
unintended(w)outcome$ or unintended(w)reaction$ or unintended(w)interaction$ 
or unintended(w)response$ or unintentional(w)effect$ or unintentional(w)event$ 
or unintentional(w)outcome$ or unintentional(w)reaction$ or 
unintentional(w)interaction$ or unintentional(w)response$ or unwanted(w)effect$ 
or unwanted(w)event$ or unwanted(w)outcome$ or unwanted(w)reaction$ or 
unwanted(w) interaction$ or unwanted(w)response$ or unexpected(w)effect$  
S unexpected(w)event$ or unexpected(w)outcome$ or unexpected(w)reaction$ 
or unexpected(w)interaction$ or unexpected(w)response$ or 
undesirable(w)effect$ or undesirable(w)event$ or undesirable(w)outcome$ or 
undesirable(w)reaction$ or undesirable(w)interaction$ or 
undesirable(w)response$ or adrs or ades or adr or drug(w)surveillance or 
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post(w)marketing(w)surveillance or postmarketing(w)surveillance or 
treatment(w)emergent or complication$ or tolerability or toxicity or harm or 
harms or harmful or safety or safe or tolerance or tolerate or toxic or risk or risks 
S s1 or s2 
S m/st1 
S s3 and s4 
 
The second update search was carried out in the CMS interface as follows; 
1)    adverse  
2)    "side effect*"  
3)    "unintended effect*"  
4)    "unintended event*"  
5)    "unintended outcome*"  
6)    "unintended reaction*"  
7)    "unintended interaction*"  
8)    "unintended response*"  
9)    "unintentional effect*"  
10)   "unintentional event*"  
11)   "unintentional outcome*"  
12)   "unintentional reaction*"  
13)   "unintentional interaction*"  
14)   "unintentional response*"  
15)   "unwanted effect*"  
16)   "unwanted event*"  
17)   "unwanted outcome*"  
18)   "unwanted reaction*"  
19)   "unwanted  interaction*"  
20)   "unwanted response*"  
21)   "unexpected effect*"  
22)   "unexpected event*"  
23)   "unexpected outcome*"  
24)   "unexpected reaction*"  
25)   "unexpected interaction*"  
26)   "unexpected response*"  
27)   "undesirable effect*"  
28)   "undesirable event*"  
29)   "undesirable outcome*"  
30)   "undesirable reaction*"  
31)   "undesirable interaction*"  
32)   "undesirable response*"  
33)   adrs  
34)   ades  
35)   adr  
36)   "drug surveillance"  
37)   "post marketing surveillance"  
38)   "postmarketing surveillance"  
39)   "treatment emergent"  
40)   complication*  
41)   tolerability  
42)   toxicity  
43)   harm  
44)   harms  
45)   harmful  
46)   safety  
47)   safe  
 231 
48)   tolerance  
49)   tolerate  
50)   toxic  
51)   risk  
52)   risks  
53)   #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or 
#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or 
#23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or 
#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or 
#45 or #46 or #47 or #48 or #49 or #50 or #51 or #52  
54)   RESTRICT RR 7 Methodology 
55)   #53 and #54 
  
 
EMBASE  
Interface: Ovid Biomed 
Date Range: 1980 to 2007 Week 38 (original search), 1980 to 2008 Week 32 
(first update search), 1980 to 2009 Week 42 (second update search) 
Date Searched: 27/09/07 (original search), 14/08/08 (first update search), 
23/10/09 (second update search) 
The main search strategy contain three facets; adverse effects, systematic 
reviews and methodology. The strategy was very pragmatic in nature and some 
terms were limited to title or exclude if they created too much noise. In addition, 
because of the limitations of this pragmatic approach to searching the search 
was supplemented by searching for adverse effects terms along with known 
experts in the field of adverse effects. The original searches retrieved 1315 
records and the first update search retrieved another 159 records and the 
second update search 203 records. 
1     (adverse adj2 (interaction$ or response$ or effect$ or event$ or reaction$ or 
outcome$)).ti,ab.  
2     side effect$.ti,ab.  
3     (unintended adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
4     (unintentional adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
5     (unwanted adj2 (interaction$ or response$ or effect$ or event$ or reaction$ 
or outcome$)).ti,ab.  
6     (unexpected adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
7     (undesirable adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
8     (adrs or ades).ti,ab.  
9     drug safety.ti,ab.  
10     (drug surveillance or ((postmarketing or post marketing) adj2 
surveillance)).ti,ab.  
11     tolerability.ti,ab.  
12     (harm or harms or harmful).ti,ab.  
13     exp postmarketing surveillance/  
14     exp iatrogenic disease/  
15     drug safety/  
16     exp drug toxicity/  
17     treatment emergent.ti,ab.  
18     drug toxicity.ti,ab.  
19     (iatrogenic or iatrogenesis).ti,ab.  
20     complication$.ti.  
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21     toxicity.ti.  
22     safety.ti.  
23     safe.ti.  
24     meta-analysis/  
25     meta-analysis.ti,ab.  
26     meta-analyses.ti,ab.  
27     metaanalysis.ti,ab.  
28     metaanalyses.ti,ab.  
29     metanalysis.ti,ab.  
30     metanalyses.ti,ab.  
31     metasynthesis.ti,ab. 
32     metasyntheses.ti,ab. 
33     meta-synthesis.ti,ab. 
34     meta-syntheses.ti,ab. 
35     narrative synthesis.ti,ab.  
36     narrative syntheses.ti,ab.  
37     bibliographic stud$.ti,ab.  
38     data selection.ti,ab.  
39     data pooling.ti,ab.  
40     pooled analysis.ti,ab.  
41     pooled analyses.ti,ab.  
42     odds ratio.ti,ab.  
43     odds ratios.ti,ab.  
44     medical literature/  
45     literature review$.ti,ab. 
46     review of studies.ti,ab.  
47     systematic review$.ti,ab.  
48     Cochrane review$.ti,ab.  
49     evidence synthesis.ti,ab.  
50     research synthesis.ti,ab.  
51     critical appraisal.ti,ab.  
52     validity assessment$.ti,ab. 
53     quality assessment$.ti,ab.  
54     data extraction.ti,ab.  
55     data synthesis.ti,ab.  
56     study selection.ti,ab.  
57     inclusion criteria.ti,ab. 
58     literature searching.ti,ab.  
59     (formulating adj3 question$).ti,ab. 
60     locating.ti,ab.  
61     (search or searches).ti. 
62     searching.ti.  
63     Publication/  
64     information storage/ or information retrieval/  
65     data base/ or exp bibliographic database/  
66     databases.ti.  
67     (medline or embase or derwent drug file or cinahl or psycinfo or idis or 
pharmline or toxline).ti.  
68     information retrieval.ti,ab.  
69     search strategies.ti,ab.  
70     search filter$.ti,ab.  
71     Different sources.ti,ab.  
72     trials.ti.  
73     ((random$ or clinical or multicent$ or case control or population based) 
and studies).ti.  
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74     RCTs.ti.  
75     Study design$.ti.  
76     (type adj2 study).ti. or types of study/  
77     Case series.ti.  
78     (Observational and studies).ti.  
79     (cohort studies or case-control studies).ti.  
80     Non-randomi?ed.ti.  
81     nonrandomi?ed.ti.  
82     Case reports.ti.  
83     Anecdotes.ti.  
84     Spontaneous report$.ti.  
85     (conflict adj2 interest$).ti,ab.  
86     (competing adj2 interest$).ti,ab.  
87     (funding or funder or funded).ti,ab.  
88     (financed or sponsored).ti,ab.  
89     (grey literature or gray literature or unpublished).ti,ab.  
90     publishing/  
91     methodological issues.ti,ab.  
92     methods.ti.  
93     methodological.ti.  
94     methodology.ti.  
95     assessing.ti.  
96     limitation$.ti.  
97     bias.ti.  
98     challenge$.ti.  
99     how to.ti.  
100     how do.ti.  
101     suggestion$.ti.  
102     instruction$.ti.  
103     reporting$.ti.  
104     quantify$.ti.  
105     guidance.ti.  
106     evaluation of methods.ti,ab.  
107     or/1-23  
108     or/24-90  
109     or/91-106  
110     107 and 108 and 109  
111     derry s$.au. and 107 
112     ioannidis j$.au. and 107  
113     aronson j$.au. and 107  
114     loke y$.au. and 107  
115     chou r$.au. and 107  
116     ashby d$.au. and 107  
117     herxheimer a$.au. and 107  
118     jefferson t$.au. and 107  
119     etminan m$.au. and 107  
120     or/110-119  
 
 
Health Technology Assessment (HTA) Database  
Interface: Administration CRD in-house database  
Date Range: 1994 – Present 
Date Searched: 26/09/07 (original search), 13/08/08 (first update search), 
04/11/09 (second update search) 
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A search on all fields retrieved thousands of  irrelevant records not relating to 
methodology as did the terms risk and safety, all search terms were therefore 
limited to the title field using the following search strategy and the risk and safety 
terms were removed. The original searches retrieved 43 records and the first 
update searches retrieved 6 records and the second update search 5 records. 
The original search and the first update search were carried out in the CAIRS 
interface with the following search strategy; 
S (adverse or side(w)effect$ or unintended(w)effect$ or unintended(w)event$ or 
unintended(w)outcome$ or unintended(w)reaction$ or unintended(w)interaction$ 
or unintended(w)response$ or unintentional(w)effect$ or unintentional(w)event$ 
or unintentional(w)outcome$ or unintentional(w)reaction$ or 
unintentional(w)interaction$ or unintentional(w)response$ or unwanted(w)effect$ 
or unwanted(w)event$ or unwanted(w)outcome$ or unwanted(w)reaction$ or 
unwanted(w) interaction$ or unwanted(w)response$ or unexpected(w)effect$)/ttl 
S (unexpected(w)event$ or unexpected(w)outcome$ or unexptected(w)reaction$ 
or unexpected(w)interaction$ or unexpected(w)response$ or 
undesirable(w)effect$ or undesirable(w)event$ or undesirable(w)outcome$ or 
undesirable(w)reaction$ or undesirable(w)interaction$ or 
undesirable(w)response$ or adrs or ades or adr or drug(w)surveillance or 
post(w)marketing(w)surveillance or postmarketing(w)surveillance or 
treatment(w)emergent or complication$ or tolerability or toxicity or harm or 
harms or harmful or tolerance or tolerate or toxic)/ttl 
S s1 or s2 
 
The second update search was carried out in the CMS interface with the 
following search strategy; 
1)    adverse:TI 
2)    "side effect*":TI 
3)    "unintended effect*":TI 
4)    "unintended event*":TI 
5)    "unintended outcome*":TI 
6)    "unintended reaction*":TI 
7)    "unintended interaction*":TI 
8)    "unintended response*":TI 
9)    "unintentional effect*":TI 
10)   "unintentional event*":TI 
11)   "unintentional outcome*":TI 
12)   "unintentional reaction*":TI 
13)   "unintentional interaction*":TI 
14)   "unintentional response*":TI 
15)   "unwanted effect*":TI 
16)   "unwanted event*":TI 
17)   "unwanted outcome*":TI 
18)   "unwanted reaction*":TI 
19)   "unwanted  interaction*":TI 
20)   "unwanted response*":TI 
21)   "unexpected effect*":TI 
22)   "unexpected event*":TI 
23)   "unexpected outcome*":TI 
24)   "unexpected reaction*":TI 
25)   "unexpected interaction*":TI 
26)   "unexpected response*":TI 
27)   "undesirable effect*":TI 
28)   "undesirable event*":TI 
29)   "undesirable outcome*":TI 
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30)   "undesirable reaction*":TI 
31)   "undesirable interaction*":TI 
32)   "undesirable response*":TI 
33)   adrs:TI 
34)   ades:TI 
35)   adr:TI 
36)   "drug surveillance":TI 
37)   "post marketing surveillance":TI 
38)   "postmarketing surveillance"::TI 
39)   "treatment emergent":TI 
40)   complication*:TI 
41)   tolerability:TI 
42)   toxicity:TI 
43)   harm:TI 
44)   harms:TI 
45)   harmful:TI 
46)   tolerance:TI 
47)   tolerate:TI 
48)   toxic:TI 
49)   #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or 
#12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or 
#23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or 
#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or 
#45 or #46 or #47 or #48 
 
 
Health Management Information Consortium (HMIC) 
Interface: Ovid Biomed 
Date Range: September 2007 (original search), July 2008 (first update search), 
September 2009 (second update search) 
Date Searched: 27/09/07 (original search), 17/08/08 (first update search), 
23/10/09 (second update search)  
A similar approach was undertaken as with searching EMBASE. However, 
differences in the size, content and indexing meant that some changes needed 
to be made. The original search retrieved 92 records, and the first update search 
17 records and the second update 7 records. 
1     (adverse adj2 (interaction$ or response$ or effect$ or event$ or reaction$ or 
outcome$)).ti,ab.  
2     side effect$.ti,ab.  
3     (unintended adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
4     (unintentional adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
5     (unwanted adj2 (interaction$ or response$ or effect$ or event$ or reaction$ 
or outcome$)).ti,ab.  
6     (unexpected adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
7     (undesirable adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
8     (adrs or ades).ti,ab.  
9     drug safety.ti,ab.  
10     (drug surveillance or ((postmarketing or post marketing) adj2 
surveillance)).ti,ab.  
11     tolerability.ti,ab.  
12     (harm or harms or harmful).ti,ab.  
 236 
13     exp adverse drug reactions/  
14     iatrogenic disease/  
15     toxicity/  
16     treatment emergent.ti,ab.  
17     drug toxicity.ti,ab.  
18     (iatrogenic or iatrogenesis).ti,ab.  
19     complication$.ti.  
20     toxicity.ti.  
21     safety.ti.  
22     safe.ti.  
23     meta-analysis/  
24     meta-analysis.ti,ab.  
25     meta-analyses.ti,ab.  
26     metaanalysis.ti,ab.  
27     metaanalyses.ti,ab.  
28     metanalysis.ti,ab.  
29     metanalyses.ti,ab.  
30     metasynthesis.ti,ab.  
31     metasyntheses.ti,ab.  
32     meta-synthesis.ti,ab.  
33     meta-syntheses.ti,ab.  
34     narrative synthesis.ti,ab.  
35     narrative syntheses.ti,ab.  
36     bibliographic stud$.ti,ab. 
37     data selection.ti,ab.  
38     data pooling.ti,ab.  
39     pooled analysis.ti,ab.  
40     pooled analyses.ti,ab. 
41     odds ratio.ti,ab.  
42     odds ratios.ti,ab.  
43     literature review$.ti,ab.  
44     review of studies.ti,ab.  
45     systematic review$.ti,ab.  
46     Cochrane review$.ti,ab.  
47     evidence synthesis.ti,ab.  
48     research synthesis.ti,ab. 
49     critical appraisal.ti,ab.  
50     validity assessment$.ti,ab.  
51     quality assessment$.ti,ab.  
52     data extraction.ti,ab. 
53     data synthesis.ti,ab.  
54     study selection.ti,ab. 
55     inclusion criteria.ti,ab.  
56     literature searching.ti,ab.  
57     (formulating adj3 question$).ti,ab.  
58     locating.ti,ab.  
59     (search or searches).ti.  
60     searching.ti.  
61     exp information materials/  
62     exp information sources/  
63     databases/  
64     databases.ti.  
65     (medline or embase or derwent drug file or cinahl or idis or pharmline or 
toxline).ti.  
66     information retrieval.ti,ab.  
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67     search strategies.ti,ab. 
68     search filter$.ti,ab.  
69     Different sources.ti,ab.  
70     trials.ti.  
71     ((random$ or clinical or multicent$ or case control or population based) 
and studies).ti.  
72     RCTs.ti.  
73     Study design$.ti.  
74     (type adj2 study).ti.  
75     Case series.ti.  
76     (Observational and studies).ti.  
77     (cohort studies or case-control studies).ti.  
78     Non-randomi?ed.ti.  
79     nonrandomi?ed.ti.  
80     Case reports.ti.  
81     Anecdotes.ti.  
82     Spontaneous report$.ti.  
83     (conflict adj2 interest$).ti,ab.  
84     (competing adj2 interest$).ti,ab.  
85     (funding or funder or funded).ti,ab.  
86     (financed or sponsored).ti,ab.  
87     (grey literature or gray literature or unpublished).ti,ab.  
88     methodological issues.ti,ab.  
89     methods.ti.  
90     methodological.ti.  
91     methodology.ti.  
92     assessing.ti.  
93     limitation$.ti.  
94     bias.ti.  
95     challenge$.ti.  
96     how to.ti.  
97     how do.ti.  
98     suggestion$.ti.  
99     instruction$.ti.  
100     reporting$.ti.  
101     quantify$.ti.  
102     guidance.ti.  
103     evaluation of methods.ti,ab.  
104     methods/  
105     exp research methodology/  
106     research/  
107     research design/  
108     research methods/  
109     or/1-22  
110     or/23-87  
111     or/88-108  
112     109 and 110 and 111  
113     derry s$.au. and 109  
114     ioannidis j$.au. and 109  
115     loke y$.au. and 109  
116     chou r$.au. and 109  
117     ashby d$.au. and 109  
118     herxheimer a$.au. and 109 
119     jefferson t$.au. and 109  
120     etminan m$.au. and 109  
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121     or/112-120  
 
Index to Theses 
Interface: http://www.theses.com/ 
Date Range: 1716 - 8 August 2007 (volume 56 part 2) (original search), up to 
17 July 2008 (volume 57 part 1) (update search), up to October 2009 (second 
update search) 
Date Searched: 15/08/07 (original search), 13/08/08 (update search), 06/11/09 
(second update search) 
The content of this database is multi-disciplinary and thousands of irrelevant 
records would have been retrieved with searching all fields. The searches were 
therefore limited to terms in the title. In addition, terms such as toxicity (482), 
tolerance (529), tolerability (4), tolerate (1), safety (483), safe (55), toxic (217), 
risk (1374) and risks (123) were excluded as they retrieved many irrelevant 
studies relating to topics such as environmental risks, toxic waste, occupational 
safety,  and the tolerance of populations. 
Due to the constrictive interface a series of one word/phrase searches was 
carried out, and the results sifted on the web interface. The original searches 
retrieved 338 records before deduplication and 3 potentially relevant records 
were entered into the endnote library, an additional 12 records were retrieved by 
the first update searches and none were entered into the endnote library and 5 
records were retrieved by the second update search and again none were 
entered into the endnote library. The search terms were; 
Adverse, side effect, side effects, unintended effect, unintended effects, 
unintended event, unintended events, unintended outcome, unintended 
outcomes, unintended reaction, unintended reactions, unintended interaction, 
unintended interactions, unintended response, unintended responses, 
unintentional effect, unintentional effects, unintentional event, unintentional 
events, unintentional outcome, unintentional outcomes, unintentional reaction, 
unintentional reactions, unintentional interaction, unintentional interactions, 
unintentional response, unintentional responses, unwanted effect, unwanted 
effects, unwanted event, unwanted events, unwanted outcome, unwanted 
outcomes, unwanted reaction, unwanted reactions, unwanted interactions, 
unwanted interaction, unwanted response, unwanted responses, unexpected 
effect, unexpected effects, unexpected event, unexpected events, unexpected 
outcome, unexpected outcomes, unexpected reaction, unexpected reactions, 
unexpected interaction, unexpected interactions, unexpected response, 
unexpected responses, undesirable effect, undesirable effects, undesirable 
event, undesirable events, undesirable outcome, undesirable outcomes, 
undesirable reaction, undesirable reactions, undesirable interaction, undesirable 
interactions, undesirable response, undesirable responses, adrs, ades, adr, post 
marketing surveillance, postmarketing surveillance , drug surveillance, treatment 
emergent, complication, complications, harm, harms, harmful. 
 
Library, Information Science & Technology Abstracts (LISTA) 
Interface: http://www.libraryresearch.com 
Date Range: mid-1960s - Present 
Date Searched: 26/09/07 (original search), 13/08/08 (update search), 25/10/09 
(second update search) 
Due to the large number of irrelevant records relating to library management 
retrieved by the terms for complication, harm, tolerance, toxicity, safety and risk 
terms these terms were restricted to the title field only and safe and safety were 
replaced by drug safety and risk was removed. The original search retrieved 873 
records and the first update search retrieved 226 records and the second update 
306 records (restricted to academic journals and books). 
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(Adverse or side W1 effect* or unintended W1 effect* or unintended W1 event* 
or unintended W1 outcome* or unintended W1 reaction* or unintended W1 
interaction* or unintended W1 response* or unintentional W1 effect* or 
unintentional W1 event* or unintentional W1 outcome* or unintentional W1  
reaction* or unintentional W1 interaction* or unintentional W1 response* or 
unwanted W1 effect* or unwanted W1 event* or unwanted W1 outcome* or 
unwanted W1 reaction* or unwanted W1 interaction* or unwanted W1 response* 
or unexpected W1 effect* or unexpected W1 event* or unexpected W1 outcome* 
or unexpected W1 reaction* or unexpected W1 interaction* or unexpected W1 
response* or undesirable W1 effect* or undesirable W1 event* or undesirable 
W1 outcome* or undesirable W1 reaction* or undesirable W1 interaction* or 
undesirable W1 response* or adrs or ades or adr or drug W1 surveillance or 
post W1 marketing W1 surveillance or postmarketing W1 surveillance or 
treatment W1 emergent) in any field  
or (complication* or tolerability or toxicity or harm or harms or harmful or 
tolerance or tolerate or toxic or drug W1 safety or risks) in title 
 
MEDLINE 
Interface: Ovid Biomed 
Date Range: 1950 to September Week 3 2007 (original search), 1950 to August 
Week 1 2008 (first update search), 1950 to October Week 3 (second update 
search) 
Date Searched: 27/09/07 (original search), 17/08/08 (first update search), 
23/10/09 (second update search) 
A similar approach was undertaken as with searching EMBASE and HMIC. 
However, differences in the size, content and indexing meant that some 
changes needed to be made. The original search retrieved 900 records. Due to 
changes in indexing practice in MEDLINE, the MeSH term clinical trial/mt was 
no longer available in MEDLINE at the time of conducting the update search and 
was therefore excluded from the update search strategy. The update search 
retrieved 111 records and 152 records from the second update search. 
1     (adverse adj2 (interaction$ or response$ or effect$ or event$ or reaction$ or 
outcome$)).ti,ab.  
2     side effect$.ti,ab.  
3     (unintended adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
4     (unintentional adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
5     (unwanted adj2 (interaction$ or response$ or effect$ or event$ or reaction$ 
or outcome$)).ti,ab.  
6     (unexpected adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
7     (undesirable adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
8     (adrs or ades).ti,ab.  
9     drug safety.ti,ab.  
10     (drug surveillance or ((postmarketing or post marketing) adj2 
surveillance)).ti,ab.  
11     tolerability.ti,ab.  
12     (harm or harms or harmful).ti,ab.  
13     product surveillance, postmarketing/  
14     adverse drug reaction reporting systems/  
15     exp Drug Hypersensitivity/  
16     iatrogenic disease/  
17     exp drug toxicity/  
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18     Abnormalities, Drug-Induced/  
19     treatment emergent.ti,ab.  
20     drug toxicity.ti,ab.  
21     (iatrogenic or iatrogenesis).ti,ab.  
22     complication$.ti.  
23     toxicity.ti.  
24     safety.ti.  
25     safe.ti.  
26     meta-analysis/  
27     meta-analysis.ti,ab.  
28     meta-analyses.ti,ab.  
29     metaanalysis.ti,ab.  
30     metaanalyses.ti,ab.  
31     metanalysis.ti,ab.  
32     metanalyses.ti,ab.  
33     metasynthesis.ti,ab.  
34     metasyntheses.ti,ab.  
35     meta-synthesis.ti,ab.  
36     meta-syntheses.ti,ab.  
37     narrative synthesis.ti,ab.  
38     narrative syntheses.ti,ab. 
39     bibliographic stud$.ti,ab.  
40     data selection.ti,ab.  
41     data pooling.ti,ab.  
42     pooled analysis.ti,ab.  
43     pooled analyses.ti,ab.  
44     odds ratio.ti,ab.  
45     odds ratios.ti,ab.  
46     odds ratio/  
47     literature review$.ti,ab.  
48     review of studies.ti,ab.  
49     systematic review$.ti,ab.  
50     Cochrane review$.ti,ab.  
51     evidence synthesis.ti,ab.  
52     research synthesis.ti,ab.  
53     critical appraisal.ti,ab.  
54     validity assessment$.ti,ab.  
55     quality assessment$.ti,ab.  
56     data extraction.ti,ab. 
57     data synthesis.ti,ab. 
58     study selection.ti,ab.  
59     inclusion criteria.ti,ab.  
60     literature searching.ti,ab.  
61     (formulating adj3 question$).ti,ab.  
62     locating.ti,ab.  
63     (search or searches).ti.  
64     searching.ti.  
65     Periodicals as topic/  
66     "information storage and retrieval"/  
67     databases as topic/ or exp databases, bibliographic/  
68     databases.ti.  
69     (medline or embase or derwent drug file or cinahl or psycinfo or idis or 
pharmline or toxline).ti.  
70     information retrieval.ti,ab.  
71     search strategies.ti,ab.  
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72     search filter$.ti,ab.  
73     Different sources.ti,ab.  
74     trials.ti.  
75     ((random$ or clinical or multicent$ or case control or population based) 
and studies).ti.  
76     RCTs.ti.  
77     Study design$.ti.  
78     (type adj2 study).ti.  
79     Case series.ti.  
80     (Observational and studies).ti.  
81     (cohort studies or case-control studies).ti.  
82     Non-randomi?ed.ti.  
83     nonrandomi?ed.ti.  
84     Case reports.ti.  
85     Anecdotes.ti.  
86     Spontaneous report$.ti.  
87     (conflict adj2 interest$).ti,ab.  
88     (competing adj2 interest$).ti,ab.  
89     (funding or funded or funder).ti,ab.  
90     (financed or sponsored).ti,ab.  
91     (grey literature or gray literature or unpublished).ti,ab.  
92     exp publication bias/  
93     methodological issues.ti,ab.  
94     methods.ti.  
95     methodological.ti.  
96     methodology.ti.  
97     assessing.ti.  
98     limitation$.ti.  
99     bias.ti.  
100   challenge$.ti.  
101     how to.ti.  
102     how do.ti.  
103     suggestion$.ti.  
104     instruction$.ti.  
105     reporting$.ti.  
106     quantify$.ti.  
107     guidance.ti.  
108     evaluation of methods.ti,ab.  
109     methods/  
110     research/mt, st  
111    exp research design/mt, st 
112    clinical trial/mt [this term was excluded from the update searches] 
113    or/1-25  
114    or/26-92  
115    or/93-112  
116    113 and 114 and 115  
117    derry s$.au. and 113  
118    ioannidis j$.au. and 113 
119    aronson j$.au. and 113 
120    loke y$.au. and 113 
121    chou r$.au. and 113  
122    ashby d$.au. and 113  
123    herxheimer a$.au. and 113  
124    jefferson t$.au. and 113  
125    etminan m$.au. and 113  
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126    or/116-125  
 
MEDLINE(R) In-Process & Other Non-Indexed Citations 
Interface: Ovid Biomed 
Date Range: September 26, 2007 (original search), August 15, 2008 (first 
update search), October 22, 2009 (second update search) 
Date Searched: 27/09/07 (original search), 16/08/08 (first update search), 
23/10/09 (second update search) 
The original search strategy retrieved 26 records and the first update search 73 
records and the second update search 92 records. 
1     (adverse adj2 (interaction$ or response$ or effect$ or event$ or reaction$ or 
outcome$)).ti,ab.  
2     side effect$.ti,ab.  
3     (unintended adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
4     (unintentional adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
5     (unwanted adj2 (interaction$ or response$ or effect$ or event$ or reaction$ 
or outcome$)).ti,ab.  
6     (unexpected adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
7     (undesirable adj2 (interaction$ or response$ or effect$ or event$ or 
reaction$ or outcome$)).ti,ab.  
8     (adrs or ades).ti,ab.  
9     drug safety.ti,ab.  
10     (drug surveillance or ((postmarketing or post marketing) adj2 
surveillance)).ti,ab.  
11     tolerability.ti,ab.  
12     (harm or harms or harmful).ti,ab.  
13     treatment emergent.ti,ab.  
14     drug toxicity.ti,ab.  
15     (iatrogenic or iatrogenesis).ti,ab.  
16     complication$.ti.  
17     toxicity.ti.  
18     safety.ti.  
19     safe.ti.  
20     meta-analysis/  
21     meta-analysis.ti,ab.  
22     meta-analyses.ti,ab.  
23     metaanalysis.ti,ab.  
24     metaanalyses.ti,ab. 
25     metanalysis.ti,ab.  
26     metanalyses.ti,ab. 
27     metasynthesis.ti,ab.  
28     metasyntheses.ti,ab.  
29     meta-synthesis.ti,ab.  
30     meta-syntheses.ti,ab.  
31     narrative synthesis.ti,ab.  
32     narrative syntheses.ti,ab.  
33     bibliographic stud$.ti,ab.  
34     data selection.ti,ab.  
35     data pooling.ti,ab.  
36     pooled analysis.ti,ab.  
37     pooled analyses.ti,ab.  
38     odds ratio.ti,ab.  
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39     odds ratios.ti,ab.  
40     odds ratio/ 
41     literature review$.ti,ab.  
42     review of studies.ti,ab.  
43     systematic review$.ti,ab.  
44     Cochrane review$.ti,ab.  
45     evidence synthesis.ti,ab.  
46     research synthesis.ti,ab.  
47     critical appraisal.ti,ab.  
48     validity assessment$.ti,ab.  
49     quality assessment$.ti,ab.  
50     data extraction.ti,ab.  
51     data synthesis.ti,ab.  
52     study selection.ti,ab.  
53     inclusion criteria.ti,ab.  
54     literature searching.ti,ab.  
55     (formulating adj3 question$).ti,ab.  
56     locating.ti,ab.  
57     (search or searches).ti.  
58     searching.ti.  
59     databases as topic/ or exp databases, bibliographic/  
60     databases.ti.  
61     (medline or embase or derwent drug file or cinahl or psycinfo or idis or 
pharmline or toxline).ti.  
62     information retrieval.ti,ab.  
63     search strategies.ti,ab.  
64     search filter$.ti,ab.  
65     Different sources.ti,ab.  
66     trials.ti.  
67     ((random$ or clinical or multicent$ or case control or population based) 
and studies).ti.  
68     RCTs.ti.  
69     Study design$.ti.  
70     (type adj2 study).ti.  
71     Case series.ti.  
72     (Observational and studies).ti.  
73     (cohort studies or case-control studies).ti.  
74     Non-randomi?ed.ti.  
75     nonrandomi?ed.ti.  
76     Case reports.ti.  
77     Anecdotes.ti.  
78     Spontaneous report$.ti.  
79     (conflict adj2 interest$).ti,ab.  
80     (competing adj2 interest$).ti,ab.  
81     (funding or funded or funder).ti,ab.  
82     (financed or sponsored).ti,ab.  
83     (grey literature or gray literature or unpublished).ti,ab.  
84     methodological issues.ti,ab.  
85     methods.ti.  
86     methodological.ti.  
87     methodology.ti.  
88     assessing.ti.  
89     limitation$.ti.  
90     bias.ti.  
91     challenge$.ti.  
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92     how to.ti.  
93     how do.ti.  
94     suggestion$.ti.  
95     instruction$.ti.  
96     reporting$.ti.  
97     quantify$.ti.  
98     guidance.ti.  
99     evaluation of methods.ti,ab.  
100     or/1-19  
101     or/20-83  
102     or/84-99  
103     100 and 101 and 102  
104     derry s$.au. and 100  
105     ioannidis j$.au. and 100  
106     aronson j$.au. and 100  
107     loke y$.au. and 100  
108     chou r$.au. and 100  
109     ashby d$.au. and 100  
110     herxheimer a$.au. and 100  
111     jefferson t$.au. and 100  
112     etminan m$.au. and 100  
113     or/103-112  
 
 245 
 Tables and figures for methodological overviews in Chapters 4 to 9 Appendix B:
 
Table 15.1 Characteristics of included studies in Chapter 4  
Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
Agency for 
Healthcare 
Research and 
Quality 2002238 
Systematic review of hormone 
replacement therapy and venous 
thromboembolism 
Venous 
thromboembolism 
3 RCTs (N=3842)  
RR 3.08 (0.21-45.14)  
1 cohort study 
(N=112593) 
RR 2.1 (1.2-3.8) 
8 case-control studies 
(N=23544) 
RR 2.05 (1.40-2.95) 
 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR (No significant heterogeneity among 
all 12 studies P>0.10) 
Statistical analysis comparing study 
designs: NR 
RCTs: No significant 
difference  
Cohort study: Significant 
increase  
Case-control studies: 
Significant increase  
CI overlap: Yes 
Alghamdi et al 
2007239 
Systematic review of preoperative 
aspirin and bleeding 
Reexploration  
4 RCTs (N=1002) 
Aspirin 41/588   Control 
7/420 
RR 3.71 (1.74-7.91) 
Chi2=1.00, df=3 P=0.80, 
I2=0% 
5 Cohort studies (N=716) 
Aspirin 10/311   Control 
11/405 
RR 1.27 (0.54-2.98) 
Chi2=1.95, df=3 P=0.58, 
I2=0% 
 
Confounding factors by study 
design: NR but carries out sensitivity 
analysis by era (before 1990 and after) 
which suggests effect size larger in early 
era studies. RCTs tended to be earlier 
era studies but no further analysis 
conducted. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
RCTs, one set of cohort studies 
Statistical analysis comparing study 
designs: NR but no significant 
heterogeneity when all RCTs and cohort 
studies are pooled. 
Reexploration 
RCTs: Significant increase 
P<0.001 
Cohort studies: No 
significant difference 
P=0.58 
CI overlap: Yes 
 
 
Bager et al Systematic review of caesarean Asthma Confounding factors by study Cohort studies: 
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Table 15.1 Characteristics of included studies in Chapter 4  
Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
2008240 delivery and atopy and allergic 
disease 
11 cohort studies (N=NR) 
OR 1.22 (1.09-1.37) 
2 case-control studies 
(N=NR) 
OR 0.84 (0.64-1.10) 
design: NR (Carries out stratified meta-
analysis for adjustment of risk ratios, a 
priori aim, study design, year of birth, 
size of study population, country, 
exclusion, proportion of C-sections and 
age. For asthma significant variations 
were seen for age and study design. No 
further data shown) 
Heterogeneity within study designs: 
NR (significant heterogeneity among all 
13 studies P<0.01) 
Statistical analysis comparing study 
designs: Higher ORs for cohort studies 
compared with case-control studies 
P<0.01. Summary OR variation with 
study characteristics, P-values two-
tailed, based on likelihood ratio tests. 
Significant increase  
Case-control studies: No 
significant difference 
CI overlap: Yes 
Bergendal et al 
2009241 
Systematic review of 
progestogen-only contraception 
and venous thromboembolism 
Venous 
thromboembolism 
1 cohort study (N=204) 
OR 0.8 (0.2-3.9)  
4 case-control studies 
(N=10004) 
OR 1.45 (0.92-2.26) 
Confounding factors by study 
design: NR but did not include the 
cohort study in the meta-analysis as 
deemed to deviate too much from other 
studies in terms of population and 
design. 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
Cohort studies: No 
significant difference 
Case-control studies: No 
significant difference 
CI overlap: Yes 
Bollini et al 
1992242 
Meta-analysis of NSAIDS and 
upper gastrointestinal tract 
Upper gastrointestinal 
tract disease  
Confounding factors by study 
design: Stated that type of study design 
Cohort studies: 
Significant increase  
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Table 15.1 Characteristics of included studies in Chapter 4  
Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
disease with primary aim to 
assess the impact of study design 
and research quality 
7 cohort studies (N=NR)  
RR 2.0 (1.2 to 3.2) Chi2 
P<0.01 
27 case-control studies 
(N=NR) 
RR 4.1 (3.2 to 5.3)** 
 
 
was independently associated with risk 
estimates, even after adjustment. Used 
multivariate regression to adjust in the 
same model for drug investigated, type 
of study design, and methodological 
quality. 
Heterogeneity within study designs: 
No significant heterogeneity: 
Community-based case-control studies 
N=8 Chi2 P>0.05.  
Significant heterogeneity: Hospital-
based case-control studies N=19 and 
one set of cohort studies 
Statistical analysis comparing study 
designs: NR but states that cohort 
studies significantly lower risk ratio 
estimate than hospital based case-
control studies. 
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
Browning and 
Martin 2007243 
Systematic review of statins and 
cancer 
Breast cancer  
7 RCTs (N=60917)  
RR 1.01 (0.79-1.30) 
I2=43% 
9 Observational studies 
(N=688052)  
RR 0.96 (0.90-1.04) I2=0% 
 
Prostate cancer 
4 RCTs (N=21740)  
RR 1.00 (0.85-1.17) I2=0% 
Confounding factors by study 
design: NR but acknowledges that 
confounding and other bias may have 
had an effect 
Heterogeneity within study designs: 
No significant heterogeneity: Five sets of 
RCTs and three sets of observational 
studies  
Significant heterogeneity: Two sets of 
observational studies 
Statistical analysis comparing study 
Breast cancer  
RCTs: No significant 
difference P=0.92 
Observational studies: 
No significant difference 
P=0.31 
CI overlap: Yes 
 
Prostate cancer 
RCTs: No significant 
difference P=0.99 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
5 Observational studies 
(N=375290)  
RR 1.08 (0.91-1.30) 
I2=77% 
 
Colorectal cancer 
9 RCTs (N=67656)  
RR 1.02 (0.89-1.16) I2=0% 
5 Observational studies 
(N=508696)  
RR 0.86 (0.77-0.96) 
I2=89% 
 
Lung cancer 
9 RCTs (N=69301) 
RR 0.96 (0.84-1.09) I2=0% 
3 Observational studies 
(N=372592) 
RR 1.07 (0.89-1.28) I2=0% 
 
Melanoma 
4 RCTs (N=24222)  
RR 0.86 (0.62-1.20) 
I2=17% 
1 Observational study 
(N=18047)  
RR 2.50 (0.83-7.55) I2=NA 
 
Gastric cancer 
designs:  NR 
 
Observational studies: 
No significant difference 
P=0.38 
CI overlap: Yes 
 
Colorectal cancer 
RCTs: No significant 
difference P=0.83 
Observational studies: 
Significant decrease 
P=0.009 
CI overlap: Yes 
 
Lung cancer 
RCTs: No significant 
difference P=0.49 
Observational studies: 
No significant difference 
P=0.50 
CI overlap:  Yes 
 
Melanoma 
RCTs: No significant 
difference P=0.38 
Observational studies: 
No significant difference 
P=0.10 
CI overlap: Yes 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
1 RCT (N=4444)  
RR 1.00 (0.35-2.85) I2=NA 
2 Observational studies 
(N=37838) 
RR 0.73 (0.38-1.40) I2=0% 
Gastric cancer 
RCTs: No significant 
difference P=0.99 
Observational studies: 
No significant difference 
P=0.34 
CI overlap: Yes 
Canonico et al 
2008244 
Systematic review of HRT and 
venous thromboembolism 
Venous 
thromboembolism  
9 RCTs (N=NR) 
HRT  311/NR   Placebo 
146/NR 
OR 2.1 (1.4-3.1) Chi2 
P=0.03, I2=58.9% 
 
8 observational studies 
(N=NR) 
OR 2.5 (1.9-3.4) Chi2  
P=0.03, I2=53.3% 
 
 
Confounding factors by study 
design: Acknowledges that ‘This 
difference could be explained by 
inclusion of procedure related venous 
thromboembolism in the women’s health 
initiative trials as well as the high degree 
of non-adherence to study drugs in the 
randomised controlled trials, resulting in 
an underestimation of hormone effects 
in the randomised controlled trials’. 
Heterogeneity within study designs: 
Significant heterogeneity: One set RCTs 
and one set of observational studies  
Statistical analysis comparing study 
designs: NR 
RCTs: Significant increase 
Observational Studies: 
Significant increase  
CI overlap: Yes 
Capurso et al 
2007245 
Systematic review of NSAIDS and 
pancreatic cancer 
Pancreatic cancer (low 
NSAID exposure) 
1 RCT (N=39,876)  
Aspirin/NSAIDS 30/19,934 
Control 21/19,942 
OR 1.43 (0.82-2.50) 
3 Cohort studies 
Confounding factors by study 
design: NR but conducts subgroup 
analysis by factors such as gender, 
aspirin use only, and nurse occupation. 
Heterogeneity within study designs: 
NR (Significant heterogeneity among 7 
studies with low exposure P=0.005, I2 
Low exposure 
RCT: No significant 
difference  
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference  
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
(N=1,072,263) 
Aspirin/NSAIDS 
883/244,404 
Control 3668/827,859 
OR 0.84 (0.64-1.09) 
3 Case-control studies 
(N=7,254)  
Aspirin/NSAIDS 347/3,302 
Control 728/3,952 
OR 1.04 (0.81-1.33) 
 
Pancreatic cancer 
(Intermediate NSAID 
exposure) 
3 Cohort studies 
(N=906,924) 
Aspirin/NSAIDS 
363/79,065     
Control 3,668/827,859 
OR 0.94 (0.63-1.40) 
3 Case-control studies 
(N=4,648) 
Aspirin/NSAIDS 123/696         
Control 728/3,952 
OR 1.15 (0.69-1.91) 
 
Pancreatic cancer (High 
NSAID exposure) 
3 Cohort studies 
=67.3%, 6 studies with intermediate 
exposure P=0.001, I2=75.0% and 6 
studies with high exposure P<0.0001, 
I2=83.4%) 
Statistical analysis comparing study 
designs: NR but states no significant 
difference. 
  
CI overlap: Yes 
 
Intermediate exposure 
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference  
CI overlap: Yes 
 
High exposure 
Cohort studies: No 
significant difference 
Case-control studies: No 
significant difference  
CI overlap: Yes 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
(N=851,932) 
Aspirin/NSAIDS 84/24,073  
Control 3668/827,859 
OR 0.94 (0.51-1.71) 
3 Case-control studies 
(N=4,267)  
Aspirin/NSAIDS  60/315    
Control 728/3,952 
OR 1.12 (0.52-2.41) 
Chan et al 
2004246 
Systematic review oral 
contraceptives and stroke 
Stroke 
4 Cohort studies 
(N=>1,000,000) 
OR 0.95 (0.51-1.78) Chi2 
P=0.01 
16 Case-control studies 
(N=15,106) 
OR 2.13 (1.59-2.86) Chi2 
P<0.001 
Confounding factors by study 
design: Authors comment on 
heterogeneity of studies, potential 
confounding and risk of bias e.g. cohort 
studies ‘might be methodologically 
superior. present more valid assessment 
of stroke risk’. 
Heterogeneity within study designs: 
Significant heterogeneity: One set 
cohort studies and one set of case 
control studies (and when all studies 
pooled) 
Statistical analysis comparing study 
designs: Differences among subgroups 
were calculated using the standard 
Gaussian Z statistic. The pooled odds 
ratio of the cohort studies was 
significantly different from that of the 
case-control studies P=0.03 
Cohort studies: No 
significant difference  
Case-control studies: 
Significant increase  
CI overlap: yes  
 
Chou et al Used studies from 4 systematic Stroke or death Confounding factors by study CI overlap: Yes 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
2006247 2007248 reviews on carotid 
endarterectomy and stroke or 
death to assess the association 
between methodological 
shortcomings and estimates of 
serious complications 
9 RCTs (N=NR) 
Rate 7.4% (4.5%-10.2%) 
102 Observational 
studies (N=NR) 
Rate 4.4% (3.8%-4.9%)   
design: NR but carries out multivariate 
regression analyses carried out on 
quality criteria. Did not include type of 
study in this part of the analyses. 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: Univariate analysis identified 
significantly higher rates in RCTs 
(P=0.0444). RCTs 1.7 times more 
adverse effects than in case-control 
studies. 
 
Col et al 
2005249 
Systematic review of menopausal 
hormone therapy and breast 
cancer 
Breast cancer 
2 RCTs (N=445)  
RR 3.41 (1.59-7.33) 
Q=0.25 
8 Observational studies 
(N=3710)  
RR 0.64 (0.50-0.82) 
Q=7.18 
 
Confounding factors by study 
design: Acknowledges possible 
confounding factors such as younger 
population with more favourable 
prognostic profiles in observational 
studies.  Also commented that 
observational studies lacked proper 
design and were more like reports of 
clinical experiences. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
RCTs and one set of observational 
studies 
Statistical analysis comparing study 
designs: Significant heterogeneity 
exists if RCT and observational data are 
pooled. 
RCTs: Significant increase 
P=0.0016 
Observational studies: 
Significant decrease 
P=0.00041 
CI overlap: No 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
Cosmi et al 
200028 
Systematic review of ticlopidine 
plus aspirin and thrombotic 
thrombocytopenic purpura (TTP) 
Thrombotic 
thrombocytopenic 
purpura (TTP) 
10 RCTs (N=NR)  
Number of cases:  0  
7 Observational studies 
(N=>43322) 
Number of cases : 9  
Case reports or series 
(N=72) 
Number of cases : 72  
The WHO Monitoring 
Centre (N=0) 
Number of cases:  0 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
CI overlap: NR 
 
Cutler et al 
2001250 
Systematic review of allogeneic 
peripheral -blood stem-cell and 
bone marrow transplantation and 
acute and chronic graft-versus-
host disease 
Transplantation (Acute 
graft) 
5 RCTs (N=699)  
RR 1.23 (1.05-1.45) 
10 Cohort studies 
(N=1371)  
RR 1.10 (0.96-1.26) 
 
Transplantation (Chronic 
graft) 
5 RCTs (N=699)  
RR 1.37 (1.08-1.74)  
9 Cohort studies 
(N=1364)  
RR 1.62 (1.24-2.12)  
Confounding factors by study 
design:   NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR  
 
Acute graft 
RCTs: Significant increase  
Cohort studies: No 
significant difference 
CI overlap: yes 
 
Chronic graft 
RCTs: Siignificant increase 
P=0.01 
Cohort studies: 
Significant increase 
P<0.001 
CI overlap: yes 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
Dolovich et al 
1998251 
Systematic review of 
benzodiazepine use in pregnancy 
and major malformations and oral 
cleft 
Major malformations  
7 cohort studies 
(N=72,866)  
Exposed 32/1090  Non-
exposed  2783/71776 
OR 0.90 (0.61-1.35) 
Chi2 P=0.62 
4 case-control studies 
(N=6,136)  
Exposed 84/166   Non-
exposed  2141/5970 
OR 3.01 (1.32-6.84) 
Chi2 P=0.008 
 
Oral cleft  
3 cohort studies 
(N=138,286)  
Exposed 1/2543  Non-
exposed  93/135743 
OR 1.19 (0.34-4.15) Chi2 
P=0.997 
6 case-control studies 
(N=14,971) 
Exposed 105/285  Non-
exposed 2742/14686   
OR 1.79 (1.13-2.82) Chi2 
P=0.01 
Confounding factors by study 
design: Acknowledges systematic 
differences between study design e.g. 
exposure to other medications, duration 
and indication for use of benzodiazepine 
and possible differences in populations.  
Heterogeneity within study designs: 
No significant heterogeneity: two sets of 
cohort studies.  
Significant heterogeneity: two sets of 
case-control studies 
Statistical analysis comparing study 
designs: NR 
Major malformations 
Cohort studies: No 
significant difference 
P=0.62 
Case-control studies: 
Significant increase 
P=0.008 
CI overlap: yes 
 
Oral cleft 
Cohort studies: No 
significant difference 
P=0.997 
Case-control studies: 
Significant increase P=0.01 
CI overlap: Yes 
Douketis et al 
1997252 
Systematic review of oral 
contraceptives and hormone 
Venous 
thromboembolism (oral 
Confounding factors by study 
design:   NR 
Oral contraceptives 
RCT: No significant 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
replacement therapy and venous 
thromboembolism. 
contraceptives) 
1 RCT (N=NR)  
RR 1.1 (0.4-2.9) 
7 cohort studies** 
RR 3.0 (2.2-4.2) 
prospective studies Chi2 
P=0.8, retrospective 
studies Chi2 P=0.3 
12 case-control studies 
(N=NR)   
RR 3.0 (2.6-3.4) Chi2 
P=<0.001 
 
Venous 
thromboembolism 
(Hormone replacement 
therapy) 
2 RCTs (N=NR)  
RR  0.7 (0.3-1.6) Chi2 
P=0.72 
1 cohort study (N=NR) 
RR 1.7 (1.0-2.9) 
5 case-control studies 
(N=NR)   
RR 2.4 (1.7-3.5) Chi2 
P=0.24 
Heterogeneity within study designs:  
No significant heterogeneity: one set of 
RCTs, one set of case-control studies, 
(one set of prospective cohort studies   
P=0.8 and one set of retrospective 
cohort studies P=0.3) 
Significant heterogeneity: One set of 
case-control studies  
Statistical analysis comparing study 
designs: NR 
 
difference  
Cohort studies: 
Significant increase  
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
Hormone replacement 
therapy 
RCTs: No significant 
difference  
Cohort studies: 
No significant difference  
Case-control studies: 
Significant increase  
CI overlap: No, RCTs 
have a lower risk ratio than 
case-control studies. 
Garg et al 
1998253 
Systematic review of hormone 
replacement therapy and ovarian 
cancer 
Ovarian cancer  
1 Cohort study (N=NR) 
RR 1.15 (0.94-1.42) 
Confounding factors by study 
design:  NR 
Heterogeneity within study designs: 
Cohort study: No 
significant difference  
Case-control studies: 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
9 Case-control studies 
(N=NR) 
RR 1.16 (1.03-1.29) 
NR (no significant heterogeneity for all 
10 studies P=0.72) 
Statistical analysis comparing study 
designs: NR 
Significant increase  
CI overlap: Yes 
 
Gillum et al 
2000254 
Systematic review oral 
contraceptives and ischemic 
stroke 
Ischemic stroke 
3 Cohort studies 
(1,069,840 person years)  
RR 3.21 (1.96-5.27) 
14 Case-control studies 
(N=9,920)  
RR 2.77 (2.22-3.45) 
Confounding factors by study 
design: Evaluated a number of potential 
confounders. Meta-regression analysis 
suggested estrogen dosage, control of 
smoking and firm diagnosis of ischemic 
stroke were the only study variables 
contributing to risk ratio estimates. Study 
design was not identified as contributing 
to risk ratio estimate. 
Heterogeneity within study designs: 
NR (Significant heterogeneity among all 
studies P=0.01) 
Statistical analysis comparing study 
designs: A 2 tailed z test was used to 
detect differences across subgroups but 
no p value was reported for study 
design. Authors state that similar 
positive associations found in case-
control studies and cohort studies 
suggesting that this aspect of study 
design was unimportant.  
Cohort studies: 
Significant increase  
Case-control studies: 
Significant increase  
CI overlap: Yes 
Grady et al 
1995255 
Systematic review of 
postmenopausal estrogen therapy 
and estrogen plus progestin and 
endometrial cancer 
Endometrial cancer 
(Postmenopausal 
estrogen therapy) 
4 Cohort studies (N=NR) 
Confounding factors by study 
design: Heterogeneity substantially 
reduced or eliminated when the studies 
where stratified by dose or duration of 
Postmenopausal 
estrogen therapy 
Cohort studies: 
Significant increase  
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
RR 1.7 (1.3-2.1) 
25 Case-control studies 
(N=NR)  
RR 2.4 (2.2-2.6) 
 
Endometrial cancer 
(Estrogen plus progestin) 
2 Cohort studies (N=NR)  
RR 0.4 (0.2-0.6) 
3 Case-control studies 
(N=NR) 
RR 1.8 (1.1-3.1) 
estrogen use suggesting that these two 
variables account for most of the 
variation in risk estimates. 
Heterogeneity within study designs: 
NR (significant heterogeneity among all 
studies) 
Statistical analysis comparing study 
designs: NR 
Case-control studies:   
Significant increase  
CI overlap: No 
 
Estrogen plus progestin 
Cohort studies: 
Significant decrease  
Case-control studies:  
Significant increase  
CI overlap: No 
Henry and 
McGettigan 
2003256 
Systematic review of NSAIDS and 
gastrointestinal complications 
Gastrointestinal 
complications 
8 Cohort studies 
(N=1,436610) 
Treatment 2410/399,399 
Control 2247/1037211 
OR 2.29 (1.50-3.51)  
Chi2 P<0.00001 
25 Case-control studies 
(N=74637)   
Treatment 3800/13610  
Control 5512/61027  
OR 3.81 (3.17-4.58)  
Chi2 P<0.00001  
Confounding factors by study 
design: NR but carries out subgroup 
analysis by type of drug 
Heterogeneity within study 
designs::Significant heterogeneity: one 
set of cohort studies and  one set of 
case-control studies 
Statistical analysis comparing study 
designs: NR but authors state that 
there is a marked difference in pooled 
odds ratios. 
Cohort studies: 
Significant increase 
P=0.0001 
Case-control studies:  
Significant increase 
P<0.00001 
CI overlap: Yes 
 
Jensen et al 
2002257 
Systematic review of anesthesia 
and postherniorrhaphy urinary 
retention 
Postherniorrhaphy 
urinary retention (local 
anesthesia  
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
Local anesthesia  
CI overlap: Yes** 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
2 RCTs (N=184) 
0/81 (0%) (-2.18-2.18 )** 
70 nonrandomised 
studies (N=8991) 
33/8991 (0.37%) (0.24-
0.49) 
 
Postherniorrhaphy 
urinary retention 
(regional anesthesia) 
1 RCT (N=25) 
 5/25 (20%) (3.40-36.60 )** 
70 nonrandomised 
studies (N=6191) 
150/6191 (2.42%) (2.04-
2.81) 
 
Postherniorrhaphy 
urinary retention (general 
anesthesia) 
2 RCTs (N=78) 
0/78 (0%) (-2.26-2.26)** 
70 nonrandomised 
studies (N=11471) 
344/11471 (3.00%) (2.69-
3.31) 
NR 
Statistical analysis comparing study 
designs: NR 
Regional anesthesia 
CI overlap: No** 
 
General anesthesia 
CI overlap: No** 
 
Johnston et al 
1998258 
Systematic review of oral 
contraceptives and subarachnoid 
haemorrhage  
Subarachnoid 
haemorrhage 
2 Cohort studies (person 
Confounding factors by study 
design: NR but presents risk ratio 
stratified by dose, smoking, 
Cohort studies: No 
significant difference 
Case-control studies: 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
years=588,151) 
RR 1.92 (0.91-4.06) 
Chi2 P=0.41 
10 Case-control studies 
(N=8,904)  
RR 1.40 (1.10-1.78) 
Chi2 P=0.30 
 
hypertension, exposure classification 
and outcome measure.  
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
cohort studies and one set of case-
control studies (no significant 
heterogeneity when all studies are 
pooled) 
Statistical analysis comparing study 
designs: Summary estimates from 
subgroups of studies were compared 
using a z statistic. The difference 
between risk ratio from cohort studies 
and case-control studies was not 
significant (p>0.10). 
Significant increase  
CI overlap: Yes 
 
Jones et al 
1999259  
Systematic review of water 
fluoridation and fractures 
Fractures 
2 Cohort studies (N=NR)  
RR 1.20 (0.43-3.32) 
Chi2 P=0.02 
6 Cross-sectional studies 
(N=NR)  
RR 1.06 (0.92-1.22) 
Chi2 P=0.009 
10 Ecological studies 
(N=NR)  
RR 1.00 (0.93-1.08) 
Chi2 P<0.000001 
 
 
Confounding factors by study 
design: NR but created a model with 
statistically significant variables (p<0.10) 
and identified that the combination of 
gender, urban/rural index, and study 
quality explained 25% of the variation. 
Did not test study design in this model. 
Heterogeneity within study designs: 
Significant heterogeneity: one set of 
cohort studies, one set of cross-
sectional studies and one set of 
ecological studies  (significant 
heterogeneity when all studies are 
pooled)  
Cohort studies: No 
significant difference  
Cross-sectional studies: 
No significant difference  
Ecological studies:  
No significant difference  
CI overlap: Yes 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
Statistical analysis comparing study 
designs: NR but authors state that 
analysis stratified by study design did 
not show any difference between pooled 
estimates. No statistical data given. 
Koster et al 
1995260 
Systematic review of oral 
contraceptives and venous 
thromboembolism 
Venous 
thromboembolism  
1 RCT (N=NR)  
RR 1.1 (0.4-2.9) 
6 Cohort studies  (N=NR)  
RR 2.1 (0.3-16) 
8 Case-control studies  
(N=NR)  
RR 4.2 (1.3-14) 
Confounding factors by study 
design:   NR but author states 
differences may be due to study bias 
Heterogeneity within study designs: 
NR (Significant heterogeneity among all 
studies P<0.001) 
Statistical analysis comparing study 
designs: NR 
RCT: No significant 
difference  
Cohort studies: No 
significant difference 
Case-control studies: 
Significant increase  
CI overlap: Yes 
Leipzig et al 
1999261 
Systematic review of psychotropic 
medications and falls 
Falls (psychotropics) 
11 Cohort studies (N=NR)  
OR 1.66 (1.40-1.97) 
6 Case-control studies 
(N=NR)  
OR 2.57 (1.90-3.49) 
2 Cross sectional studies 
((N=NR)  
OR 1.40 (1.08-1.81) 
 
Falls (antidepressants) 
11 Cohort studies (N=NR)  
OR 1.62 (1.23-2.14) 
12 Case-control studies 
(N=NR)  
Confounding factors by study 
design: NR but stratification of studies 
by subject residence, community 
studies, age, ascertainment of 
medication and falls had no effect on the 
pooled odds ratios. 
Heterogeneity within study designs: 
NR (Significant heterogeneity among all 
studies of psychotropics, neuroleptics, 
and seductive hypnotics but not the 
other interventions) 
Statistical analysis comparing study 
designs: NR but authors state 
stratification by study design had no 
effect on the pooled odds ratios. No 
Psychotropics 
Cohort studies: 
Significant increase  
Case-control studies:  
Significant increase  
Cross sectional studies:  
Significant increase  
CI overlap: No, cohort 
studies have higher odds 
ratio than cross-sectional 
studies 
 
Antidepressants 
Cohort studies: 
Significant increase  
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
OR 1.89 (1.41-2.52) 
4 Cross sectional studies 
(N=NR)  
OR 1.51 (1.16-1.98) 
 
Falls (neuroleptics) 
10 Cohort studies (N=NR)  
OR 1.90 (1.35-2.67)1 
10 Case-control studies 
(N=NR)   
OR 1.20 (0.90-1.61) 
2 Cross sectional studies 
(N=NR)  
OR 1.59 (1.18-2.13) 
 
Falls (sedative/hypnotics) 
9 Cohort studies (N=NR)  
OR 1.25 (0.98-1.60) 
9 Case-control studies 
(N=NR) 
OR 1.63 (1.31-2.02) 
4 Cross sectional studies 
(N=NR)  
OR 1.60 (1.41-1.82) 
 
Falls (benzodiazepines) 
8 Cohort studies (N=NR) 
OR 1.40 (1.11-1.76) 
3 Case-control studies 
statistical analysis presented. 
 
Case-control studies:  
Significant increase  
Cross sectional studies:  
Significant increase  
CI overlap: Yes 
 
Neuroleptics 
Cohort studies: 
Significant increase   
Case-control studies: No 
significant difference  
Cross sectional studies:  
Significant increase   
CI overlap: Yes 
 
Sedative/Hypnotics 
Cohort studies:  No 
significant difference  
Case-control studies:  
Siignificant increase  
Cross sectional studies:  
Siignificant increase  
CI overlap: Yes 
 
Benzodiazepines 
Cohort studies: 
Siignificant increase  
Case-control studies:  
significant increase  
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
(N=NR) 
OR 2.57 (1.46-4.51) 
2 Cross sectional studies 
(N=NR) 
OR 1.34 (0.95-1.88) 
Cross sectional studies:  
No significant difference  
CI overlap: Yes 
Leipzig et al 
1999262 
Systematic review of 
cardiovascular medications and 
falls 
Falls (thiazides) 
8 Cohort studies (N=NR)  
OR 1.05 (0.96-1.21) 
3 Case-control studies 
(N=NR)  
OR 1.97 (0.89-4.36) 
1 Cross sectional studies 
(N=NR)  
OR 1.15 (0.70-1.90) 
 
Falls (loop diuretics) 
7 Cohort studies (N=NR)  
OR 0.90 (0.68-1.18) 
3 Case-control studies 
(N=NR)  
OR 0.76 (0.51-1.16) 
1 Cross sectional study 
(N=NR)  
OR 1.49 (0.77-2.89) 
 
Falls (digoxin) 
9 Cohort studies (N=NR)  
OR 1.29 (1.01-1.65) 
5 Case-control studies 
Confounding factors by study 
design: NR but stratification of studies 
by subject residence, community 
studies, age, ascertainment of 
medication and falls had no effect on the 
pooled odds ratios. 
Heterogeneity within study designs: 
NR (no significant heterogeneity with all 
studies) 
Statistical analysis comparing study 
designs: NR but authors state 
stratification by study design had no 
effect on the pooled odds ratios. No 
statistical analysis presented. 
 
Thiazides 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
 
Loop diuretics 
Cohort studies: No 
significant difference  
Case-control studies:  
No significant difference  
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
 
Digoxin 
Cohort studies: 
Significant increase  
Case-control studies: 
No significant difference  
Cross sectional studies:  
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difference in adverse 
effects by study design 
(N=NR) 
OR 1.31 (0.91-1.87) 
3 Cross sectional studies 
(N=NR)  
OR 1.13 (0.90-1.42) 
 
Falls (nitrates) 
8 Cohort studies (N=NR)  
OR 1.29 (0.99-1.68) 
4 Case-control studies 
(N=NR)  
OR 0.87 (0.59-1.28) 
2 Cross sectional studies 
(N=NR)  
1.12 (0.82-1.54) 
 
Falls (beta-blockers) 
9 Cohort studies (N=NR)  
OR 1.00 (0.78-1.30) 
7 Case-control studies 
(N=NR) 
OR 0.83 (0.51-1.35) 
2 Cross sectional studies 
(N=NR)  
OR 0.87 (0.64-1.18) 
 
Falls (calcium channel 
blockers) 
8 Cohort studies (N=NR)  
No significant difference  
CI overlap: Yes 
 
Nitrates 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
 
Beta-blockers 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
 
Calcium channel 
blockers 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
Cross sectional studies: 
No significant difference  
 264 
Table 15.1 Characteristics of included studies in Chapter 4  
Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
OR 1.05 (0.82-1.36) 
4 Case-control studies 
(N=NR) 
OR 0.88 (0.54-1.43) 
1 Cross sectional study 
(N=NR) 
OR 0.69 (0.44-1.09) 
 
Falls (ACE inhibitors) 
7 Cohort studies (N=NR)  
OR 1.09 (0.76-1.55) 
2 Case-control studies 
(N=NR)  
OR 1.69 (0.89-3.21) 
1 Cross sectional study 
(N=NR)  
OR 1.19 (0.68-2.07) 
 
Falls (Centrally acting 
antihypertensives) 
4 Cohort studies (N=NR)  
OR 0.80 (0.39-1.66) 
5 Case-control studies 
(N=NR)  
OR 1.41 (0.71-2.79) 
2 Cross sectional studies 
(N=NR)  
OR 1.21 (0.85-1.73) 
 
CI overlap: Yes 
 
ACE inhibitors 
Cohort studies: No 
significant difference  
Case-control studies:  
No significant difference   
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
 
Centrally acting 
antihypertensives 
Cohort studies: 
No significant difference  
Case-control studies: 
No significant difference  
Cross sectional studies:  
No significant difference  
CI overlap: Yes 
 
Type 1A antiarrhythmics 
Cohort studies: 
No significant difference  
Case-control studies: 
Significant increase  
Cross sectional studies: 
No significant difference  
CI overlap: Yes 
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Falls (type 1A 
antiarrhythmics) 
5 Cohort studies (N=NR)  
OR 0.95 (0.46-1.97) 
4 Case-control studies 
(N=NR)  
OR 3.68 (1.20-11.27) 
1 Cross sectional study 
(N=NR)  
OR 1.73 (0.87-3.41) 
 
Loe et al 
2005263 
Systematic review of neonatal 
safety and  indomethacin 
tocolysis (an NSAID) 
Intraventricular 
hemorrhage  
9 RCTs (N=533)  
Study Group 22/263  
Comparison group 23/270 
OR 1.02 (0.55-1.89) 
Heterogeneity: P=0.93 
10 Observational studies 
(N=1241)  
Study Group 134/572 
Comparison group 126/669  
OR 1.31 (0.79-2.15) 
Heterogeneity: P=0.01 
 
Bronchopulmonary 
dysplasia 
3 RCTs (N=156)  
Study Group 15/76 
Comparison group 6/80 
Confounding factors by study 
design: Meta-regression analysis with 
study location, study year, and presence 
or absence of tocolytics as covariates 
did not alter the results for RCTs or 
observational studies.  Acknowledges 
that discrepancies may be due to 
differences in interventions, population, 
clinical studies and follow-up, as well as 
confounding / selection bias in non-
randomised study designs. 
Heterogeneity within study designs: 
No significant heterogeneity: Five sets of 
RCTs and two sets of observational 
studies  
Significant heterogeneity: Three sets of 
observational  studies  
Statistical analysis comparing study 
designs: NR 
Intraventricular 
haemorrhage 
RCTs: No significant 
difference  
Observational studies: 
No significant difference  
CI overlap: Yes 
 
Bronchopulmonary 
dysplasia 
RCTs: Significant increase  
Observational studies: 
No significant difference  
CI overlap: Yes 
 
Patent ductus arteriosus 
RCTs: No significant 
difference  
Observational studies: 
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difference in adverse 
effects by study design 
OR 2.80 (1.07-7.31) 
Heterogeneity: P=0.12 
9 Observational studies 
(N=998)  
Study Group 118/451 
Comparison group 136/547 
OR 1.03 (0.76-1.40) 
Heterogeneity: P=0.49 
 
Patent ductus arteriosus 
6 RCTs (N=308)  
Study Group 21/153  
Comparison group 18/155 
OR 1.25 (0.64-2.54) 
Heterogeneity: P=0.78 
11 Observational studies 
(N=1948)  
Study Group 179/563 
Comparison group 
368/1385 
OR 1.07 (0.76-1.52) 
Heterogeneity: P=0.05 
 
Necrotizing enterocolitis 
6 RCTs (N=329)  
Study Group 7/162  
Comparison group 2/167 
OR 2.43 (0.73-8.03) 
Heterogeneity: P=0.95 
 No significant difference  
CI overlap: Yes 
 
Necrotizing enterocolitis 
RCTs: 
No significant difference  
Observational studies: 
No significant difference  
CI overlap: Yes 
 
Mortality 
RCTs: 
No significant difference  
Observational studies:  
No significant difference  
CI overlap: Yes 
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effects by study design 
11 Observational studies 
(N=2725)  
Study Group 157/956 
Comparison group 
385/1769 
OR 1.08 (0.37-3.13) 
Heterogeneity: P=0.00 
 
Mortality 
9 RCTs (N=572)  
Study Group 15/283  
Comparison group  11/289 
OR 1.39 (0.65-2.97) 
Heterogeneity: P=0.99 
9 Observational studies 
(N=1234) 
Study Group 69/547 
Comparison group 84/687 
OR  0.99 (0.70-1.40) 
Heterogeneity: P=0.21 
Loke YK et al. 
2004264 
Compares frequencies of adverse 
drug reactions of amiodarone 
from clinical trials identified from 
systematic reviews and 
MEDLINE, with case reports from 
MEDLINE and with spontaneous 
reports from the WHO 
International Drug Monitoring 
Programme 
Relative frequencies to 
respiratory adverse drug 
reactions  
Heart   
Meta-analysis of 6 clinical 
trials  1.80 
WHO cases (N=474), 0.44 
Published case reports  
(N=13), 0.11 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR but different frequencies in 
the reporting of adverse effects were 
identified. 
 
CI overlap: NA 
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Thyroid  
WHO cases (N=1829), 
1.70 
Meta-analysis of 5 clinical 
trials  1.20 
Published case reports 
(N=51), 0.44  
Nervous system  
Meta-analysis of 5 clinical 
trials, 0.96 
WHO cases (N=964), 0.89 
Published case reports 
(N=54), 0.46 
Liver 
WHO cases (N=832), 0.77 
Meta-analysis of 5 clinical 
trials 0.49 
Published case reports 
(N=31), 0.26 
Gastrointestinal tract  
WHO cases (N=526), 0.49 
Meta-analysis of 5 clinical 
trials, 0.47 
Published case reports 
(N=2), 0.02 
Eyes 
Meta-analysis of 4 clinical 
trials, 0.47  
WHO cases (N=216), 0.20 
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difference in adverse 
effects by study design 
Published case reports 
(N=12), 0.10 
Skin    
WHO cases (N=1124), 
1.04 
Meta-analysis of 6 clinical 
trials, 0.35 
Published case reports 
(N=31), 0.26 
Loke et al 
2008265 
Systematic review of 
thiazolidinediones and fractures 
Fractures among women 
5 RCTs (N=4400) 
Thiazolidinedione 
111/1903  Control 76/2497 
OR 2.23 (1.65-3.01) 
I2=0% 
1 Cohort study 
OR 1.38 (1.03-1.82) 
1 Case-control study 
OR  2.56 (1.43-4.58) 
Confounding factors by study 
design: NR but authors acknowledge 
that the trials contained relatively young 
participants and the case-control study 
involved an older population. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
RCTs  
Statistical analysis comparing study 
designs: NR 
Fractures among women 
RCTs: Significant increase 
P<0.001 
Cohort study: Significant 
increase  
Case-control study: 
Significant increase 
CI overlap: Yes 
 
 
MacLennan et 
al 1995266 
Systematic review of oestrogen 
replacement therapy and 
colorectal cancer 
Colorectal cancer 
1 RCT (N=168)  
RR 1.0 (0.14-7.1) 
4 Cohort studies 
(N=169400)  
RR 0.91 (0.60-1.38) 
Woolf’s test, P=0.89 
9 Case-control studies 
(N=8631)  
RR 0.92 (0.71-1.20) 
Confounding factors by study 
design: Acknowledges insufficient 
information on dose duration to check 
variables. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
cohort studies. 
Significant heterogeneity: one set of 
case-control studies. 
Statistical analysis comparing study 
Colorectal cancer 
RCT: No significant 
difference  
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference  
CI overlap: Yes 
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effects by study design 
Woolf’s test, P<0.01 
 
designs: NR 
McAlister et al 
1998267 
Systematic review of 
perioperative allogeneic blood 
transfusion 
Mortality  
5 RCTs (N=1923) 
Treatment 164/978  Control 
169/945 
RR 0.94 (0.76-1.16) 
1 Cohort Study (N=273)  
Treatment 5/94 Control 
7/179 
RR 1.36 (0.44-4.17) 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR (No indication of heterogeneity for all 
6 studies P>0.45) 
Statistical analysis comparing study 
designs: NR 
Mortality 
RCTs: No significant 
difference  
Cohort Studies: No 
significant difference  
CI overlap: Yes 
 
McGettigan and 
Henry 2006268 
Systematic review of NSAIDS and 
cardiovascular events 
Cardiovascular events 
(celecoxib) 
3 Cohort studies (N=NR) 
RR 1.22 (0.69-2.16) 
8 Case-control studies 
(N=NR) 
RR 1.01 (0.90-1.13) 
 
Cardiovascular events 
(rofecoxib < or = 
25mg/d*) 
2 Cohort studies (N=NR) 
RR 1.51 (0.73-3.13) 
3 Case-control studies 
(N=NR) 
RR 1.21 (1.08-1.36) 
 
Cardiovascular events 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR (Significant heterogeneity for all 
studies) 
Statistical analysis comparing study 
designs: NR 
 
Celecoxib 
Cohort studies: No 
significant difference  
Case-control studies:  
No significant difference  
CI overlap: Yes 
 
Rofecoxib < or = 25mg/d* 
Cohort studies: No 
significant difference  
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
Rofecoxib > or = 25mg/d* 
2 Cohort studies  
Significant increase  
4 Case-control studies  
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(rofecoxib > or = 
25mg/d*) 
2 Cohort studies (N=NR) 
RR 2.46 (1.29-4.71) 
4 Case-control studies 
(N=NR) 
RR 1.89 (1.43-2.51) 
 
Cardiovascular events 
(naproxen) 
3 Cohort studies (N=NR) 
RR 0.94 (0.85-1.04) 
12 Case-control studies 
(N=NR)   
RR 0.96 (0.84-1.10) 
 
Cardiovascular events 
(diclofenac) 
2 Cohort studies (N=NR) 
RR 1.36 (0.51-3.65) 
7 Case-control studies 
(N=NR) 
RR 1.36 (1.21-1.54) 
 
Cardiovascular events 
(ibuprofen) 
5 Cohort studies (N=NR) 
RR 1.12 (0.90-1.38) 
11 Case-control studies 
Significant increase  
CI overlap: Yes 
 
Naproxen 
Cohort studies: No 
significant difference  
Case-control studies:  No 
significant difference  
CI overlap: Yes 
 
Diclofenac 
Cohort studies: No 
significant difference  
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
Ibuprofen 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
CI overlap: Yes 
 
Any/Other NSAIDS 
Cohort studies: No 
significant difference  
Case-control studies: 
No significant difference  
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difference in adverse 
effects by study design 
(N=NR) 
RR 1.06 (0.95-1.18) 
 
Cardiovascular events 
(any/other NSAIDS) 
5 Cohort studies (N=NR) 
RR 1.10 (0.95-1.29) 
14 Case-control studies 
(N=NR) 
RR 1.10 (0.98-1.24) 
CI overlap: Yes 
McGettigan and 
Henry 2008269 
Compares the risk ratios of 
cardiovascular events from  
systematic reviews of RCTs and  
systematic reviews of 
observational studies 
 
Cardiovascular events 
(rofecoxib) 
Review 1: 37 RCTs 
(N=13053) 
Treatment 98/6638 Control 
72/6415 
RR 1.38 (1.01-1.87) 
Review 3: 13 
observational studies 
(N=NR) 
RR 1.36 (1.18-1.56) 
Chi2 P<0.00001,  I2=84.3% 
 
Cardiovascular events 
(celecoxib) 
Review 1: 41 RCTs 
(N=13929) 
RR 1.51 (1.02- 2.04)  
Treatment 84/8976  
Confounding factors by study 
design: Controlled for some study 
design factors including age, gender, 
dose, and type of drug. Found that 
discrepant estimates for celecoxib and 
ibuprofen were due to higher doses of 
drugs used in RCTs than in 
observational studies (where reported). 
Heterogeneity within study designs: 
Significant heterogeneity: 3 sets of 
observational studies  
Statistical analysis comparing study 
designs: NR  
 
Rofecoxib      
RCTs: Significant increase   
Observational Studies: 
Significant increase  
CI overlap: Yes 
 
Celecoxib 
RCTs: Significant increase   
Observational Studies: 
No significant difference  
CI overlap: Yes 
 
Naproxen 
RCTs: No significant 
difference  
Observational Studies: 
No significant difference  
CI overlap: Yes 
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Control29/4953 
Review 3: 13 
observational studies 
(N=NR) 
RR 1.09 (0.95-1.25) 
Chi2 P<0.00001 I2=86.7% 
 
Cardiovascular events 
(naproxen) 
Review 1: 42 RCTs 
(N=NR) 
RR 0.92 (0.67-1.26) 
Review 3: 15+ 
observational studies 
(N=NR) 
RR 1.0 (0.91-1.09) 
 
Cardiovascular events 
(ibuprofen) 
Review 1: 24 RCTs 
(N=NR) 
RR 1.51 (0.96-2.37) 
Review 3: 16+ 
observational studies 
(N=NR) 
RR 1.09 (0.99-1.20) 
 
Cardiovascular events 
(diclofenac) 
Ibuprofen 
RCTs: No significant 
difference  
Observational Studies: 
No significant difference  
CI overlap: Yes 
 
Diclofenac 
RCTs: Significant increase  
Observational Studies: 
Significant increase   
CI overlap: Yes 
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Review 1:  26 RCTs 
(N=NR) 
RR 1.63 (1.12-2.37) 
Review 3: 12 
observational studies 
(N=NR) 
RR 1.35 (1.16-1.58)  
Chi2 P<0.00001 I2=87.0%  
 
Nalysnyk et al 
2003270 
Systematic review of in-hospital 
adverse effects Post-CABG 
Non-fatal Myocardial 
Infarction 
34 RCTs (N=2604) 
Mean 2.64% (1.82-3.46) 
18 Cohort studies 
(N=9369) 
Mean 2.21% (1.47-2.95) 
 
Non-fatal stroke 
19 RCTs (N=3790) 
Mean 1.00% (0.69-1.31) 
33 Cohort studies 
(N=27342) 
Mean 1.52% (1.17-1.87) 
 
Gastrointestinal bleeding  
4 RCTs (N=730) 
Mean 1.23% (0.43-2.03) 
4 Cohort studies 
(N=12167) 
Confounding factors by study 
design: Acknowledges discrepancies 
and potential influences of variables, 
e.g. study (geographic location, number 
of study centres) and group variables 
(elective CABG only versus some 
patients with emergency CABG, some 
patients with a history of prior CABG 
versus primary CABG). 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: Reports significant difference 
between RCTs and cohort studies in 
non-fatal stroke p<0.01, renal failure 
p<0.05 and mortality p<0.05. No 
statistical analysis presented for non-
fatal MI and too few studies to detect 
differences with GI bleeding. 
 
Non-fatal Myocardial 
Infarction 
CI overlap: Yes 
 
Non-fatal stroke 
CI overlap: Yes 
 
GI bleeding 
CI overlap: Yes 
 
Renal failure 
CI overlap: Yes 
 
Mortality 
CI overlap: Yes 
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Mean 1.53% (0.746-2.31) 
 
Renal failure 
10 RCTs (N=2189) 
Mean 0.39% (-0.06-0.84) 
13 Cohort studies 
(N=20609) 
Mean 0.98% (0.71-1.25) 
 
Mortality 
48 RCTs (N=4949) 
Mean 1.51% (1.10-1.93) 
57 Cohort studies 
(N=70984) 
Mean 1.80% (1.45-2.15) 
Ofman et al 
2002271 
Systematic review of NSAIDs and 
severe upper gastrointestinal 
complications perforations, ulcers 
and bleeds 
Gastrointestinal 
complications 
perforations, ulcers and 
bleeds  
16 RCTs (N=4431)  
OR 5.36 (1.76-16.1) 
9 Cohort studies 
(N=758776 patient-years) 
RR 2.7 (2.1-3.5) 
23 Case-control studies 
(N=25732)  
OR 3.0 (2.5-3.7) 
Confounding factors by study 
design: NR but states that data were 
insufficient to justify subgroup analysis 
by age, comorbid conditions, drug or 
dose. 
Heterogeneity within study designs: 
NR (Only pooled homogeneous studies 
for each study design) 
Statistical analysis comparing study 
designs: NR 
RCTs: Significant increase  
Cohort studies: 
Significant increase  
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
 
Oger and 
Scarabin 
Systematic review of hormone 
replacement therapy and venous 
Venous 
thromboembolism  
Confounding factors by study 
design: NR   
Cohort study: Significant 
increase  
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1999272 thromboembolism 1 cohort study (N=NR)  
RR 2.1 (1.2-3.8) 
7 case-control studies 
(N=NR) 
RR 2.1 (1.4-3.0) 
Chi2, P=NS 
 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
case-control studies 
Statistical analysis comparing study 
designs: NR 
Case-control studies: 
Significant increase  
CI overlap: Yes 
 
Papanikolaou et 
al 2006136 
Compares evidence on 15 harms 
with drugs, vitamins, vaccines and 
surgical procedures in RCTs 
identified from Cochrane reviews 
and non-RCTs from MEDLINE 
Convulsions with 
pertussis vaccine 
15 RCTs (N=124387)   
RR 0.47 (0.31-0.73) 
2 Non-RCTs (N=NR)   
RR 0.29 (0.23-0.37) 
 
Hypotonic 
hyporesponsiveness with 
pertussis vaccine 
11 RCTs (N=121573)        
RR 0.26 (0.08-0.81)  
Q, P<0.10 
1 Non-RCT (N= NR)   
RR 0.40 (0.18-0.89) 
 
Major extracranial bleed 
with oral anitcoagulant 
therapy 
16 RCTs (N=22049)    
RR 3.31 (2.35-4.67) 
5 Non-RCTs (N=403397)   
Confounding factors by study 
design: Acknowledges differences in 
populations between randomised and 
non-randomised studies.  
Heterogeneity within study designs:  
No significant heterogeneity: 12 sets of 
RCTs and 4 sets of non-RCTs 
Significant heterogeneity: 2 sets of 
RCTs and 5 sets of non-RCTs.  
Statistical analysis comparing study 
designs: Differences in risk ratio 
beyond chance between randomised 
and nonrandomised studies occurred for 
2 of the 13 topics.  
The estimated increase in risk ratio 
differed more than 2 fold in 7 of the 13 
topics. 
The estimated increase in risk differed 
more than 2 fold in 5 of the 8 topics. 
Convulsions with 
pertussis vaccine 
RCTs: Significant 
decrease  
Non-RCTs: Significant 
decrease  
CI overlap: Yes 
 
Hypotonic 
hyporesponsiveness 
with pertussis vaccine 
RCTs: Significant 
decrease  
Non-RCTs: Significant 
decrease  
CI overlap: Yes 
 
Major extracranial bleed 
with oral anitcoagulant 
therapy 
RCTs: Significant increase  
Non-RCTs: Significant 
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difference in adverse 
effects by study design 
RR 2.48 (1.39-4.44) 
Q, P<0.10 
 
Symptomatic intracranial 
bleed with anticoagulant 
versus antiplatelet 
15 RCTs (N=22794)     
RR 2.64 (1.95-3.58) 
2 Non-RCTs (N=273722)  
RR 8.25 (5.58-12.18) 
 
Major extracranial bleed 
with anticoagulant 
versus antiplatelet 
6 RCTs (N=11721)        
RR 1.78 (0.93-3.40) 
1 Non-RCT (N=4249)   
RR 1.23 (1.05-1.44) 
 
Major extracranial bleed 
with antiplatelet therapy 
9 RCTs (N=41399)         
RR 1.68 (1.34-2.12) 
2 Non-RCTs (N=24966)    
RR 1.30 (0.85-1.97) 
Q, P<0.10 
 
Symptomatic intracranial 
bleed with antiplatelet 
increase  
CI overlap: Yes 
 
Symptomatic intracranial 
bleed with anticoagulant 
versus antiplatelet 
RCTs: Significant increase  
Non-RCTs: Significant 
increase  
CI overlap: No 
 
Major extracranial bleed 
with anticoagulant 
versus antiplatelet 
RCTs: No significant 
difference  
Non-RCTs: Significant 
increase  
CI overlap: Yes 
 
Major extracranial bleed 
with antiplatelet therapy 
RCTs: Significant increase  
Non-RCTs: No significant 
difference  
CI overlap: Yes 
 
Symptomatic intracranial 
bleed with antiplatelet 
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effects by study design 
therapy 
9 RCTs (N=41399)          
RR 1.22 (1.00-1.50) 
2 Non-RCTs (N=36190)    
RR 1.80 (1.02-3.19) 
Q, P<0.10 
 
Visceral or vascular 
injury with labaroscopy 
versus open surgery for 
inguinal hernia 
22 RCTs (N=4914)     
RR 1.56 (0.75-3.29) 
1 Non-RCT (N=5506)    
RR 17.30 (3.91-76.80) 
 
Wound infection with 
laparoscopy versus open 
surgery for appendicitis 
34 RCTs (N=4324)        
RR  0.56 (0.43-0.72) 
2 Non-RCTs (N=150017)     
RR 0.58 (0.50-0.68) 
 
Spontaneous miscarriage 
with folate 
supplementation 
3 RCTs (N=7600)          
RR 1.12 (0.98-1.29) 
therapy 
RCTs: No significant 
difference  
Non-RCTs: Significant 
increase  
CI overlap: Yes 
 
Visceral or vascular 
injury with labaroscopy 
versus open surgery for 
inguinal hernia 
RCTs: No significant 
difference  
Non-RCTs: Significant 
increase  
CI overlap: No 
 
Wound infection with 
laparoscopy versus open 
surgery for appendicitis 
RCTs: Significant 
decrease  
Non-RCTs: Significant 
decrease  
CI overlap: Yes 
 
Spontaneous 
miscarriage with folate 
supplementation 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
2 Non-RCTs (N=20509)   
RR 1.07 (0.96-1.20) 
 
Multiple gestation with 
folate supplementation 
3 RCTs (N=6241)         
RR 1.40 (0.93-2.11) 
3 Non-RCTs (N=690395)    
RR 1.07 (0.98-1.17) 
Q, P<0.10 
 
Major bleed with platelet 
glycoprotein IIB/IIIA 
blocker therapy in PCI 
12 RCTs (N=17469)        
RR 1.36 (1.04-1.77) 
Q, P<0.10 
1 Non-RCT (N=18821)    
RR 1.74 (0.83-3.66) 
 
Acute myocardial 
infarction with rofecoxib 
versus naproxen therapy 
1 RCTs (N=8076)          
RR 2.86 (1.28-6.39) 
1 Non-RCT (N=90629)  
RR 1.31 (0.69-2.48) 
Q, P<0.10 
 
RCTs: No significant 
difference  
Non-RCTs: No significant 
difference  
CI overlap: Yes 
 
Multiple gestation with 
folate supplementation 
RCTs: No significant 
difference  
Non-RCTs: No significant 
difference  
CI overlap: Yes 
 
Major bleed with platelet 
glycoprotein IIB/IIIA 
blocker therapy in PCI 
RCTs: Significant increase  
Non-RCTs: No significant 
difference  
CI overlap: Yes 
 
Acute myocardial 
infarction with rofecoxib 
versus naproxen therapy 
RCTs: Significant increase  
Non-RCTs: No significant 
difference  
CI overlap: Yes 
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effects by study design 
 
Ross et al 
1998273 
Systematic review of granulocyte-
macrophage colony-stimulating 
factor (GM-CSF) treated AIDS 
patients and new bacterial 
infections, opportunistic infections 
New bacterial infections, 
opportunistic infections 
1 RCT (N=30) 
Treatment 6/16  37.5% 
(14.28-61.72)**  
Control 3/14  
10 Case series (N=119) 
Treatment 16/105  15% 
(8.13-21.87)**   
Control 3/14  
 
 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR (Assesses degree of heterogeneity 
to determine whether meta-analysis 
appropriate. Lack of quality and quantity 
of data meant could not pool data). 
Statistical analysis comparing study 
designs: NR 
New bacterial infections, 
opportunistic infections 
CI overlap: Yes ** 
 
 
Salhab et al 
2005274 
Systematic review of ovulation 
induction in IVF and breast cancer 
Breast cancer 
11 Cohort studies  
(N=NR)  
Treatment 601/60050  
Control NR 
RR 1.06 (0.94-1.19)** 
(P=0.337) 
4 Case-control studies 
(N=22233)  
Cases 253/11303 Controls 
273/10930 
RR 0.88 (0.72-1.08)** 
(P=0.224) 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference  
CI overlap: Yes 
Schwarz et al 
2008275 
Systematic review of loratadine 
and hypospadias 
Hypospadias  
2 Case-control studies 
OR 0.95 (0.43-2.08) 
Confounding factors by study 
design: NR  
Heterogeneity within study designs: 
Cohort studies: No 
significant difference  
Case-control studies: No 
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difference in adverse 
effects by study design 
2 Cohort studies 
OR 1.23 (0.32-4.69) 
NR  
Statistical analysis comparing study 
designs: NR 
 
significant difference  
CI overlap: Yes 
 
Scott et al 
2007276 
Systematic review of NSAIDs and 
myocardial infarction 
Myocardial infarction 
(naproxen) 
4 Cohort studies 
(N=571679 patient years)  
RR 0.96 (0.90-1.03) 
11 Case-control studies 
(N=384324)  
OR 1.03 (0.83-1.29)  
 
Myocardial infarction 
(ibuprofen) 
3 Cohort studies 
(N=552150 patient years) 
RR 0.90 (0.82-0.97) 
8 Case-control studies 
(N=286089)  
OR 1.08 (0.80-1.46)  
 
Myocardial infarction 
(celecoxib) 
3 Cohort studies 
(N=330651 patient years)  
RR 1.06 (1.00-1.13) 
7 Case-control studies 
(N=319841) 
Confounding factors by study 
design: Acknowledges that 
discrepancies may arise from selection 
of controls and populations studied.  
Heterogeneity within study designs: 
NR (Significant heterogeneity among all 
6 cohort studies for all NSAIDS   
Chi2 P<0.001, I2=92.1% and for all 14 
case-control studies Chi2 P<0.001, 
I2=97.9%) 
Statistical analysis comparing study 
designs: NR 
 
Naproxen 
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference   
CI overlap: Yes 
 
Ibuprofen 
Cohort studies: 
Significant decrease  
Case-control studies: 
No significant difference   
CI overlap: Yes 
 
Celecoxib 
Cohort studies: No 
significant difference  
Case-control studies: No 
significant difference  
CI overlap: Yes 
 
Rofecoxib 
Cohort studies: 
Significant increase  
Case-control studies: No 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
OR 1.01 (0.73-1.39)  
 
Myocardial infarction 
(rofecoxib) 
3 Cohort studies 
(N=322443 patient years)  
RR 1.25 (1.17-1.34) 
7 Case-control studies 
(N=203487)  
OR 1.19 (0.70-2.01) 
significant difference  
CI overlap: Yes 
Scott et al 
2008277 
Systematic review of NSAIDS and 
cardiac failure 
Cardiac failure  
6 RCTs (N=15750) 
NSAIDS 40/8542   Placebo 
13/7208 
OR 2.31 (1.34-4.00) 
Chi2 P=0.37, I2=6.9% 
2 Cohort studies (82785 
patient years) 
RR 1.97 (1.73-2.25) 
Chi2 P=0.33, I2= 0% 
5 Case-control studies 
(N=50519) 
OR 1.36 (0.99-1.85) 
Chi2 P<0.001, I2= 90.9% 
Confounding factors by study 
design: NR but discusses the problems 
of over the counter NSAIDS in 
observational studies and that 2 RCTs 
and one case-control study excluded 
patients with previous cardiac failure. 
Also commented on short-term follow-up 
in RCTs. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
RCTs and one set of cohort studies. 
Significant heterogeneity: one set of 
case-control studies.  
Statistical analysis comparing study 
designs: NR 
RCTs: Significant increase  
Cohort studies: 
Significant increase  
Case-control studies: No 
significant difference  
CI overlap: Yes 
 
Siegel et al 
2009278 
Systematic review of anti-tumour 
necrosis factor and 
immunomodulator therapy and 
lymphoma 
Lymphoma  
9 RCTs (N=3399) 
2 cases, 5.2/10,000 patient 
years 
Confounding factors by study 
design: NR but discusses the possible 
differences in patients by study design. 
Heterogeneity within study designs: 
CI overlap: Yes 
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difference in adverse 
effects by study design 
0.052% (0.013 – 0.207) 
3 Cohort studies 
(N=4122) 
7 cases, 4.6/10,000 patient 
years 
0.046% (0.022-0.097)** 
14 Case series (N=1384) 
4 cases, 18.8 /10,000 
patient years 
0.188% (0.071-0.502)** 
NR 
Statistical analysis comparing study 
designs: NR 
Singh et al 
2007279 
Systematic review of 
thiazolidinediones and heart 
failure 
Heart failure 
3 RCTs (N=10731)  
Treatment 314/5350  
Control 210/5381 
OR 2.10 (1.08-4.08) 
Chi2 P=0.09, I2=58.8% 
4 Observational studies 
(N=67382)  
OR 1.55 (1.33-1.80) 
Chi2 P=0.13, I2=46.9% 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
No significant heterogeneity: one set of  
observational studies  
Significant heterogeneity: one set of 
RCTs  
Statistical analysis comparing study 
designs: NR 
RCTs: Significant increase 
P=0.03 
Observational studies: 
Significant increase 
P<0.00001 
CI overlap: Yes 
 
Smith et al 
2003280 
Systematic review of hormonal 
contraceptives and cervical 
cancer 
Cervical cancer (short 
duration users of 
contraceptives) 
4 Cohort studies (N=NR) 
RR 1.8 (1.4-2.4) 
Chi2 P>0.1 
16 Case-control studies 
(N=NR) 
RR 1.1 (1.0-1.2) 
Confounding factors by study 
design:  NR but conducts subgroup 
analysis on other factors such as HPV 
status, sexual partners, cervical 
screening, smoking, barrier 
contraceptives, country, invasive 
cervical cancer, in situ cervical cancer, 
squamous cervical cancer, 
adenocarcinoma of the cervix but not by 
Short duration users 
Cohort studies: 
Significant increase  
Case-control studies: 
No significant difference  
CI overlap: No 
 
Medium duration users 
Cohort studies: 
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Reference Study Design Included Studies  Methodological Assessment Increase/decrease/no 
difference in adverse 
effects by study design 
Chi2 P=0.004 
 
Cervical cancer (medium 
duration users of 
contraceptives) 
4 Cohort studies (N=NR) 
RR 2.2 (1.7-2.9) 
Chi2 P=0.007 
17 Case-control studies 
(N=NR) 
RR 1.5 (1.4-1.7) 
Chi2 P=0.03 
 
Cervical cancer (long 
duration users of 
contraceptives) 
3 Cohort studies (N=NR) 
RR 3.3 (2.4-4.5) 
Chi2 P=0.02 
10 Case-control studies 
(N=NR) 
RR 2.0 (1.8-2.3) 
Chi2 P=0.03 
study design. 
Heterogeneity within study designs: 
No significant heterogeneity: one set of 
cohort studies 
Significant heterogeneity: 2 sets of 
cohort studies and 3 sets of case-control 
studies (significant heterogeneity when 
all studies are pooled) 
Statistical analysis comparing study 
designs: NR but authors state that RR 
consistently higher in the cohort studies 
than case-control studies even within 
stratified categories of duration. States 
that the reason for this is unclear. 
 
Significant increase  
Case-control studies:  
Significant increase  
CI overlap: Yes 
 
Long duration users 
Cohort studies: 
Significant increase  
Case-control studies: 
Significant increase  
CI overlap: No 
Takkouche et al 
2007281 
Systematic review of psychotropic 
medications and fracture 
Fracture 
(benzodiazepines) 
7 Cohort studies (N=NR) 
RR 1.31 (1.18-1.45)  
Q test P=0.36 
16 Case-control studies 
Confounding factors by study 
design: NR but conducts subgroup 
analysis by selected characteristics. 
Benzodiazepines: Did not find any 
evidence of a substantial difference in 
pooled RRs according to duration of 
Benzodiazepines 
Cohort studies: 
Significant increase   
Case-control studies: 
Significant increase   
CI overlap: Yes 
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difference in adverse 
effects by study design 
(N=NR) 
RR 1.36 (1.23-1.51)  
Q test P=0.0001 
 
Fracture 
(antidepressants) 
3 Cohort studies (N=NR) 
RR 1.28 (1.04-1.58)  
Q test P=0.79 
13 Case-control studies 
(N=NR) 
RR 1.66 (1.41-1.96)  
Q test P=0.00001 
 
Fracture (non-barbiturate 
antiepileptic drugs) 
4 Cohort studies (N=NR) 
RR 1.34 (0.96-1.88)  
Q test P=0.21 
9 Case-control studies  
RR 1.64 (1.24-2.16)  
Q test P=0.00001 
 
Fracture (antipsychotics) 
2 Cohort studies 
RR 1.11 (0.70-1.75)  
Q test P=0.42 
10 Case-control studies 
RR 1.68 (1.32-2.14)  
action, study quality score or by limiting 
to hip fractures alone. 
Antidepressants: Did not find any 
evidence of a substantial difference in 
pooled RRs according to study quality 
score. Antiepileptic drugs: Low quality 
studies had higher RR. Antipsychotics: 
Results similar according to anatomic 
site of fracture and quality scoring. 
Hypnotics: Results similar according to 
quality scoring. 
Heterogeneity within study designs: 
No significant heterogeneity: 6 sets of 
cohort studies. 
Significant heterogeneity:  6 sets of 
case-control studies.  
Statistical analysis comparing study 
designs: NR but authors state that they 
did not find any substantial difference in 
pooled risk ratio according to study 
design for studies of Benzodiazepines 
and that cohort studies showed a lower 
pooled risk ratio than case-control 
studies for studies of antidepressants. 
 
 
 
Antidepressants 
Cohort studies:  
Significant increase   
Case-control studies:  
Significant increase   
CI overlap: Yes 
 
Antiepileptic drugs 
Cohort studies: 
No significant difference  
Case-control studies: 
Significant increase   
CI overlap: Yes 
 
Antipsychotics 
Cohort studies: No 
significant difference   
Case-control studies: 
Significant increase   
CI overlap: Yes 
 
Hypnotics  
Cohort studies: No 
significant difference   
Case-control studies: No 
significant difference  
CI overlap: Yes  
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difference in adverse 
effects by study design 
Q test P=0.00001 
 
Fracture (hypnotics) 
3 Cohort studies  
RR 1.04 (0.86-1.25)  
Q test P=0.49 
10 Case-control studies  
RR 1.22 (0.97-1.54)  
Q test P=0.008 
 
Fracture (opioids) 
3 Cohort studies 
RR 1.32 (1.02-1.70)  
Q test P=0.18 
3 Case-control studies  
RR 1.42 (1.04-1.93)  
Q test P=0.001 
Opioids  
Cohort studies: 
Significant increase  
Case-control studies: 
Significant increase  
CI overlap: Yes 
Torloni et al 
2009282 
Systematic review of 
ultrasonography in pregnancy 
Low birth weight 
10 RCTs (N=24271) 
OR 1.06 (0.84-1.35) 
I2=69.3% 
6 Cohort studies 
(N=18622) 
OR 1.11 (0.84-1.46) 
I2=72.8% 
1 Case control 
study(N=12,546) 
1.38 (1.25-1.51) 
 
Confounding factors by study 
design: NR  
Heterogeneity within study designs: 
Significant heterogeneity:  one set of 
RCTs and one set of cohort studies.  
Statistical analysis comparing study 
designs: NR 
Low birth weight 
RCTs; No significant 
difference   
Cohort studies: No 
significant difference   
Case control study: 
Significant increase 
CI overlap: Yes 
 
Dyslexia 
RCT: No significant 
difference   
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difference in adverse 
effects by study design 
Dyslexia 
1 RCT (N=603) 
OR 0.75 (0.41-1.37) 
1 Cohort study (N=806) 
OR 1.78 (1.08-2.93) 
 
Impaired hearing 
1 RCT (N=2008) 
OR 0.97 (0.62-1.53) 
1 Cohort study (N=723) 
OR 0.89 (0.31-2.57) 
Cohort study: Significant 
increase 
CI overlap: Yes 
 
Impaired hearing 
 RCT: No significant 
difference   
Cohort study: No 
significant difference   
CI overlap: yes 
 
Tramer et al 
1997283 
Systematic review of propofol and 
bradycardia 
Bradycardia  
19 Trials (N=1208)  
23.3% (154/660) (20.07- 
26.53)** 
2 Case series (N=24578)  
4.8% (1179/24578) (4.53-
5.07)** 
 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR but authors state that 
compared with controlled studies 
bradycardia was 3-4 times less likely to 
be reported in the case series. 
CI overlap: No** 
 
 
Tramer et al 
2000183 
Presents a model to estimate the 
incidence of rare adverse events 
with NSAIDS using 
heterogeneous information 
Symptomatic ulcer  
3 RCTs (N=NR) 
Intervention 262/17 743  
1.48%  (1.30-1.66)** 
1 Cohort study (N=NR) 
Intervention 131/33 880 
0.39%  (0.32-0.46)** 
 
 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: Calculated difference in 
incidence by study design using risk 
ratio. Cohort study significantly lower 
incidence of symptomatic ulcer than 
CI overlap: No 
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RCTs RR 2.3 (1.7-3.1)  
Vohra et al 
2007284 
Systematic review of spinal 
manipulation 
All adverse events 
2 RCTs (N=191) 
Number of adverse events:  
4 
1 cases series (N=NR) 
Number of adverse events:  
3 
6 case reports (N=NR) 
Number of adverse events:  
7 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
CI overlap: NR 
 
Wang et al 
2008285 
Systematic review of medical 
cannabinoids 
Serious adverse events 
23 RCTs (N=NR) 
Number of serious adverse 
events: 164 
8 observational studies 
(N=NR) 
Number of serious adverse 
events: 39 
 
Nonserious adverse 
events 
23 RCTs (N=NR) 
Number of nonserious 
adverse events: 4615 
8 observational studies 
(N=NR) 
Number of nonserious 
adverse events: 3553 
Confounding factors by study 
design: NR 
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
CI overlap: NR 
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Woolcott et al 
2009286 
Systematic review of falls in the 
elderly 
Falls (antihypertensives) 
3 cohort studies (N=NR) 
OR 1.34 (0.93-1.91) 
2 case-control studies 
(N=NR) 
OR 1.09 (0.80-1.50) 
1 cross-sectional study 
(N=NR) 
OR 1.11 (0.78-1.58) 
 
Falls (diuretics) 
1 cohort study  (N=NR) 
OR 1.05 (0.97-1.15) 
5 case-control studies 
(N=NR) 
OR 1.11 (0.94-1.32) 
3 cross-sectional studies 
(N=NR) 
OR 1.11 (1.00-1.24) 
 
Falls (b-blockers) 
1 case-control study 
(N=NR) 
OR 0.87 (0.55-1.37) 
3  cross-sectional studies  
(N=NR) 
OR 1.02 (0.79-1.24) 
 
Falls 
Confounding factors by study 
design: NR  
Heterogeneity within study designs: 
NR 
Statistical analysis comparing study 
designs: NR 
Antihypertensives 
Cohort studies: No 
significant difference   
Case-control studies: No 
significant difference   
Cross-sectional study: 
No significant difference   
CI overlap: Yes 
 
Diuretics 
Cohort study: No 
significant difference   
Case-control studies: No 
significant difference   
Cross-sectional studies: 
No significant difference   
CI overlap: Yes 
 
B-Blockers 
Case-control study: No 
significant difference   
Cross-sectional studies: 
No significant difference   
CI overlap: Yes 
 
Sedatives/hypnotics 
Cohort studies: 
Significant increase 
Case-control study: 
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(sedatives/hypnotics) 
3 cohort studies (N=NR) 
OR 1.24 (1.05-1.45) 
1 case-control study 
(N=NR) 
OR 1.62 (1.31-2.00) 
3 cross-sectional studies 
(N=NR) 
OR 1.56 (1.39-1.76) 
Significant increase 
Cross-sectional studies: 
Significant increase 
CI overlap: Yes 
 
 
Key 
CI – Confidence Interval 
N – Number of study participants 
NR – Not reported 
OR – Odds Ratio 
RR – Risk ratio 
WMD – Weighted Means Difference 
**- data were calculated from information presented in paper 
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Beral et al 2008307  Pools risk ratio for prospective studies and for case-control 
studies for ovarian cancer with oral contraceptive use. 
Hypothesis is that oral contraceptives have a protective 
effect. 
Blankensteijn 2000287 Compares mortality and morbidity rates after conventional 
abdominal aortic aneurysm repair from prospective and 
retrospective studies. Does not categorise by study design 
(such as RCT, cohort study or case-control study). 
Bonovas et al 2007 
308 
Compares risk ratio from RCTs, cohort studies and case-
control studies for statins and the risk of colorectal cancer. 
Hypothesis suggests a protective effect of statins. 
Boyd et al 1993649 
and update Boyd et 
al 2003348 
Compares risk ratio of breast cancer from dietary fat from 
cohort studies and case-control studies. Does not include a 
health care intervention. 
Brumback et al 
1999332 
Includes cohort studies and case-control studies for the 
adverse effects of chorionic villus sampling. Presents 
number of defects/1000 for each individual study. Does not 
pool or compare data. 
Choi et al 2003288 Reports on the pooled risk of postdural puncture headache 
with neuraxial blockade in prospective and retrospective 
studies and RCTs. Does not compare RCTs to other formal 
study designs such as cohort studies or case-control 
studies. 
Col et al 2003319 Discusses the differences in the results of observational  
and RCTs on the association of chronic heart disease and 
menopausal hormone therapy. Does not present pooled 
results from the different type of studies. 
Curran et al 1999290 Summaries the complications of primary repair of colon 
injury using retrospective data, prospective studies and 
randomized studies. Does not categorise by study design 
(such as RCT, cohort study or case-control study). 
Collaborative Group 
on Hormonal Factors 
in Breast Cancer, 
1996 289 
Presents the pooled risk ratio of breast cancer with oral 
contraceptives from prospective studies and case-control 
studies. Does not compare the results from case-control 
studies with other formal study designs such as cohort 
studies.  
Costa and Doyle 
2006333 
Presents risk ratio data of trophoblastic neoplasm with oral 
contraceptives for individual RCTs and observational 
studies. Does not pool the results of the different study 
designs. 
Demicheli et al 
2003339 
Pools adverse events following hepatitis B vaccination 
separately for RCTs and case-control studies. Does not 
compare similar adverse events. Any adverse events up to 
5 days after vaccination are included in the RCTs, whereas 
the case-control studies include only MS and demyelinating 
disease up to a year after vaccination are included in the 
case-control studies.   
Dezfulian et al 
2003291 
Includes RCTs, prospective and retrospective studies for 
infection rates with catheters. Compares odds ratios for all 
studies with odds ratios of RCTs and prospective studies 
combined.  Does not compare RCTs with other formal study 
designs, such as cohort studies or case-control studies. 
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Egger et al 1998140 States risk ratio from 6 observational studies comparing 
high and low B carotene intake or serum B carotene 
concentrations with risk ratio from 4 RCTs comparing B 
carotene supplementation to placebo. Does not compare 
risk ratio with similar comparators. 
Eikelboom et al 
2001292 
Compares odds ratios of intracranial haemorrhage with 
bolus thrombolytic therapy in 9 phase 2 RCTs and 6 phase 
3 RCTs. Does not compare RCTs to other study designs.  
Ernst et al 1998340 Presents data from RCTs and case reports for adverse 
effects with St. John’s wort. No data for the same adverse 
effects from the 2 study designs are presented. 
Etminan et al 2003309 Includes case-control and cohort studies of NSAIDS and 
the risk of Alzheimer’s disease. Hypothesis suggests 
NSAIDS may have protective effect. 
Fernandez et al 
2001310 
Includes case-control and cohort studies of oral 
contraceptives and the risk of colorectal cancer. Hypothesis 
suggests oral contraceptives may have protective effect.  
García Rodríguez et 
al 2001293 
Pools risk ratio or upper gastrointestinal complications with 
aspirin for cohort and nested case-control studies together 
and non-nested case-control studies. Does not pool cohort 
studies separately from case-control studies. 
Glanz et al 2006305 Uses a stimulation model to compare beta estimates for 
idiopathic thrombocytopenic pupura (ITP) with measles-
mumps-rubella (MMR) vaccine in simulated cohort, risk-
interval, self-controlled case series (SCCS), case-control 
designs. Does not compare different real life studies. 
Gordon et al 2010294 Compares pneumothorax rates with and without 
ultrasonography guidance in 6 comparative studies and 2 
RCTs. The 2 RCTs are included within the comparative 
study analysis.  
Greiser et al 2005347 Pools the odds ratios and risk ratio of breast cancer with 
menopausal hormone therapy for cohort studies and RCTs 
combined and for case-control studies. Does not pool the 
results for cohort studies and RCTs separately. 
Grullon and Grimes 
1997334 
Includes RCTs, cohort studies, case series, and a case-
control study on the safety of early postpartum discharge. 
Presents the results for individual studies grouped by study 
design but does not pool the results by study design. 
Hall and Lucke 
2006171 
Includes RCTs, observational studies and ecological 
studies on the risk of suicide with SRRIs. Presents the 
results of each of the individual studies grouped by study 
design but does not pool the results by study design 
Hawkey CJ. BMJ 
1990;300:278-84.320  
 
Includes cohort studies and case-control studies on the risk 
of peptic ulcers with NSAIDs. Identifies higher risk 
estimates with NSAIDS in case-control studies than cohort 
(attributed to bias associated with this study design). Does 
not present pooled estimates by study design. 
Henry et al 2001230 Compares agreement between RCTs and observational 
studies for the impact of laparoscopic cholecystectomy, 
compared with open or mini-laparotomy, on post-operative 
infections and bile duct injury; the impact of antioxidants on 
death from malignancy and cardiovascular disease; and the 
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Table 15.2 Excluded studies in Chapter 4 
Study  Reason for exclusion 
effects of hormone replacement therapy (HRT) on 
cardiovascular and overall mortality (healthy cohort effect). 
Abstract only does not give enough information. 
Herbert-Croteau 
1998311 
Pools risk ratio for cohort studies and for case-control 
studies for colon cancer with hormone replacement therapy 
(HRT). Hypothesis is that hormone replacement therapy 
(HRT) has a protective effect. 
Herbert et al 2007295 Compares motor vehicle crashes with benzodiazepines 
using a case-controlled and case-crossover design with one 
dataset. Does not compare by study design such as RCT, 
cohort studies or case-control studies. 
Janowsky et al 
2000335 
Includes cohort studies, case-control studies and cross-
sectional studies on the risk of connective tissue diseases 
with silicone breast implants. Presents the results for 
individual studies grouped by study design but does not 
pool the data by study design. 
Kashyap et al 2004312 Pools incidence data in cohort studies and case-control 
studies for ovarian cancer with assisted reproductive 
technology. Suggests that treated patients may have a 
lower incidence of ovarian cancer. 
Katerndahl et al 
1992321 
Calculates the risk ratio of cardiovascular disease with oral 
contraceptives. Summarises study characteristics. Identifies 
that cohort studies has lower risk ratios than case-control 
studies but does not present any quantification of this 
difference. 
Kuoppala et al 
2008322 
Presents risk ratio estimates for RCTs, cohort studies, and 
case-control studies in diagrammatic format but does not 
present pooled data. States that effect estimates do depend 
on study design.  
Larsson et al 2006313 Pools case-control and cohort studies for the risk of 
pancreatic cancer with aspirin and NSAIDs. Hypothesis 
suggests aspirin may reduce the risk. 
Lawlor et al 2003323 Includes RCT, cohort studies and case-control studies on 
the association between antidepressant medication and 
breast cancer. Presents a forest plot by study design but 
does not report the pooled risk ratios by study design. 
Levine et al 1997296 Compares prospectively the impact of study design on 
safety data for ACE inhibitors. Study designs compared are 
one RCT, one phase IV postmarketing open clinical trial, 
one phase IV postmarketing open clinical trial and one 
postmarketing research survey. Does not compare multiple 
studies of the same design or compare traditional types of 
study design with the RCT. 
Loke et al 2009324 Includes 4 RCTs and 2 case-control studies. Presents 
pooled ORs for serious atrial fibrillation and serious and 
non-serious atrial fibrillation and individual ORs of atrial 
fibrillation for the 2 case-control studies.  
Magee et al 2001325 Descriptive comparison of characteristics of participants, 
interventions, and outcomes assessed between a meta-
analysis of trials of beta-blocker therapy in pregnancy, and 
a prospective cohort of beta-blocker users. Does not 
include any quantification of the impact of different study 
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Table 15.2 Excluded studies in Chapter 4 
Study  Reason for exclusion 
types on harm data. 
Marang-van de 
Mheen et al 2007 297 
Compares occurrence of adverse outcomes and mortality in 
in-hospital patients and after surgery with respect to data 
collection method, unit of analysis, number of reviewers and 
definition of adverse outcome. No comparison by type of 
study design (such as RCT or case-control study). 
Marra et al 2006298 Compares the odds ratios of prospective and retrospective 
studies for asthma after antibiotic exposure during infancy. 
Does not compare study design, such as RCT, case-control 
or cohort studies. 
Martel et al 2005299 Compares pooled odds ratio of thrombocytopenia with 
unfractionated and low-molecular-weight heparin 
thrombopropylaxis for RCTs and for RCTs and 
nonrandomized prospective studies combined. Does not 
compare the pooled results for RCTs with other discrete 
study designs. 
Martin 2005134 Discusses the reasons for differences between 
observational and controlled trial data for the safety of 
albumin. No comparable data presented. 
Miller et al 2002345 Contains duplicate data from Agency for Healthcare 
Research and Quality 2002238 
Miwa et al 1997326 Discusses gastrointestinal, liver and skin events with 
NSAIDS in spontaneous reports and epidemiological 
studies. Does not include any quantification of the impact of 
different study types.  
Meenan346 Contains duplicate data from Chou et al 2006,247and Chou 
et al 2007248 
Molloy et al 2002300 Reports on the pooled odds ratios for bowel and major 
vascular injuries from laparoscopic entry in prospective and 
retrospective studies. Does not compare by study design 
(such as cohort and case-control studies). 
Nakhai-Pour et al 
2008327 
Compares the pooled results of one RCT, 7 cohort studies 
and 22 case-control studies. Only presents the ORs for the 
pooled case-control studies. 
O’Brien et al 2008341 Presents odds ratios for 3 pooled case-control studies for 
cardiac malformations and pooled differences in rates of 
cardiac malformations for  6 cohort studies. Does not 
present the same outcome measures for the different study 
designs. 
Padwal and Laupacis 
2004336 
Includes case-control, cohort studies and RCTs on 
antihypertensive therapy and type 2 diabetes. Presents risk 
ratio by individual studies but does not pool by study design 
Pladevall-Vila et al 
1996314 
Includes case-control and cohort studies of oral 
contraceptives and the risk of rheumatoid arthritis. Pooled 
risk ratio only given for cohort studies.  Hypothesis suggests 
oral contraceptives may have protective effect.  
Reynolds et al 
2002315 
Pools the results from RCTs and from RCTs and non-
randomised trials for umbilical artery pH values and 
umbilical artery base excess after analgesia in labour. 
Suggests  epidural analgesia is associated with improved 
neonatal acid-base status. 
Rossi et al 1983328 Compares detection of new adverse drug reactions in 
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Table 15.2 Excluded studies in Chapter 4 
Study  Reason for exclusion 
phase 4 studies with spontaneous reports. No quantification 
of the impact of different study types. 
Rothwell et al 1996301 Pools the risk of mortality and stroke and/or death due to 
endarterectomy for  prospective and retrospective studies. 
Does not group by formal study design (such as RCT, 
cohort.study or case-control study). 
Safdar et al 2002302 Pools odds ratios of haemolytic uremic syndrome after 
antibiotic treatment for retrospective and prospective 
studies.  Does not group by formal study design (such as 
RCT, cohort.study or case-control study). 
Schaffer et al 2006349  Risk duration meta-analysis – looking at the decline in 
annualised risk of NSAID-related gastrointestinal events 
over time during long-term exposure in RCTs and cohort 
studies. Does not compare the magnitude of adverse 
effects by study design. 
Shah et al 2005337 Compares odds ratios of observational studies (cohort and 
case-control studies combined) to hazard ratios from 
individual RCTs for the risk of breast cancer with 
postmenopausal hormone therapy. Does not pool RCT data 
and separates observational data by duration of use of 
therapy.   
Singh and Loke 
2006342 
Presents odds ratio from observational studies and number 
of case reports/number of spontaneous reports for 
pancreatitis with statins. Difficult to compare odds ratios to 
numbers of cases. 
Spector and 
Hochberg 1990650 
Presents pooled odds ratios for case-control studies and 
cohort studies for the association of oral contraceptives and 
rheumatoid arthritis. Hypothesis suggests a protective effect 
of oral contraceptives. 
Steffensmeier et al 
2006329 
Discussion comparing case reports and RCTs on the 
association between β-adrenergic blockers and depression. 
Does not present any quantification of the impact of the 
different study types. 
Steinberg et al 
1994330 
Updated meta-analysis with primary aim to assess cancer 
risk by duration of estrogen use. Tests sources of 
heterogeneity such as source of controls, study design and 
types of estrogen. Does not report frequencies or risk ratio 
of adverse effects. 
Thavagnanam et al 
2007331 
Systematic review of the association between children born 
by caesarean section and asthma. Analysis was conducted 
in subgroups of the studies defined by study design. 
However, the results are not reported. 
Toh and Hernández-
Díaz 2007. 316 
Pools odds ratios for fracture risk with statins for case-
control and cohort studies. Hyposthesis suggests protective 
effect. 
Uboweja et al 2006338 Includes case-control studies, cohort study and cross-
sectional survey for the effect of inhaled corticosteroids on 
the risk of cataract. Presents the risk by individual study 
does not pool the results by study design. 
Vamvakas 1995303 Presents pooled risk ratio for prospective and retrospective 
studies on perioperative blood transfusion and cancer 
recurrence. Does not group by formal study design (such as 
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Table 15.2 Excluded studies in Chapter 4 
Study  Reason for exclusion 
RCT, cohort.study or case-control study). 
Van staa et al 2008306 Uses a stimulation model to compare gastrointestinal 
events and myocardial infarction with Cox-2 inhibitors with 
data from General Practice Research Database (GPRD) 
(now Clinical Practice Research Datalink (CPRD)) and 
RCTs. 
Vendermeer et al 
2004343 
Compares 2 systematic reviews one looked primarily at 
adverse events and included only observational studies and 
the other review looked solely at adverse events and 
included only RCTs. The results of the comparison are not 
presented as conference abstract only available.  
Viboud et al 2001304 Compares statistical efficiency of case-crossover and case-
control study designs using one dataset on severe 
cutaneous adverse reactions.  
Wiens et al 2006317 Presents pooled risk ratio of fracture outcomes with 
antihypertensive drugs in case-control and cohort studies. 
Hypothesis suggests that antihypertensive drugs have 
protective effect on fracture outcomes. 
Yaffe et al 1998318 Pools risk ratio for prospective cohort studies and for case-
control studies for dementia with estrogen therapy. 
Hypothesis is that estrogen therapy has a protective effect. 
Zhang et al 2001344 Uses a systematic review of analgesic nephopathy and 
chronic renal disease to compare case-control studies and 
cohort studies. Conference abstract only. Not enough 
information. 
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Figure 15.1 Meta-analysis of ratio of risk ratios from RCTs versus cohort 
studies 
 
Only two methodological evaluations gave results that did not cross the line of no 
effect. Loke 2008 identified a greater incidence of fractures with thiazolidinediones 
in RCTs than cohort studies, although both study designs agreed that there was a 
significant increase in fractures. Torloni 2009b identified a greater estimate for 
dyslexia after ultrasonography in pregnancy in cohort studies than RCTs.  
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Total (95% CI)
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Weight
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Figure 15.2 Meta-analysis of ratio of risk ratios from RCTs versus case-control 
studies 
 
Only two methodological evaluations gave results that did not cross the line of no 
effect, Douketis 1997b (oral contraceptives and venous thromboembolism) and 
Torloni 2009a (low birth weight and ultasonography in pregnancy). Both identified 
higher estimates of an adverse effect with case-control studies than RCTs.  
Study or Subgroup
AHRQ 2002
Capurso 2007a
Douketis 1997a
Douketis 1997b
Koster 1995
Loke 2008
MacLennan 1995
Ofman 2002
Scott 2008
Torloni 2009a
Total (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 19.76, df = 9 (P = 0.02); I² = 54%
Test for overall effect: Z = 0.90 (P = 0.37)
Weight
1.8%
14.6%
9.0%
10.0%
4.8%
13.8%
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7.7%
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IV, Random, 95% CI
1.50 [0.10, 22.60]
1.38 [0.75, 2.53]
0.37 [0.13, 1.00]
0.29 [0.12, 0.73]
0.26 [0.06, 1.23]
0.87 [0.45, 1.68]
1.09 [0.15, 7.88]
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1.70 [0.90, 3.19]
0.77 [0.60, 0.99]
0.84 [0.57, 1.23]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.05 0.2 1 5 20
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Figure 15.3 Meta-analysis of ratio of risk ratios from RCTs versus studies 
described as ‘observational’ 
 
 
Col 2005 (HRT and breast cancer), Papanikolaou 2006d (anticoagulant and bleed) 
and Papanikolaou 2006h (labaroscopy and injury) were the only methodological 
evaluations which gave ratios of risk ratios that did not cross the line of no effect.  
Col 2005 identified a higher estimate in RCTs than ‘observational studies’, whereas 
Papanikolaou 2006d and 2006h identified a lower estimate of adverse effects in 
‘observational studies’ than RCTs. 
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Weight
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Figure 15.4 Meta-analysis of ratio of risk ratios from cohort versus case-
control studies 
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14 sets of results gave ratios of risk ratios that did not cross the line of no effect. A 
higher estimate of adverse effects was identified in cohort studies than case-control 
studies in Bager 2008 (caesarean delivery and asthma), Leipzig 1999ac 
(neuroleptics and falls), Scott 2008 (NSAIDS and cardiac failure), Smith 2003a 
(short duration hormonal contraceptives and cervical cancer), Smith 2003b (medium 
duration hormonal contraceptives and cervical cancer) and Smith 2003c (long 
duration hormonal contraceptives and cervical cancer).  
 
On the other hand, a lower estimate of adverse effects was identified in cohort 
studies than case-control studies in Bollini 1992 (NSAIDS and upper gastrointestinal 
tract disease), Chan 2004 (oral contraceptives and stroke), Dolovich 1998a 
(benzodiazepine in pregnancy and major malformations), Grady 1995a (HRT and 
endometrial cancer), Grady 1995b (estrogen plus progestin and endometrial 
cancer), Henry 2003 (NSAIDS and gastrointestinal complications), Leipzig 1999aa 
(psychotropics and falls), and Leipzig 1999bi (antiarrhythmics and falls). 
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Figure 15.5 Meta-analysis of ratio of risk ratios from cohort versus cross-
sectional studies 
 
 
Although in Woolcott 2009d a significant increase in falls was identified from both 
the cohort studies and the cross-sectional studies, the ratio of odds ratios from 
these studies gave results that did not cross the line of no effect. A lower estimate of 
adverse effects was identified in Woolcott 2009d in cohort studies than in cross-
sectional studies. 
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Heterogeneity: Tau² = 0.00; Chi² = 18.94, df = 17 (P = 0.33); I² = 10%
Test for overall effect: Z = 0.59 (P = 0.55)
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-0.24686
0.043803
-0.09097
-0.50414
0.132425
0.141314
0.139262
0.419854
-0.08778
-0.41376
-0.59941
0.18831
-0.05557
-0.22957
SE
0.526359
0.157936
0.196373
0.230145
0.140989
0.210111
0.26148
0.365529
0.170911
0.209878
0.203322
0.264976
0.337195
0.411573
0.509032
0.257161
0.069978
0.102004
Weight
0.8%
7.4%
5.0%
3.8%
9.0%
4.4%
3.0%
1.6%
6.5%
4.5%
4.7%
2.9%
1.8%
1.2%
0.8%
3.0%
24.6%
15.0%
100.0%
IV, Random, 95% CI
1.13 [0.40, 3.18]
1.19 [0.87, 1.62]
1.07 [0.73, 1.58]
1.19 [0.76, 1.88]
0.78 [0.59, 1.03]
1.04 [0.69, 1.58]
0.91 [0.55, 1.52]
0.60 [0.30, 1.24]
1.14 [0.82, 1.60]
1.15 [0.76, 1.74]
1.15 [0.77, 1.71]
1.52 [0.91, 2.56]
0.92 [0.47, 1.77]
0.66 [0.30, 1.48]
0.55 [0.20, 1.49]
1.21 [0.73, 2.00]
0.95 [0.82, 1.09]
0.79 [0.65, 0.97]
0.97 [0.89, 1.07]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Coh studies lower risk Coh studies higher risk
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Figure 15.6 Meta-analysis of ratio of risk ratios from case-control studies 
versus cross-sectional studies 
  
 
Although in Leipzig 1999aa (psychotropics and falls) there was an increase in falls 
identified from the case-control studies and the cross-sectional studies, the ratio of 
odds ratios for falls was higher in case-control studies than cross-sectional studies. 
In Leipzig 1999a case-control studies estimates of risk were higher than in cross-
sectional studies. 
  
Study or Subgroup
Leipzig 1999aa
Leipzig 1999ab
Leipzig 1999ac
Leipzig 1999ad
Leipzig 1999ae
Leipzig 1999ba
Leipzig 1999bb
Leipzig 1999bc
Leipzig 1999bd
Leipzig 1999be
Leipzig 1999bf
Leipzig 1999bg
Leipzig 1999bh
Leipzig 1999bi
Woolcott 2009a
Woolcott 2009b
Woolcott 2009c
Woolcott 2009d
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 22.98, df = 17 (P = 0.15); I² = 26%
Test for overall effect: Z = 1.11 (P = 0.27)
log[Risk Ratio]
0.607434
0.224467
-0.28141
0.018576
0.651236
0.538272
-0.67321
0.14781
-0.25259
-0.04707
0.24323
0.350775
0.152969
0.754791
-0.01818
0
-0.15906
0.03774
SE
0.2035
0.201362
0.211453
0.128238
0.336306
0.47875
0.397225
0.217468
0.254723
0.293301
0.33952
0.433285
0.393378
0.669257
0.241125
0.10253
0.259675
0.123595
Weight
6.9%
7.0%
6.5%
12.1%
3.1%
1.6%
2.3%
6.2%
4.9%
3.9%
3.0%
1.9%
2.3%
0.9%
5.3%
14.8%
4.7%
12.6%
100.0%
IV, Random, 95% CI
1.84 [1.23, 2.74]
1.25 [0.84, 1.86]
0.75 [0.50, 1.14]
1.02 [0.79, 1.31]
1.92 [0.99, 3.71]
1.71 [0.67, 4.38]
0.51 [0.23, 1.11]
1.16 [0.76, 1.78]
0.78 [0.47, 1.28]
0.95 [0.54, 1.70]
1.28 [0.66, 2.48]
1.42 [0.61, 3.32]
1.17 [0.54, 2.52]
2.13 [0.57, 7.90]
0.98 [0.61, 1.58]
1.00 [0.82, 1.22]
0.85 [0.51, 1.42]
1.04 [0.82, 1.32]
1.07 [0.95, 1.21]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
cc studies lower risk cc studies higher risk
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Figure 15.7 Meta-analysis of ratio of incidence from RCTs versus cohort 
studies 
 
Two methodological evaluations gave results that did not cross the line of no effect, 
Nalysnyk 2003b and Tramer 2000. Nalysnyk 2003b identified a lower incidence of 
non-fatal stroke post-CABG in RCTs than cohort studies. Tramer 2000 identified a 
lower incidence of symptomatic ulcer with NSAIDS in cohort studies than RCTs.  
 
 
 
Figure 15.8 Meta-analysis of ratio of incidence from RCTs versus studies 
described as ‘observational’ 
 
 
The confidence intervals for the ratio of incidence from Chou 2006 (carotid 
endarterectomy and stroke/death) and Jensen 2002b (regional anesthesia and 
posthernioohaphy urinary retention) did not cross the line of no effect. In each case 
there was a higher incidence of adverse effects in RCTs than observational studies.  
  
Study or Subgroup
Nalysnyk 2003a
Nalysnyk 2003b
Nalysnyk 2003c
Nalysnyk 2003d
Nalysnyk 2003e
Siegal 2009
Tramer 2000
Total (95% CI)
Heterogeneity: Chi² = 100.21, df = 6 (P < 0.00001); I² = 94%
Test for overall effect: Z = 7.13 (P < 0.00001)
log[]
0.177786
-0.41871
-0.21825
-0.92141
-0.17568
0.122602
1.333651
SE
0.241727
0.202625
0.489786
0.605246
0.17512
1.038938
0.111622
Weight
10.6%
15.0%
2.6%
1.7%
20.1%
0.6%
49.5%
100.0%
IV, Fixed, 95% CI
1.19 [0.74, 1.92]
0.66 [0.44, 0.98]
0.80 [0.31, 2.10]
0.40 [0.12, 1.30]
0.84 [0.60, 1.18]
1.13 [0.15, 8.66]
3.79 [3.05, 4.72]
1.75 [1.50, 2.04]
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Trials show lower risk Trials show higher risk
Study or Subgroup
Chou 2006
Jensen 2002a
Jensen 2002b
Jensen 2002c
Total (95% CI)
Heterogeneity: Tau² = 0.78; Chi² = 7.51, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 1.39 (P = 0.17)
log[Risk Ratio]
0.519875
0.524249
2.111965
-1.56862
SE
0.218595
1.78792
0.611672
1.845651
Weight
47.2%
9.8%
33.8%
9.3%
100.0%
IV, Random, 95% CI
1.68 [1.10, 2.58]
1.69 [0.05, 56.18]
8.26 [2.49, 27.41]
0.21 [0.01, 7.76]
2.37 [0.70, 8.05]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Trials show lower risk Trials show higher risk
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Figure 15.9 Meta-analysis of ratio of incidence from RCTs versus case series 
 
 
Tramer 1997 (propofol and bradycardia) and Ross 1998 (granulocyte-macrophage 
colony-stimulating factor and infections) gave results that did not cross the line of no 
effect with both reporting a higher incidence of adverse effects in RCTs than case 
series. Siegel 2009 (anti-tumor necrosis factor and immunomodulator therapy and 
lymphoma) had very small numbers of adverse effects and therefore a very wide 
confidence interval.  
Study or Subgroup
Ross 1998
Siegal 2009
Tramer 1997
Total (95% CI)
Heterogeneity: Tau² = 0.90; Chi² = 12.94, df = 2 (P = 0.002); I² = 85%
Test for overall effect: Z = 1.10 (P = 0.27)
log[Risk Ratio]
0.903046
-1.2852
1.579837
SE
0.450728
0.864573
0.076765
Weight
34.6%
23.2%
42.2%
100.0%
IV, Random, 95% CI
2.47 [1.02, 5.97]
0.28 [0.05, 1.51]
4.85 [4.18, 5.64]
1.98 [0.59, 6.64]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Trials show lower risk Trials show higher risk
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Table 15.3 Data sources for information on adverse effects 
Electronic Resources Examples 
Internet Search 
Engines 
These tools can provide 
information on adverse 
effects by searching the 
Internet. Internet 
searches may be a 
particularly good source 
for identifying grey 
literature, such as 
reports and conference 
proceedings. 
Google (www.google.com/) 
Yahoo (www.yahoo.com/) 
AltaVista (www.altavista.com/) 
Database Gateways  
These gateways enable 
searches of a selection 
of individual 
bibliographic databases 
at the same time.  
SAFETY searches 41 different databases 
(http://library.dialog.com/bluesheets/html/bloS.html)  
TOXCENTER (Toxicology Center) searches 18 different 
databases (http://www.stn-
international.de/stndatabases/databases/toxcenter.html) 
TOXICOLOGY searches 40 different databases. 
(http://library.dialog.com/bluesheets/html/bloT.html) 
Full-text Databases  
These databases 
provide access to the 
full-text of articles and 
some enable searches 
of full-text articles.  
Iowa Drug Information Service (IDIS) 
(www.uiowa.edu/~idis/idistday.htm) 
PharmaNewsFeed (includes full-text of the newsletters 
Inpharma, Pharmacoeconomics & Outcomes News and 
Reactions) (http://pharmanewsfeed.com/)  
Bibliographic 
Databases  
These databases 
provide summary 
information of articles 
(typically the title, 
source, abstract and 
keywords). They can be 
divided into; 
those specifically 
related to adverse 
effects, those 
containing a large 
section of adverse 
effects information, 
such as pharmaceutical 
databases and generic 
databases that contain 
some information on 
adverse effects. 
Adverse effects databases 
SEDBASE: Side Effects of Drugs (closed in 1997 but 
its print counterparts, Meyler's Side Effects of Drugs, Side 
Effects of Drugs Annual (SEDA)102, and Marler's 
Pharmacological & Chemical Synonyms continue to be 
up dated)651 
TOXLINE (Toxicology Literature Online) 
(http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?TOXLINE)  
ToxFile (Dialog version of TOXLINE) 
(http://library.dialog.com/bluesheets/html/bl0156.html) 
Pharmaceutical databases 
Derwent Drug File (previously RingDoc) 
(http://scientific.thomsonreuters.com/products/drugfile/) 
International Pharmaceutical Abstracts (IPA) 
(http://scientific.thomsonreuters.com/products/ipa/) 
Medicines Management (www.nelm.nhs.uk/en/NeLM-
Area/Evidence/Medicines-Management/) 
Pharmline (www.pharm-line.nhs.uk/home/default.aspx) 
(closed 2010) 
Generic databases 
BIOSIS (www.biosis.org/) 
EMBASE (www.embase.com/) 
MEDLINE (www.nlm.nih.gov/) 
PASCAL (http://international.inist.fr/article21.html) 
Science Citation Index (SCI) 
(http://scientific.thomsonreuters.com/products/sci/) 
Conference Conference Papers Index (CPI) 
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Electronic Resources Examples 
Databases 
These databases 
contain abstracts from 
scientific conferences.  
(www.csa.com/factsheets/cpi-set-c.php) 
Inside Conferences 
(www.bl.uk/services/bibliographic/datalicensing.html) 
ISI Proceedings Science & Technology (STP) 
(scientific.thomsonreuters.com/products/proceedings/) 
ISI Proceedings Social Sciences & Humanities 
(SSHP) 
(scientific.thomsonreuters.com/products/proceedings/) 
Referenced Summary 
Databases 
These databases 
contain summary 
information on 
interventions (usually 
drugs) and are fully 
referenced. 
DRUGDEX (www.micromedex.com/products/drugdex/)  
Lexi-Comp Database (www.crlonline.com/) 
POISINDEX (www.micromedex.com/products/reprorisk/) 
REPRORISK 
(www.micromedex.com/products/reprorisk/),  
Thériaque Database (www.theriaque.org) 
XPharm (www.xpharm.com/) 
Internet Reference 
Collections  
Some Internet sites 
provide collections of 
bibliographies or 
reference lists related to 
adverse effects. 
The Drug Safety Research Unit (DSRU) 
(www.dsru.org/) 
Herbmed.org (www.herbmed.org) 
Motherisk (www.motherisk.org/) 
Organization of Teratology Information Specialists 
(www.otispregnancy.org/)  
Spontaneous 
Reporting 
Systems/Post-
marketing Monitoring 
Data  
This includes 
mandatory reports from 
pharmaceutical 
companies on adverse 
events reported to 
them, and adverse 
event reports that 
physicians, 
pharmacists, nurses, 
dentists and the public 
submit directly to 
regulatory agencies. 
 
Some information is 
free from regulatory 
agencies on the 
Internet, 652 however, 
most data are available 
for a fee through 
databases or requests 
services. 
Internet 
Adverse Drug Reactions Database (www.adverse-
drug-reaction.net) 
FDA Drug Approval 
(www.accessdata.fda.gov/scripts/cder/drugsatfda/) 
Canada’s Adverse Drug Reaction Database (www.hc-
sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php) 
MedWatch FDA (www.fda.gov/medwatch/safety.htm)  
Prescription-Event Monitoring (PEM) 
(www.dsru.org/main.html) 
UK Yellow Card scheme: Drug Analysis Prints (DAPs) 
(www.mhra.gov.uk)  
World Health Organisation’s (WHO) International 
Drug Monitoring Programme in Uppsala (which 
includes Britain and 76 other countries) (www.who-
umc.org) 
 
Databases 
DIOGENES: Adverse Drug Events Database for data 
from the Food and Drug Administration (FDA) US 
MedWatch service 
(www.foiservices.com/brochure/diogenes.cfm). 
PharmaPendium (www.info.pharmapendium.com/) 
 
Request services 
FDA's Adverse Event Reporting System (AERS) and 
Spontaneous Reporting System (SRS) 
(www.foiservices.com/brochure/ADR_search.cfm or 
www.ntis.gov/products/adverse.aspx or 
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Electronic Resources Examples 
www.fda.gov/cder/aers/extract.htm). 
Vigibase Services: Uppsala Monitoring Centre (WHO) 
collects individual reports from 77 countries  
(www.umc-products.com/DynPage.aspx?id=10671). 
Practice Based 
Databases 
These databases 
provide case reports of 
adverse effects. 
Analysis of information 
from these sources can 
be found in primary 
research, which may 
then be included in a 
systematic review.397 
Clinical Practice Research Datalink (CPRD) 
http://www.cprd.com/intro.asp 
(Previously General Practice Research Database 
(GPRD) www.gprd.com/) 
 
 
Original Texts  
Bulletins/Newsletters 
Some bulletins and 
newsletters specialise 
in summarising case 
reports of adverse 
effects. 
Adverse Drug Reaction Bulletin 
(http://adr.org.uk/?page_id=97_) 
Australian Adverse Drug Reactions Bulletin 
(www.tga.gov.au/adr/aadrb.htm) 
Canadian Adverse ReactionNewsletter (CARN) (www.hc-
sc.gc.ca/dhp-mps/medeff/bulletin/index-eng.php) 
Clin-Alert (http://cla.sagepub.com/) 
Current Problems in Pharmacovigilance 
(www.mhra.gov.uk/Publications/Safetyguidance/ 
CurrentProblemsinPharmacovigilance/index.htm) 
Drugs and Therapy Perspectives 
(http://perspectives.adisonline.com/) 
Reactions (http://reactions.adisonline.com/or via 
http://pharmanewsfeed.com/) 
Journals  
There are a number of 
specialist journals, 
however, most adverse 
effects appear in 
journals that do not 
specialise in adverse 
drug reactions.31  
 
Hand searching 
journals may be 
appropriate when the 
journals titles are not 
indexed or poorly 
indexed in databases. 
Specialist Journals 
Drug Safety (http://drugsafety.adisonline.com/) 
Pharmacoepidemiology and Drug Safety 
(www.pharmacoepi.org/publications/journal.cfm) 
Toxicological Reviews (toxicology.adisonline.com/) 
 
Generic Journals (with highest number of articles on 
adverse effects)31 
Lancet (www.thelancet.com/) 
New England Journal of Medicine 
(http://content.nejm.org/) 
BMJ (www.bmj.com/) 
Annals of Pharmacotherapy (www.theannals.com/) 
Contact Dermatitis 
(www.blackwellpublishing.com/submit.asp?ref=0105-
1873) 
Textbooks/Monograph 
Collections 
These can be in book 
and/or electronic format 
and may or may not 
contain references to 
Adverse Drug Reactions653  
AHFSFirst Professional Medicines Compendium  
(www.medicinescomplete.com) 
ABPI electronic Medicines Compendium (eMC) 
(http://emc.medicines.org.uk/) 
British National Formulary (BNF) (www.bnf.org/) 
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Electronic Resources Examples 
the original research. 
Some simply provide 
lists of potential 
adverse effects for a 
drug whilst others 
provide detailed 
summary information. A 
few are organised by 
adverse effect rather 
than by the intervention. 
 
Clinical Pharmacology 
(www.clinicalpharmacology.com) 
Davies Textbook of Adverse Drug Reactions654 
Drugs.com (www.drugs.com) 
Drug Facts and Comparison 
(www.factsandcomparisons.com/) 
Emedicine (www.emedicine.com/) 
Epocrates Online (www.epocrates.com/) 
General Practice Notebook  
(www.gpnotebook.co.uk) 
Martindale: the complete drug reference  
(www.medicinescomplete.com) 
Medscape DrugInfo (www.medscape.com/druginfo) 
The Merck Manual (www.merck.com) 
Meylers’s Side Effects Of Drugs102  
The Maudsley Prescribing Guidelines655 
Modell’s Drugs in current use and new drugs656 
Mosby's Medical Drug Reference657 
Physicians Desk Reference (PDR)658 
PDR Guide to Drug Interactions, Side Effects and 
Indications659 
RxList (www.rxlist.com) 
Rxmed (www.rxmed.com) 
Side Effects of Drugs annual (SEDA) 660 
The Merck Manual (www.merck.com/mmpe/index.html) 
USP DI® Volume I, Drug Information for the Health 
Care Professional 
(http://library.dialog.com/bluesheets/html/bl0461.html) 
Specialist Textbooks 
These specialise in 
particular populations 
(such as pregnant 
women), particular 
adverse effects (such 
as liver disease) or 
particular types of drug 
(such as psychotropic 
drugs). 
Catalog of Teratogenic Agents661 
Drugs in Pregnancy and Lactation662 
Drugs during Pregnancy and Lactation663 
Drug use in pregnancy664 
Drug Induced Liver Disease665 
Litt’s Drug Eruption Reference Manual666  
or Litt’s Drug Eruption Global Database  
(www.drugeruptiondata.com/index.php?p=b_intro) 
Psychotropic Drug Directory667 
Authors/Experts 
Authors or experts in 
the field may know of 
unpublished studies 
which include data on 
adverse effects.392 
Authors may have 
recorded data on 
adverse effects not 
reported in the 
published study. 
Clinical Pharmacologists 
Researchers  
Trialists 
 
Industry  
Drug companies or 
manufacturers of 
Individual Drug Companies 
Eli Lilly (www.lillytrials.com/) 
GlaxoSmithKline (www.gsk-clinicalstudyregister.com/),  
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Electronic Resources Examples 
medical devices may 
provide details of 
unpublished studies. 
However such data can 
be classed as 
commercially sensitive 
and therefore not be 
accessible. 
 
Drug company data can 
be identified through 
individual drug 
companies, drug 
company portals, 
regulatory agencies 
(see above) and 
conferences (see 
above) 
Roche (www.roche-trials.com/results.html) 
Drug Company Portals 
International Federation of Pharmaceutical 
Manufacturers and Associations (IFPMA) clinical 
trials portal (www.ifpma.org/clinicaltrials.html)  
Lead Discovery (www.leaddiscovery.co.uk) 
Pharmaceutical Industry Clinical Trials database  
(https://www.cmrinteract.com/clintrial/) 
PhRMA Clinical Study Results Database  
(www.clinicalstudyresults.org/) 
Reference Checking  
Bibliographies and 
reference lists can be 
used to identify further 
studies. 
For example, reference lists from included studies or from 
systematic reviews in the topic area. 
Citation 
Searches/Cited 
Reference Searching 
Identifies studies which 
have cited a particular 
reference. This may be 
particularly useful for 
adverse effects data, as 
case reports/series of 
suspected new adverse 
effects may be followed 
up by more detailed 
studies. 
Google Scholar (http://scholar.google.com/) 
Scopus (www.scopus.com/ ) 
Web of Science 
(scientific.thomsonreuters.com/products/wos/) 
 
Discussion web 
sites/Emails 
Such sources can 
provide unique data on 
adverse effects.397, 668 
For example, software ‘robots’ can be used to monitor the 
Internet for postings about specific products.411 
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Table 15.4 Characteristics of included studies for Chapter 5  
Reference Sample size, type of adverse effect and 
intervention 
Outome Measures and Results Methodological Assessment 
Al Hefzi et al 
1987354 
51-250 relevant references on major side effects 
with 5 antineoplastic drugs  
Case Study 1: Amsacrine 
29-57 relevant references  
Case Study 2: Etoposide  
51-71 relevant references 
Case Study 3: Ifosfamide 
17-29 relevant references 
Case Study 4: Teniposide 
22-34 relevant references 
Case Study 5: Vindesine 
35-59 relevant references 
 
Relevant references  
Case Study 1: Amsacrine 
IDIS: 29 
De Haen’s Drugs in Use$: 25 
IPA: 3 
Case Study 2: Etoposide 
IDIS: 51 
De Haen’s Drugs in Use$: 20 
IPA: 0 
Case Study 3: Ifosfamide 
IDIS: 17 
De Haen’s Drugs in Use$: 10 
IPA: 2 
Case Study 4: Teniposide 
IDIS: 22 
De Haen’s Drugs in Use $: 11 
IPA: 1 
Case Study 5: Vindesine 
IDIS: 35 
De Haen’s Drugs in Use$: 23 
IPA: 1 
All Case Studies: 5 antineoplastic 
drugs 
IDIS: 159 
De Haen’s Drugs in Use$: 89 
IPA: 7 
1. Generalisability: The number of relevant 
references for each case study was low and 
each case study was limited to one drug. 
However, taking the results of the case 
studies collectively and the inclusion of 
multiple adverse effects improves the 
generalisabilty of the study.  
2. Database overlap: The authors recorded 
the number of records on adverse reactions 
for each of the five drugs retrieved from the 
three databases. No account of overlapping 
records or unique relevant references was 
made. 
3. Limitations of the search strategies: 
Although no consideration of any potential 
limitations of the search strategies were 
presented, the search strategies were very 
broad and only used variants of the drug 
names. 
4. Comparative outcomes: The total 
number of citations retrieved for each 
database is unclear so that precision or 
number needed to read could not be 
calculated. The cost and search functionality 
of each database were not reported. 
 
Bagnall et al 
2002355  
52 relevant references from a systematic 
review669 on 8 atypical antipsychotics for 
schizophrenia (amisulpride, clozapine, 
olanzapine, quetiapine, risperidone, setindole, 
Included papers (after duplication at 
retrieval stage) 
EMBASE: 16 (95% CI 10 to 23) 
MEDLINE: 13 (95% CI 7 to 20) 
1. Generalisability: The number of relevant 
references was relatively small at 52 and 
was limited to one class of drugs. However 
multiple adverse effects were included.  
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intervention 
Outome Measures and Results Methodological Assessment 
ziprasidone, zotepine) and death/suicide, tardive 
dyskinesia, neuroleptic malignant syndrome, 
agranulocytosis, seizures, weight gain, hepatic 
dysfunction, and cardiac dysfunction 
Industry Submissions: 11 (95% CI 6 to 
18) 
Reference Lists/Hand searching: 7 (95% 
CI 3 to 13) 
PsycINFO: 2 (95% CI 0 to 7) 
ADIS LMS Drug Alerts Online*: 1 (95% 
CI 0 to 5) 
BIOSIS*: 1 (95% CI 0 to 5) 
TOXLINE: 1 (95% CI 0 to 5) 
ADIS Inpharma*, British Library Inside 
Conferences*, CAB HEALTH*, CPI*, 
Derwent Drug File*,  ExtraMED*, IDIS*, 
IPA*, JICST-EPlus*, Mental Health 
Abstracts$*, NTIS*, PASCAL*, Pharma 
marketing*, PHARMLINE$*, and 
SEDBASE$: 0 (95% CI 0 to 4) 
* searched with effectiveness search 
strategy only 
2. Database overlap: The authors recorded 
the number of relevant references from each 
source after duplication (no record was made 
of the order in which the references were 
duplicated). No record was made of 
overlapping or unique relevant references. 
3. Limitations of the search strategies: 
The authors did not take into consideration 
any limitations of the search strategies, 
however, they used a broad search strategy 
for adverse effects and the results of an 
exhaustive search for effectiveness studies. 
They did not record whether the records 
were identified before duplication or whether 
the records were available from each data 
source but not identified. 
4. Comparative outcomes: The removal of 
duplicate relevant references before analysis 
is a major flaw in this study. Issues such as 
the precision or number needed to read as a 
result of searching each database, the cost, 
and search functionality were not reported. 
Belgado 
1997356 
No details reported on the number of references 
or the adverse effects. 5 queries of drug 
interventions.  
Median score for overall ability to 
answer 5 questions  
Drugdex: A 
Facts and Comparisons: A 
Lexi-Comp’s Clinical Reference Library: 
B 
Clinical Pharmacology: C 
Drug Information Fulltext: C 
1. Generalisability: It is difficult to asses 
generalisability as no details of the 5 queries 
tested or the relevant references retrieved 
were reported.  
2. Database overlap: Neither unique nor 
total relevant references were reported. 
3. Limitations of the search strategies: No 
consideration of the limitations of the search 
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intervention 
Outome Measures and Results Methodological Assessment 
Physician’s GenRx: C 
Physician’s Desk Reference: D 
 
Median score for user-friendliness (0 
is most user friendly, 100 least)  
Clinical Pharmacology: 14 
Drugdex: 14 
Physician’s GenRx: 21.5 
Lexi-Comp Clinical Reference Library: 
28.5 
Physician’s Desk Reference: 35.5 
Facts and Comparisons: 65.5 
Drug Information Fulltext: 70 
strategies were presented. 
4. Comparative outcomes: The 
comparisons were made using a scoring 
system the overall ability of each resource to 
answer 5 questions on adverse effects and a 
0 to 100mm visual analogue scale for overall 
ease of use. The cost of each resource was 
discussed, however, sensitivity, precision or 
number needed to read were not reported. 
 
Biarez et al 
1991357 
838-1826 relevant references on any adverse 
effects with 10 drugs (carboplatin, diclofenac 
sodium, dihydrotachysterol, dinitrochlorobenzene, 
fluconazole, hydrocortisone acetate, 
methergoline, methoxsalen, piromidic acid, 
tetrachlorodecaoxide).  
Mean relevant references, precision 
(%) and cost per relevant item  
EMBASE: 84, 52%, $1.10 
TOXLINE: 31, 31%, $0.66 
MEDLINE: 22, 28%,$0.64 
BIOSIS: 19, 31%, $1.96 
IDIS: 16, 43%, $1.30 
Core MEDLINE: 9, 32% 
PHARMLINE$: 6, 21%, $3.6 
PASCAL: 3, 41%, $3.40 
IPA:3, 30%, $1.52 
 
Unique references (for one of the ten 
drugs only - Carboplatin) 
EMBASE: 62 
BIOSIS: 26 
TOXLINE: 10 
1. Generalisability: The total number of 
records used to compare the databases is 
unclear. However, it can be assumed to be 
fairly large at between 838 and 826 records. 
A range of drugs and adverse effects were 
included. 
2. Database overlap: A more detailed 
analysis was carried out on one of the ten 
drugs which included unique and overlapping 
records. 
3. Limitations of the search strategies: 
The search strategies incorporated generic 
terms for the drugs and terms such as 
adverse effects, adverse reaction and side 
effect. The authors did not consider the 
limitations of the search strategies and did 
not record the availability of records on each 
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IDIS: 8 
PASCAL: 7 
PHARMLINE$: 3 
IPA: 2 
MEDLINE: 2  
data source. 
4. Comparative outcomes: The sensitivity 
of searching each database was recorded. 
Eight of the nine databases were searched 
via Datastar so search functionality would 
have been similar. A cost analysis was 
carried out for one of the ten drugs, however, 
the results of this will now be outdated. 
Clauson et 
al 2007358 
No details of the relevant references were 
reported on unspecified adverse effects of 
unspecified drugs in 13 queries.  
Mean scores for scope*, 
completeness** and ease of use*** 
Clinical Pharmacology: 13, 2.69, 3.62 
Micromedex :13, 3.00, 2.69 
Facts and Comparisons: 12, 2.92, 3.00 
Lexi-Comp Online: 12, 2.92, 2.00 
RxList.com: 10, 2.40, 3.00 
Epocrates Online Premium:  9, 2.89, 
1.78 
Epocrates Online Free: 9, 2.89, 1.78 
* correct answer present for any of 13 
questions 
** 1 is cursory answer, 3 is complete 
answer 
***number of steps or clicks to reach 
answer 
1. Generalisability: 13 queries on adverse 
drug reactions were assessed. However, it is 
difficult to assess the generalisability of the 
results as no details were given of either the 
drugs or adverse effects studied or the 
number of relevant references.  
2. Database overlap: Neither the number of 
total nor unique relevant references were 
reported. 
3. Limitations of the search strategies: No 
limitations of the search strategies were 
considered. 
4. Comparative outcomes: Comparisons 
were made using a scoring system. Scores 
were given for scope (if a correct answer was 
present in the database), completeness (how 
comprehensive an answer), and ease of use 
(how simple, direct and user friendly the 
database was). The differences between the 
results from subscription and free databases 
were presented. However, sensitivity, 
precision or number needed to read were not 
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reported. 
Fishman et 
al 1996359 
7 relevant references on the gastrointestinal side 
effects of Cyclosporine. 
Relevant references 
MEDLINE: 6 (5 unique) 
IPA: 3 (2 unique) 
1. Generalisability: The generalisability of 
this study was limited by the small number of 
relevant references and a narrow inclusion 
criteria..  
2. Database overlap: The total and unique 
number of relevant references was 
presented. 
3. Limitations of the search strategies: 
The authors recorded whether the records 
were identified using a specific search 
strategy of the drug and adverse effect 
terms. The availability of records on each 
data source was recorded as a total for all 10 
queries (including the one query on adverse 
effects). In total one reference was identified 
in MEDLINE but not IPA because of 
variations in indexing vocabulary, and 4 
references were identified in IPA but not in 
MEDLINE because of variations in indexing 
vocabulary and availability of an abstract. 
4. Comparative outcomes: The precision 
and cost of searching was not recorded, 
however, the authors did discuss searching 
functionality and content differences between 
the two databases.  
Golder et al 
2006360 
 
84 relevant references from a systematic 
review670 on any adverse effects of 7 antiepileptic 
drugs (gabapentin, lamotrigine, levetiracetam, 
oxcarbazepine, tiagabine, topiramate and 
Included references 
EMBASE: 73 (11 unique)  
MEDLINE: 67 (5 unique)  
Effectiveness search: 57 (1 unique from 
1. Generalisability: The number of relevant 
references was fairly limited by size (84 
records) and by inclusion criteria (one class 
of drugs), however, all types of serious 
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vigabatrin) SCI)  
TOXLINE: 5 (1 unique) 
Industry Submission: 3 (3 unique) 
Personal Communication: 1 (1 unique) 
adverse effects were included. 
2. Database overlap: The total and unique 
number of relevant references was 
presented. 
3. Limitations of the search strategies: In 
MEDLINE and EMBASE a record was kept 
of the number of records available from the 
set of included studies, not identified by the 
search strategies. 
4. Comparative outcomes: No analysis of 
the precision of the search strategies, cost of 
searching, or search functionality was carried 
out. 
Haramburu 
et al 1991361 
151 relevant references from 30 case studies  
Case Study 1:  
5 relevant references (3 unique) on stomatitis 
with 
sotalol hydrochloride 
Case Study 2: 
0 relevant references on hypoglycaemic coma 
with 
piridoxilate and erythrityl tetranitrate 
Case Study 3:  
1 relevant reference (1 unique) on hypoglycaemic 
coma with triamterene and cyclothiazide 
Case Study 4: 3 relevant references (3 unique) 
on hypoglycaemic coma with  
cyamemazine 
Case Study 5: 1 relevant reference (1 unique) on 
hepatic cirrhosis with 
Relevant references 
Case Study 1:  
MEDLINE and PASCAL: 4 
Reference books: 3 
Case Study 2: 
MEDLINE and PASCAL:  0 
Reference books: 0 
Case Study 3: 
MEDLINE and PASCAL: 1 
Reference books: 0 
Case Study 4: 
Reference books: 3 
MEDLINE and PASCAL: 0 
Case Study 5: 
Reference books: 1 
MEDLINE and PASCAL: 0 
Case Study 6: 
1. Generalisability: The results are likely to 
be fairly generalisable as 151 relevant 
references were identified covering 30 drugs 
and 16 adverse effects. 
2. Database overlap: The total and unique 
number of relevant references was 
presented. 
3. Limitations of the search strategies: 
Only the number of identified records were 
recorded. However, with textbook searches 
this is likely to also represent the number of 
available records. 
4. Comparative outcomes: Precision and 
cost were not recorded although some 
indication as to search functionality was 
presented. 
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androgens 
Case Study 6: 1 relevant reference (1 unique) on 
erythematous eruption with  
chlorpropamide 
Case Study 7: 0 relevant references on hepatic 
cytolysis with fipexide 
Case Study 8: 3 relevant references (3 unique) 
on hepatic cytolysis with rifampicin 
Case Study 9: 
0 relevant references on hepatic cytolysis with 
ifenprodil 
Case Study 10: 3 relevant references (3 unique) 
on hepatic cytolysis with 
hydroxysine 
Case Study 11: 0 relevant references on 
ulcerogenic colitis with fenofibrate 
Case Study 12:  
8 relevant references (6 unique) on ulcerogenic 
colitis with altizide and spironolactone 
Case Study 13: 0 relevant references on 
ulcerogenic colitis with dihydralazine 
Case Study 14: 0 relevant references on pruritic 
eruption with betamethasone 
Case Study 15: 27 relevant references (25 
unique) on galactorrhea with capipramine 
Case Study 16: 4 relevant references (3 unique) 
on galactorrhea with toloxatone 
Case Study 17: 0 relevant references on 
neutropenia with dihydroergotamine 
Case Study 18: 14 relevant references (10 
Reference books: 1 
MEDLINE and PASCAL: 0 
Case Study 7: 
MEDLINE and PASCAL: 0 
Reference books: 0 
Case Study 8: 
Reference books: 2 
MEDLINE and PASCAL: 1 
Case Study 9: 
Reference books: 0 
MEDLINE and PASCAL: 0 
Case Study 10:  
MEDLINE and PASCAL:  3 
Reference books: 0 
Case Study 11: 
Reference books               0 
MEDLINE and PASCAL 0                        
Case Study 12: 
MEDLINE and PASCAL 7                        
Reference books               3 
Case Study 13: 
Reference books                0 
MEDLINE and PASCAL  0                        
Case Study 14: 
Reference books                0 
MEDLINE and PASCAL  0                        
Case Study 15: 
MEDLINE and PASCAL: 16 
Reference books: 13 
Case Study 16: 
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unique) on hepatic cytolysis with  
acenocoumarol 
Case Study 19:  
10 relevant references (9 unique) on hepatic 
cytolysis 
sotalol 
Case Study 20: 4 relevant references (4 unique) 
on subcutaneous necrosis with 
amikacin 
Case Study 21: 10 relevant references (7 
unique) on hepatic cholestasis with pirprofen 
Case Study 22: 31 relevant references (20 
unique) on hepatic cholestasis with  
penicillamine 
Case Study 23: 4 relevant references (3 unique) 
on thrombocytopenia with pefloxacin 
Case Study 24: 1 relevant reference (1 unique) 
on impotence with isosobide dinitrate 
Case Study 25: 11 relevant references (7 
unique) on lupus with carbamazepine 
Case Study 26: 4 relevant references (4 unique) 
on hyperprolactinemia with ranitidine 
Case Study 27:  
0 relevant reference on hyperprolactinemia with 
adrafinil 
Case Study 28: 6 relevant references (5 unique) 
on thrombocytopenia with clobazam 
Case Study 29: 0 relevant references on hepatic 
cholestasis with theophylline 
Case Study 30: 0 relevant references on 
Reference books: 3 
MEDLINE and PASCAL: 2 
Case Study 17: 
Reference books: 0 
MEDLINE and PASCAL: 0 
Case Study 18: 
Reference books: 10 
MEDLINE and PASCAL: 8 
Case Study 19: 
MEDLINE and PASCAL: 8 
Reference books: 3 
Case Study 20: 
Reference books: 4 
MEDLINE and PASCAL: 0 
Case Study 21: 
Reference books: 7 
MEDLINE and PASCAL: 6 
Case Study 22: 
MEDLINE and PASCAL: 22 
Reference books: 20 
Case Study 23: 
MEDLINE and PASCAL: 3 
Reference books: 2 
Case Study 24: 
MEDLINE and PASCAL: 1 
Reference books: 0 
Case Study 25: 
MEDLINE and PASCAL: 8 
Reference books: 7 
Case Study 26: 
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photosensitivity with domperidone Reference books: 3 
MEDLINE and PASCAL: 1 
Case Study 27: 
Reference books: 0 
MEDLINE and PASCAL: 0 
Case Study 28: 
MEDLINE and PASCAL: 5 
Reference books: 2 
Case Study 29: 
Reference books: 0 
MEDLINE and PASCAL: 0 
Case Study 30: 
Reference books: 0 
MEDLINE and PASCAL: 0 
 
All Case Studies: 30 drugs 
MEDLINE and PASCAL: 100 (68 
unique) 
Reference books (Martindale The Extra 
Pharmacopoeia, Meyler’s Side Effects 
of Drugs, Side Effects of Drugs Annuals, 
Textbook of Adverse Reactions, Clin 
Alert, and Reactions): 83 (51 unique) 
Kahn and 
Joseph 
2004362 
No details of the relevant references were 
reported on various adverse effects of 
Carbamexepine. 
Total points* and search time 
Micromedex: 11, 36 minutes 
Lexi-Comp: 11, 57 minutes 
 
*graded for completeness and accuracy 
out of 21 
1. Generalisability: The generalisabilty of 
this study is likely to be low as the analysis 
was limited to one named drug. 
2. Database overlap: Neither the number of 
total nor unique relevant references were 
reported. 
3. Limitations of the search strategies: No 
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limitations of the search strategies were 
considered. 
4. Comparative outcomes: The time spent 
answering the queries using each resource 
gives an indication of their comparative 
usefulness along with the graded score for 
the query. The authors also gave a narrative 
comparison of the databases. 
Lapidus and 
Bond 
2008363 
Scores presented for adverse reactions to garlic.  Score (0 = no information, 
3=extensive information) 
Micromedex 3 
The Review of Natural Products 3 
Natural Medicines 3 
Natural Standard 3 
1. Generalisability: The generalisabilty of 
this study is likely to be low as the analysis 
was limited to one named herbal 
intervention. 
2. Database overlap: Neither the number of 
total nor unique relevant references were 
reported. 
3. Limitations of the search strategies: No 
limitations of the search strategies were 
considered. 
4. Comparative outcomes: Scores were 
based on the completeness of answers to 
questions (no information, minimal, partial, 
extensive).  
Madden et 
al 1977364 
40-171 relevant references on any adverse 
effects of 3 drugs 
Case Study 1:  
13-49 relevant references on Beclomethasone 
dipropionate 
Case Study 2:  
39-72 relevant references on                                                             
Bleomycin                                                                 
Relevant references   
Case Study 1: Beclomethasone 
dipropionate 
Excerpta Medica Drugdoc  (EMBASE) 
14  
Medlars (MEDLINE): 13 
TOXLINE: 8
ADIS: 6 
1. Generalisability: Between 57 and 171 
relevant references were included for 3 drugs 
and unspecified adverse effects. 
2. Database overlap: The total number of 
relevant references primarily discussing 
adverse drug reactions was given. Unique 
references were only presented for selected 
databases in combination with only one other 
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Case Study 3:  
40-50 relevant references on Tolbutamide 
 
De Haen$: 4 
IDIS: 4 
Case Study 2: Bleomycin                                                                 
Excerpta Medica Drugdoc  (EMBASE) : 
28 
Medlars (MEDLINE) : 16 
TOXLINE: 12 
ADIS: 6 
De Haen$: 5 
IDIS: 5 
Case Study 3: Tolbutamide 
Excerpta Medica Drugdoc (EMBASE) : 
15 
ADIS: 14 
Medlars (MEDLINE) : 9 
TOXLINE: 8 
De Haen$: 3 
IDIS: 1 
All Case Studies: 3 drugs 
Excerpta Medica Drugdoc  (EMBASE) : 
57 
Medlars (MEDLINE) : 38 
TOXLINE: 28 
ADIS: 26 
De Haen$: 12 
IDIS: 10 
database at a time. For example, common 
and unique records were presented for, 
Excerpta Medica Drugdoc and Medlars, 
Excerpta Medica Drugdoc and Toxline, 
Medlars and Toxline, DeHaen and IOWA, 
Medlars and ADIS, and lastly IOWA and 
ADIS. 
3. Limitations of the search strategies: No 
limitations of the search strategies were 
stated, however, the authors used a simple 
approach in which they searched for the drug 
terms only and then classified each 
reference (one classification being adverse 
drug reactions).  
4. Comparative outcomes: The precision 
and cost of searching was not recorded, 
however the authors did discuss searching 
functionality and content differences between 
the databases.  
 
Roush et al 
1991365 
50-56 case reports were identified for Pancreatitis 
with Enalapril. 
Cases reported 
Manufacturer: 50 
MEDLINE: 3 (5 references) 
Food and Drug Administration (FDA) : 3  
1. Generalisability: The searches were 
conducted for one named drug with a 
specific adverse effect and between 50 and 
56 case reports were identified. 
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2. Database overlap: It was unclear to the 
authors whether the reported cases were the 
same. 
3. Limitations of the search strategies: 
The search strategy was limited to MeSH 
terms only for the named drug and adverse 
effect. No consideration of the limitations of 
this approach were presented and case 
reports may have been missed on MEDLINE.  
4. Comparative outcomes: The precision 
and cost of the searches was not recorded. 
Comparisons are difficult to conduct with 
such a specific and small sample, however, 
the number of case reports identified from 
the manufacturer is striking and requires 
further investigation. 
Sodha et al 
1994366 
111 unique publications (to one database) on any 
adverse effects of Carbamazepine. Total 
numbers of the relevant references are not 
presented.  
 
Unique publications 
Ciba-Geigy internal database, CG-DOC: 
82 
RingDoc (now Derwent Drug File) : 19 
EMBASE: 7 
MEDLINE: 3 
1. Generalisability: The total number of 
relevant references was not reported and 
references were limited to adverse reactions 
to a named drug.  
2. Database overlap: Only the numbers of 
unique references were presented. 
3. Limitations of the search strategies: 
The limitations of the search strategies were 
not presented. However the discussion 
suggests available records not retrieved by 
the searches were recorded. 
4. Comparative outcomes: The total 
number of relevant records, the precision, 
cost and search functionality would have 
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been useful measures for comparison. 
Details of how the content of the CG-DOC 
database is compiled would also have been 
useful. 
Stone et al 
1998367 
8-24 relevant references on any adverse effects 
of 2 natural products  
Case Study 1:  
8-18 relevant references on aromatherapy  
Case Study 2:  
2-6 relevant references on colloidal silver 
 
Relevant references  
Case Study 1: Aromatherapy 
MEDLINE: 8 
CINAHL: 4 
Alta Vista: 3 
EMBASE: 3 
CCIS: 0 
Health Reference Center: 0 
IPA: 0 
Uncover: 0 
Case Study 2: Colloidal silver 
MEDLINE: 2  
Alta Vista: 1 
EMBASE: 1 
IPA: 1 
Uncover: 1 
CINAHL: 0 
CCIS: 0 
Health Reference Center: 0 
Both Case Studies: 2 natural 
products 
MEDLINE: 10 
CINAHL: 4 
Alta Vista: 4 
EMBASE: 4 
IPA: 1 
1. Generalisability: The number of relevant 
references for each case study was small 
and each case study was limited to one 
named intervention. 
2. Database overlap: The total number of 
relevant records was recorded for each 
source for each case study.  The percentage 
of unique references was given for each 
source for all 10 case studies (2 of which 
were on adverse effects). 
3. Limitations of the search strategies: 
Details of the search strategies used were 
not presented, however, the difficulties of 
searching for the topics were highlighted. 
4. Comparative outcomes: The sensitivity, 
precision, cost and search functionality would 
have been useful measures for comparison.  
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Uncover: 1 
CCIS: 0 
Health Reference Center: 0 
Thompson 
Scientific 
2004368 
32 relevant references on any adverse effects 
(including possible fatal toxicity, nausea, 
abdominal pain, fever, hypertension) with 
Velcade (bortezomib) 
Relevant references, references with 
abstract 
Derwent Drug File (previously RingDoc) 
16      16 (44% unique) 
EMBASE: 14, 5 
MEDLINE: 6, 2 
 
Number of adverse effects identified 
Derwent Drug File: 39 
MEDLINE and EMBASE: 10 (no unique) 
 
1. Generalisability: The number of relevant 
references was relatively small (32 records) 
and was limited to one drug. However, a 
range of adverse effects were included 
2. Database overlap: The author states the 
unique records for one of the three 
databases only (Derwent Drug File). 
3. Limitations of the search strategies: No 
details of the search strategies or their 
limitations were presented.  
4. Comparative outcomes: No record of 
sensitivity, precision, or cost of the searches 
were presented. The study was carried out 
by the producers of Derwent Drug File, 
resulting in a conflict of interest from the 
authors.  
Tourville and 
McLeod 
1975369 
Case Study 1:  
11-32 relevant references on any adverse effects 
with amoxcillin and ampicillin 
Case Study 2:  
62-200 relevant references on Hepatitis with 
Halothane                                                    Case 
Study 3:  
22-80 relevant references on Aplastic anemia 
with Chloramphenicol 
Case Study 4:  
14-47 relevant references on  
Relevant references and search time 
(minutes) 
Case Study 1: Amoxcillin and 
ampicillin 
DeHaen Drugs in Research$: 11, 4mins 
DeHaen Drugs in Use: Card Search$: 7, 
8mins 
IPA: 6, 15 mins 
IDIS: 5, 20 mins 
DeHaen Drugs in Use: Index Search$: 
3, 7mins 
1. Generalisability: The total number of 
relevant references was 129 - 418 and 
included 7 drugs and a mixture of adverse 
effects were included 
2. Database overlap: No account of unique 
references was made. 
3. Limitations of the search strategies: 
The search strategies were not presented or 
discussed. 
4. Comparative outcomes: No record of 
sensitivity, or precision were presented. The 
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Blood dyscrasias with Phenytoin  
Case Study 5:  
4-16 relevant references on Interstitial nephritis 
with  
Methicillin  
Case Study 6:  
19-43 relevant references on  Nephrotoxicity with 
Amphotericin 
Case Studies 2-6: 
386 relevant references on                                   
5 drugs 
Case Study 2: Halothane-induced 
hepatitis 
DeHaen Drugs in Use: Card Search$  
62  31mins 
IPA: 48     11 mins 
DeHaen Drugs in Use: Index Search$: 
46    11 mins 
IDIS: 44, 28 mins 
Case Study 3: Chloramphenicol-
induced aplastic anemia 
IDIS: 22, 27 mins 
DeHaen Drugs in Use: Card Search$: 
21, 26mins 
IPA: 21, 11mins 
DeHaen Drugs in Use: Index Search$: 
16, 8 mins 
Case Study 4: Phenytoin and blood 
dyscrasias 
IPA: 14, 10mins 
IDIS: 13, 30mins 
DeHaen Drugs in Use: Card Search$: 
12, 26mins 
DeHaen Drugs in Use: Index Search$: 
8, 5 mins 
Case Study 5: Methicillin and 
interstitial nephritis 
DeHaen Drugs in Use: Card Search$  4, 
15mins 
IPA: 3, 8mins 
IDIS: 6, 8mins 
study considered the time taken to search 
the different data sources and discussed the 
cost of each source.  
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DeHaen Drugs in Use: Index Search$: 
3, 12 mins 
Case Study 6: Amphotericin-induced 
nephrotoxicity 
DeHaen Drugs in Use: Card Search$: 
19, 24 mins 
DeHaen Drugs in Use: Index Search$: 
12, 5 mins 
IPA: 7, 9 mins 
IDIS: 5, 13 mins 
Case Studies 2-6: 5 drugs 
DeHaen Drugs in Use: Card Search$: 
122, 122 mins 
IPA: 93, 99 mins 
IDIS: 90, 106 mins 
DeHaen Drugs in Use: Index Search$: 
85, 41 mins 
Van Putte 
1991370 
97-283 relevant references on any adverse 
effects on 2 named drugs 
Case Study 1:  
56-82 relevant references on Doxycycline  
Case Study 2:  
97-201 relevant references on Corticosteroids 
 
 
Relevant References and Precision 
Case Study 1: Doxycycline 
RingDoc (now Derwent Drug File)  56 
(36 unique), 51% (56/109) 
EMBASE: 42 (15 unique), 41% (42/103) 
MEDLINE: 21 (2 unique), 55% (21/38) 
BIOSIS: 13 (0 unique), 62% (13/21) 
Case Study 2: Corticosteriods 
RingDoc (now Derwent Drug File)  97 
(75 unique), 82% (97/119) 
MEDLINE: 64 (34 unique), 48% 
(64/134) 
EMBASE: 44 (26 unique), 51% (44/86) 
1. Generalisability: The case studies 
included between 56 and 82 relevant 
references, and 97 and 201 relevant 
references. Each case study was either 
limited to a named drug or class of drugs, 
however, a range of adverse effects were 
included 
2. Database overlap: The total number of 
relevant references and unique relevant 
references were presented. 
3. Limitations of the search strategies: 
The number of records retrieved by the 
search strategies were reported but not 
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BIOSIS: 44 (32 unique), 47% (44/93) 
Both Case Studies : 2 types of drugs 
RingDoc (now Derwent Drug File): 153 
EMBASE: 86 
MEDLINE: 85 
BIOSIS:  57 
those available in each database. Details of 
the searches were not presented. 
4. Comparative outcomes: The number of 
non-relevant references were presented, 
enabling the calculation of precision. No 
record of cost or search functionality were 
presented.  
 
Verheijen-
Voogd 
1974371 
Case Study 1:  
18 relevant references on Endocarditis lenta with 
tooth extraction 
Case Study 2:  
48-54 relevant references on the effects on the 
heart with Succinlycholine 
Relevant references and precision 
Case Study 1: Tooth extraction 
MEDLINE: 16 (15 unique), 89% (16/18) 
EMBASE: 3 (2 unique), 100% (3/3) 
Case Study 2: Succinylcholine 
EMBASE: 36 (33-36 unique), 67% 
(36/54) 
MEDLINE: 18 (15-18 unique), 67% 
(18/27) 
 
Relevant references not retrieved  
(because of errors in indexing or 
search formulation) 
Case Study 1: Tooth extraction 
MEDLINE: 2  
EMBASE: 8   
1. Generalisability: The number of 
references was not reported. The sources 
were evaluated as to whether they answered 
queries on side effects 
2. Database overlap: Partially. the total 
number of relevant references was 
presented for both case studies, however, 
unique relevant references were only 
presented for one of the case studies. 
3. Limitations of the search strategies: 
Although some discussion of the difficulties 
of searching were presented, full details of 
the search strategies were not presented. 
The number of relevant references not 
retrieved as a result of errors in indexing or 
search formulation were calculated for one 
case study.  
4. Comparative outcomes: No record of 
cost was presented, but precision of the 
searches and some discussion of search 
functionality were presented. 
Walker Any adverse effects with unspecified Herbal Number of questions answered (out 1. Generalisability: The number of 
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Table 15.4 Characteristics of included studies for Chapter 5  
Reference Sample size, type of adverse effect and 
intervention 
Outome Measures and Results Methodological Assessment 
2002372 Products. No details of the relevant references 
were reported. 
of 8) 
AltMedDex: 7 
Natural Medicines Comprehensive 
Database: 6 
The Natural Pharmacist: 5 
Lawrence Review of Natural Products: 2 
The Complete German Commission E 
Monograph: 2 
Physicians Desk Reference for Herbal 
Medicines: 0 
Tyler’s Honest Herbal: 0 
references was not reported. The sources 
were evaluated as to whether they answered 
8 queries on side effects, details of the 
queries were not presented. 
2. Database overlap: The overlap between 
the sources was not reported 
3. Limitations of the search strategies: 
The search strategies were not presented or 
discussed. 
4. Comparative outcomes: No record of 
precision or cost were presented.  
 
Key 
* - searched together, $ - database now closed 
 
Abbreviations 
CCIS - Micromedex Computerized Clinical Information Service 
CPI - Conference Papers Index 
FDA - Food and Drug Administration 
IPA - International Pharmaceutical Abstracts  
IDIS - Iowa Drug Information Service (IDIS) 
JICST-EPlus - Japan Science and Technology Corporation, Information Center for Science and Technology 
NTIS - National Technical Information Service  
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Table 15.5 Excluded studies in Chapter 5 
Study  Reason for exclusion 
Abuelsoud 
and Alnaim 
2005373 
Compares DrugDex and Altavista for answering 100 drug 
information queries, including unknown number on adverse drug 
reactions. Does not separate the results for the questions on 
adverse drug reactions. 
Akaho and 
Miyake 
1983374 
Compares Iowa Drug Information Service (IDIS) and EMBASE for 
answering one query on the efficacy of a drug and Chemical 
Abstracts (manual and online) for 2 queries on chemical 
substances. Does not include any questions on adverse effects. 
Alnaim and  
Abuelsoud 
2007375 
Compares DrugDex, Lexi-Drugs and AltaVista for 100 drug 
information queries, including unknown number on adverse drug 
reactions.  Does not separate the results for the queries on adverse 
drug reactions. 
Alper et al 
2001376 
Compares STAT!Ref, MDConsult, DynaMed, MAXX, 
MDChoice.com, American Family Physician, SUMSearch, Medical 
Matrix, Primary Care Clinical Practice Guidelines, Medscape, 
Webdoctor, Virtual Hospital, CliniWeb, and Turning Research into 
Practice (TRIP) in answering 20 queries, including 2 on adverse 
drug reactions. Does not separate the results for the queries on 
adverse drug reactions. 
Anderson et 
al 2000 377 
Compares TRACE, BIOSIS, CAB, CAS, EMBASE, Life Sci, 
MEDLINE, and TOXLINE for answering 10 queries on 
toxicity/ecotoxicity of chemicals. Does not include any queries on 
adverse effects. 
Barillot et al 
1997378 
Compares EMBASE, MEDLINE, TOXLINE, BIOSIS, Chemical 
Abstracts (CAS), PHARMLINE International Pharmaceutical 
Abstracts (IPA), PASCAL, and BIBLIOGRAPHIF for 20 specific 
drug interactions. Does not include any adverse effects. 
Bawden et al 
1982 379 
Compares Chemical Abstracts (printed), Excerta Medica (printed), 
TOXLINE, Ringdoc, books and reference citations for answering 8 
queries on chemical toxicology. Explicitly excludes adverse 
reactions and side-effects of drugs. 
Bell et al 
1976380 
Compares seven reference publications (Evaluation of drug 
interactions, Drug interactions, Stockley's drug interactions, 
Cohen's drug interactions: Grant's drug interaction index: 
Hartshorn's handbook of drug interactions S. Garb's undesirable 
drug interactions) for answering information on 20 potential drug 
interactions. Does not include any adverse effects. 
Bergk et al 
2005381 
Compares German summary of product characteristics (SPC) with 
DRUGDEX, Hansten/Horn's Drug Interactions Analysis and 
Management, and Stockley's Drug Interactions for information on 
drug interactions. Does not include any adverse effects. 
Brown 
1998382 
Descriptive study of MEDLINE and EMBASE for pharmaceutical 
information. No formal evaluation. 
Butros and 
McGuinness
2004383 
Descriptive study of textbook drug information sources on adverse 
effects, toxicology, poisoning. No formal evaluation. 
Choi et al 
1999384 
Compares The Corner Drug Store, Home Medical Advisor, Mayo 
Clinic Family Pharmacist, Medical Drug Reference, Mosby's 
Medical Encyclopedia, and PharmAssist for consumer drug 
prescription information for 20 drugs.  Includes separate analysis for 
side effects but limited to consumer information sources only. 
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Table 15.5 Excluded studies in Chapter 5 
Study  Reason for exclusion 
Cluxton et al 
1979385 
Compares deHAEN Drugs in Use system, the Iowa Drug 
Information Service (IDIS), Index Medicus, MEDLINE and 
International Pharmaceutical Abstracts (IPA) for obtaining 
bioavailability data to on 5 drugs. Does not include any adverse 
effects. 
Cohen 
2001671 
Compares doses in the Physicians’ Desk Reference and articles 
from MEDLINE. 
Cohen 
200166 
Compares initial doses recommended by the Joint National 
Committee and the Physicians’ Desk Reference. 
Costigan and 
Wood 
1986386 
Compares a printed index, a text searching computer system, and a 
computerised chemical databank system for searching NIOSH 
Registry of Toxic Effects of Chemical Substances (RTECS) to 
answer 7 queries on the toxic effect of chemical substances. Does 
not include any adverse effects. 
Day 1993387 Descriptive comparison of AHFS Drug Information, Drug 
Evaluations Annual, Drug Facts and Comparisons, Martindale, 
Physicians’ Desk Reference and USP Drug Information. No formal 
evaluation. 
Duffull and 
Begg 1992388 
Compares Drugdex, Drugs and Pharmacology, MEDLINE and IDIS, 
Inpharma, Reactions and an in-house database to answer 60 drug-
related queries, including 32 on adverse drug reactions. Does not 
separate the results for the questions on adverse drug reactions. 
Galt et al 
2005389 
Compares Eprocrates Rx-Pro, Lexi-Drugs, and Micromedex using 
47 drug information queries, including 10 queries on adverse drug 
reactions. Does not separate the results for the questions on 
adverse drug reactions. 
Gehanno et 
al 1998390 
Compares BIOSIS, EMBASE, MEDLINE, NIOSH-TIC, and 
TOXLINE for 2 toxicology queries. Does not include any adverse 
effects. 
Frost Widnes 
and Schjott 
2008672 
Compares advice from the product monographs in the Felleskatalog 
(FK), published by the pharmaceutical companies, and the five 
regional Drug Information Centres (DICs) in Norway. 
Haramburu 
et al 1989391 
Conference abstract. Not enough detail. 
  
Ioannidis et 
al 2002392 
Examines the feasibility of obtaining information on adverse effects 
from the authors of RCTs. No comparative evaluation. 
 
John 1985393 Compares MEDLARS, EMBASE, ISI BIOMED, BIOSIS, CancerLit, 
PsycINFO, Psyndex, ISI ISTPB (Index to Scientific and Technical 
Proceeding and books) for medical information by authors from 
Frankfurt University, categorised by medical faculty. No category for 
adverse effects was included. 
Joy et al 
1986394 
Descriptive analysis of 1448 requests from health-care 
professionals and consumers in a university hospital drug 
information service. Presentation of the 10 most frequently used 
sources for drug information but no formal comparative evaluation. 
Kupferberg 
et al 2004395 
Compares AHFS Drug Information, Drugdex, eFacts (Drug Facts 
and Comparison), Lexi-Drugs Online (Lexi-Comp) and PDR 
Electronic Library) for 10 drug information queries, including 2 on 
adverse drug reactions. Does not separate the results for the 
queries on adverse drug reactions. 
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Study  Reason for exclusion 
Majekodunmi 
et al 2006 396 
Conference abstract. Not enough detail. 
 
Medawar et 
al 2002397 
Discusses the potential value of web site discussion lists, but 
includes no formal comparative evaluation. 
Medawar 
and 
Herxheimer 
2003398 
Compares yellow card reports with patient reports but includes no 
formal comparative evaluation. 
Milne 1978399 Compares MEDLINE and IDIS for 60 queries, including unknown 
number of queries on adverse drug reactions. Does not separate 
the results for the queries on adverse drug reactions. 
Robinson et 
al 2000400 
Compares TOXLINE, BIOSIS, EMBASE, MEDLINE, CAS, LifeSci, 
and TRACE in answering 10 toxicology queries. Does not include 
any adverse effects. 
Rosenberg et 
al 1983401 
Comparative content evaluation of the De Haen and Drugdex 
information systems. No analysis of information on adverse effects 
but does include drug interaction content scores. 
Rovers et al 
1993402 
Compares EMBASE, MEDLINE, TOXLINE and TOXLIT for 26 drug 
information queries, including unknown number on adverse drug 
reactions. Does not separate the results for the queries on adverse 
drug reactions. 
Snow 
1982403 
Compares Information Retrieval Limited, BIOSIS, SciSearch, 
MEDLINE, Excerpta, CA Search, and IPA in answering 9 
toxicology, drug-interaction and other general pharmacy queries. 
Does not include any queries specifically on adverse drug 
reactions. 
Tatsioni et al 
2003404 
Uses 20 safety warnings from the US FDA web site and assesses 
whether they are available on the Internet by searching seven 
search engines (Google, Lycos, Excite, Yahoo, HotBot, Infoseek, 
and Copernic). No comparative evaluation of search engines. 
Vidal et al 
2005405 
Compares the BNF, Martindale, AHFS and Drug Prescribing in 
renal failure for drug information, particularly dose adjustment. Does 
not include any queries on adverse drug reactions. 
Wilkinson 
and 
Hollander 
1973406 
Compares Index Medicus and Drug Literature Index for toxicity 
studies for 8 drugs. Does not include adverse drug reactions. 
Wright 
2001407 
Descriptive account of numerous factual and bibliographic 
databases supplied by 11 producers for toxicology information. 
Does not include adverse drug reactions. 
Wukovitz 
2001408 
Descriptive account of Internet search engines and library catalogs 
for toxicology information. Does not include adverse drug reactions. 
 
Yokel et al 
1978409 
Compares Poisindex, ToxiFile, Clinical Toxicology of Commercial 
Products, and the National Clearinghouse for Poison Control 
Centers' cards for toxicity and poisoning information. Does not 
include adverse drug reactions. 
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Table 15.6 Characteristics of included studies in Chapter 6 
Reference Study Design Reference set of relevant records 
and validation set of relevant 
records 
Search strategy Sensitivity Precision 
Badgett et 
al 1999
427, 
428
 
Any serious adverse drug 
reactions of 9 
antidepressant agents in 
MEDLINE (Interface 
unclear) 
Reference set of 323 records (32 
controlled studies, 19 publications of 
postmarketing databases and 272 
case reports) from 3298 records 
identified from MEDLINE (254), 
EMBASE (99), and PsycLit. Search 
strategies then tested on 9076 
records and identified 644 records 
(576 case reports/series, 15 
uncontrolled cohorts, 45 controlled 
studies, 27 publications of 
postmarketing databases) from 9076 
MEDLINE (545), EMBASE (493), and 
PsycLit (22). Validation set of 132 
records on adverse effects of 
antihypertensive agents on foetuses 
from 1240 records from MEDLINE 
and toxicology textbooks. 
Reference Set 
(ae or co or po).fs  
 
 
(ae or co or po).fs or CASE REPORT/ and HUMAN/  
 
 
Validation Set 
(ae or co or po).fs or CASE REPORT/ and HUMAN/ 
 
(ae or co or po or de).fs  or CASE REPORT/ and 
HUMAN/ 
 
95% 
(520/545) 
(95% CI 
93% to 97%) 
 
99% 
(539/545) 
(95% CI 
98% to 
100%) 
 
86% 
(113/132) 
(95% CI 
78% to 91%) 
 
95% 
(125/132) 
(95% CI 
89% to 98%) 
Because of 
the study 
design 
precision 
could not be 
determined   
Golder et al 
2006
360
 
 
Any adverse effects of 7 
antiepileptic drugs 
(gabapentin, lamotrigine, 
levetiracetam, 
oxcarbazepine, tiagabine, 
topiramate and vigabatrin) 
in EMBASE and 
MEDLINE using OVID 
Biomed 
84 studies (uncontrolled trials, cohort 
studies, case-control studies) from 
8095 records from systematic review 
which searched MEDLINE, EMBASE, 
TOXLINE, industry submissions, 
carried out reference checking, 
contacted experts, and results of 
effectiveness searches. 
No validation set of records. 
MEDLINE 
(ae or co or de).fs or (safe or safety or side effect* or 
undesirable effect* or treatment emergent or 
tolerability or toxicity or adrs or (adverse adj2 (effect or 
effects or reaction or reactions or event or events or 
outcome or outcomes)).ti,ab 
 
‘Named adverse effects’$ or (ae or co or de).fs or 
(safe or safety or side effect* or undesirable effect* or 
treatment emergent or tolerability or toxicity or adrs or 
(adverse adj2 (effect or effects or reaction or reactions 
or event or events or outcome or outcomes)).ti,ab 
96% (64/67) 
(95% CI 
87% to 99%) 
 
97% (65/67) 
(95% CI 
90% to 
100%) 
 
97% (71/73) 
(95% CI 
90% to 
2.8% 
(64/2325) 
(95% CI 2.1% 
to 3.5%) 
 
2.8% 
(65/2329) 
(95% CI 2.1% 
to 3.5%) 
 
2.3% 
(71/3127) 
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Reference Study Design Reference set of relevant records 
and validation set of relevant 
records 
Search strategy Sensitivity Precision 
 
EMBASE 
DRUG/ae,to or (safe or safety or side effect* or 
undesirable effect* or treatment emergent or 
tolerability or toxicity or adrs or (adverse adj2 (effect or 
effects or reaction or reactions or event or events or 
outcome or outcomes)).ti,ab 
 
‘Named adverse effects’$ or (safe or safety or side 
effect* or undesirable effect* or treatment emergent or 
tolerability or toxicity or adrs or (adverse adj2 (effect or 
effects or reaction or reactions or event or events or 
outcome or outcomes)).ti,ab 
 
100%) 
 
99% (72/73) 
(95% CI 
93% to 
100%) 
 
(95% CI 1.8% 
to 2.9%) 
 
2.8% 
(72/2557) 
(95% CI 2.2 % 
to 3.5%) 
 
Wieland et 
al 2005
121, 
430
 
Breast cancer as an 
adverse effect of Oral 
contraceptives in PubMed 
58 reports (48 case-control studies, 7 
cohort studies, 1 RCT) from unclear 
sample size obtained from a 
systematic review which searched 
databases, checked references and 
contacted experts. No validation set of 
records. 
A1. Exploding MeSH term search 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND breast neoplasms [mh] AND 
(contraceptives, oral [mh]) AND (risk [mh] OR follow-
up studies [mh] OR case-control studies [mh])  
 
A2. MeSH term search with major topics and 
subheadings 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND “breast neoplasms” [majr:noexp] AND 
(contraceptives, oral [mh:noexp] OR contraceptives, 
oral/pharmacology [mh] OR contraceptives, 
oral/therapeutic use [mh] OR estrogens/therapeutic 
use [mh] OR contraceptives, oral/adverse effects 
[mh]) AND (risk [mh:noexp] OR risk factors 
[mh:noexp] OR follow-up studies [mh:noexp] OR odds 
ratio [mh:noexp])  
 
83% (48/58) 
(95% CI 
71% to 91%) 
 
83% (48/58) 
(95% CI 
71% to 91%) 
 
83% (48/58) 
(95% CI 
71% to 91%) 
 
100% 
(58/58)  
(95% CI 
94% to 
100%) 
 
6% (48/797) 
(95% CI 4.5% 
to 7.9%) 
 
11% (48/424) 
(95% CI 8.5% 
to 14.7%) 
 
2% (48/2525) 
(95% CI 1.4% 
to 2.5%) 
 
0.9% 
(58/6120) 
(95% CI 0.7% 
to 1.2%) 
 
2% (49/2754) 
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Reference Study Design Reference set of relevant records 
and validation set of relevant 
records 
Search strategy Sensitivity Precision 
A3. MeSH term search without study methodology 
terms 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND breast neoplasms [majr:noexp] AND 
(contraceptives, oral [mh:noexp] OR 
contraceptives,oral/pharmacology [mh] OR 
contraceptives, oral/therapeutic use [mh] OR 
estrogens/therapeutic use [mh] OR contraceptives, 
oral/adverse effects [mh])  
 
A4. MeSH term search without intervention terms 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND breast neoplasms [majr:noexp] AND 
(risk [mh:noexp] OR risk factors [mh:noexp] OR 
follow-up studies [mh:noexp] OR odds ratio 
[mh:noexp])  
 
A5. Text word search with automatic term mapping 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND breast cancer AND (oral contraceptive 
OR oral contraceptives OR estrogen OR estrogens 
OR hormones OR hormonal) AND (risk OR follow-up 
OR epidemiologic)  
 
A6. Text word search with truncation and double 
quotes 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND “breast cancer” AND (oral 
contraceptiv* OR “estrogen” OR “hormones” OR 
“hormonal”) AND (“risk” OR epidemiologic)  
 
A7. Text word search without study methodology text 
84% (49/58) 
(95% CI 
73% to 93%) 
 
84% (49/58) 
(95% CI 
73% to 93%) 
 
84% (49/58) 
(95% CI 
73% to 93%) 
 
100 % 
(58/58) 
(95% CI 
94% to 
100%) 
 
(95% CI 1.3% 
to 2.3%) 
 
3% (49/1456) 
(95% CI 2.5% 
to 4.4%) 
 
0.7% 
(49/7268) 
(95% CI 0.5% 
to 0.9%) 
 
0.8% 
(58/7240) 
(95% CI 0.6% 
to 1.0%) 
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Reference Study Design Reference set of relevant records 
and validation set of relevant 
records 
Search strategy Sensitivity Precision 
words 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND “breast cancer” AND (oral 
contraceptiv* OR “estrogen” OR “hormones” OR 
“hormonal”)  
 
A8. Text word search without intervention text words 
1966:1995 [dp] AND “human” [MESH] AND journal 
article [pt] AND “breast cancer” AND (“risk” OR 
epidemiolog*) 
 
 
KEY  
MEDLINE abbreviations; ae = adverse effects, co = complications, po = poisoning, de = drug effects 
EMBASE abbreviations; ae = adverse effects, de = drug effects, to = drug toxicity 
OVID syntax; .fs refers to floating subheadings, / indicates subject heading, * indicates truncation, Adj2 indicates proximity searching within 2 words, .ti,ab 
limits to title or abstract, $ indexing terms for named adverse effects were used (e.g. LIVER DISEASES/ci). In small number of instances were no 
appropriate indexing term was available, textwords were searched in title and abstract. 
Pubmed syntax; [dp] limits to date of publication field, “” overrides any automatic mapping and searches for term as textword, [pt] limits to publication type 
field, [mh] limits to MeSH, [MESH] limits to MeSH, [majr] indicates a major MeSH, assigned to records where the term relates to one of the main topics 
discussed in the article, [mh:moexp] limits to MeSH with no automatic explosion, so does not include more specific MeSH terms further down the hierarchy, 
[majr:noexp] limits to major MeSH with no automatic explosion. 
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Table 15.7 Excluded studies in Chapter 6 
Study Reason for exclusion 
Adept 2004431 MEDLINE search for adverse effects. No evaluation. 
BMJ Clinical 
Evidence 2006432 
MEDLINE and EMBASE search filters for adverse effects. No 
evaluation. 
Brass 1987433 No search terms reported. No evaluation.  
Buckingham et al 
2005434 
Guidance on searching for adverse effects in PubMed. No 
evaluation. 
Centre for Reviews 
and Dissemination 
2001435 
Guidance on searching for adverse effects in MEDLINE and 
EMBASE. No evaluation. 
Cleyndert 2006436 Guidance on searching EMBASE for adverse effects. No 
evaluation. 
Deng 2008447 Non-english. No translation available. 
Haynes et al 
2005440 
 
This study aimed to develop search filters for detecting clinically 
sound and relevant causation studies in EMBASE. Causation 
studies were studies that looked at genes, treatments and 
environmental exposure. 
Garcia and 
Guzman 2008673 
Evaluates the contribution of the MeSH Term "Drug Toxicity" for 
searching for drug-related adverse events in PubMed/MEDLINE. 
Abstract only. 
Golder et al 
2006448 
Evaluates search strategies for retrieving systematic reviews of 
adverse effects in CDSR and DARE. Does not include any 
searches for primary studies. 
Institute of 
Medicine 1991437 
Presents search strategies for adverse effects after pertussis and 
rubella vaccination. No evaluation. 
Rikken and Vos 
1994443 
Co-word-analysis. No filter proposed. 
Rikken and Vos 
1995444 
Co-word-analysis. No filter proposed. 
Schellevis and Van 
Der Horst 2006445 
Non-english. No translation available. 
Thompson Dialog 
2004438 
Guidance on searching MEDLINE and EMBASE for adverse 
effects on DIALOG. No evaluation. 
Van Den Bruel 
2005446 
Non-english. No translation available. 
Walker-Diks et al 
2008441 
This study aimed to develop search filters for detecting clinically 
sound and relevant causation studies in CINAHL. Causation 
studies were studies that looked at genes, treatments and 
environmental exposure. 
Wilczynski et al 
2003442  
 
This study aimed to develop search filters for detecting clinically 
sound and relevant causation studies in MEDLINE. Causation 
studies were studies that looked at genes, treatments and 
environmental exposure. 
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Table 15.8 Methodological quality of included studies in Chapter 6 
 Badgett 1999 Golder 2006 Wieland 2005 
Were the search 
strategies used 
adequately 
described to 
allow 
reproducibility?   
The combinations of 
search terms tested 
is unclear but the 
recommended 
search strategy is 
stated. However, the 
interface used is not 
stated and can only 
be inferred from the 
syntax of the search 
strategies. 
5 approaches to 
searching are 
stated. However, 
all the 
combinations 
tested are not 
presented. The 
recommended 
search strategies 
are stated for 
MEDLINE and 
EMBASE. 
8 search 
approaches are 
clearly stated. 
 
Were the search 
terms 
objectively 
derived? 
It is unclear how the 
search terms for 
testing were 
derived. 
 
No, 5 approaches 
to searching 
identified from 
previous guidance 
and systematic 
reviews were 
used. 
 
No, search 
terms for 
testing were 
identified by 
visually 
examining the 
title, abstract 
and MeSH of 
each relevant 
record. 
Was an 
adequate 
reference set 
obtained? 
The references were 
obtained from 
MEDLINE, 
EMBASE, PsycLit. 
The search 
strategies for each 
database are not 
presented in detail. 
However, the 
authors searched for 
nine antidepressant 
agents (MeSH and 
text words) and 
terms for specific 
known adverse 
effects or the 
following textwords, 
malignan$, rare, 
surviv$, risk#, 
adverse, serious, 
severe, poison$, 
pathology$ or 
toxic$. The use of 
some adverse 
effects terms in the 
search strategy is a 
limitation of the 
The reference set 
was obtained from 
a large number of 
sources with a 
fairly broad search 
strategy. The use 
of adverse effects 
terms in the 
search is a major 
limitation, 
however. 
 
The reference 
set was taken 
from a 
systematic 
review which 
identified 
studies from 
review articles, 
computer 
searches and 
discussion with 
colleagues. 
Details of the 
search 
strategies and 
databases are 
not presented. 
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 Badgett 1999 Golder 2006 Wieland 2005 
study. 
Did two or more 
researchers 
screen the 
records for 
relevant 
studies? 
No, the studies were 
screened by a single 
physician. 
 
Yes, 2 
researchers 
independently 
screened the 
records. 
 
Unclear 
 
Were clear 
inclusion criteria 
for the reference 
set given? 
No, the authors 
state that ‘reports of 
serious adverse 
drug reactions’ were 
included. Study 
designs identified for 
inclusion were 
controlled studies, 
publications of 
postmarketing 
databases, and 
case reports. 
Yes, in the full 
HTA publication. 
All adverse effects 
were considered 
from RCTs and 
observational 
studies. 
 
Yes. 
Epidemiological 
studies with 
over 100 
women with 
breast cancer 
were included 
that contained 
data on the use 
of hormone 
contraceptives 
and 
reproductive 
history. 
Were confidence 
intervals 
calculated for 
the performance 
estimates? 
The reference sets 
were fairly large at 
254 records and 545 
records. The 
authors did not 
describe the 
confidence intervals 
around the point 
estimates of 
sensitivity.  
 
The reference set 
contained 84 
relevant records. 
The authors did 
not describe the 
confidence 
intervals around 
the point 
estimates of 
sensitivity.  
 
The reference 
set contained 
58 relevant 
records. 
The authors did 
not describe 
the confidence 
intervals 
around the 
point estimates 
of sensitivity. 
Were the results 
tested on a 
validation set of 
records? 
Yes, the search was 
tested for sensitivity 
on 132 records 
(precision could not 
be calculated). An 
additional term of 
‘drug effects’ was 
added to the search 
strategy, it is unclear 
how this term was 
identified. 
No. 
 
No. 
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Table 15.9 Characteristics of included studies in Chapter 7 
Reference Design Data 
Sources 
Main Outcome 
Measures 
Quality 
Assessment 
Bennett et 
al 2003 480 
Compares 
number of 
case reports 
of 14 specific 
serious 
adverse 
reactions 
associated 
with 16 
different 
drugs. 
Published 
cases 
identified via 
MEDLINE. 
Unpublished 
cases mainly 
from FDA 
Adverse 
Events 
Reporting 
System, but 
included 
queries to 
physicians 
and 
pharmaceutic
al companies 
and patients.  
Identified 350 
published 
case studies 
and 1353 
unpublished 
case studies. 
There were a far 
greater number of 
unpublished cases 
than published 
case reports for 15 
adverse reactions, 
except for deep 
vein 
thrombosis/pulmon
ary embolism with 
thalidomide where 
published cases 
greatly 
outnumbered 
unpublished. 
 
 
Confounding: 
Not assessed, 
as this study 
looked 
principally at 
case reports. 
Misclassificati
on: Duplicate 
case reports 
were classified 
as published. 
External 
validity: Good, 
covered wide 
range of topics 
.in 2001. 
Cosmi  et 
al  2000 28 
Compares 
cases of 
thrombotic 
thrombocytop
enic purpura 
(TTP) with 
Ticlopidine 
plus aspirin in 
RCTs, 
observational 
studies and 
case 
reports/series 
 
 
Published 
case reports 
from 
MEDLINE, 
EMBASE, 
and the 
Cochrane 
Controlled 
Trials 
Register. 
Unpublished 
case reports 
from The 
WHO 
Monitoring 
Centre    
72 published case 
reports/series 
0 unpublished case 
reports 
       
 
Confounding: 
Not assessed, 
as this study 
looked 
principally at 
case reports. 
Misclassificati
on: Not clear 
how authors 
distinguished 
published from 
unpublished 
External 
validity: Limited 
to ticlopidine 
plus aspirin 
Hemminki 
1980 458  
Comparison 
of proportion 
of trials that 
gave 
information 
on adverse 
effects. 
Both 
published 
and 
unpublished 
data 
licensing 
applications 
of 
psychotropic 
drugs in 
Finland and 
% of controlled 
trials giving 
information on 
adverse effects.  
Psychotropic 
drugs  
Finland  
201 published 
trials: 56%*  
116 unpublished 
trials: 77%*  
Confounding: 
While there was 
some 
assessment of 
trial quality, 
there was no 
assessment or 
adjustment for 
potential 
differences in 
design or 
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Reference Design Data 
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Main Outcome 
Measures 
Quality 
Assessment 
Sweden and 
applications 
in Finland of 
random 
sample of 
non 
psychotropic 
drugs. 
Covered 335 
published 
trials and 301 
unpublished 
trials. 
 
Sweden  
104 published 
trials: 73% 
99 unpublished 
trials: 83%  
 
Non-psychotropic 
drugs 
Finland  
30 published trials: 
43%*  
24 
unpublished trials: 
83%*  
 
* difference 
significant at 5% 
level 
characteristics 
amongst 
published and 
unpublished 
studies. 
Misclassificati
on: Not clear 
how the author 
searched for 
published data, 
presumably 
from reference 
lists of licensing 
applications. 
Authors state 
that  “A report 
was defined as 
published if it 
had appeared in 
or been 
accepted for a 
journal or book, 
or was a report 
of a meeting.” 
External 
validity: Wide 
range of drugs 
from 191 
licensing 
applications, but 
these covered 
the 1960’s and 
70’s and may 
not reflect 
current practice. 
Hemminki 
and 
McPherson 
2000 467 
Comparison 
of 
cardiovascula
r and 
thrombolytic 
events with 
postmenopau
sal hormone 
therapy from 
meta-
analysis of 
published 
trials97, with 
analysis 
using 
unpublished 
Published 
trials from 
MEDLINE 
and 
reference 
checking. 
Unpublished 
trials from 
access to 
confidential 
drug 
licensing 
documents 
from Finnish 
Drug 
Agency. 
Cardiovascular 
events 
22 published trials  
OR 1.39 (0.48-
3.95)  
28 unpublished 
and published trials  
OR 1.78 (0.70-
4.52). 
 
Cardiovascular 
and thrombolytic 
events 
22 published trials  
OR 1.64 (0.65-
4.21)  
Confounding: 
No mention of 
confounders. 
Misclassificati
on: No 
definitions of 
published and 
unpublished 
studies were 
presented and 
the authors 
acknowledge 
that not all the 
data in the 
unpublished 
category may 
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Main Outcome 
Measures 
Quality 
Assessment 
data. There were 
22 published 
and 6 
unpublished 
trials. 
28 unpublished 
and published trials  
OR 1.97 (0.84-
4.58) 
have been 
genuinely 
unpublished. 
External 
validity: Poor, 
only a few 
studies within a 
single class. 
Loke et al 
2004 264 
Comparison 
of relative 
frequency of 
specific 
adverse 
events 
related to 
amiodarone 
therapy 
Amiodarone 
case reports, 
obtained 
from 
MEDLINE 
search as 
compared to 
spontaneous 
report 
collected by 
WHO 
Uppsala 
Monitoring 
Centre. 
Rank order of 
frequency of 
specific adverse 
effects was 
different between 
the published 
cases compared to 
unpublished. 
 
Confounding: 
Not assessed 
as this study 
looked 
principally at 
case reports. 
Misclassificati
on: As the 
unpublished 
data was 
aggregated 
(with no 
individual data 
available), there 
was no way of 
checking if any 
of the cases 
had been 
published. 
External 
validity: Limited 
to amiodarone 
only. 
MacLean et 
al 2003 468, 
475 
Meta-
analysis of 
dyspepsia 
with NSAIDs. 
Published 
trials from 
MEDLINE, 
EMBASE, 
HEALTHSTA
R, 
and BIOSIS. 
Unpublished 
trial from 
FDA New 
Drug 
Applications 
obtained 
through 
Freedom of 
Information 
request.  
15 published trials 
(N=1455) 
RR 1.21 (0.81 – 
1.81) 
 
11 unpublished 
trials (N=2368) 
RR 1.07 (0.70 – 
1.63) 
 
combined 
RR 1.14 (0.86 – 
1.53) 
 
Confounding: 
Compared by 
publication 
status; 
population (age 
and gender) 
and dosing 
characteristics 
(drug indication 
and dose level), 
methodological 
attributes 
(randomization, 
withdrawals, 
blinding) and 
sponsorship of 
included 
studies. Meta-
regression used 
to assess 
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differences by 
publication 
status and 
adjusted for 
differences 
between 
studies. 
Misclassificati
on: Handsearch 
of FDA 
documents, 
then compared 
drug, dose, 
indication and 
duration against 
published 
papers to arrive 
at correct 
classification. 
External 
validity: 
Limited to 
NSAIDs only. 
Ross et al 
1997 469 
Meta-
analysis of 
serious 
adverse 
events in 
hypertensive 
patients 
receiving 
isradipine. 
Published 
trials from 
MEDLINE, 
Current 
Contents and 
checking 
bibliographie
s. 
Unpublished 
trials from 
manufacturer
. There were 
32 published 
trials and 33 
unpublished 
trials but not 
all trials were 
included in 
meta-
analysis of 
adverse 
effects.   
Major adverse 
events 
2 published trials 
(N=414) 
OR 0.92 (0.49-
1.72) 
8 unpublished trials 
(N=1988)  
OR  1.04  (0.64-
1.71) 
combined 
OR 0.99 (0.67-
1.46) 
 
Angina 
2 published trials 
(N=414) 
OR 0.92 (0.49-
1.72)  
8 unpublished trials 
(N=1105) 
OR  0.99 (0.50-
1.97) 
combined 
OR 0.95 (0.60-
1.51) 
Confounding: 
The authors 
acknowledge 
that the 
unpublished 
trials were all 
from industry.  
Misclassificati
on: Compared 
number of 
patients 
included, 
treatment 
regimens used 
and duration of 
trial to identify 
duplicate 
studies. In 
cases where 
studies were 
published 
subsequent to 
reports, only the 
published study 
was included in 
the analysis. 
External 
validity: 
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Assessment 
Limited to 
isradipine only. 
Tramer et 
al 1997 283 
Systematic 
review of 
propofol and 
bradycardia 
Published 
studies from 
MEDLINE, 
reference 
lists, 
scientific 
abstracts. 
Unpublished 
case reports 
from 12 
national drug 
monitoring 
centres. 17 
published 
case reports 
and 187 
unpublished 
case reports. 
Bradycardia 
16 published case 
reports 
95 spontaneous 
reports 
 
Asystole 
14 published case 
reports 
65 spontaneous 
reports 
 
Death 
1 published case 
reports 
25 Spontaneous 
reports 
 
Confounding: 
Not assessed 
as this study 
looked 
principally at 
case reports 
with regard to 
publication 
status. 
Misclassificati
on: Not clear 
how authors 
identified 
duplicate case 
reports. 
External 
validity: 
Limited to 
propofol only. 
Wallace et 
al 2006 470 
Meta-
analysis of 
serious 
adverse 
events with 
SSRIs  
Published 
trials from 
MEDLINE, 
CINAHL, 
Biosis, 
Cochrane 
Library, 
reference 
checking, 
journal table 
of contents 
and experts. 
Unpublished 
UK 
Committee 
on Safety of 
Medicine 
(CSM) 
website. 7 
published 
and 4 
unpublished 
trials 
Serious adverse 
events for SSRIs 
7 published trials 
(N=1303) 
Treatment 56/657  
Placebo 28/646 
RR 2.0 (1.3 – 3.0)  
 
4 unpublished trials 
(N=842)  
Treatment 52/472 
Placebo 20/370 
 
combined :  
RR 1.97 (1.42 – 
2.75) 
Confounding: 
Although 
characteristics 
of the studies 
were described, 
there was no 
discussion of 
adjustment for 
any study 
differences 
between 
published and 
unpublished 
Misclassificati
on: Not clear 
how authors 
distinguished 
published from 
unpublished 
External 
validity: Limited 
to SSRIs only. 
Whittington 
et al 2004 
471 
Meta-
analysis of 
serious 
adverse 
events 
attributable to 
SSRIs.  
Published 
trials sought 
from 
EMBASE, 
MEDLINE, 
PsycINFO, 
CINAHL, the 
Serious adverse 
events  
1 published trial 
(N=180) 
Treatment 11/93 
Placebo  2/87 
RR 5.15 (1.17 – 
Confounding: 
Although 
characteristics 
of the studies 
were described, 
there was no 
discussion of 
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Main Outcome 
Measures 
Quality 
Assessment 
Cochrane 
Library, 
reference 
checking, 
journal table 
of contents 
and 
contacting 
experts. 
Unpublished 
data from a 
report by the 
UK 
Committee 
on Safety of 
Medicine 
(CSM). 
Comparable 
unpublished 
and 
published 
data 
identified for 
paroxetine 
only. 
22.56) 
 
1 unpublished trial 
(N=275) 
22/182    Placebo  
6/93 
RR 1.87 (0.79 – 
4.46) 
 
combined 
RR 2.55 (1.23 – 
5.30) 
 
Suicide attempt 
or ideation 
1 published trial 
(N=180) 
Treatment 5/93 
Placebo  0/87 
RR 10.30 (0.58 – 
183.53) 
 
1 unpublished trial 
(N=484) 
9/285    Placebo  
7/198 
 
combined 
RR 1.51 (0.62 – 
3.69) 
adjustment for 
any study 
differences 
between 
published and 
unpublished 
Misclassificati
on: Not clear 
how authors 
distinguished 
published from 
unpublished 
External 
validity: Limited 
to SSRIs only. 
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Study  Reason for Exclusion 
Barbui et al 
2008472 
Compares suicidal tendencies in patients who received paroxetine 
or placebo. States that there is no difference between drug and 
placebo groups in published and unpublished trials. No further 
information given. 
Bohlius et al 
2005473 
Compares the reporting of adverse effects from the same study 
when published or made available in FDA reports to that of data 
submitted to FDA. 
Hochberg et 
al 2009474 
Compares agreement in adverse event count rates from the US 
FDA Adverse Event Reporting System with published studies. 
Does not present any numerical rates or frequencies but makes 
comparisons using the following classifications; ‘favours drug A’, 
favours drug B’ and no difference detected. 
MacLean et al 
1999475 
Conference abstract containing preliminary analysis of data in 
MacLean et al 2003.468 
Nissen et al 
2007476 
Includes 27 unpublished trials out of 42. Concludes if exclude 
unpublished trials, precision would decrease. No further details 
given. 
Psaty et al 
2004197 
Describes the evidence (published and unpublished) which led to 
the removal of a drug from the market.  
Rising et al 
2008477 
Compares the presence or absence of an ‘adverse events table’ in 
the unpublished and published studies. No further details given. 
Scharf et al 
2006455 
Compares adverse effects in published reports and adverse effects 
in the National Cancer Institute (NCI) Clinical Data Update System 
(CDUS). CDUS is a primary resource for clinical trial data. 
Steinberg et 
al 1997478 
Compares the protective effect of oral contraceptives on ovarian 
cancer using a meta-analysis of observational studies and 
Individual Patient Data (IPD).674 
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Reference Design Main Outcome Measures Quality Assessment 
Als-Nielsen 
et al 2003 
496, 497 
370 trials - 146 funded by Profit 
organisations, 67 from non- profit 
organisations, 51 mixed funding and 
106 no reported funding. Trials were 
randomly selected from 25 Cochrane 
Reviews across broad range of medical 
topics and adverse effects. 
Compared number of trials reporting adverse 
effects in experimental and control arms 
according to funding.  
Complete absence of any AE data was more 
common in nonprofit (35/67, 52.3%) vs. profit 
(18/146, 12.3%). 
Higher frequency of adverse effects in 
experimental group was noted in 33/146 (23%) 
studies funded by for-profit organisations 
compared to 3/67 (4%) of non-profit funded 
studies. 
Occurrence of adverse effects was not 
associated significantly with conclusions 
(logistic regression – no statistics given). 
 
Confounding: Adverse effects data taken from 
Cochrane reviews; rigorous inclusion criteria 
used in systematic reviews suggests that trials 
would be reasonably homogenous. Logistic 
regression was used to assess confounding 
factors (such as treatment effect, adverse 
effects and other potentially confounding trial 
variables (methodological quality, sample size, 
whether preset sample size was estimated and 
reached, meta-analysis, year of publication and 
journal impact factor). The results of logistic 
regression were not given though. 
Misclassification: funding source unclear for 
106 (29%) of the included studies, results given 
separately (data excluded from this review) 
Blinding: Mainly unblinded, but authors carried 
out blinded assessment in 60 trials, with good 
intraclass coefficient between blinded and 
unblinded assessment at 0.93 (95% CI 0.89-
0.96). 
External validity: Good, covered wide range of 
topics in 2001. 
Juni et al 
2004 99 
11 observational studies (2 funded by 
Merck, 8 non-Merck funded and 1 
mixed funding) in  meta-analysis of MI 
with Naproxen  
Substantial heterogeneity found  in meta-
analysis of the cardiovascular adverse events 
with naproxen.  Meta-regression showed that 
heterogeneity was largely due to three Merck 
funded studies that showed substantial 
cardioprotective effects of naproxen(P=0.001 
and P=0.056). Any rise in cardiovascular risk 
with rofecoxib in trials against naproxen could 
then be attributed to the protective effect of 
Confounding: authors used meta-regression to 
explore effects of variables (case-control or 
cohort, and aspirin use) on estimates of 
cardiovascular risk. However, only 2 of the 
11case-control studies were solely Merck 
funded, and it is hard to draw robust 
conclusions based on regression analysis of 
only 2 studies. 
Misclassification: one study had mixed funding 
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naproxen rather than harm from rofecoxib 
(Merck's product). 
(Merck, Pharmacia, National Institute for Health 
(NIH), but was categorised as industry funded. 
Blinding: not reported 
External validity: poor - considers only one 
drug within systematic review. 
Kemmeren 
et al 2001 
498 
10 observational studies (5 non-
industry funded and 4 Industry 
sponsored) in meta-analysis of venous 
thrombosis with 2nd and 3rd generation 
oral contraceptives 
Pooled odds ratio of venous thrombosis with 3rd 
generation oral contraceptives was 1.3 (95% CI 
1.0 to 1.7) in studies (N=4) funded by 
pharmaceutical companies  while odds ratio in 
other studies (N=5) was 2.3 (95% CI 1.7 to 3.2) 
when compared to 2nd generation oral 
contraceptives. 
Confounding: compared adjusted and 
unadjusted odds ratios and presented stratified 
analysis by first time users, age, duration of use, 
confirmed cases and funding source.   
Misclassification: Not reported 
Blinding: Not reported 
External validity: Poor, only a few studies of a 
single class. 
Nieto et al 
2007 499 
504 studies  (trials and observational 
studies) of inhaled corticosteroids 
identified from MEDLINE. 275 with 
pharmaceutical funding, 142 with no 
pharmaceutical funding and 87 with no 
declared funding. 
Statistically significant differences in adverse 
effects more commonly reported by non-
pharmaceutical funded studies (73.0% of 74) as 
compared to those funded solely by drug 
manufacturer (26.5% of 226) 
Crude and multivariate association showed that 
pharmaceutical funded studies were 
less likely to report significant differences in 
adverse effects - crude prevalence ratios 0.53 
(95% CI 0.44 to 0.64) but this was non-
significant after adjustment for confounding 0.94 
(95% CI 0.77 to 1.15) 
more likely to conclude drug is safe despite 
statistically significant increase in adverse 
effects Prevalence Ratio 3.68 (95% CI 2.14 to 
6.33)  
 
Confounding: The authors conducted 
multivariate analysis which controlled for study 
design variables, including studying 
beclomethasone versus other corticosteroids, 
bronchial administration versus intranasal, 
medium or high daily dose versus low dose, 
studying children, studying healthy adults, 
studying patients with asthma, studying patients 
with rhinitis, studying corisol, studying growth, 
studying bone metabolism, studying non-
specific clinical adverse effects, studying non-
specific laboratory results, studying efficacy as 
an aim, studying safety as an aim, randomised 
study, multi-centre study, and randomized 
clinical trial. Industry studies were more likely to 
be efficacy trials, while non-industry funded 
studies were aimed at adverse 
effects.Adjustment for confounding factors 
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indicated that the observed difference in 
adverse effects data may be mediated by 
factors other than funding source.  
Misclassification: source of funding for 87 
(17.3%) studies was unknown and these studies 
were classed as non pharmaceutical funded.  
Blinding: Not reported 
External validity: Poor, limited to inhaled 
corticosteroids 
Rochon et al 
1994 500 
56 randomised controlled trials of 
NSAIDs from MEDLINE. All trials had 
an association with a pharmaceutical 
manufacturer.  
Description of toxicity of manufacturer drug. 
22/54 trials (40.7%) reported that one drug was 
less toxic than the competitor drug (10 provided 
evidence of statistical significance). 
In 19 of 22 trials (86.4%) report favoured 
manufacturer’s drug rather than competitor’s 
drug. 
In 3/ 22 trials (13.6%), manufacturers’ drug was 
reported as more toxic than the comparison 
(placebo). 
32/54 trials (59.2%) reported comparable 
toxicities. 
Confounding: not discussed – for instance 
manufacturer may have deliberately chosen to 
use a comparator drug with poor safety profile, 
and the trial findings reflect a true difference. 
Misclassification: original aim of study was to 
evaluate non-industry funded research, but 
authors changed their aims posthoc as they  
could not  identify any non-industry studies 
Blinding: not reported 
External validity: poor, limited to NSAIDs only 
 
Stelfox et al 
1998 501 
69 authors of articles on calcium 
channel blockers  (original research, 
reviews and letters) were surveyed on 
their financial ties. 43 had financial 
relationship with manufacturers of 
calcium-channel antagonists, 40 with 
competing product and 47 with any 
manufacturer. 
Blinded researchers classified tone of the 
articles as 'supportive, neutral or critical'. There 
was a financial relationship with manufacturer of 
calcium channel antagonists for 23/24 (96%) 
authors of supportive articles compared to 
11/30 (37%) of authors of critical articles. 
There was a financial relationship with 
manufacturer of competing drug for 21/24 (88%) 
authors of supportive articles compared to 
11/30 (37%) of authors of critical articles. 
Confounding: temporal sequence of 
sponsorship is unclear; authors who are known 
to write positive articles may then be offered 
sponsorship, while established critics are 
seldom offered funding. Also, supportive 
authors were just as likely to receive funding 
from competing manufacturers. 
Misclassification: There were 20/89 authors 
who did not respond to survey and had to be 
excluded. No way of establishing accuracy of 
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For the supportive articles, 24/24 (100%) 
authors had financial relationship with any 
manufacturer. 
Whereas for the critical articles, 13/30 (43%) 
authors had financial relationship with any 
manufacturer. 
 
declared sponsorship status. 
Blinding: Yes, but there may have been 
information in the articles which could have led 
the researchers to become aware of potential 
pharmaceutical funding for a particular author. 
External validity: Poor, limited to calcium 
channel blockers only. 
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Table 15.12 Excluded studies in Chapter 8 
Study Reason for exclusion 
Chou et al 2006,247 
2007248 
Compares ‘mostly government’ with ‘other’. Other was non-
governmental but also non-industry source (for example, 
insurance company, non-profit organisation).  
Vandenbroucke JP et 
al 2000502 (letter) 
Duplicate information in Kemmeren et al 2001498 
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Chou et al 
2006,247 
2007248 
9 RCTs and 102 
observational studies on 
stroke and death with 
Carotid Endarteectomy  
 
16 RCTs on myocardial 
Infarction with  
Rofecoxib  
Pooled Rate of stroke or death in 
surgical data (95% CI) 
Author 
At least one non-surgeon author: 
5.6% (4.6% to 6.5%) 
Multiple surgeon authors: .2% (3.5% 
to 4.9%) 
Single surgeon author: 2.8% (1.7% 
to 3.8%) 
 
(p=0.0327 single versus multiple 
surgeons, p<0.0001 single surgeon 
versus non-surgeon, p=0.0181 
multiple surgeons versus non-
surgeon) 
 
Published in high Journal Impact 
Factor journal  
Journal Impact Factor: >7, 7.8% 
(4.8% to 10.8%) 
Journal Impact Factor: < or = 7, 4.3% 
(3.8% to 4.9%) (p=0.0262) 
 
Setting 
Europe: 5.7% (4.2% to 7.3%) 
Other, not reported or unclear or 
international 5.3% (3.6% to 6.9%) 
North America or Canada                                 
4.2% (3.6% to 4.8%)  
 
(p=0.0771, North America versus 
1. Confounding factors by study design: Analysed 8 quality 
criteria, study design factors, severity of adverse effects and 
demographic or risk factor variables as well as author affliation, 
journal impact factor, year of publication and country setting 
separately using univariate analyses.  
2. Blinding: Not reported. 
3. Validity and Representativeness: Limited to one surgical 
intervention and 2 adverse effects or one drug and one adverse 
effect. 
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Europe, p=0.2395, North America 
versus other, p=0.8560, Europe 
versus other) 
 
Pooled odds ratio for myocardial 
infarction, rofecoxib versus 
control 
Published in high Journal Impact 
Factor journal  
Journal Impact Factor: >7, 4.99 
(2.28, 10.93) 
Journal Impact Factor < or = 7, 1.39 
(0.86, 2.25) (P=0.0164) 
 
Setting 
Other: 2.22 (1.05, 4.70) 
North America: 1.41 (0.63, 3.15) 
(p=0.4306) 
 
Publication year 
After 2001: 2.71 (0.99, 7.40) 
Before or during 2001: 1.72 (0.97, 
3.06) (p=0.4563) 
Jorgensen et 
al 2007509, 510 
143 studies on the harms of 
mammography screening 
Harms Mentioned 
Authors working with screening       
29% 
Authors not working with screening: 
40% 
 
Acknowledge overdiagnosis 
(unblended, blinded, and 
1. Confounding factors by study design: Compared the type of 
article (original research, editorial etc) by author group and found 
little difference. 
2. Blinding: Blinded data extraction to author names of affiliation. 
3. Validity and Representativeness: Limited to one diagnostic 
screening test with a range of adverse effects. 
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combined analysis) 
Authors with no apparent conflict of 
interest: 40% (17/43), 30% (9/30), 
27% (13/48) 
Authors in screening-affiliated 
speciality or funded by cancer 
charities: 11% (4/37), 12% (6/50), 
19% (5/27) 
Authors working with screening:                    
8% (5/63), 8% (5/63), 13% (9/68) 
 
Downplay or reject overdiagnosis 
(unblended, blinded, and 
combined analysis) 
Authors with no apparent conflict of 
interest: 0% (0/1), 0% (0/9), 7% 
(1/14) 
Authors in screening-affiliated 
speciality or funded by cancer 
charities: 33% (2/6), 33% (3/9), 17% 
(1/6)  
Authors working with screening:                  
62% (8/13), 58% (7/12), 40% (6/15) 
Rothwell et al 
1996301 
51 studies on stroke and 
death with carotid 
endarterectomy  
Mortality risk (95% CI) 
Neurologist author: 1.8 (1.2 to -2.5) 
Multiple-surgeon authors: 1.7 (95% 
CI 1.4-1.9) 
Neurologist assessor: 1.4 (95% CI 
0.2-2.7) 
Single surgeon author: 0.7 (95% CI 
0.4-1.0) 
1. Confounding factors by study design: Author afflication, year of 
publication and whether studies were performed prospectively or 
retrospectively were analyzed in a multiple regression analysis. 
2. Blinding: Not reported 
3. Validity and Representativeness: Limited to one surgical 
intervention and 2 adverse effects. 
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Risk of stroke and/or death  
Neurologist assessor: 7.7 (95% CI 
5.0-10.2) 
Neurologist author: 6.4 (95% CI 4.6-
8.1) 
Multiple-surgeon authors: 5.5 (95% 
CI 4.8-6.1) 
Single surgeon author: 2.3 (95% CI 
1.8-2.7) 
 
Year of Publication 
1980 to 1984: 4.3% (95% CI 2.26-
6.42) 
1985 to 1989: 5.28% (95% CI 4.40-
6.16) 
1990 to 1994: 6.08% (95% CI 5.30-
6.86) 
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 Tables for overview of methods used to search for adverse Appendix C:
effects data in systematic reviews in Chapter 10 
Table 15.14 Systematic reviews by type of intervention 1994 to 2011 
Year of publication Type of intervention 
Drug Surgical/ 
dental 
Physical Diagnostic/ 
screening 
Other 
1994 (N=5) 5 (100%) 1 (20%) 1 (20%) 0 0 
1995 (N=13) 10 (77%) 0 0 0 3 (23%) 
1996 (N=21) 10 (48%) 6 (29%) 2 (10%) 0 4 (19%) 
1997 (N=24) 16 (67%) 2 (8%) 1 (4%) 0 6 (25%) 
1998 (N=24) 19 (79%) 2 (8%) 0 0 4 (17%) 
1999 (N=29) 21 (72%) 1 (3%) 2 (7%) 1 (3%) 4 (14%) 
2000 (N=19) 14 (74%) 3 (16%) 1 (5%) 0 2 (11%) 
2001 (N=31) 21 (68%) 3 (10%) 2 (6%) 0 9 (29%) 
2002 (N=46) 23 (50%) 7 (15%) 4 (9%) 0 12 (26%) 
2003 (N=56) 32 (57%) 2 (4%) 6 (11%) 1 (2%) 16 (29%) 
2004 (N=31) 26 (84%) 6 (19%) 1 (3%) 0 3 (10%) 
2005 (N=77) 68 (88%) 7 (9%) 4 (5%) 0 3 (4%) 
2006 (N=72) 56 (78%) 6 (8%) 6 (8%) 1 (1%) 3 (4%) 
2007 (N=78) 61 (78%) 10 (13%) 7 (9%) 1 (1%) 0 
2008 (N=94) 65 (69%) 18 (19%) 9 (10%) 2 (2%) 3 (3%) 
2009 (N=110) 85 (77%) 19 (17%) 4 (4%) 2 (2%) 4 (4%) 
2010 (N=104) 75 (72%) 15 (14%) 9 (9%) 2 (2%) 6 (6%) 
Jan-Jun 2011 (N=15) 14 (93%) 1 (7%) 0 0 0 
Total 621 (73%) 109 (13%) 59 (7%) 10 (1%) 82 (10%) 
 
*The sum of reviews by intervention is greater than the total number of reviews 
because 32 reviews examined more than one type of intervention (e.g. drug and 
non-drug antihypertensive therapy). 
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Table 15.15 Systematic reviews by types of study designs included 1994-2011 
Year Only RCTs RCTs CCTs Uncontrolled 
trials 
Cohort Case-
control 
studies 
Cases 
series 
Case 
reports 
Surveillance 
or registry 
Cross-
sectional 
Ecological 
studies 
Any 
unclear 
No study 
designs 
reported 
1994 1 (20%) 2 (40%) 1 (20%) 0 1 (20%) 0 0 1 (20%) 0 0 1 (20%) 2 (40%) 2 (40%) 
1995 3 (23%) 6 (46%) 1 (8%) 0 4 (31%) 7 (54%) 0 0 0 0 0 4 (31%) 1 (8%) 
1996 1 (5%) 5 (24%) 1 (5%) 1 (5%) 6 (29%) 6 (29%) 2 (10%) 4 (19%) 0 1 (5%) 0 7 (33%) 1 (5%) 
1997 7 (29%) 13 (54%) 3 (13%) 0 5 (21%) 5 (21%) 3 (13%) 1 (4%) 1 (4%) 0 0 7 (29%) 2 (8%) 
1998 7 (29%) 13 (54%) 1 (4%) 1 (4%) 7 (29%) 7 (29%) 2 (8%) 2 (8%) 1 (4%) 2 (8%) 0 7 (29%) 1 (4%) 
1999 10 (34%) 16 (55%) 3 (10% 0 8 (28%) 8 (28%) 1 (3%) 0 0 6 (21%) 1 (3%) 8 (28%) 1 (3%) 
2000 6 (32%) 10 (53%) 2 (11%) 0 7 (37%) 8 (42%) 3 (16%) 5 (26%) 0 3 (16%) 0 2 (11%) 0 
2001 13 (42%) 16 (52%) 2 (6%) 1 (3%) 8 (26%) 6 (19%) 1 (3%) 2 (6%) 1 (3%) 1 (3%) 2 (6%) 8 (26%) 0 
2002 11 (24%) 28 (61%) 4 (9%) 1 (2%) 15 (33%) 11 (24%) 3 (6%) 6 (9%) 1 (2%) 5 (11%) 0 16 (35%) 2 (4%) 
2003 15 (27%) 31 (55%) 7 (13%) 2 (4%) 21 (38%) 15 (27%) 9 (16%) 7 (13%) 2 (4%) 5 (9%) 2 (4%) 14 (25%) 3 (5%) 
2004 10 (33%) 22 (71%) 4 (13%) 1 (3%) 12 (39%) 6 (19%) 2 (6%) 2 (6%) 0 0 0 11 (35%) 0 
2005 34 (44%) 52 (68%) 5 (6%) 3 (4%) 31 (40%) 16 (21%) 7 (10%) 7 (10%) 1 (%) 3 (4%) 0 7 (10%) 1 (1%) 
2006 20 (28%) 43 (60%) 5 (7%) 1 (1%) 31 (43%) 25 (35%) 7 (10%) 4 (6%) 0 7 (10%) 0 14 (19%) 0 
2007 39 (50%) 61 (78%) 4 (5%) 1 (1%) 26 (33%) 15 (19%) 4 (5%) 3 (4%) 1 (1%) 3 (4%) 0 5 (6%) 1 (1%) 
2008 32 (34%) 56 (60%) 9 (10%) 4 (4%) 34 (36%) 22 (23%) 1 (1%) 2 (2%) 0 3 (4%) 0 15 (16%) 6 (6%) 
2009 36 (33%) 64 (58%) 15 (14%) 5 (5%) 42 (38%) 28 (25%) 14 (13%) 4 (4%) 0 8 (7%) 0 14 (13%) 4 (4%) 
2010 27 (26%) 68 (65%) 11 (11%) 2 (2%) 47 (45%) 28 (27%) 9 (9%) 5 (5%) 0 5 (5%) 0 23 (22%) 0 
2011 8 (53%) 11 (73%) 2 (13%) 0 5 (33%) 3 (20%) 0 0 0 2 (13%) 0 1 (7%) 0 
Total 280 (33%) 517 (61%) 80 (9%) 23 (3%) 310 (37%) 216 (25%) 68 (8%) 55 (6%) 8 (1%) 54 (6%) 6 (1%) 165 (19%) 25 (3%) 
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Table 15.16 Databases and other sources searched in systematic reviews of 
adverse effects 1994-2011 
Year of publication 
(number of reviews*) 
Databases searched 
Median (range) 
Other sources 
Median (range) 
Total sources 
Median (range) 
1994 (N=3) 2 (2 – 8)  1 (0 – 1) 3 (3 – 8) 
1995 (N=12) 1 (1 – 5)  1 (1 – 2) 2.5 (2 – 6) 
1996 (N=20) 1 (0 – 3) 1 (0 – 3)  3 (1- 5) 
1997 (N=23) 1 (0 - 3) 1 (0 – 4) 2 (1 – 6) 
1998 (N=23) 2 (1 – 9) 2 (0 – 5) 3 (1 – 11) 
1999 (N=29) 1 (1 – 7) 2 (0 – 4) 3 (1 – 9) 
2000 (N=19) 2 (1 – 7) 2 (0 – 4)  4 (2 – 10) 
2001 (N=30) 2 (1 – 25) 2 (0 – 5)  4 (2 – 27) 
2002 (N=46) 3 (1 – 8) 1 (0 – 4) 4 (2 – 11)  
2003 (N=55) 4 (1 – 10) 2 (0 – 48) 6 (2 – 58) 
2004 (N=31) 3 (1 – 9) 2 ( 0 – 5) 4 (1 – 13) 
2005 (N=77) 3 (1 – 14) 1 (0 – 10) 4 (2 – 24) 
2006 (N=72) 3 (1 – 12)  1 (0 – 4) 5 (2 – 14) 
2007 (N=78) 3 (0 – 13) 1 (0 - 37) 2 (5 -50) 
2008 (N=93) 3 (0 – 18) 1 (0 – 6) 4 (1 – 21) 
2009 (N=108) 3 (1 – 15) 1 (0-7) 5 (2-18) 
2010 (N=103) 3 (1-17) 1 (0-6) 4 (2-20) 
2011 (N=15) 3 (1-9) 2 (0-6) 5.5 (2-14) 
 
*only reviews in which the number of sources are reported were included. 
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Table 15.17 Systematic reviews searching the top four databases 1994-2011 
Year of publication MEDLINE EMBASE CENTRAL Cochrane Library 
1994 (N=5) 3 (60%) 1 (20%) 0 (0%) 0 (0%) 
1995 (N=13) 11 (85%) 1 (8%) 0 (0%) 0 (0%) 
1996 (N=21) 18 (86%) 2 (10%) 0 (0%) 1 (5%) 
1997 (N=24) 22 (92%) 0 (0%) 0 (0%) 0 (0%) 
1998 (N=24) 22 (92%) 9 (38%) 0 (0%) 1 (4%) 
1999 (N=29) 29 (100%) 7 (24%) 0 (0%) 1 (3%) 
2000 (N=19) 19 (100%) 9 (47%) 3 (16%) 1 (5%) 
2001 (N=31) 29 (94%) 12 (39%) 4 (13%) 7 (23%) 
2002 (N=46) 46 (100%) 23 (50%) 8 (17%) 9 (20%) 
2003 (N=56) 54 (96%) 35 (63%) 20 (36%) 17 (30%) 
2004 (N=31) 30 (97%) 16 (52%) 13 (42%) 4 (13%) 
2005 (N=77) 76 (99%) 41 (53%) 27 (35%) 17 (22%) 
2006 (N=72) 72 (100%) 49 (68%) 18 (25%) 18 (25%) 
2007 (N=78) 75 (96%) 50 (64%) 29 (37%) 17 (22%) 
2008 (N=94) 89 (95%) 58 (62%) 17 (18%) 28 (30%) 
2009 (N=110) 105 (95%) 68 (62%) 31 (28%) 25 (23%) 
2010 (N=104) 102 (98%) 69 (66%) 26 (25%) 30 (29%) 
2011 (N=15) 15 (100%) 12 (80%) 9 (60%) 0 (0%) 
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Table 15.18 Systematic reviews searching the top four non-database sources 
1994-2011 
Year of 
publication 
Reference 
lists 
Contacting 
experts 
Industry 
data 
Scanned conference 
reports 
1994 (N=5) 2 (40%) 0 (0%) 0 (0%) 0 (0%) 
1995 (N=13) 10 (77%) 1 (8%) 0 (0%) 0 (0%) 
1996 (N=21) 13 (62%) 3 (14%) 3 (14%) 0 (0%) 
1997 (N=24) 17 (71%) 4 (17%) 3 (13%) 0 (0%) 
1998 (N=24) 18 (75%) 8 (33%) 3 (13%) 0 (0%) 
1999 (N=29) 20 (69%) 9 (31%) 7 (24%) 3 (10%) 
2000 (N=19) 15 (79%) 4 (21%) 4 (21%) 4 (21%) 
2001 (N=31) 26 (84%) 9 (29%) 4 (13%) 2 (6%) 
2002 (N=46) 39 (85%) 10 (22%) 6 (13%) 1 (2%) 
2003 (N=56) 45 (80%) 15 (27%) 6 (11%) 8 (14%) 
2004 (N=31) 26 (84%) 7 (23%) 7 (23%) 7 (23%) 
2005 (N=77) 63 (82%) 9 (12%) 12 (16%) 16 (21%) 
2006 (N=72) 58 (81%) 16 (22%) 6 (8%) 13 (18%) 
2007 (N=78) 62 (79%) 12 (15%) 9 (12%) 19 (24%) 
2008 (N=94) 69 (73%) 14 (15%) 12 (13%) 20 (21%) 
2009 (N=110) 76 (69%) 18 (16%) 13 (12%) 19 (17%) 
2010 (N=104) 74 (71%) 14 (13%) 11 (11%) 27 (26%) 
2011 (N=15) 9 (60%) 3 (20%) 4 (27%) 3 (20%) 
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Table 15.19 Systematic reviews with reproducible search strategies 1994-2011 
Year of publication Number and percentage of reviews with 
reproducible search strategies  
1994 (N=5) 0 (0%) 
1995 (N=13) 0 (0%) 
1996 (N=21) 0 (0%) 
1997 (N=24) 0 (0%) 
1998 (N=24) 0 (0%) 
1999 (N=29) 1 (3%) 
2000 (N=19) 1 (5%) 
2001 (N=31) 1 (3%) 
2002 (N=46) 8 (17%) 
2003 (N=56) 7 (13%) 
2004 (N=31) 1 (3%) 
2005 (N=77) 4 (5%) 
2006 (N=72) 4 (6%) 
2007 (N=78) 7 (9%) 
2008 (N=94) 3 (3%) 
2009 (N=110) 11 (10%) 
2010 (N=104) 22 (21%) 
2011 (N=15) 4 (27%) 
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Table 15.20 Systematic reviews with date or language restrictions 1994-2011 
Year of 
publication 
Reviews with date 
restrictions (N=219) of those 
with dates stated (N=661) 
Reviews with language 
restrictions (N=146) of those 
with language stated (N=480) 
1994 (N=5) 75% (3/4) 100% (2/2) 
1995 (N=13) 70% (7/10) 63% (5/8) 
1996 (N=21) 60% (9/15) 50% (3/6) 
1997 (N=24) 56% (9/16) 27% (3/11) 
1998 (N=24) 45% (9/20) 36% (4/11) 
1999 (N=29) 32% (6/19) 33% (5/15) 
2000 (N=19) 41% (7/17) 30% (3/10) 
2001 (N=31) 67% (16/24) 17% (3/18) 
2002 (N=46) 22% (7/33) 19% (6/31) 
2003 (N=56) 26% (12/46) 21% (7/34) 
2004 (N=31) 35% (9/26) 14% (2/14) 
2005 (N=77) 29% (16/55) 37% (19/51) 
2006 (N=72) 30% (16/54) 16% (6/37) 
2007 (N=78) 18% (11/62) 35% (15/43) 
2008 (N=94) 36% (25/69) 42% (18/43) 
2009 (N=110) 25% (22/88) 28% (18/65) 
2010 (N=104) 35% (31/89) 36% (26/73) 
2011 (N=15) 31% (4/13) 13% (1/8) 
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 Protocol for case study systematic review evaluating Appendix D:
fractures with rosiglitazone and pioglitazone for Chapters 11 and 12 
 
Objective 
Primary objective: To determine systematically the relative and absolute risks of 
fractures with long term use of rosiglitazone or pioglitazone for type 2 diabetes.  
Secondary objective: To review the effect of rosiglitazone or pioglitazone on bone 
mineral density to ascertain its biological plausibility. 
 
Background 
There are over 2 million people with diabetes mellitus in the UK. Type 2 diabetes is 
the most common form accounting for around 90% of cases,675 and the number is 
increasing rapidly due to an ageing population and rapidly rising numbers of 
overweight and obese people.   
The costs to people’s quality of life, the economy, society, and the NHS are high.676 
Diabetes can also lead to serious complications such as heart disease, blindness, 
kidney failure, stroke and nerve damage leading to amputation. 
 
Treatment for diabetes tends to consist of lifestyle changes and medication. 
Thiazolidinediones or glitazones are one of the medicines available to patients. 
There are two glitazones available in the UK pioglitazone and rosiglitazone (since 
conducting this review rosiglitazone has been withdrawn from the UK market). Both 
of these are recommended by NICE. Glitazones are hypoglycaemic drugs used to 
lower blood glucose levels and glycated haemoglobin levels. They lower blood 
glucose by increasing the sensitivity of the body's cells to insulin (so more glucose 
is taken into cells for the same amount of insulin in the bloodstream). They are not 
usually used alone, but are taken in addition to metformin or a sulphonylurea. 
 
Several problems, such as myocardial infarction, heart failure, cardiovascular 
mortality, weight gain, upper respiratory tract infection, injury, headache, 
hypoglycaemia, hepatotoxicity,  hyperglycaemia, diarrhoea, anaemia, edema, 
anemia and weight gain,  have been identified with glitazones. Some adverse 
effects have been studied as secondary outcomes in systematic reviews of 
effectiveness. 677-685 However, recently systematic reviews have tended to focus on 
the adverse effects of glitazones as a primary outcome particularly on 
cardiovascular effects279, 476, 620, 686-695 and edema.600, 696 However, other adverse 
effects which had been the focus of systematic reviews include weight gain,697 
cancer692 and fractures.265, 698  
 
This systematic review will update and expand on a systematic review by Loke et al 
2009265 on fractures as an adverse effect of thiazolidinediones.  
 
The searches for the systematic review proposed here will include a large number 
of sources searches to enable analysis of how searching each data source affects 
the numbers of retrieved relevant papers. The search will include many non-
databases source and retrieve data from unpublished data sources and industry.   
 
Sources 
In addition to the sources listed in Box 1 published and unpublished data will be 
sought from: 
contacting industry, authors and experts,  
checking the reference lists of all included studies and relevant systematic reviews; 
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citation searches on all included studies using Google Scholar 
(http://scholar.google.com/), Scopus (www.scopus.com/) and Web of Science 
(scientific.thomsonreuters.com/products/wos/). 
 
 
Box 1: Sources to be searched 
 
Internet Search Engines 
General 
AltaVista  
Google  
 
Academic 
Google Scholar  
Intute  
 
Bibliographic Databases 
Adverse effects databases 
TOXLINE (Toxicology Literature Online) 
 
Pharmaceutical databases 
ADIS Clinical Trials Insight 
Derwent Drug File (previously RingDoc)  
Thomson Reuters Integrity  
Iowa Drug Information Service (IDIS)  
International Pharmaceutical Abstracts (IPA)  
 
Generic databases 
BIOSIS Previews  
British Library Direct 
CENTRAL  
CINAHL  
EMBASE  
MEDLINE  
Medscape DrugInfo 
PASCAL  
Science Citation Index (SCI) 
Scirus 
Conference Databases 
Conference Papers Index (CPI)  
Conference Proceedings Citation Index- Science (CPCI-S)  
Inside Conferences  
 
Synthesized Database 
Medical Evidence Matters 
 
Referenced Summary Databases 
ADIS R&D Insight  
Lexi-Comp Database  
Reactions PharmacoVigilance Insight (previously PharmaNewsFeed)  
XPharm  
 
Internet Reference Collections  
The Drug Safety Research Unit (DSRU) Prescription-Event Monitoring (PEM)  
MedWatch FDA  
 
Spontaneous Reporting Systems/Post-marketing Monitoring Data  
Internet 
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ADROM™ portal  
Canada’s Adverse Drug Reaction Database  
UK Yellow Card scheme: Drug Analysis Prints (DAPs)   
 
Databases 
PharmaPendium  
 
Request services 
FDA's Adverse Event Reporting System (AERS) and Spontaneous Reporting System (SRS)  
 
Registries of Clinical Trials  
Individual Drug Companies 
GlaxoSmithKline  
 
Company Portals 
Clinical Study Results Database  
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) clinical 
trials portal   
Lead Discovery  
 
Other Portals 
Australian New Zealand Clinical Trials Registry (ANZCTR)  
ClinicalTrials.gov  
Current Controlled Trials  
NIH Clinical Research Studies  
Trials Central  
WHO International Clinical Trials Registry Platform (ICTRP)  
 
Books and Journals 
Bulletins/Newsletters 
Adverse Drug Reaction Bulletin 
Canadian Adverse ReactionNewsletter (CARN)  
Clin-Alert  
Drug Safety Update (previously Current Problems in Pharmacovigilance) 
Drugs and Therapy Perspectives  
Medicines Safety Update (previously Australian Adverse Drug Reactions Bulletin) 
Reactions Weekly 
 
Specialist Journals 
Drug Safety  
Pharmacoepidemiology and Drug Safety  
 
Generic Journals (with highest number of articles on adverse effects)
31
 
Lancet  
New England Journal of Medicine  
BMJ  
Annals of Pharmacotherapy  
 
Diabetes Journals 
Diabetes  
Diabetes Care  
Diabetes Research and Clinical Practice  
Diabetic Medicine  
 
Referenced Monographs 
Adverse Drug Reactions  
AHFSFirst Professional Medicines Compendium  
Clinical Pharmacology  
Davies Textbook of Adverse Drug Reactions 
Emedicine  
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General Practice Notebook  
Martindale: the complete drug reference   
Meylers’s Side Effects Of Drugs  
Side Effects of Drugs annual (SEDA)  
ToxEd  
 
Partially-Referenced Monographs 
Drug Safety Portal 
The Merck Manual  
 
Non-Referenced Monographs 
ABPI electronic Medicines Compendium (eMC)  
Drugs.com  
Mosby's Medical Drug Reference 
Physicians’ Desk Reference (PDR) 
RxList  
Rxmed  
 
Referenced Lists of Adverse Effects 
Litt’s Drug Eruption Global Database 
 
Non-referenced Lists of Adverse Effects 
British National Formulary (BNF)  
Davis’s Drug Guide 
Epocrates Online  
Modell’s Drugs in current use and new drugs 
 
 
The search strategies will be developed in order to assess the comparative value of 
different databases and the effectiveness of published search strategies in retrieving 
information on adverse effects. 
 
Search Strategies for Database Comparisons 
In order to compare the results from multiple data sources, the search strategies 
used will be as similar as possible allowing for differences in indexing and search 
interface. 
 
Search terms for the intervention (thiazolidinedione) and outcome (fractures) only 
will be used to create a search string (Box 2). Disease terms will not be used as 
thiazolidinediones are rarely prescribed for other conditions and there may be 
relevant papers which do not mention diabetes in the title, abstract or indexing. 
 
No date or language restrictions will be applied to the database search strategies. 
However, due to logistical restraints only English language papers or papers for 
which a translation is readily available will be included. No restriction will be placed 
on the search strategies regarding type of study design (Box 3). 
 
 
Box 2: Search Facets 
 
 
P (population) –  Type 2 diabetes 
I (intervention) – Thiazolidinediones 
C (comparators) – Any 
O (outcome) –  Fractures (adverse effect)  
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Box 3: Proposed Search Strategies  
 
MEDLINE 
1. thiazolidinediones/ OR  rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd.af OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd OR exp 
osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
EMBASE 
1.  2,4 thiazolidinedione derivative/ OR  exp glitazone derivative/ OR rosiglitazone$.af. OR 
avandia.af. OR avandaryl.af OR avaglim.af. OR avandamet.af. OR glitazone$.af. OR 
thiazolidinedion$.af. OR tzd.af OR ppar gamma agonist$.af. OR peroxisome proliferator 
activated receptor gamma agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR 
duetact.af OR competact.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 
73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af. OR bmd OR exp 
osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
 
 
Eligibility criteria 
Primary outcome - fractures 
Randomized controlled trials (RCTs) and controlled observational studies will be 
selected that reported on fracture risk with thiazolidinedione exposure as compared 
to those without exposure. 
The specific inclusion criteria for RCTs are (1) parallel group randomized trial of any 
thiazolidinedione (rosiglitazone or pioglitazone) of at least 12 months duration; (2) 
study participants with impaired glucose tolerance or type 2 diabetes mellitus; (3) 
control arm which could be placebo or oral active comparators, with the only 
difference between the treatment groups being the use of thiazolidinediones; and (4) 
clear reporting of fracture outcomes. 
 
For the observational studies, controlled studies assessing fracture risk with 
thiazolidinedione exposure versus non-exposure will be selected, so long as the 
presented data allows extraction or calculation of odds ratio/relative risk or hazard 
ratios. 
 
Secondary outcome – effects on bone mineral density  
RCTs and controlled observational studies of any duration which reported on 
change in bone mineral density with thiazolidinedione exposure compared to non-
exposure will be included. 
 
Validity assessment 
The reporting of allocation concealment and the use of blinding in RCTs  will be 
assessed. In accordance with the Cochrane handbook of systematic reviews, the 
strength of adverse effects data in both the RCTs and the observational studies will 
be checked by recording how the investigators monitored and recorded adverse 
effects.  
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Data extraction strategy 
Two reviewers will assess the eligibility and quality of studies for adverse event 
reporting. Data will be extracted independently by one reviewer using a 
standardised data extraction form and checked by one other reviewer. The 
reviewers will obtain full consensus on inclusion of the studies and data extraction 
after resolving any discrepancies though discussion with a third reviewer. Authors 
will be contacted if any items require clarification. 
 
Study characteristics 
The dose and duration of thiazolidinedione therapy, and baseline characteristics of 
participants in the RCTs will be recorded. For the observational studies, the data 
sources, study participants, ascertainment of exposure and outcomes will be 
recorded. 
 
Assessment of risk of bias 
In accordance with the recommendations of the Cochrane Adverse Effects Methods 
Group, participant selection (including baseline characteristics), nature of follow-up, 
ascertainment of exposure, and definition and monitoring of adverse outcomes will 
be assessed. Confounders that were adjusted for, as well as the adjusted and 
unadjusted estimates of effect size, will be recorded where available. 
 
Data analysis 
RevMan 5.024 (Nordic Cochrane Centre) will be used to conduct random effects 
meta-analysis using M-H fixed effects model for the clinical trial data, and  inverse 
variance method for pooled odds ratios from the observational studies (OR). 
Similarity between the risk ratio and odds ratio is assumed because fractures are 
uncommon events. 
 
For the observational studies, where possible pool adjusted odds ratios from the 
primary studies will be calculated, otherwise raw outcome data will be used to yield 
unadjusted odds ratios (which may be particularly susceptible to confounding). 
 
In view of the potential diversity of study designs, the analysis will be stratified 
based on the groupings: 
 using unadjusted odds ratios for the relevant outcomes, with no correction 
for baseline differences or confounding 
 using odds ratios adjusted for potential confounders 
 
Exclusion Criteria 
Animal models, preclinical and biological studies, editorials and opinions will be 
excluded. 
 
Statistical heterogeneity,  
Statistical heterogeneity will be assessed using I2 statistic, with I2 values of 30-60% 
representing a moderate level of heterogeneity. 
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 Search strategies for case study systematic review in Appendix E:
Chapters 11 and 12: 
 
Internet Search Engines 
General 
AltaVista  
Host: www.altavista.com/ 
Date searched: 24/08/10 
Number of records retrieved: 8,340,000 results, browsed first 3 pages (30 results) 
Search strategy: (rosiglitazone OR rosiglitazones OR avandia OR avandaryl OR 
avaglim OR avandamet OR glitazone OR glitazones OR thiazolidinedione OR 
thiazolidinediones OR tzd OR pioglitazone OR pioglitazones OR actos OR actoplus 
OR duetact OR competact OR glustin OR nyracta OR venvia) AND (fracture OR 
fractures OR bone OR bones OR bmd OR osteoporosis) 
 
Google  
Host: www.google.com/ 
Date searched: 24/08/10 
Number of records retrieved: 1,430,000 results, browsed first 3 pages (30 results, 
one link did not work) 
Search strategy: (rosiglitazone OR rosiglitazones OR avandia OR avandaryl OR 
avaglim OR avandamet OR glitazone OR glitazones OR thiazolidinedione OR 
thiazolidinediones OR tzd OR pioglita7zone OR pioglitazones OR actos OR 
actoplus OR duetact OR competact OR glustin OR nyracta OR venvia) AND 
(fracture OR fractures OR bone OR bones OR bmd OR osteoporosis) 
 
Academic 
Google Scholar  
Host: http://scholar.google.co.uk/ 
Date searched: 24/08/10 
Number of records retrieved: 120,000 records, browsed first 3 pages (30 results) 
Search strategy: (rosiglitazone OR rosiglitazones OR avandia OR avandaryl OR 
avaglim OR avandamet OR glitazone OR glitazones OR thiazolidinedione OR 
thiazolidinediones OR tzd OR pioglitazone OR pioglitazones OR actos OR actoplus 
OR duetact OR competact OR glustin OR nyracta OR venvia) AND (fracture OR 
fractures OR bone OR bones OR bmd OR osteoporosis) 
 
Intute  
Host: http://www.intute.ac.uk/ 
Date searched: 24/08/10 
Number of records retrieved: 0 
Search strategy: (rosiglitazone OR rosiglitazones OR avandia OR avandaryl OR 
avaglim OR avandamet OR glitazone OR glitazones OR thiazolidinedione OR 
thiazolidinediones OR tzd OR pioglitazone OR pioglitazones OR actos OR actoplus 
OR duetact OR competact OR glustin OR nyracta OR venvia) AND (fracture OR 
fractures OR bone OR bones OR bmd OR osteoporosis) 
 
Bibliographic Databases 
Adverse effects databases 
TOXLINE (Toxicology Literature Online)  
Host: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?TOXLINE  
Date range: 1965 to present  
Date searched: 21/07/10 
Number of records retrieved: 141 (only 8 not in Pubmed) 
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Search strategy:  (rosiglitazone* OR avandia OR avandaryl OR avaglim OR 
avandamet OR glitazone* OR thiazolidinedion* OR tzd OR “ppar  gamma agonist*” 
OR “peroxisome proliferator activated receptor gamma agonist*” OR pioglitazone* 
OR actos OR actoplus OR duetact OR competact OR glustin OR nyracta OR 
venvia) AND (fracture* OR bone* OR bmd OR osteoporo*)  
 
Pharmaceutical databases 
ADIS Clinical Trials Insight 
Host: Wolters Kluwer Pharma Solutions: http://bi.adisinsight.com/Login/Login.aspx 
Date range: Version 7.3.1, 16 Feb 2010 
Date searched: 21/07/10 
Number of records retrieved: 70 
Search strategy: Drug is Rosiglitazone OR Rosiglitazone-hydrochloride OR 
Rosiglitazone-maleate OR Rosiglitazone/glimepiride OR Rosiglitazone/metformin 
OR Avandaryl OR Avandia OR Avandamet OR Peroxisome-proliferator-activated-
receptor-agonists OR Pioglitazone OR Pioglitazone-hydrochloride OR 
Pioglitazone/glimepiride OR Pioglitazone/metformin OR Pioglitazone/TAK-536 OR 
Actos OR Actoplus-Met OR Duetact OR Nyracta OR Venvia  AND  
Text contains ‘"fracture*" OR "bone*" OR "osteoporo*"’ 
OR 
Drug is Rosiglitazone OR Rosiglitazone-hydrochloride OR Rosiglitazone-maleate 
OR Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandaryl OR 
Avandia OR Avandamet OR Peroxisome-proliferator-activated-receptor-agonists 
OR Pioglitazone OR Pioglitazone-hydrochloride OR Pioglitazone/glimepiride OR 
Pioglitazone/metformin OR Pioglitazone/TAK-536 OR Actos OR Actoplus-Met OR 
Duetact OR Nyracta OR Venvia  AND  
Text contains ‘"bmd"’ 
 
Derwent Drug File (previously RingDoc)  
Host: Dialogweb 
Date range: 1983-2010/Aug 
Date searched: 03/09/10 
Number of records retrieved: 141 
Search strategy:  
s rosiglitazone? 
s avandia 
s avandaryl 
s avaglim 
s avandamet 
s glitazone? 
s thiazolidinedion?  
s tzd 
s ppar(w)gamma(w)agonist? 
s peroxisome(w)proliferator(w)activated(w)receptor(w)gamma(w)agonist? 
s pioglitazone? 
s actos 
s actoplus 
s duetact 
s competact 
s glustin 
s nyracta 
s venvia 
s RN=111025-46-8 
s RN=122320-73-4 
s s1:s20  
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s fracture? 
S bone? 
S bmd 
S osteoporo? 
s s22:s25 
s s26 and s21 
 
Thomson Reuters Integrity 
Host: http://integrity.prous.com/integrity/xmlxsl/pk_home.util_home 
Date range: 1988 – 20/08/10 
Date searched: 20/08/10 
Number of Records Retrieved: 96 records 
Search strategy:  
Title/text = bone* or bmd or osteoporo* or fracture* 
AND 
Product > Drug Name = rosiglitazone or pioglitazone 
 
Iowa Drug Information Service (IDIS)  
Host: http://www.uiowa.edu/~idis/idisweb.htm/  
Date range: 1966 to 2010  
Date searched: 15/07/10 
Number of records retrieved: 60 (Indexes over 200 journals, plus FDA, NICE and 
AHRQ material Links to the full-text but searches are of title, abstract and 
descriptors. (Descriptors are assigned by trained pharmacists)). 
Search strategy:  
(rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR glitazone* 
OR thiazolidinedion* OR tzd OR “ppar  gamma agonist*” OR “peroxisome 
proliferator activated receptor gamma agonist*” OR pioglitazone* OR actos OR 
actoplus OR duetact OR competact OR glustin OR nyracta OR venvia) [drug field] 
AND  
(fracture* OR bone* OR bmd OR osteoporo*) [all fields] 
 
International Pharmaceutical Abstracts (IPA)  
Host: Dialogweb  
Date range: 1970-2010/Aug 
Date searched: 03/09/10 
Number of records retrieved: 28 
Search strategy: 
s rosiglitazone? 
s avandia 
s avandaryl 
s avaglim 
s avandamet 
s glitazone? 
s thiazolidinedion?  
s tzd 
s ppar(w)gamma(w)agonist? 
s peroxisome(w)proliferator(w)activated(w)receptor(w)gamma(w)agonist? 
s pioglitazone? 
s actos 
s actoplus 
s duetact 
s competact 
s glustin 
s nyracta 
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s venvia 
s RN=111025-46-8 
s RN=122320-73-4 
s s1:s20  
s fracture? 
S bone? 
S bmd 
S osteoporo? 
s s22:s25 
s s26 and s21 
 
Generic databases 
BIOSIS Previews  
This search required a 2 stage approach as the University of York subscription only 
runs from 1969-2008. 
Stage 1 
Host: ISI web of science 
Date range: 1969-2008 
Date searched: 21/07/10 
Number of records retrieved: 702 
Search strategy:  
TS=(rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR 
glitazone* OR thiazolidinedion* OR tzd OR (ppar SAME gamma SAME agonist*) 
OR (peroxisome SAME proliferator SAME activated SAME receptor SAME gamma 
SAME agonist*) OR pioglitazone* OR actos OR actoplus ORduetact OR competact 
OR glustin OR nyracta OR venvia) AND TS=(fracture* OR bone* OR bmd OR 
osteoporo*) 
 
Stage 2 
Host: Dialogweb 
Date range: 1993-2010/Aug 
Date searched: 03/09/10 
Number of records retrieved: 178 additional records 
Search strategy: 
s rosiglitazone? 
s avandia 
s avandaryl 
s avaglim 
s avandamet 
s glitazone? 
s thiazolidinedion?  
s tzd 
s ppar(w)gamma(w)agonist? 
s peroxisome(w)proliferator(w)activated(w)receptor(w)gamma(w)agonist? 
s pioglitazone? 
s actos 
s actoplus 
s duetact 
s competact 
s glustin 
s nyracta 
s venvia 
s RN=111025-46-8 
s RN=122320-73-4 
s s1:s20  
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s fracture? 
S bone? 
S bmd 
S osteoporo? 
s s22:s25 
s s26 and s21 
s py=2007:2011 
s s27 and s28 
 
British Library Direct 
Host: http://direct.bl.uk/bld/SearchResults.do 
Date range: Last 5 years 
Date searched: 15/07/10 
Number of records retrieved: 117  
Search strategy:  
(rosiglitazone OR rosiglitazones OR avandia OR avandaryl OR avaglim OR 
avandamet OR glitazone OR glitazones OR thiazolidinedione OR thiazolidinediones 
OR tzd OR pioglitazone OR pioglitazones OR actos OR actoplus OR duetact OR 
competact OR glustin OR nyracta OR venvia) AND (fracture OR fractures OR bone 
OR bones OR bmd OR osteoporosis) 
 
CENTRAL 
Host: The Cochrane Library  
Date Range: Issue 7, 2010 
Date Searched: 21/07/10 
Number of Records Retrieved: 12 
Search strategy:  
#1 MeSH descriptor Thiazolidinediones  
#2 rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR 
glitazone* OR thiazolidinedion* OR tzd OR “ppar  gamma agonist*” OR “peroxisome 
proliferator activated receptor gamma agonist*” OR pioglitazone* OR actos OR 
actoplus OR duetact OR competact OR glustin OR nyracta OR venvia  
#3 MeSH descriptor Fractures, Bone explode all trees  
#4 MeSH descriptor Bone Density 
#5 MeSH descriptor Osteoporosis explode all trees 
#6 fracture* OR bone* OR bmd OR osteoporo* 
#7 (#1 OR #2) AND (#3 OR #4 OR #5 OR #6) 
 
CINAHL 
Interface: EBSCOhost www.ebscohost.com/ 
Date range: 2006-2010  
Date searched: 21/07/10 
Number of records retrieved: 70 
Search strategy:  
 (MH "Thiazolidinediones")  OR   (MH "Rosiglitazone") OR (MH "Pioglitazone")  OR  
Rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR 
glitazone* OR thiazolidinedione* OR tzd OR pioglitazone* OR actos OR actoplus 
ORduetact OR competact OR glustin OR nyracta OR venvia 
AND 
(MH "Fractures+")   OR fracture* OR (MH "Bone Density") OR bone* OR bmd OR 
(MH "Osteoporosis+") OR osteoporosis 
 
EMBASE  
Interface: Wolters Kluwer Health OvidSP http://www.ovid.com/ 
Date range: 1996 to 2010 Week 28 
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Date searched: 21/07/10 
Number of records retrieved: 1017 
Search strategy:  
1.  2,4 thiazolidinedione derivative/ OR  exp glitazone derivative/ OR 
rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. OR 
avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR 
nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af. OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
MEDLINE  
Interface: Wolters Kluwer Health OvidSP http://www.ovid.com/ 
Date range: 1996 to July Week 1 2010 
Date searched: 21/07/10 
Number of records retrieved: 251 
Search strategy:  
1. thiazolidinediones/ OR  rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR 
avaglim.af. OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd 
OR ppar gamma agonist$.af. OR peroxisome proliferator activated receptor gamma 
agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR 
competact.af. OR glustin.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 
122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af 
OR exp osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
Medscape  
Host: http://www.medscape.com/ 
Date range: January 1990 – 9th July 2010 
Date searched: 09/07/10 
Search results: 115 records  
Search Strategy: Terms are automatically ANDed and searching with terms such as 
fracture and bone also retrieves fractures and bones 
rosiglitazone fracture 44  
rosiglitazone bone 56 
rosiglitazone bmd 5 
rosiglitazone osteoporosis  20 
rosiglitazones 0 
avandia fracture 44 
avandia bone 56 
avandia bmd 5 
avandia osteoporosis 20 
avandaryl fracture 1 
avandaryl bone 1 
avandaryl bmd 0 
avandaryl osteoporosis 1 
avaglim 0 
avandamet fracture 3 
avandamet bone 1 
avandamet bmd 0 
avandamet osteoporosis 2 
glitazone fracture 4 
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glitazone bone 4 
glitazone bmd 0 
glitazone osteoporosis 2 
glitazones fracture 6 
glitazones bone 11 
glitazones bmd 1 
glitazones osteoporosis 4 
thiazolidinedione fracture 25 
thiazolidinedione bone 32 
thiazolidinedione bmd 0 
thiazolidinedione osteoporosis 7 
thiazolidinediones fracture 32 
thiazolidinediones bone 44 
thiazolidinediones bmd 1 
thiazolidinediones osteoporosis 13 
tzd fracture 18 
tzd bone 15 
tzd bmd 0 
tzd osteoporosis 9 
pioglitazone fracture 34 
pioglitazone bone 49 
pioglitazone bmd 1 
pioglitazone osteoporosis 15 
pioglitazones 0 
actos fracture 34 
actos bone 49 
actos bmd 1 
actos osteoporosis 15 
actoplus fracture 0 
actoplus bone 0 
actoplus bmd 0 
actoplus osteoporosis 0 
duetact fracture 0 
duetact bone 0 
duetact bmd 0 
duetact osteoporosis 0 
competact fracture 0 
competact bone 0 
competact bmd 0  
competact osteoporosis 0 
glustin 0 
nyracta 0 
Venvia 0 
 
PASCAL  
Interface: http://stanalyst.inist.fr/ 
Date range: 1973 - present 
Date searched: 20/08/10 
Number of records retrieved: 64 
Search strategy : 
mc=(rosiglitazone ou pioglitazone ou "thiazolidinedione derive" ou "derive de la 
thiazolidinedione") ou (mc=agoniste et mc="recepteur ppar*") ou (glitazone* ou 
thiazolidinedione* ou avandaryl ou avandia ou avaglim ou avandamet ou actos ou 
actoplus ou duetact ou competact ou glustin ou nyracta ou venvia) et (mc=(fracture* 
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ou "densite minerale osseuse" ou osteoporo* ou "pathologie du systeme 
osteoarticulaire" ou "systeme osteoarticulaire*") ou fractur*) 
 
Science Citation Index (SCI)  
Host: http://scientific.thomsonreuters.com/products/sci/ 
Date range: 1899-present 
Host: ISI Web of Knowledge, Web of Science 
Date searched: 21/07/10 
Number of records retrieved: 312 
Search strategy: 
TS=(rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR 
glitazone* OR thiazolidinedion* OR tzd OR (ppar SAME gamma SAME agonist*) 
OR (peroxisome SAME proliferator SAME activated SAME receptor SAME gamma 
SAME agonist*) OR pioglitazone* OR actos OR actoplus ORduetact OR competact 
OR glustin OR nyracta OR venvia) AND TS=(fracture* OR bone* OR bmd OR 
osteoporo*) 
 
Scirus 
Date range: 1900-2011 (limited to journal articles only) 
Host: http://www.scirus.com/ 
Date searched: 23/09/10 
Number of records retrieved: 2152 (1928 after within database deduplication) 
Search strategy: 
(rosiglitazon* OR avandia OR avandaryl OR avaglim OR avandamet OR glitazon* 
OR thiazolidinedion* OR tzd OR pioglitazon* OR actos OR actoplus OR duetact OR 
competact OR glustin OR nyracta OR venvia) (fracture OR fractures OR bone OR 
bones OR bmd OR osteoporosis) 
 
Conference Databases 
Conference Papers Index (CPI)  
Host: http://www.proquest.co.uk/en-UK/catalogs/databases/detail/cpi-set-c.shtml 
Date range: 1982 – current (updated bimonthly) 
Date searched: 15/07/10 
Number of records retrieved: 31 
Search strategy: 
The searches were not restricted to any field but searched ‘anywhere’ which 
includes all fields including a keyword field. 
rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR glitazone* 
OR thiazolidinedion* OR tzd OR “ppar  gamma agonist*” OR “peroxisome 
proliferator activated receptor gamma agonist*” OR pioglitazone* OR actos OR 
actoplus OR duetact OR competact OR glustin OR nyracta OR venvia 
AND  
fracture* OR bone* OR bmd OR osteoporo* 
 
Conference Proceedings Citation Index- Science (CPCI-S)  
Host: ISI Web of Knowledge, Web of Science 
Date range: 1990-present 
Date searched: 15/07/10 
Number of records retrieved: 45 
Search strategy: 
TS=(rosiglitazone* OR avandia OR avandaryl OR avaglim OR avandamet OR 
glitazone* OR thiazolidinedion* OR tzd OR (ppar SAME gamma SAME agonist*) 
OR (peroxisome SAME proliferator SAME activated SAME receptor SAME gamma 
SAME agonist*) OR pioglitazone* OR actos OR actoplus ORduetact OR competact 
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OR glustin OR nyracta OR venvia) AND TS=(fracture* OR bone* OR bmd OR 
osteoporo*) 
 
Inside Conferences  
Host: Dialogweb 
Date range: 1993-2010/Sep 
Date searched: 03/09/10 
Number of records retrieved: 7 
Search strategy: 
s rosiglitazone? 
s avandia 
s avandaryl 
s avaglim 
s avandamet 
s glitazone? 
s thiazolidinedion?  
s tzd 
s ppar(w)gamma(w)agonist? 
s peroxisome(w)proliferator(w)activated(w)receptor(w)gamma(w)agonist? 
s pioglitazone? 
s actos 
s actoplus 
s duetact 
s competact 
s glustin 
s nyracta 
s venvia 
s RN=111025-46-8 
s RN=122320-73-4 
s s1:s20  
s fracture? 
S bone? 
S bmd 
S osteoporo? 
s s22:s25 
s s26 and s21 
 
Synthesized Databases 
Medical Evidence Matters 
Host: http://proquest.umi.com/login 
Searched: 24/11/10 
Search results: References to Nissen and Scheen, 2 RCTs on fractures. Presents 
data from papers. 
 
Referenced Summary Databases 
ADIS R&D Insight  
Host: Wolters Kluwer Pharma Solutions http://bi.adisinsight.com/Login/Login.aspx 
Date Range: Version 7.3.1, 16 Feb 2010 
Date Searched: 21/07/10 
Number of Records Retrieved: 1 Monograph for rosiglitazone refers to BARI-2D 
conference paper. No included references.  
Search strategy: 
Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandia® OR 
Avandamet® OR Avandamet® XR OR Peroxisome proliferator-activated receptor 
agonists research programme - Eli Lilly OR Pioglitazone OR Pioglitazone/alogliptin 
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OR Pioglitazone/glimepiride OR Pioglitazone/metformin OR Pioglitazone/TAK 536 
OR Actos® OR ACTOplus met® OR ACTOplus met® XR OR Duetact™ OR 
Competact® OR Glustin™ OR Avaglim® OR Avandaryl® AND Text contains 
"fracture*" OR "bone*" OR "osteoporo*" 
OR 
Drug is Rosiglitazone OR Rosiglitazone-hydrochloride OR Rosiglitazone-maleate 
OR Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandaryl OR 
Avandia OR Avandamet OR Peroxisome-proliferator-activated-receptor-agonists 
OR Pioglitazone OR Pioglitazone-hydrochloride OR Pioglitazone/glimepiride OR 
Pioglitazone/metformin OR Pioglitazone/TAK-536 OR Actos OR Actoplus-Met OR 
Duetact OR Nyracta OR Venvia  AND Text contains ‘"bmd"’ 
 
DRUGDEX 
Host: MICROMEDEX 2.0 
Interface: http://www.thomsonhc.com/ 
Date Searched: 07/10/10 
Number of records retrieved: 6 monographs with 5 references in total. 1 included 
reference - 1 RCT fracture 
 
monographs for rosiglitazone, ROSIGLITAZONE MALEATE/METFORMIN 
HYDROCHLORIDE and ROSIGLITAZONE MALEATE/GLIMEPIRIDE 
 
Lexi-Comp Database 
Date range: June 2010 
Interface: http://www.crlonline.com/ 
Date searched: 18/08/10 
Number of Records retrieved: Lexi-comp mongraph for rosiglitazone and 
pioglitazone refer to fractures as adverse effects (contains references at end of 
text). 6 included references 3 RCT fractures, 1 observational study of fractures and 
2 observational studies of bone mineral density Also contains monographs from 
AHFS Information and Martindales. 21 references including those from AHFS 
Information and Martindales. In totals 7 included references (representing 6 
studies), 4 RCT fractures (representing 3 studies), 1 observational study of fractures 
and 2 observational studies of bone mineral density 
 
XPharm  
Host: www.xpharm.com/ 
Date Range: 2007 
Interface: http://www.sciencedirect.com/science/referenceworks/9780080552323. 
Date searched: 27/10/10 
Number of Records retrieved: 3 referenced monographs (rosiglitazone, pioglitazone, 
thiazolidinediones). No mention of fractures in text on adverse effects. 
 
Internet Reference Collections  
The Drug Safety Research Unit (DSRU) Scientific Publications 
Host: http://www.dsru.org/ 
Date Range: 1979- present 
Date Searched: 21/07/10 
Number of Records Retrieved: 3 
Search strategy: 
Rosiglitazone 1 record, 0 potentially relevant 
Rosiglitazones 0 
Avandia 0 
Avandaryl 0 
avaglim 0 
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avandamet 0  
glitazone 0 
glitazones 0 
thiazolidinedione 0 
thiazolidinediones 0 
tzd 0 
pioglitazone 3 records, 0 potentially relevant 
pioglitazones 0  
actos 0 
actoplus  
duetact 
competact 0 
glustin 0 
nyracta 0 
venvia 0 
 
MedWatch FDA  
Host: http://www.fda.gov/medwatch/safety.htm 
Date Range:  
Date Searched: 21/07/10 
Number of Records Retrieved: 9 records after dedup, 2 potentially relevant letters. 
No included references. 
Search strategy: 
rosiglitazone fracture 4 records, 1 potentially relevant letter, 2 links to potentially 
relevant letter 
rosiglitazone fractures 4 records, 1 potentially relevant letter, 2 links to potentially 
relevant letter 
rosiglitazone bone 3 records, 1 potentially relevant letter 
rosiglitazone bmd 0 
rosiglitazone osteoporosis 1 record, 1 potentially relevant letter 
rosiglitazones 0 
avandia fracture 4 records, 1 potentially relevant letter, 2 links to potentially relevant 
letter 
avandia fractures 4 records, 1 potentially relevant letter, 2 links to potentially 
relevant letter 
avandia bone 3 records, 1 potentially relevant letter 
avandia bmd 0 
avandia osteoporosis 1 record, 1 potentially relevant letter 
avandaryl 0 
avaglim 0 
avandamet fracture 2 records, 1 potentially relevant letter, 1 link to potentially 
relevant letter 
avandamet fractures 2 records, 1 potentially relevant letter, 1 link to potentially 
relevant letter 
avandamet bone 1 record, 1 potentially relevant letter 
avandamet bmd 0 
avandamet osteoporosis 1 record, 1 potentially relevant letter 
glitazone 0 
glitazones 0   
thiazolidinedione fracture 0 
thiazolidinedione fractures 0 
thiazolidinedione bone 0 
thiazolidinedione bmd 0 
thiazolidinedione osteoporosis 0 
thiazolidinediones fracture 1 record, 1 potentially relevant letter 
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thiazolidinediones fractures 1 record, 1 potentially relevant letter 
thiazolidinediones bone 2 records, 1 potentially relevant letter 
thiazolidinediones bmd 0 
thiazolidinediones osteoporosis 0 
tzd 0 
pioglitazone fracture 3 records, 1 potentially relevant letter, 2 links to potentially 
relevant letter 
pioglitazone fractures 3 records, 1 potentially relevant letter, 2 links to potentially 
relevant letter 
pioglitazone bone 2 records, 1 potentially relevant letter 
pioglitazone bmd 0 
pioglitazone osteoporosis 0 
pioglitazones 0 
actos fracture 3 records, 1 potentially relevant letter, 2 links to potentially relevant 
letter 
actos fractures 3 records, 1 potentially relevant letter, 2 links to potentially relevant 
letter 
actos bone 2 records, 1 potentially relevant letter 
actos bmd  
actos osteoporosis 0 
actoplus  
duetact 
competact 0 
glustin 0 
nyracta 0 
venvia 0 
 
Internet 
ADROM™ portal (Information from the FDA’s Adverse Event Reporting System 
(AERS)) 
Host: https://www.prosoftedc.com/aers/aers.html 
Date Range: Q1 2004 to Q3 2009 
Date Searched: 19/08/10 
Search Results:  
Rosiglitazone – 14 reports (Ankle fracture 1 female, Foot: 1 female,  forearm: 1 
female, hip 3 females, osteoporotic: 2 females, spinal compression: 2 males, spinal: 
2 females, unspecified: 1 female, wrist: 1 female) 
Pioglitazone – 4 reports (Ankle: 2 females, Fibula: 2 females) 
 
Canada’s Adverse Drug Reaction Database  
Host: http://www.hc-sc.gc.ca/dhp-mps/medeff/databasdon/index-eng.php 
Date Range: 1965 to 2010-03-31 
Date Searched: 19/08/10 
Number of Records Retrieved: 2 
Search strategy: 
Controlled index so searched for rosiglitazone and pioglitazone and all cases of 
fracture or bone or osteoporosis 
Rosiglitazone fracture 18 patients with fractures (some patients had more than one 
fracture) 
Ankle fracture 1 (1 male), Femur fracture 1 (1 female), Foot fracture 5 (4 females 
and 1 male), Hip fracture 1 (1 female), Humerus fracture 1 (1 female), Lumber 
vertebral fracture 1 (1 female), Multiple fractures 2 (2 female), Pathological fracture 
4 (4 female), Rib fracture 1 (1 female), Unspecified fracture 2 (2 female), Upper limb 
fracture 2 (2 females), Wrist fracture 1 (1 female) 
pioglitazone fracture 0 
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UK Yellow Card scheme: Drug Analysis Prints (DAPs)  
Host: http://www.mhra.gov.uk 
Date Range: 01 June 1963- 28 June 2010 
Date Searched: 18/08/10 
Number of Records Retrieved: DAPS for rosiglitazone and pioglitazone. 
Rosiglitazone 27 reports (Unspecified fracture 3, ankle fracture 5, fibula fracture 1, 
foot fracture 4, hip fracture 2 lower limb fracture 1, spinal fracture 1, forearm fracture 
1, hand fracture 1, humerus fracture 2, radius fracture 1, ulna fracture 1, wrist 
fracture 4) 
Pioglitazone 8 reports (Ankle fracture 1, femur fracture 1, foot fracture 1, tibia 
fracture 1, lumber vertebral fracture 1, thoracic vertebral fracture 1, humerus 
fracture 1, wrist fracture 1) 
 
Databases 
PharmaPendium  
Host: http://www.info.pharmapendium.com/  
Date Range: 1938 – July 2010  
Date Searched: 27/10/10 
Number of Records Retrieved: 13 EMEA approval documents and one FDA 
approval package document. 576 post-marketing reports (AERS) 
Metformin Hydrochloride; Rosiglitazone Maleate 43 reports, 8 male and 35 female, 
Foot fracture (8), Wrist fracture (7), Ankle fracture (5), Fracture (5), Fibula fracture 
(4), Radius fracture (4), Upper limb fracture (4), Hip fracture (3) ,Humerus fracture 
(3), Hand fracture (2), ,Lower limb fracture (2), Multiple fractures (2), Stress fracture 
(2), Tibia fracture (2), Compression fracture (1), Forearm fracture (1), Osteoporotic 
fracture (1), Pathological fracture (1), Thoracic vertebral fracture (1) 
Rosiglitazone Maleate 296 reports, 78 male and 214 female. Fracture (64), Foot 
fracture (51), Upper limb fracture (31), Ankle fracture (26), Hip fracture (20), 
Humerus fracture (19), Multiple fractures (19), Lower limb fracture (16), Wrist 
fracture (15), Femur fracture (13), Hand fracture (11), Pathological fracture (8), Rib 
fracture (8), Spinal fracture (7), Stress fracture (7), Patella fracture (6), Pelvic 
fracture (6), Radius fracture (6), Ulna fracture (5), Osteoporotic fracture (4), Bone 
fissure (3), Femoral neck fracture (3), Forearm fracture (3), Fracture nonunion (3), 
Lumbar vertebral fracture (3), Tibia fracture (3), Clavicle fracture (2), Fractured 
sacrum (2), Scapula fracture (2), Compression fracture (1), Facial bones fracture 
(1), Fibula fracture (1), Fractured coccyx (1), Pubic rami fracture (1), Sternal fracture 
(1) 
Rosiglitazone Maleate; Glimepiride 13 reports, 0 male and 13 female Hip fracture 
(3), Osteoporotic fracture (2), Spinal fracture (2), Ankle fracture (1), Foot fracture 
(1), Forearm fracture (1), Fracture (1), Humerus fracture (1), Upper limb fracture (1), 
Wrist fracture (1) 
Pioglitazone Hydrochloride 224 reports, 42 male and 179 female. Ankle fracture 
(23), Foot fracture (20), Hip fracture (19), Upper limb fracture (19), Spinal fracture 
(18), Tibia fracture (18), Rib fracture (17), Fracture (14), Humerus fracture (14), 
Lower limb fracture (14), Fibula fracture (13), Radius fracture (13), Femoral neck 
fracture (11), Pathological fracture (11), Pelvic fracture (11), Compression fracture 
(10), Hand fracture (10), Stress fracture (10), Wrist fracture (10), Lumbar vertebral 
fracture (8), Ulna fracture (8), Femur fracture (7), Multiple fractures (5), Facial bones 
fracture (4), Thoracic vertebral fracture (4), Clavicle fracture (3), Forearm fracture 
(3), Fractured coccyx (3), Ilium fracture (3), Pubic rami fracture (3), Acetabulum 
fracture (2), Bone fissure (2), Greenstick fracture (2), Patella fracture (2), Avulsion 
fracture (1), Cervical vertebral fracture (1), Fractured sacrum (1), Skull fracture (1), 
Ankle fracture (23), Foot fracture (20), Hip fracture (19), Upper limb fracture (19), 
Spinal fracture (18), Tibia fracture (18), Rib fracture (17), Fracture (14), Humerus 
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fracture (14), Lower limb fracture (14), Fibula fracture (13), Radius fracture (13), 
Femoral neck fracture (11), Pathological fracture (11), Pelvic fracture (11), 
Compression fracture (10), Hand fracture (10), Stress fracture (10), Wrist fracture 
(10), Lumbar vertebral fracture (8), Ulna fracture (8), Femur fracture (7), Multiple 
fractures (5), Facial bones fracture (4), Thoracic vertebral fracture (4), Clavicle 
fracture (3), Forearm fracture (3), Fractured coccyx (3), Ilium fracture (3), Pubic rami 
fracture (3), Acetabulum fracture (2), Bone fissure (2), Greenstick fracture (2), 
Patella fracture (2), Avulsion fracture (1), Cervical vertebral fracture (1), Fractured 
sacrum (1), Skull fracture (1) 
 
Request services 
FDA's Adverse Event Reporting System (AERS) and Spontaneous Reporting 
System (SRS)  
Host: http://www.foiservices.com/brochure/ADR_search.cfm or 
http://www.ntis.gov/products/adverse.aspx or 
http://www.fda.gov/cder/aers/extract.htm  
Date range: 01 Nov 1997-31 Dec 2009 
Rosiglitazone fractures 72 reports (Ankle Fracture 6 (1 male and 5 females), femur 
fracture 2 (2 females), foot fracture 9 (8 females, 1 unknown), forearm fracture 1 (1 
female), unspecified 7 (3 males, 3 females, 1 unknown), fracture nos 1 (1 female), 
hand fracture 3 (2 female, 1 unknown), hip fracture 4 (4 female), humerus 2 (2 
female), lower limb fracture 7 (4 female, 2 male, 1 unknown), osteoporotic fracture 3 
(3 female), pathological fracture 1 (1 female), radius fracture 4 (4 female), rib 
fracture 6 (3 females and 3 males),  skull fracture nos 3 (3 males), spinal 
compression fracture 3 (2 males and 1 female), spinal fracture 4 (2 females, 1 male, 
1 unknown), upper limb fracture 3 (2 female, 1 unknown), upper limb fracture nos 1 
(1 female), wrist fracture 2 (2 female)) 
 
Pioglitazone Fractures, 95 reports 
Acetabulum fracture 2 (2 males), ankle fracture 13 (12 females and 1 male), 
avulsion fracture 1 (1 male), compression fracture 2 (2 female), femoral neck 
fracture 2 (1 male and 1 unknown), femur fracture 9 (3 female and 6 male), fibula 
fracture 5 (4 female and 1 male), foot fracture 7 (6 female and 1 male), unspecified 
fracture 2 (2 females), unspecified fracture nos 1 (1 female), hand fracture 3 (2 
females and 1 male), hip fracture 10 (5 male, 4 females, 1 unknown), humerus 
fracture 1 (1 male), ilium fracture 2 (2 males), lower limb fracture 3 (2 females and 1 
male), multiple fractures 1 (1 female), pelvic fracture 8 (6 males and 2 females), 
radius fracture 3 (2 male and 1 female), rib fracture 6 (5 males and 1 female), skull 
fracture 1 (1 female), spinal fracture 1 (1 female), spinal fracture nos 1 (1 female), 
tibia fracture 2 (2 males), ulna fracture 2 (1 male and 1 female), upper limb fracture 
1 (1 female), upper limb fracture nos 1 (1 female), wrist fracture 5 (3 females and 2 
males) 
 
Registries of Clinical Trials  
Individual Drug Companies 
GlaxoSmithKline  
Host: http://www.gsk-clinicalstudyregister.com 
Date Range:  
Date Searched: 23/08/10 
Number of Records Retrieved: 147 results, 39 protocols (117 phase III and IV 
studies and 38 protocols. 30 observational studies and 1 protocol) 
Description: Searched for rosiglitazone in phase III and IV studies and observational 
studies. 
Ongoing studies RCT - GSK TIDE study not due for completion until 2015 
 382 
RCT – GSK RECORD follow-up study due for completion 2012 
 
Takeda Pharmaceuticals (https://www.takeda.co.uk/) 
Emailed if have register on several occasions. No response. 
 
Drug Company Portals 
Clinical Study Results Database  
Host: http://www.clinicalstudyresults.org/ 
Date Searched: 23/08/10 
Number of Records Retrieved: 229 records 
Search strategy: 
Series of searches were undertaken; 
avandamet 15  
Avandamet,Avandamet XR 1 
Avandia 5 
Avandia XR 10 
Avandia:avandia 189 
actos 7 
actos, fortamet 2 
 
International Federation of Pharmaceutical Manufacturers and Associations 
(IFPMA) clinical trials portal  
Host: clinicaltrials.ifpma.org/ 
Date searched: 24/08/10 
Number of records retrieved: 84 records - Gaasbeek, BMD 48 weeks RCT in Kidney 
disease 
Search strategy: 
rosiglitazone AND fracture 11 (use synonyms selected includes avandia) 
rosiglitazone AND fractures 8 
rosiglitazone AND bone 33 
rosiglitazone AND bmd 6 
rosiglitazone AND osteoporosis 8 
avandaryl 0 
avaglim 0 
avandamet AND fracture 0 
avandamet AND fractures 0 
avandamet AND bone 2 
avandamet AND bmd 1 
avandamet AND osteoporosis 0 
glitazone  AND fracture 1 
glitazone  AND fractures 1 
glitazone  AND bone 2 
glitazone  AND bmd 0 
glitazone  AND osteoporosis 1 
glitazones  AND fracture 14 (use synonyms selected includes thiazolidinediones) 
glitazone  AND fractures 10 
glitazones  AND bone 31 
glitazones  AND bmd 6 
glitazones  AND osteoporosis 10 
thiazolidinedione AND fracture 7 
thiazolidinedione AND fractures  6 
thiazolidinedione AND bone 9 
thiazolidinedione AND bmd 1 
thiazolidinedione AND osteoporosis 6 
tzd AND fracture 10 
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tzd and fractures 4 
tzd AND bone 13 
tzd AND bmd 2 
tzd AND osteoporosis 5 
pioglitazone AND fracture 13 (use synonyms selected includes actos) 
pioglitazone AND fractures 7 
pioglitazone AND bone 38 
pioglitazone AND bmd 6 
pioglitazone AND osteoporosis 17 
actoplus AND fracture 0 
actoplus AND fractures 0 
actoplus AND bone 0 
actoplus AND bmd 0 
actoplus AND osteoporosis 0 
duetact AND fracture 0 
duetact AND fractures 0 
duetact AND bone 0 
duetact AND bmd 0 
duetact AND osteoporosis 0 
competact 0 
glustin AND fracture 0 
glustin AND fractures 0 
glustin AND bone 0 
glustin AND bmd 0 
glustin AND osteoporosis 0 
nyracta 0 
Venvia 0 
 
Lead Discovery 
Host: http://www.leaddiscovery.co.uk 
Date searched: 24/08/10 
Number of records retrieved: 36 records after deduplicaton. All from 
clinicaltrials.gov. 0 potentially relevant.  
Search strategy: 
Rosiglitazone 4 records, 0 potentially relevant 
Rosiglitazones 0 
Avandia 1, 0 potentially relevant 
Avandaryl 0 
avaglim 0 
avandamet 0  
glitazone 0 
glitazones 0 
thiazolidinedione 5 records, 0 potentially relevant 
thiazolidinediones  0 
tzd 0 
pioglitazone 27 records, 0 potentially relevant 
pioglitazones 0 
actos 0 
actoplus 0 
duetact 0 
competact 0 
glustin 0 
nyracta 0 
venvia 0 
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Other Portals 
Australian New Zealand Clinical Trials Registry (ANZCTR)  
Host: http://www.anzctr.org.au/ 
Date range: Last updated 12/07/10 
Date searched: 15/07/10 
Number of records retrieved: 15 records retrieved after duplicates removed. 1 
potentially relevant record. Grey (BMD 1 year rct, registered in 2007 = emailed 
author – replied no publication yet)  
Search strategy: 
Rosiglitazone 5 records, 1 potentially relevant 
Rosiglitazones 0 
Avandia 0 
Avandaryl 0 
avaglim 0 
avandamet 0  
glitazone 3 records, 1 potentially relevant 
glitazones 2 records,0 potentially relevant 
thiazolidinedione 8 records, 2 potentially relevant 
thiazolidinediones 8 records, 2 potentially relevant 
tzd 0 
pioglitazone 6 records, 1 potentially relevant 
pioglitazones 0 
actos 0 
actoplus 0 
duetact 0 
competact 0 
glustin 0 
nyracta 0 
venvia 0 
 
ClinicalTrials.gov 
Host: http://www.clinicaltrials.gov/ 
Date range: Last updated 13/07/10 
Date searched: 15/07/10 
Number of records retrieved: Series of searches carried out. 25 trials retrieved after 
deduplication 
rosiglitazone AND fracture 4 
rosiglitazone AND bone 11 
rosiglitazone AND bmd 4 
rosiglitazone AND osteoporosis 2 
avandia AND fracture 4 
avandia AND bone 11 
avandia AND bmd 4 
avandia AND osteoporosis 2 
avandaryl 0 
avaglim 0 
avandamet AND fracture 0 
avandamet AND bone 1 
avandamet AND bmd 1 
avandamet AND osteoporosis 0 
glitazone AND fracture 6 
glitazone AND bone 9 
glitazone  AND bmd 4 
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glitazone  AND osteoporosis 4 
thiazolidinedione AND fracture 6 
thiazolidinedione AND bone 9 
thiazolidinedione AND bmd 4 
thiazolidinedione AND osteoporosis 4 
tzd AND fracture 3 
tzd AND bone 3 
tzd AND bmd 0 
tzd AND osteoporosis 1 
pioglitazone AND fracture 4 
pioglitazone AND bone 15 
pioglitazone AND bmd 6 
pioglitazone AND osteoporosis 2 
actos AND fracture 4 
actos AND bone 15 
actos AND bmd 6 
actos AND osteoporosis 2 
actoplus  
duetact 
competact 1 
glustin AND fracture 4 
glustin AND bone 15 
glustin AND bmd 6 
glustin AND osteoporosis 2 
nyracta AND fracture 4 
nyracta AND bone 11 
nyracta AND bmd 4 
nyracta AND osteoporosis 2 
venvia AND fracture 4 
venvia AND bone 11 
venvia AND bmd 4 
venvia AND osteoporosis 2 
  
Current Controlled Trials  
Host: http://www.controlled-trials.com 
Date range: Last updated 14/07/10 
Date searched: 15/07/10 
Number of records retrieved: Series of searches carried out. Excluded 
clincialtrials.gov as this database was searched directly. 0 records retrieved 
Search strategy: 
rosiglitazone* AND fracture* 0 
rosiglitazone* AND bone 0 
rosiglitazone* AND bmd 0 
rosiglitazone* AND osteoporo* 0  
avandia 0 
avandaryl 
avaglim  
avandamet 0  
glitazone*  AND fracture* 0 
glitazone*  AND bone 0 
glitazone*  AND bmd 0 
glitazone*  AND osteoporo* 0  
thiazolidinedione* AND fracture* 0 
thiazolidinedione* AND bone 0 
thiazolidinedione* AND bmd 0 
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thiazolidinedione* AND osteoporo* 0 
tzd 0 
pioglitazone* AND fracture* 0 
pioglitazone* AND bone 0 
pioglitazone* AND bmd 0 
pioglitazone* AND osteoporo* 0 
actos 0 
competact 0 
glustin 0 
nyracta 0 
Venvia 0 
 
NIH Clinical Research Studies  
Host: http://clinicalstudies.info.nih.gov 
Date range: Last updated 15/07/10 
Date searched: 16/07/10 
Search results: Series of searches carried out. 2 records after duplicate records 
removed. No relevant records identified. 
Search strategy: 
rosiglitazone 0 
rosiglitazones 0 
avandia 0 
avandaryl 0 
avaglim 0 
avandamet 0 
glitazone 
glitazones  
thiazolidinedione 0 
thiazolidinediones 0  
tzd 0 
pioglitazone 2 
pioglitazones 0 
actos 1 
actoplus 0 
duetact 0 
competact 0 
glustin 0 
nyracta 0 
Venvia 0 
 
Trials Central  
Host: http://www.trialscentral.org 
Date Range: NS 
Date Searched: 16/07/10 
Search Results: Browse Find Clinical and Medical Drug Interventions for 
Hypoglycemic Agents, Rosiglitazone, pioglitazone. 133 entries for rosiglitazone, 141 
entries for pioglitazone. Entries browsed – 6 potentially relevant. 
 
WHO International Clinical Trials Registry Platform (ICTRP)  
Host: http://apps.who.int/trialsearch 
Date Range: Last updated 13/07/10 
Date Searched: 16/07/10 
Number of Records Retrieved: Series of searches carried out. 15 records retrieved 
after duplicates removed. 
Search strategy: 
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rosiglitazone* AND fracture* 0 
rosiglitazone* AND bone 5 
rosiglitazone* AND bmd 1 
rosiglitazone* AND osteoporo* 0  
avandia AND fracture* 0 
avandia AND bone 1 
avandia AND bmd 0 
avandia AND osteoporo* 0 
avandaryl 0 
avaglim 0 
avandamet AND fracture* 0 
avandamet AND bone 0 
avandamet AND bmd 0 
avandamet AND osteoporo* 0 
glitazone*  AND fracture* 0 
glitazone*  AND bone 1  
glitazone*  AND bmd 1 
glitazone*  AND osteoporo* 0  
thiazolidinedione* AND fracture* 1 
thiazolidinedione* AND bone 3 
thiazolidinedione* AND bmd 0 
thiazolidinedione* AND osteoporo* 2 
tzd AND fracture* 1 
tzd AND bone 1 
tzd AND bmd 0 
tzd AND osteoporo* 1 
pioglitazone* AND fracture* 0 
pioglitazone* AND bone 6 
pioglitazone* AND bmd 2 
pioglitazone* AND osteoporo* 1 
actos AND fracture* 0 
actos AND bone 0 
actos AND bmd 0 
actos AND osteoporo* 0 
actoplus 0 
duetact 0 
competact 0 
glustin 0 
nyracta 0 
Venvia 0 
 
Books and Journals 
Bulletins/Newsletters 
Adverse Drug Reactions Bulletin 
Host: http://www.ovid.com/site/catalog/Journal/3145.jsp 
Date Range: Volume 38 February 1973 - Volume 262 June 2010. 
Date Searched: 14/07/2010 
Search Results: No articles on rosi or pio. Bulletin on Drug-induced bone disease. 
(Dec 2005 pg. 903-906) but no mention of rosiglitazone or pioglitazone 
 
Canadian Adverse ReactionNewsletter (CARN)  
Host: http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/index-eng.php 
Date Range: January 1991; 1:1 - July 2010;3(2) 20 - Issue 3 - July 2010 
Date Searched: 14/07/10 
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Search Results: 3 articles on rosiglitazone but not in relation to fractures. No articles 
on pioglitazone. 
 
Clin-Alert 
Host: http://cla.sagepub.com 
Date range: 1990:28:1- 30 June 2010;48:9 
Date searched: 14/07/10 
Search results: 4 articles. Thiazolidinediones: Bone fractures. Volume 47, number 4 
February 28, 2009, Thiazolidinediones: fracture risk. Volume 46, number 10, May 
31 2008, Pioglitazone: FDA safety alert: increased risk of fractures. Volume 45 
number 1 2007, Rosilitazone: FDA safety alert: increased risk of fractures. Volume 
42 number 1 2007.  4 articles (two for Thiazolidinediones, one for pio and one for 
rosi). 4 references.  1 included reference, 1 fracture obs 
 
Drug Safety Update (previously Current Problems in Pharmacovigilance) 
Host: 
http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm 
Date Range: Current Problems in Pharmacovigilance 01 May 1990 - 01 May 2006, 
Drug Safety Update 01 Aug 2007 –Volume 3, Issue 12, July 2010 
Date Searched: 14/07/10 
Search Results: Rosiglitazone and pioglitazone: cardiovascular safety and fracture 
risk Drug Safety Update: Volume 1, Issue 3, October 2007 References Letters to 
healthcareprofessionals were sent in March and April, 2007. See 
http://www.mhra.gov.uk/mhra/HealthcareProfessionalLetters 
 
Drugs and Therapy Perspectives  
Host: http://www.ingentaconnect.com/content/adis/dtp 
Date Range: 1993;1:1 –Volume 26 Number 8, 1 August 2010 
Date Searched: 14/07/10 
Search Results: 1 referenced article – “Glitazones accelerate bone loss and 
increase the risk of fracture in patients with type 2 diabetes mellitus. Drugs & 
Therapy Perspectives: 1 January 2010 - Volume 26 - Issue 1 - pp 22-23 doi: 
10.2165/11203640-000000000-00000” containing 11 references of which 7 were 
included references/studies. 2 fracture RCTs, 2 bone RCTs, 1 observational study 
on fractures, 2 observational study on fractures. 
 
Medicines Safety Update (previously Australian Adverse Drug Reactions 
Bulletin) 
Host: http://www.tga.gov.au/adr/aadrb.htm  
Date Range: Australian Adverse Drug Reactions Bulletin 1995;14:1-2009;28:6. 
Medicines Safety Update 1:2010- 3:2010 
Date Searched: 14/07/10 
Search Results: “Thiazolidinediones and reduced bone density.  Australian Adverse 
Drug Reactions Bulletin. Volume 26, Number 5, October 2007”. Contains 4 
references. 2 included references, 1 fracture RCT, 1 bone RCT. 
 
Reactions PharmacoVigilance Insight (previously PharmaNewsFeed) 
Host: Wolters Kluwer Pharma Solutions http://bi.adisinsight.com/Login/Login.aspx 
Date Range: Version 7.3.1, 16 Feb 2010 
Date Searched: 21/07/10 
Search results: Includes full-text of the newsletters Inpharma, Pharmacoeconomics 
& Outcomes News and Reactions, Medline / Embase indexed journal titles. 20 news 
on rosiglitazone or pioglitazone with 38 references to the literature. 4 included 
references, 1 RCT fracture, 2 bone obs 1 bone RCT 
Search strategy: 
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Rosiglitazone OR Rosiglitazone-hydrochloride OR Rosiglitazone-maleate OR 
Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandia OR Avandaryl 
OR Avandamet OR Peroxisome-proliferator-activated-receptor-agonists OR 
Pioglitazone OR Pioglitazone-hydrochloride OR Pioglitazone/alogliptin OR 
Pioglitazone/candesartan-cilexetil OR Pioglitazone/glimepiride OR 
Pioglitazone/glimepiride/metformin OR Pioglitazone/metformin OR 
Pioglitazone/metformin/glimepiride Pioglitazone/sitagliptin Pioglitazone/TAK-536 
Actos Actoplus-Met Duetact Nyracta Venvia 
AND 
Text contains ‘"fracture*" OR "bone*" OR "osteoporo*" 
OR 
Drug is Rosiglitazone OR Rosiglitazone-hydrochloride OR Rosiglitazone-maleate 
OR Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandaryl OR 
Avandia OR Avandamet OR Peroxisome-proliferator-activated-receptor-agonists 
OR Pioglitazone OR Pioglitazone-hydrochloride OR Pioglitazone/glimepiride OR 
Pioglitazone/metformin OR Pioglitazone/TAK-536 OR Actos OR Actoplus-Met OR 
Duetact OR Nyracta OR Venvia  AND  
Text contains ‘"bmd"’ 
 
Rosiglitazone OR Rosiglitazone-hydrochloride OR Rosiglitazone-maleate OR 
Rosiglitazone/glimepiride OR Rosiglitazone/metformin OR Avandia OR Avandaryl 
OR Avandamet OR Peroxisome-proliferator-activated-receptor-agonists OR 
Pioglitazone OR Pioglitazone-hydrochloride OR Pioglitazone/alogliptin OR 
Pioglitazone/candesartan-cilexetil OR Pioglitazone/glimepiride OR 
Pioglitazone/glimepiride/metformin OR Pioglitazone/metformin OR 
Pioglitazone/metformin/glimepiride OR Pioglitazone/sitagliptin OR 
Pioglitazone/TAK-536 OR Actos Actoplus-Met OR Duetact OR Nyracta OR Venvia 
AND 
Text contains “bmd” 
 
Reactions Weekly 
Host: http://www.ovid.com/site/catalog/Journal/615.jsp 
Date Range: 11 January v383 1992 – v1309 10 July 2010 
Date Searched: 14/07/10 Search Results: 19 news articles with 37 references to the 
literature. 4 included references, 1 RCT fracture, 2 bone obs 1 bone RCT 
 
Specialist Journals 
Drug Safety (http://www.ingentaconnect.com/content/adis/dsf)  1998;18:1-
2010;33:6 
Pharmacoepidemiology and Drug Safety 
(http://www.pharmacoepi.org/publications/journal.cfm) 1998;7:1 – 2010;19:6 
 
Generic Journals (with highest number of articles on adverse effects)31 
Lancet (http://www.thelancet.com/) 1998;351:9095-2010;375:9731 
New England Journal of Medicine (http://content.nejm.org/) 1998:338;1- 
2010;362:24 
BMJ (www.bmj.com/) 1998;316:7124-2010;340:7759 
Annals of Pharmacotherapy (www.theannals.com/) 1998;32:1- 2010:44:6 
 
Diabetes Journals 
Diabetes (http://diabetes.diabetesjournals.org/) 1998; 47:1 - 2010;59:6 
Diabetes Care (http://care.diabetesjournals.org/) 1998;21:1-2010;33:6 
Diabetes Research and Clinical Practice 
(http://www.journals.elsevierhealth.com/periodicals/diab) 1998;39:1- 2010;89:1 
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Diabetic Medicine (http://www.wiley.com/bw/journal.asp?ref=0742-3071) 
1998:15:1-2010:27;6 
 
 
Referenced Monographs 
Adverse Drug Reactions653  
Host: Print edition/Book  
Date range: 2006 
Date searched: 09/07/10 
Search results: Chapter on musculoskeletal disorders discusses fractures but does 
not refer to either rosiglitazone and pioglitazone. Brief mention of rosiglitazone and 
pioglitazone in respect to hypoglycaemia in chapter on endocrine and metabolic 
disorders. 
 
AHFS drug information 
Host: http://www.medicinescomplete.com 
Date Range: June 2010 
Date Searched: 09/07/10 
Search results: Monographs for rosiglitazone and pioglitazone. Both contain section 
on fracture risk with 11 references in the rosigltiazone monograph and 7 references 
in the pioglitazone monograph. 12 references in total of which 4 were included 
references. 2 RCT fractures, 1 bone observational study, 1 fracture observational 
study 
 
Clinical Pharmacology  
Host: http://www.clinicalpharmacology.com 
Date Range: Not stated 
Date Searched: 09/07/10 
Search Results: Monographs for rosiglitazone and pioglitazone. Both contain 
section on fractures with references. 3 references in total. 1 fracture RCT. 
 
Davies Textbook of Adverse Drug Reactions654 
Host: Print edition/Book 
Date Range: 1998 5th edition 
Date Searched: 09/07/10 
Search Results: Organised by adverse effects. Chapter on muscle, bone and 
connective tissue disorders with section on fractures. No mention of any glitazones. 
 
Emedicine  
Host: http://www.emedicine.com 
Date Range: Not stated 
Date Searched: 09/07/10 
Search Results: Provides clinical overviews of over 6,800 topics. Entry for diabetes. 
Mentions risk of fractures with glitazones and reference to Loke et al 2009 CMAJ 
 
General Practice Notebook  
Host: http://www.gpnotebook.co.uk 
Date Searched: 09/07/10 
Search Results: Online encyclopaedia of medicine providing concise synopsis of the 
entire field of clinical medicine focussed on the needs of the General Practitioner.14 
pages retrieved with rosiglitazone or pioglitazone in title. Monograph entries for 
rosiglitazone and entry for pioglitazone, text on fractures refers to Loke et al 2009 
CMAJ.  
 
Martindale: the complete drug reference  
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Host: http://www.medicinescomplete.com 
Date Range: 22 Jun 2010: Martindale 3rd quarter 2010 update 
Date Searched: 09/07/10 
Search results: Evaluated information on drugs and medicines used throughout the 
world. Preparations summaries of more than 176,000 proprietary products from 40 
countries or regions are included.Monograph entry for Rosiglitazone and 
Pioglitazone. Text on fractures in monograph of rosiglitazone contained 6 
references and pioglitazone one reference. (7 in total), 4 included references  3 
RCTs fracture (representing 2 studies), 1 bone observational study 
 
Meylers’s Side Effects Of Drugs The International Encyclopedia of Adverse 
Drug Reactions and Interactions. Fifteenth Edition.  
Edited by: Jeffrey K. Aronson. Elsevier. 2006 and Pharmapendium 
Date Searched: 20/08/10 
Search results: 1 monograph for thiazolidinediones but  no mention of fractures, 
bone density or osteoporosis 
 
Side Effects of Drugs annual (SEDA) 
Host: Book published by Elsevier 
Edition: Aronson J. (editor) Side Effects of Drugs annual (SEDA) 31. 2009. San 
Diego, CA: Elsevier 
Date searched: July 2010 
Search results: Provides information relating to adverse drug reactions and 
interactions with references to published articles throughout text. Entry for 
thazolidinediones (glitazones) with section on fracture risk. Text discusses fracture 
risk and has 6 references. 5 included references, 2 fracture RCTs, 1 fracture 
observational, 2 bone RCTs 
 
ToxEd  
Host: https://members.toxed.com/login.aspx 
Edition: July 2010 
Date searched: 09/07/10 
Search results: Monograph for thiazolidinediones with references. Section on 
adverse reactions but no mention of fractures. 
 
Partially Referenced Monographs 
Drug Safety Portal 
Host: https://www.prosoftedc.com/aers/aers.html 
Date Range:  
Date Searched:  
Search Results: Contains FDA approved labeling for drugs.  Entry for 
rosiglitazone and pioglitazone. Fractures discussed in text. Refers to ADOPT study 
for rosi and PROactive study for pio. No citations for these studies given. 
 
The Merck Manual  
Host: http://www.merck.com/mmpe/index.html 
Date Range: Content last modified August 2007 
Date Searched: 07/07/10 
Search Results: Entry for diabetes with links online to lexi-com drug information. 
Entry for rosiglitazone discusses possible risk of fractures, bibliography at end of 
text but references not cited in text, entry for pioglitazone discusses possible risk of 
fractures, bibliography at end of text but references not cited in text.  2 references 
on fracture risk, both includes bone observational studies. 
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Non-referenced Monographs 
ABPI electronic Medicines Compendium (eMC)  
Host: http://emc.medicines.org.uk 
Date Searched: 09/07/10 
Search Results: Package leaflet, medicines guide and summary of product 
characteristics for rosiglitazone and pioglitazone. Discusses evidence on fracture 
but text is not referenced. 
 
Drugs.com, Drug Side Effects  
Host: http://www.drugs.com/sfx 
Date Searched: 09/07/10 
Search results: Provides peer-reviewed information on more than 24,000 
prescription drugs, over-the-counter medicines & natural products. Contains an 
entry for rosiglitazone and pioglitazone. Discusses possible side effects based on 
the literature but is not referenced. Refers to the ADOPT study. 
 
Mosby's Medical Drug Reference657 
Host: Print and Pharmapendium 
Edition: 2006 (now discontinued) 
Date Searched: August 2010 
Search results: Monographs for rosiglitazone and pioglitazone but no mention of 
fractures. 
 
Physicians Desk Reference (PDR)658 
Host: Print edition: Physicians Desk Reference (PDR) 2010 64th edition. Oradell, 
N.J.:Medical Economics Co. 
Edition: 2010, 64th edition 
Date searched: 07/07/10 
Search Results: Entry for rosiglitazone and pioglitazone. Fractures discussed in 
text. Refers to ADOPT study for rosi and PROactive study for pio. No citations for 
these studies given. Other references presented. 
 
RxList: The Internet Drug Index 
Host: http://www.rxlist.com 
Date searched: 02/07/10 
Search results: Monograph for rosiglitazone refers to the ADOPT study but the text 
is not referenced Monograph for pioglitazone refers to the PROACTIVE study but 
text is not referenced.  
 
Rxmed: Pharmaceutical Information   
Host: http://www.rxmed.com 
Date searched: 02/07/10 
Search Results: No entry for rosiglitazone or pioglitazone. 
 
 
Referenced Lists of Adverse Effects 
Litt’s Drug Eruption Global Database  
Host: http://www.drugeruptiondata.com/index.php 
Date Range: Drugs and references added each month 
Date Searched: 16/07/10 
Search Strategy: Searched on drug names: rosiglitazone, pioglitazone  
Search results: Entry for rosiglitazone and pioglitazone, fractures listed among 
adverse effects with 4 references for each drug (5 in total). 2 included studies, 1 
RCT fracture, 1 observational study on fractures. 
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Non-referenced Lists of Adverse Effects 
British National Formulary (BNF)  
Host: http://www.bnf.org/ 
Edition: March 2010 No.58 
Date Searched: 09/07/10 
Search Results: Entry for rosiglitazone and pioglitazone. Lists fractures as a risk 
factor. No data or references presented. 
 
Davis’s Drug Guide 
Host: http://www.drugguide.com/ 
Date Searched: 09/07/10 
Search Results: Entry for rosiglitazone and pioglitazone. Adverse effects listed but 
not referenced. 
 
Epocrates Online  
Host: www.epocrates.com (free trial online, subscription required) 
Date searched: 09/07/10 
Search results: Monograph for rosiglitazone and pioglitazone. Lists serious and 
common adverse reactions. Fractures listed as serious adverse reaction for both 
rosiglitazone and pioglitazone. No text, data or references presented. 
 
Modell’s Drugs in current use and new drugs656 
Edition: 2006  
Date searched: 24 August 2010 
Search results: Entry for rosiglitazone and pioglitazone but no mention of fractures. 
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 Included and excluded studies for case study systematic Appendix F:
review in Chapters 11 and 12 
 
Table 15.21 Included studies for case study systematic review 
Fracture RCTs 
Study 1 
DeFronzo RA. Actos Now for Prevention of Diabetes (ACT NOW). NCT00220961. 
Proceedings of the American Diabetes Association 68th Scientific Sessions: Late Breaking 
Clinical Studies. 2008 Jun 6–10; San Fransisco. Alexandria (VA) : The American Diabetes 
Association; 2008. 
Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, et al. ACTos NOW 
for the Prevention of Diabetes (ACT NOW) study. Diabetologia. 2008. 
Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CKS, Seeli AC, et al. 
Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing 
conversion of impaired glucose tolerance to diabetes in Asian Indians: Results of the Indian 
Diabetes Prevention Programme-2 (IDPP-2). Diabetologia. 2009 June;52(6):1019-26. 
Study 2 
Dormandy 2009 (PROACTIVE) Dormandy, J., M. Bhattacharya, et al. (2009). "Safety and 
Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes an Overview of Data 
from Proactive." Drug Safety 32: 187-202. 
Dormandy J, Charbonnel B, Eckland DJ, et al (2006) Secondary Prevention of 
Macrovascular Events in Patients With Type 2 Diabetes in the PROactive Study 
(PROspective PioglitAzone Clinical Trial In MacroVascular Events): A Randomised 
Controlled Trial. Lancet 366: 1279-1289. 
Study 3 
Gerstein, H., R. Ratner, et al. (2010). "Effect of rosiglitazone on progression of coronary 
atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the 
assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes 
patients with cardiovascular history trial." Circulation 121(10): 1176-87.  
GSK (2008) A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active 
Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of 
Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease 
(APPROACH) [study no AVD100521]. Brentford (UK): GlaxoSmithKine: 2008. 
http://www.gsk-clinicalstudyregister.com/ 
Study 4 
GSK (2008) Comparison of the action of the fixed association rosiglitazone-metformin and 
the free association of metformin plus glicazide on B-cell function in patients suffering from 
type 2 diabetes not controlled by metformin alone. Open, randomised, multi-centre, parallel 
group study over 3 years [study no AVAF4001]. GlaxoSmithKline. 
Study 5 
GSK (2009) A randomized, parallel group, double-blind, multi-center study comparing the 
efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment [study no 
AVT105913]. Brentford (UK): GlaxoSmithKine: 2009. http://www.gsk-
clinicalstudyregister.com/ 
Study 6 
GSK (2005) A randomised, multi-centre, phase IV, double-blind, parallel group study 
comparing the effects of 52 weeks administration of AVANDAMET and metformin plus 
sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly 
controlled on metformin [study no AVM100264]. Brentford (UK): GlaxoSmithKine: 2006. 
http://www.gsk-clinicalstudyregister.com/ 
Study 7 
GSK (2007) RAS Rosiglitazone and atherosclerosis study: A 1 year randomised, double 
blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the 
progression of intima-media thickness in the carotid artery in subjects with insulin resistance 
syndrome and/or type 2 diabetes mellitus [study no BRL-049653/334]. Brentford (UK): 
GlaxoSmithKine: 2007. http://www.gsk-clinicalstudyregister.com/ 
Study 8 
GSK (2008) Rosiglitazone and Plaque Study: A 12 Month Randomised, Double-blind, 
 395 
Table 15.21 Included studies for case study systematic review 
Placebo-controlled, Magnetic Resonance Imaging Study to Evaluate the Effect of 
Rosiglitazone on the Structure and Composition of Carotid Atherosclerotic Plaques in 
Subjects with Type 2 Diabetes Mellitus and Coexisting Vascular or hypertension [study no 
49653/351]. Brentford (UK): GlaxoSmithKine: 2008. http://www.gsk-
clinicalstudyregister.com/ 
Study 9 
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone 
evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes 
(RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35. 
GSK (2008) RECORD: Rosiglitazone evaluated for cardiac outcomes and regulation of 
glycaemia in diabetes: A long term, open label, randomised study in patients with type 2 
diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea 
with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia [study no BRL-
049653/231]. Brentford (UK): GlaxoSmithKine: 2008. http://www.gsk-
clinicalstudyregister.com/ 
Study 10 
Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus 
glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 
2006;26(10):1388-95. 
Study 11 
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-
associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression 
trial (ADOPT). Diabetes Care. 2008 May;31(5):845-51. 
GSK (2007) A randomized, double-blind study to compare the durability of glucose lowering 
and preservation of pancreatic beta-cell function of rosiglitazone monotherapy compared to 
metformin or glyburide/gibenclamide in patients with drug-naive, recently diagnosed type 2 
diabetes mellitus [study no BRL-049653/048]. Brentford (UK): GlaxoSmithKine: 2007. 
http://www.gsk-clinicalstudyregister.com/ 
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic 
Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. NEJM. 
2006;355(23):2427-43. 
Kahn SE, Haffner SM, Lachin JM, Herman WH, Zinman B, Holman RR, et al. Increased 
incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome 
Progression Trial). Diabetologia. 2007 Sep;50:0077. 
Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, et al. Effect of 
rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. 
Journal of Clinical Endocrinology & Metabolism.  Jan;95(1):134-42. 
Study 12 
Kaku K, Daida H, Kashiwagi A, Yamashina A, Yamazaki T, et al. (2009) Long-term effects of 
pioglitazone in Japanese patients with type 2 diabetes without a recent history of 
macrovascular morbidity. Current Medical Research and Opinion 25: 2925-2932. 
Study 13  
Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of 
pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 
diabetes: the PERISCOPE randomized controlled trial. JAMA : the journal of the American 
Medical Association. 2008;299(13):1561-73. 
Study 14 
Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on 
oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract 
2008;79:453-60. 
Study 15 
Tolman KG, Freston JW, Kupfer S, Alfonso P. Liver safety in patients with type 2 diabetes 
treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study in 
the US. Drug Safety. 2009;32(9):787-800. 
Fracture Observational Studies 
Study 1 
Aubert R, Herrera V, Chen W, Haffner S, Pendergrass M (2010) Rosiglitazone and 
pioglitazone increase fracture risk in women and men with type 2 diabetes Diabetes, Obesity 
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and Metabolism 12: 716-721. 
Aubert R (2009) Thiazolidinedione Treatment Increases the Risk of Fracture. 69th Annual 
Scientific Sessions of the American Diabetes Association, . Morial Convention Center, New 
Orleans, Louisiana. 
Study 2 
Bilik D, McEwen L, Brown M, Pomeroy N, Kim C, et al. (2010) Thiazolidinediones and 
Fractures: Evidence from Translating Research into Action for Diabetes. J Clin Endocrinol 
Metab. 
Study 3 
Colhoun HM, GRP TSDRNE. Thiazolidinedione Associated Fractures Are Not Limited to 
Distal Fractures and Occur in Men as Well as Women; 2010 26-29 June; Orlando, Florida. 
Study 4 
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM (2009) Thiazolidinediones and 
fractures in men and women. Arch Intern Med 169: 1395-1402. 
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM (2009) Thiazolidinediones and 
Fractures in Men and Women. Pharmacoepidemiology and Drug Safety 18: S193-S193. 
Study 5 
Douglas IJ, Evans SJ, Pocock S, Smeeth L (2009) The Risk of Fractures Associated with 
Thiazolidinediones: A Self-controlled Case-Series Study. Plos Medicine 6. 
Study 6 
Gau CS, Lin YS (2009) Use of Thiazolidinediones and the Risk of Fracture in Patients with 
Type II Diabetes in Taiwan. Pharmacoepidemiology and Drug Safety 18: S192-S193. 
Study 7 
Fracture diagnoses in patients receiving monotherapy with antidiabetic agents, including 
hand and foot fractures. GSK WEUSRTP2181. Brentford (UK): GlaxoSmithKine: 2008. 
http://www.gsk-clinicalstudyregister.com/ 
Study 8 
Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, et al. (2010) Thiazolidinedione Use 
and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus. Journal of 
Clinical Endocrinology & Metabolism 95: 592-600. 
Study 9 
Hsiao FY, Mullins CD (2010) The association between thiazolidinediones and hospitalisation 
for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control 
study. Diabetologia 53: 489-496. 
Study 10 
Irvine D, Wise L (2008) An analysis of glitazone use and small bone fractures using the 
General Practice Research Database (GPRD) database. Pharmacoepidemiology and Drug 
Safety 17: 397. 
Study 11 
Jones SG, Momin SR, Good MW, Shea TK, Patric K (2009) Distal Upper and Lower Limb 
Fractures Associated With Thiazolidinedione Use. American Journal of Managed Care 15: 
491-496. 
Study 12 
Lee J, Choi NK, Jung SY, Kim YJ, Seong JM, et al. (2009) Evaluation of Thiazolidinedione 
Related Risk of Fracture. Pharmacoepidemiology and Drug Safety 18: S153-S153. 
Study 13 
Mancini T, Mazziotti G, Doga M, Carpinteri R, Simetovic N, et al. (2009) Vertebral fractures 
in males with type 2 diabetes treated with rosiglitazone. Bone 45: 784-788. 
Study 14 
Meier C, Kraenzlin ME, Bodmer M, Jick SS, et al. (2008) Use of thiazolidinediones and 
fracture risk (ref art 594579 and 594582). Arch Intern Med 168: 820-825. 
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, et al. (2008) Thiazolidinedione use and 
osteoporotic fracture risk. Calcified Tissue International 82: S29. 
Study 15 
Rodriguez A, Cipres L, Tofe S, Polavieja P, Reviriego J (2010) Clinical evaluation of 
combined therapy for type 2 diabetes. Current Medical Research and Opinion 26: 1171-
1183. 
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Study 16 
Solomon DH, Cadarette SM, Choudhry NK, Canning C, et al. (2009) A cohort study of 
thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 94: 
2792-2798. 
Study 17 
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, et al. (2009) Risk of cardiovascular 
disease and all cause mortality among patients with type 2 diabetes prescribed oral 
antidiabetes drugs: retrospective cohort study using UK general practice research database. 
BMJ 339. 
Study 18 
Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T (2008) Serum pentosidine 
levels are positively associated with the presence of vertebral fractures in postmenopausal 
women with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 93: 1013-1019. 
Bone Mineral Density RCTs 
Study 1 
BILEZIKIAN J, BORGES J, PANELO A, CHANG C, NINO A, et al. Effects of 
Rosiglitazone/Metformin FDC on BMD after 80 Weeks of Treatment in Drug-Naive T2DM 
Subjects; 2010 26-29 June; Orlando, Florida. 
Study 2 
Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP (2008) Association of 
pioglitazone treatment with decreased bone mineral density in obese premenopausal 
patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin 
Endocrinol Metab 93: 1696-1701. 
Glintborg D, Andersen M, Hagen C, Hermann A (2007) Pioglitazone treatment significantly 
decreased bone mineral density in a randomised placebo-controlled study in patients with 
polycystic ovary syndrome. Calcified Tissue International 80: S161. 
Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP (2008) Association of 
Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal 
Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. 10th 
European Congress of Endocrinology (ECE 2008), Berlin (Germany). 
Study 3 
Grey A, Bolland M, Gamble G, Wattie D, et al. (2007) The peroxisome proliferator-activated 
receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density 
in healthy postmenopausal women: a randomized, controlled trial (ref art 574984). J Clin 
Endocrinol Metab 92: 1305-1310. 
Grey A, Bolland M, Gamble G, Wattie D, Home A, et al. (2007) The peroxisome-proliferator-
activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral 
density in healthy postmenopausal women: A randomized, controlled trial. Bone 40: S133-
S133. 
Reid IR, Grey AB (2009) TZDs and bone. 20th World Diabetes Congress : abstr 0127,   . 
Montreal: Available from: URL: http://www.worlddiabetescongress.org/ . Odense University 
Hospital, Dept. of Endocrinology, Odense C, Denmark. 
Study 4 
GSK (2005) A six-month double-blind, randomised, parallel-group study to compare the 
effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy 
(less than or equal to 15 mg daily) on body fat distribution when administered to subjects 
with type 2 diabetes mellitus [study no BRL-049653/369]. GlaxoSmithKline. 
Study 5 
Sui HG, X.-s. Geng, X.-q. (2009) Effects of Metformin and Rosiglitazone on Bone Mineral 
Density in Newly Diagnosed Male Patients with Type 2 Diabetes Mellitus    CHINESE 
JOURNAL OF PREVENTION AND CONTROL OF CHRONIC NON COMMUNICABLE 
DISEASES  17: 577-578. 
Observational Studies on Bone Mineral Density 
Study 1 
Carteni B, D'Adamo M, Micchelini B, Guglielmi V, Donadel G, et al. (2008) Effect of 
thiazolidinediones on bone metabolism in diabetic patients. Diabetologia 51: S370-S371. 
D'Adamo M, Carteni B, Micchelini B, Guglielmi V, Donadel G, et al. (2008) Effect of 
thiazolidinediones on bone metabolism in diabetic patients. Diabetes 57: A599-A599. 
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Study 2 
Li HC, R. Cai, H. Wu, G. Lv, Z. Sheng, C. Cheng, X. Li, F. Yu, Y.  (2010) The effect of 
thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes  
JOURNAL OF BONE AND MINERAL METABOLISM  28: 77-81. 
Study 3 
Schwartz A, Sellmeyer D, Vittinghoff E (2006) Thiazolidinedione Use and Bone Loss in 
Older Diabetic Adults. J Clin Endocrin Metab 91: 3349-3354. 
Schwartz AV, Sellmeyer DE, Feingold KR, Strotmeyer E, Resnick HE, et al. (2002) 
Thiazolidinedione (TZD) use and bone density in older adults with diabetes. Diabetes 51: 
961. 
Schwartz AV, Sellmeyer DE, Vintinghoff E, Palermo L, Feingold KR, et al. (2005) 
Thiazolidinedione (TZD) use and change in bone density in older diabetic adults. Diabetes 
54: A41-A41. 
Study 4 
Yaturu S, Bryant B, Jain SK (2007) Thiazolidinedione treatment decreases bone mineral 
density in type 2 diabetic men (ref art 576504). Diabetes Care 30: 1574-1576. 
Yaturu S (2006) Decreased bone mineral density with thiazolidinediones. Journal of Bone 
and Mineral Research 21: S178-S178. 
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Study Reason for 
exclusion 
Fracture RCTs 
DeFronzo RA. Actos Now for Prevention of Diabetes (ACT NOW). 
NCT00220961. Proceedings of the American Diabetes Association 68th 
Scientific Sessions: Late Breaking Clinical Studies. 2008 Jun 6–10; San 
Fransisco. Alexandria (VA) : The American Diabetes Association; 2008 
No data from 
abstract. Loke et 
al 2008
265
 
contacted 
authors. 
Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, et 
al. ACTos NOW for the Prevention of Diabetes (ACT NOW) study. 
Diabetologia. 2008. 
Not enough data 
 
Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to 
sulfonylurea or metformin on oral glucose tolerance in patients with type 2 
diabetes. Diabetes Res Clin Pract 2008;79:453-60. 
No data from 
abstract. Loke et 
al 2008
265
 
contacted 
authors. 
Abe M, Okada K, Kikuchi F, Matsumoto K. Clinical investigation of the 
effects of pioglitazone on the improvement of insulin resistance and blood 
pressure in type 2-diabetic patients undergoing hemodialysis. Clinical 
Nephrology 2008;70:220-28 
No fractures in 
both study arms 
Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K. 
Clinical effectiveness and safety evaluation of long-term pioglitazone 
treatment for erythropoietin responsiveness and insulin resistance in type 
2 diabetic patients on hemodialysis. Expert Opinion on Pharmacotherapy 
2010;11:1611-20. 
No fractures in 
both study arms 
Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. 
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic 
Subjects With Nonalcoholic Steatohepatitis. Gastroenterology 
2008;135:1176-84. 
No fractures in 
both study arms 
American Diabetes Association 2010 Diabetes drug rosiglitazone not 
associated with increased risk of death, stroke, or heart attacks in BARI 
2D study? 
Compares 
insulin 
sensitising drugs 
with insulin 
providing drugs. 
No separate 
analysis for 
rosiglitazone or 
pioglitazone 
presented. 
Beck-Nielsen. H. Results of the RECORD1 Trial. 20th World Diabetes 
Congress : abstr. 0125, 18 Oct 2009. Available from: URL: 
http://www.worlddiabetescongress.org/ . Odense University Hospital, 
Dept. of Endocrinology, Odense C, Denmark  
Rosiglitazone 
group had 
increased upper 
and distal lower 
limb fractures 
(no data) 
Gruntmanis U, Fordan S, Ghayee HK, Abdullah SM, See R, Ayers CR, et 
al. The Peroxisome Proliferator-Activated Receptor-gamma Agonist 
Rosiglitazone Increases Bone Resorption in Women with Type 2 
Diabetes: A Randomized, Controlled Trial. Calcified Tissue International 
2010;86:343-49.  
Less than 12 
months follow-
up 
 
A 16 week randomized, double-blind, parallel group study to evaluate the 
efficacy and safety of a new medication (GSK523338) to lower LDL-c and 
HbA1c in subjects with type 2 diabetes mellitus. GSK AVS101946. 
Brentford (UK): GlaxoSmithKine: 2007. http://www.gsk-
clinicalstudyregister.com/ 
Compares 
different 
dosages of 
rosiglitazone 
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A 24 week randomized, double-blind, double-dummy, multicenter study to 
compare the efficacy of formulation X and AVANDIA (8mg OD) in subjects 
with diabetes mellitus. GSK AXR100723. Brentford (UK): GlaxoSmithKine: 
2007. http://www.gsk-clinicalstudyregister.com/ 
No data on 
control 
 
A 24 week randomized, double-blind, double-dummy, multicenter study to 
evaluate the safety, efficacy and tolerability of oral formulation X and 
AVANDIA (4mg BD) in patients with type 2 diabetes. GSK BRL-
049653/183. Brentford (UK): GlaxoSmithKine: 2005. http://www.gsk-
clinicalstudyregister.com/ 
No data on 
control 
 
A randomized, open-label, parallel group study to evaluate the 
management of rosiglitazone-related fluid retention by investigating the 
effect of diuretics on plasma volume in subjects with type 2 diabetes 
mellitus treated for twelve weeks with rosiglitazone 4mg bd in addition to 
background anti-diabetic agents. GSK BRL-049653/342. Brentford (UK): 
GlaxoSmithKine: 2007. http://www.gsk-clinicalstudyregister.com/ 
Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G. 
Effect of various diutretic treatments on rosiglitazone-induced fluid 
retention. J Am Soc Neph 2006;17(12):3482-90. 
Adverse effects 
not listed by 
rosiglizone 
treatment and 
control 
A randomized, double blind, placebo controlled, parallel group study to 
assess the safety and efficacy of three dose levels of rosiglitazone 
maleate in the treatment of chronic plaque psoriasis. GSK BRL-
049653/330. Brentford (UK): GlaxoSmithKine: 2005. http://www.gsk-
clinicalstudyregister.com/ 
Compares 
different 
dosages of 
rosiglitazone 
A randomized, double-blind, placebo-controlled, parallel group study to 
assess the safety and efficacy of rosiglitazone maleate in the treatment of 
chronic plaque psoriasis. GSK BRL-049653/331. Brentford (UK): 
GlaxoSmithKine: 2007. http://www.gsk-clinicalstudyregister.com/ 
Combination of 
drugs used, not 
RSG alone 
A 16 week randomized, double blind, parallel group, placebo-controlled 
study to evaluate the effect of rosiglitazone on myocardial glucose uptake 
in subjects with type 2 diabetes mellitus and stable coronary heart 
disease. GSK BRL-049653/352. Brentford (UK): GlaxoSmithKine: 2005. 
http://www.gsk-clinicalstudyregister.com/ 
Less than 12 
months follow-
up 
A 24-week, double blind, double dummy, randomized, parallel group study 
to investigate the effects of rosigliazone (extended release tablets), 
donepezil, and placebo as monotherapy on cognition and overall clinical 
response in APOE 4-stratified subjects with mild-to-moderate Alzheimer’s 
disease (REFLECT-1). GSK AVA105640. Brentford (UK): 
GlaxoSmithKine: 2008. http://www.gsk-clinicalstudyregister.com/ 
Mild to moderate 
Alzheimer's 
disease and less 
than 12 months 
follow-up 
A 54-week, double-blind, randomized, placebo-controlled, parallel-group 
study to investigate the effects of rosiglitazone (extended release tablets) 
as adjunctive therapy to acetylcholinesterase inhibitors on cognition and 
overall clinical response in APOE 4-stratified subjects with mild to 
moderate Alzheimer’s disease (REFLECT-3). GSK AVA102670. Brentford 
(UK): GlaxoSmithKine: 2009. http://www.gsk-clinicalstudyregister.com/ 
Mild to moderate 
Alzheimer's 
disease 
A 54-week, double-blind, randomized, placebo-controlled, parallel-group 
study to investigate the effects of rosiglitazone (extended release tablets) 
as adjunctive therapy to donepezil on cognition and overall clinical 
response in APOE 4-stratified subjects with mild to moderate Alzheimer’s 
disease (REFLECT-2). GSK AVA102672. Brentford (UK): 
GlaxoSmithKine: 2009. http://www.gsk-clinicalstudyregister.com/ 
Mild to moderate 
Alzheimer's 
disease 
 
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-
Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) 
Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 
Less than 12 
months follow-
up 
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exclusion 
Diabetes Mellitus Who Are Inadequately Controlled On Insulin. GSK BRL-
049653/347. Brentford (UK): GlaxoSmithKine: 2006. http://www.gsk-
clinicalstudyregister.com/ 
Hollander P, Weston WM, Huang C, Chou H, and Porter LE. Low dose 
rosiglitazone significantly improves glycemic 
control without increasing adverse events in patients with T2DM not well 
controlled on insulin. Diabetes 2005;54(suppl 
1):A3-4. Abstract 12-OR. 
A Phase III, 24 week, multi-centre, double-blind, randomized, parallel 
group study comparing the effects of Avandamet (8mg/200mg). Plus 
insulin to placebo plus insulin on change in Hba1c, in subjects with type 2 
diabetes starting insulin therapy. GSK SB-712753/009. Brentford (UK): 
GlaxoSmithKine: 2007. http://www.gsk-clinicalstudyregister.com/ 
Home P, Bailey C, Donaldson J, Chen H, Stewart M. A double-blind 
randomized study comparing the effects of continuing or not continuing 
rosiglitazone+metformin therapy when starting insulin therapy in people 
with type 2 diabetes. Diabetic Med. 2007 
Less than 12 
months follow-
up 
A phase III, 24 week, multi-centre, randomisedm, double-blind, parallel 
group, dose escalation study of Advandamet (rosiglitazone/metformin) 
and high dose metformin monotherapy in subjects with poorly controlled 
type 2 diabetes mellitus. GSK SB-712753/002. Brentford (UK): 
GlaxoSmithKine: 2007. http://www.gsk-clinicalstudyregister.com/ 
Bailey C, Bagdonas A, Rubes J, McMorn S, Donaldson J, Biswas N, 
Stewart M. Rosiglitazone/metformin fixed-dose combination compared 
with uptitrated metformin alone in type 2 diabetes. Clinical Therapeutics. 
2005;27(10): 1548-61. 
Less than 12 
months follow-
up 
Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison 
of fixed-dose rosiglitazone/metformin combination therapy with 
sulphonylurea plus metformin in overweight individuals with Type 2 
diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol 
Diabetes 2008; 116: 6– 1 3 
Related 
publication to 
GSK 
AVM100264 but 
contains no 
fracture data 
Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone 
and carotid IMT progression rate in a mixed cohort of patients with type 2 
diabetes and the insulin resistance syndrome: main results from the 
Rosiglitazone Atherosclerosis Study. J Intern Med. 2007 Mar;261(3):293-
305. 
 
Related 
publication to 
GSK BRL-
049653/334 but 
contains no 
fracture data 
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, 
Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for 
Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): 
study design and protocol. Diabetologia. 2005 Sep;48(9):1726-35.  
Related 
publication to 
GSK BRL-
049653/231 but 
contains no 
fracture data 
Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, 
Komajda M, Curtis P; RECORD Study Group. Rosiglitazone RECORD 
study: glucose control outcomes at 18 months. Diabet Med. 2007 
Jun;24(6):626-34. 
Related 
publication to 
GSK BRL-
049653/231 but 
contains no 
fracture data 
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, 
Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone 
evaluated for cardiovascular outcomes--an interim analysis. N Engl J 
Med. 2007 Jul 5;357(1):28-38. 
Related 
publication to 
GSK BRL-
049653/231 but 
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contains no 
fracture data 
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, 
Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT 
Study Group. Obesity is a major determinant of the association of C-
reactive protein levels and the metabolic syndrome in type 2 diabetes. 
Diabetes. 2006 Aug;55(8):2357-64. 
Related 
publication to 
GSK BRL-
049653/048 but 
contains no 
fracture data 
Karalliedde 200 1. Karalliedde J, Buckingham RE. Choice of monotherapy 
in newly diagnosed type 2 diabetic patients: Clinical perspective of 
ADOPT. Therapy 2007;4:535-40.  
2. Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-
related adverse effects: Facts, fiction and putative management 
strategies. Drug Safety 2007;30:741-53.  
ADOPT trial but 
no fracture data 
Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini 
A, Jones NP, Gomis R, Home PD; RECORD Study Group. Effect of the 
addition of rosiglitazone to metformin or sulfonylureas versus 
metformin/sulfonylurea combination therapy on ambulatory blood 
pressure in people with type 2 diabetes: a randomized controlled trial (the 
RECORD study). Cardiovasc Diabetol. 2008 Apr 24;7:10. 
Related 
publication to 
GSK BRL-
049653/231 but 
contains no 
fracture data 
Mayor S. Rosiglitazone associated with slower monotherapy failure... 
International Diabetes Federation 19th World Diabetes Congress, Cape 
Town, South Africa, 3rd-7th December 2006. British Journal of Diabetes & 
Vascular Disease 2006;6:290-90 
ADOPT trial but 
no fracture data 
Nesto RW. Effect of rosiglitazone versus glipizide on pregression of 
coronary atherosclerosis in patients with type 2 diabetes and coronary 
artery disease. American Heart Association Scientific Sessions. 
November 12, 2008, New Orleans, LA. 
http://directnews.americanheart.org/extras/pdfs/approach_slides.pdf 
Related 
publication to 
GSK 
AVD100521 but 
contains no 
fracture data 
Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of 
pioglitazone/metformin fixed-dose combination therapy compared with 
pioglitazone and metformin monotherapy in treating patients with T2DM. 
Current Medical Research and Opinion 2009;25:2915-23.  
Less than 12 
months follow-
up 
Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Kolatkar 
NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group. 
Assessment on the prevention of progression by rosiglitazone on 
atherosclerosis in diabetes patients with cardiovascular history 
(APPROACH): study design and baseline characteristics. Am Heart J. 
2008; 156(6): 1074-9. 
Related 
publication to 
GSK 
AVD100521 but 
contains no 
fracture data 
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, 
Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, 
Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. 
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N 
Engl J Med. 2010 May 6;362(18):1675-85. 
Nonalcoholic 
steatohepatitis 
Scheen AJ, Tan MH, Betteridge DJ, Birkeland K, Schmitz O, et al. (2009) 
Long-term glycaemic effects of pioglitazone compared with placebo as 
add-on treatment to metformin or sulphonylurea monotherapy in 
PROactive (PROactive 18). Diabetic Medicine 26: 1242-1249. 
subgroup 
analysis of data 
in Dormandy 
2009 
Tripathy D, Banerji MA, Bray GA, Buchanan TA, Clement S, Henry RR, et 
al. ACTos NOW for the Prevention of Diabetes (ACT NOW) study. 
Diabetologia 2008.  
Impaired 
glucose 
intolerance 
(ACTos NOW) 
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Study Reason for 
exclusion 
Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, 
Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed 
MI. A diabetes outcome progression trial (ADOPT): an international 
multicenter study of the comparative efficacy of rosiglitazone, glyburide, 
and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 
2002 Oct;25(10):1737-43. 
Related 
publication to 
GSK BRL-
049653/048 but 
contains no 
fracture data 
Viberti GC KS, Haffner S, Herman W, Holman R, Lachin J, Zinman B, 
Heise MJN, Kravitz B, O'Neill C, ADOPT Study Group. Results of the 
ADOPT trial  In: Diabetic Medicine 23 (Suppl. 4): 43 (plus oral 
presentation) abstr. 97, Dec 2006 . King's College London School of 
Medicine, London, England; GlaxoSmithKline, King of Prussia, 
Pennsylvania, USA  2006.  
ADOPT trial but 
no fracture data 
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, 
Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; for the ADOPT 
Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline 
characteristics of Type 2 diabetic patients in North America and Europe. 
Diabet Med. 2006 Dec;23(12):1289-94. 
Related 
publication to 
GSK BRL-
049653/048 but 
contains no 
fracture data 
Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; 
ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive 
recently diagnosed patients with type 2 diabetes in North America and 
Europe. Diabetes. 2004 Dec;53(12):3193-200. 
Related 
publication to 
GSK BRL-
049653/048 but 
contains no 
fracture data 
Zinman B, Haffner SM, Herman WH, Holman RR, et al. Effect of 
rosiglitazone, metformin, and glyburide on bone biomarkers in patients 
with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 
2010;95:134-42.  
Combination of 
drugs used, not 
RSG alone 
Fractures observational studies  
Giorgadez No actual 
description of 
numbers of 
fractures 
An open-label extension study of the long-term safety and efficacy of 
rosiglitazone extended-release (RSG XR) as adjunctive therapy to 
acetylcholinesterase inhibitors in subjects with mild-to-moderate 
Alzheimer’s desease (REFLECT-4). GSK AVA102675. Brentford (UK): 
GlaxoSmithKine: 2009. http://www.gsk-clinicalstudyregister.com/ 
no control arm 
An open-label extension study of the long-term safety and efficacy of 
rosiglitazone extended release (RSG XR) in subjects with mild to 
moderate Alzheimer’s disease (REFLECT-5). GSK AVA102677. Brentford 
(UK): GlaxoSmithKine: 2009. http://www.gsk-clinicalstudyregister.com/ 
no control arm 
AVA-177: Avandia in daily practice. GSK 49653/177 (AVA-177/2000). 
Brentford (UK): GlaxoSmithKine: 2005. http://www.gsk-
clinicalstudyregister.com/ 
no control arm 
AVA-295: Avandia in daily practice GSK 49653/295 (AVA-295/2001). 
Brentford (UK): GlaxoSmithKine: 2006. http://www.gsk-
clinicalstudyregister.com/ 
no control arm 
AVANTAGE: Monitoring a patient cohort with Avandia – Evaluation of 
safety data. GSK ROSF4003 (101732). Brentford (UK): GlaxoSmithKine: 
2005. http://www.gsk-clinicalstudyregister.com/ 
no control arm 
A 24-week open study to investigate the effectiveness, tolerability and Crossover study 
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exclusion 
efficacy to reach HbA1c-goals of a new oral antidiabetic drug 
(Avandamet) in patients with type 2 diabetes with inadequate glycemic 
control under metformin monotherapy. GSK 712753/100420 (ZIEL). 
Brentford (UK): GlaxoSmithKine: 2005. http://www.gsk-
clinicalstudyregister.com/ 
The association between exposure to spironolactone or amiloride and 
fracture risk among subjects treated with thiazolidinediones. GSK 
WWE113332/WEUSKOP4103. Brentford (UK): GlaxoSmithKine: 2005. 
http://www.gsk-clinicalstudyregister.com/ 
Does not have 
non-TZD 
comparator 
group 
Influence of guidance-compliant treatment of diabetes mellitus type 2 on 
effectiveness and costs (LEADIT/ADIT). GSK AVA371. Brentford (UK): 
GlaxoSmithKine: 2006. http://www.gsk-clinicalstudyregister.com/ 
Compares 
guidelines vs. no 
guidelines, and 
not TZD vs. no 
TZD 
Spanheimer 2007 Observation of an increased incidence of fractures in 
female patients who received long-term treatment with ACTOS 
(pioglitazone HOI) tablets for type 2 diabetes mellitus. 
http://www.fda.gov/medwatch/safety/ 2007/Actosmar0807.pdf 
Aggregated data 
from Takeda 
RCTs - no study 
level data 
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients 
with diabetes mellitus, and the impact of insulin and oral antidiabetic 
medication on relative fracture risk. Diabetologia 2005;48:1292-99.  
No specific TZD 
data 
Melton LJIIII, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) 
Fracture risk in type 2 diabetes: Update of a population-based study. 
Journal of Bone and Mineral Research 23: 1334-1342. 
Had risk data 
but was 
excluded as it 
was unclear 
what the control 
group was and 
how the risk was 
statistically 
calculated. 
Monami M, Cresci B, Colombini A, Pala L, Balzi D, et al. (2008) Bone 
Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients A 
case-control study. Diabetes Care 31: 199-203 
No data 
Bone Mineral Density RCTs 
Sui H, Guo XS, Geng XQ. Effects of Metformin and Rosiglitazone on 
Bone Mineral Density in Newly Diagnosed Male Patients with Type 2 
Diabetes Mellitus   Chinese Journal of Prevention and Control of Chronic 
Non Communicable Diseases  2009;17:577-8.  
Chinese 
language 
BANERJI MA, SIGNAEVSKI M, LEBOVITZ HE (2010) Changes in Bone 
Mineral Density in Patients with Type 2 Diabetes Treated with 
Rosiglitazone vs. Glypizide. A Randomized Trial. American Diabetes 
Association 70th Scientific Session. Orlando, Florida. 
Risk data 
available but 
format not 
suitable for 
meta-analysis. 
 
Schindler KR, A. Tura, A. Gmeinhardt, B. Touzeau-Romer, V. Haider, D. 
Pacini, G. Ludvik, B. (2009) The Effect of Rosiglitazone on Insulin 
Sensitivity, Beta Cell Function, Bone Mineral Density, and Body 
Composition in HIV-positive Patients on Highly-active Antiretroviral 
Therapy (HAART)    HORMONE AND METABOLIC RESEARCH  41: 573-
579. 
This has data 
but is on HIV 
patients 
receiving a 
variety of 
different drugs.  
Strotmeyer ES, Boudreau RM, Marshall LM, Schwartz AV, Bauer DC, et 
al. (2008) Higher Bone Mineral Density Loss in Older Men with Diabetes: 
The Osteoporotic Fractures in Men Study. Journal of Bone and Mineral 
Risk data not 
usable in meta-
analysis 
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Research 23: S59. 
Tsagareli M, Giorgadze E, Jikurauli N, Chachibaia V, Lomidze M, et al. 
(2009) Bone turnover and bone mineral density in type2 diabetes patients 
treated with rosiglitazone. Bone -New York- 44 S386. 
Before and after 
study with no 
controls 
Barbour KE, Zmuda JM, Strotmeyer ES, Horwitz MJ, Boudreau R, Evans 
RW, et al. Correlates of Trabecular and Cortical Volumetric Bone Mineral 
Density of the Radius and Tibia in Older Men: The Osteoporotic Fractures 
in Men Study. Journal of Bone and Mineral Research 2010;25:1017-28.  
Does not 
actually 
compare TZD 
vs. non TZD  
Glowczewski JE, Munn AL, Thomas ML, Brunner JE. Incidence and 
Clinical Significance of Thiazolidinedione Induced Edema and Weight 
Gain in Type 2 Diabetic Patients. ASHP Midyear Clinical Meeting 
2001;36:P-427E. 
No comparative 
data  
Ing SW, Osei K, Gaillard T, Sinnott LT, Jackson RD. Rosiglitazone-
induced Change in Bone Mineral Density among African Americans with 
Type 2 Diabetes Mellitus or Impaired Glucose Tolerance. Journal of Bone 
and Mineral Research 2008;23:S321-S21. 
Does not 
actually 
compare TZD 
vs. non TZD 
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 MEDLINE and EMBASE searches tested in Chapter 12 Appendix G:
 
MEDLINE (OVID: 1996 to July Week 1 2010) 
Searched: 21/07/10 
Original Search 
1. thiazolidinediones/ OR rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
Badgett et al 1999
427, 428
 
1. thiazolidinediones/ OR rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd.af OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. ((ae OR co OR po OR de).fs OR case report/) AND humans/ 
4. 1 AND 2 AND 3  
 
BMJ Clinical Evidence
432
 
1. thiazolidinediones/ OR rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd.af OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. (ae OR to OR po OR co).fs. OR (safe OR safety).ti,ab. OR side effect$.ti,ab. OR 
((adverse OR undesirable OR harm$ OR serious OR toxic) adj3 (effect$ OR reaction$ OR 
event$ OR outcome$)).ti,ab. OR exp product surveillance, postmarketing/ OR exp adverse 
drug reaction reporting systems/ OR exp clinical trials, phase iv/ OR exp poisoning/ OR exp 
substance-related disorders/ OR exp drug toxicity/ OR exp abnormalities, drug induced/ OR 
exp drug monitoring/ OR exp drug hypersensitivity/ OR (toxicity OR complication$ OR 
noxious OR tolerability).ti,ab. OR exp Postoperative Complications/ OR exp Intraoperative 
Complications/ 
4. 1 AND 2 AND 3  
 
Buckingham et al 2005a
434
 Without the quick filter (hedge) 
1. thiazolidinediones/ae, ct, po, to  
2. exp fractures, bone/ci, ep, et OR bone density/ab, ci, ep, et, tm OR exp osteoporosis/ab, 
ci, ep, et,tm 
3. 1 AND 2  
 
Buckingham et al 2005b
434
 With the quick filter (hedge) 
1. thiazolidinediones/ae, ct, po, to  
2. exp fractures, bone/ci, ep, et OR bone density/ab, ci, ep, et, tm OR exp osteoporosis/ab, 
ci, ep, et,tm 
3. case control studies/ OR cohort studies/ OR risk/ 
4. 1 AND 2 AND 3  
 
Golder et al 2006a
360
 Most sensitive search strategy  
1. thiazolidinediones/ OR rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd.af OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
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pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. exp Fractures, Bone/ci OR bone density/ci OR exp osteoporosis/ci  
4. (ae OR co OR de).fs 
5 (safe OR safety OR side effect* OR undesirable effect* OR treatment emergent OR 
tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects OR reaction OR 
reactions OR event OR events OR outcome OR outcomes))).ti,ab 
5. 1 AND 2 AND (3 OR 4 OR 5) 
 
Golder et al 2006b
360
 Most sensitive search strategy excluding use of specified 
adverse effects 
1. thiazolidinediones/ OR rosiglitazone$.af. OR avandia.af. OR avandaryl.af OR avaglim.af. 
OR avandamet.af. OR glitazone$.af. OR thiazolidinedion$.af. OR tzd.af OR ppar gamma 
agonist$.af. OR peroxisome proliferator activated receptor gamma agonist$.af. OR 
pioglitazone$.af. OR actos.af. OR actoplus.af OR duetact.af OR competact.af. OR glustin.af. 
OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 73 4.rn.  
2. exp Fractures, Bone/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af  
3. (ae OR co OR de).fs 
4 (safe OR safety OR side effect* OR undesirable effect* OR treatment emergent OR 
tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects OR reaction OR 
reactions OR event OR events OR outcome OR outcomes))).ti,ab 
5. 1 AND 2 AND (3 OR 4) 
The addition of the fracture terms means that the Golder et al 2006a
360
 ‘most sensitive 
search strategy’ is essentially the same as the Golder et al 2006b
360
 ‘most sensitive search 
strategy excluding use of specified adverse effects’.  
 
Wieland et al 2005a
121, 430
 Exploding MeSH term search 
1. humans/ AND journal article.pt  
2. exp fractures, bone/ OR bone density/ OR exp osteoporosis/  
3. thiazolidinediones/  
4. exp risk/ OR exp follow-up studies/ OR exp case-control studies/ 
5. 1 AND 2 AND 3 AND 4  
 
Wieland et al 2005b
121, 430
 Maximise Precision: MeSH term search with major topics 
and subheadings 
1. humans/ AND journal article.pt  
2. *Fractures, Bone/ OR * bone density/ OR *osteoporosis/ 
3. thiazolidinediones/  
4. risk/ OR risk factors/ OR follow-up studies/ OR odds ratio/ 
5. 1 AND 2 AND 3 AND 4 
 
Wieland et al 2005c
121, 430
 MeSH term search without study methodology terms 
1. humans/ AND journal article.pt  
2 *Fractures, Bone/ OR * bone density/ OR *osteoporosis/ 
3. thiazolidinediones/  
4. 1 AND 2 AND 3 
 
Wieland et al 2005d
121, 430
 Text word search with automatic term mapping 
1. humans/ AND journal article.pt  
2. exp fractures, bone OR fracture.tw OR fractures.tw OR exp bone and bones/ OR bone.tw 
OR bones.tw OR bmd.tw OR osteoporosis.tw 
3. rosiglitazone.tw. OR avandia.tw. OR avandaryl.tw OR avaglim.tw. OR avandamet.tw. OR 
glitazone.tw. OR glitazones.tw OR thiazolidinediones.tw. OR tzd.tw OR ppar gamma 
agonist.tw. OR peroxisome proliferator activated receptor gamma agonist.tw. OR 
pioglitazone.tw. OR actos.tw. OR actoplus.tw OR duetact.tw OR competact.tw. OR 
glustin.tw. OR nyracta.tw. OR venvia.tw. 
4. exp risk/ OR risk.tw OR follow-up.tw OR exp epidemiology/ OR epidemiology.tw OR 
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epidemiologic.tw 
5. 1 AND 2 AND 3 AND 4  
 
Wieland et al 2005e
121, 430
 Text word search with truncation and double quotes 
1. humans/ AND journal article.pt  
2. fracture$.tw OR bone$.tw OR bmd.tw OR osteoporo$.tw 
3. rosiglitazone$.tw. OR avandia.tw. OR avandaryl.tw OR avaglim.tw. OR avandamet.tw. 
OR glitazone$.tw. OR thiazolidinedion$.tw. OR tzd.tw OR ppar gamma agonist$.tw. OR 
peroxisome proliferator activated receptor gamma agonist$.tw. OR pioglitazone$.tw. OR 
actos.tw. OR actoplus.tw OR duetact.tw OR competact.tw. OR glustin.tw. OR nyracta.tw. 
OR venvia.tw. 
4. risk.tw OR epidemiolog$.tw 
5. 1 AND 2 AND 3 AND 4 
 
Wieland et al 2005f
121, 430
 Text word search without study methodology text words 
1. humans/ AND journal article.pt  
2. fracture$.tw OR bone$.tw OR bmd.tw OR osteoporo$.tw 
3. rosiglitazone$.tw. OR avandia.tw. OR avandaryl.tw OR avaglim.tw. OR avandamet.tw. 
OR glitazone$.tw. OR thiazolidinedion$.tw. OR tzd.tw OR ppar gamma agonist$.tw. OR 
peroxisome proliferator activated receptor gamma agonist$.tw. OR pioglitazone$.tw. OR 
actos.tw. OR actoplus.tw OR duetact.tw OR competact.tw. OR glustin.tw. OR nyracta.tw. 
OR venvia.tw. 
4. 1 AND 2 AND 3  
 
EMBASE (OVID: 1996 to 2010 Week 28) 
Searched: 21/07/10 
 
Original Search 
1. 2,4 thiazolidinedione derivative/ OR exp glitazone derivative/ OR rosiglitazone$.af. 
OR avandia.af. OR avandaryl.af OR avaglim.af. OR avandamet.af. OR glitazone$.af. OR 
thiazolidinedion$.af. OR tzd OR ppar gamma agonist$.af. OR peroxisome proliferator 
activated receptor gamma agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR 
duetact.af OR competact.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 
73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af. OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. 1 AND 2  
 
BMJ Clinical Evidence
432
 
1. 2,4 thiazolidinedione derivative/ OR exp glitazone derivative/ OR rosiglitazone$.af. 
OR avandia.af. OR avandaryl.af OR avaglim.af. OR avandamet.af. OR glitazone$.af. OR 
thiazolidinedion$.af. OR tzd.af OR ppar gamma agonist$.af. OR peroxisome proliferator 
activated receptor gamma agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR 
duetact.af OR competact.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 
73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. (ae OR si OR to OR co).fs. OR (safe OR safety).ti,ab. OR side effect$.ti,ab. OR ((adverse 
OR undesirable OR harm$ OR serious OR toxic) adj3 (effect$ OR reaction$ OR event$ OR 
outcome$)).ti,ab. OR exp adverse drug reaction/ OR exp drug toxicity/ OR exp intoxication/ 
OR exp drug safety/ OR exp drug monitoring/ OR exp drug hypersensitivity/ OR exp 
postmarketing surveillance/ OR exp drug surveillance program/ OR exp phase iv clinical 
trial/ OR (toxicity OR complication$ OR noxious OR tolerability).ti,ab. OR exp postoperative 
complication/ OR exp Peroperative Complication/ 
4. 1 AND 2 AND 3  
 
Golder et al 2006a
360
 Most sensitive search strategy 
1. 2,4 thiazolidinedione derivative/ OR exp glitazone derivative/ OR rosiglitazone$.af. 
OR avandia.af. OR avandaryl.af OR avaglim.af. OR avandamet.af. OR glitazone$.af. OR 
thiazolidinedion$.af. OR tzd.af OR ppar gamma agonist$.af. OR peroxisome proliferator 
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activated receptor gamma agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR 
duetact.af OR competact.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 
73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af  
3. exp fracture/si OR exp osteoporosis/si 
4. (safe OR safety OR side effect* OR undesirable effect* OR treatment emergent OR 
tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects OR reaction OR 
reactions OR event OR events OR outcome OR outcomes))).ti,ab 
5. 1 AND 2 AND (3 OR 4) 
 
Golder et al 2006b
360
 Most sensitive search strategy excluding use of specified 
adverse effects  
1. 2,4 thiazolidinedione derivative/ OR exp glitazone derivative/ OR rosiglitazone$.af. 
OR avandia.af. OR avandaryl.af OR avaglim.af. OR avandamet.af. OR glitazone$.af. OR 
thiazolidinedion$.af. OR tzd.af OR ppar gamma agonist$.af. OR peroxisome proliferator 
activated receptor gamma agonist$.af. OR pioglitazone$.af. OR actos.af. OR actoplus.af OR 
duetact.af OR competact.af. OR nyracta.af. OR venvia.af. OR 111025 46 8.rn. OR 122320 
73 4.rn.  
2. exp fracture/ OR fracture$.af OR bone density/ OR bone$.af OR bmd.af OR exp 
osteoporosis/ OR osteoporo$.af 
3. 2,4 thiazolidinedione derivative/ae,to OR exp glitazone derivative/ae,to 
4. (safe OR safety OR side effect* OR undesirable effect* OR treatment emergent OR 
tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects OR reaction OR 
reactions OR event OR events OR outcome OR outcomes))).ti,ab 
5. 1 AND 2 AND (3 OR 4) 
 
Legend 
MEDLINE Subheadings: ab=Abnormalities, ae=Adverse Effects, co=Complications, 
ct=contraindications, ci=Chemically Induced, de=Drug Effects, ep=Epidemiology, 
et=Etiology, po=Poisoning, to=Toxicity, tm=Transmission 
EMBASE Subheadings: ae=Adverse Drug Reaction, co=Complication, to=Drug 
Toxicity, si=Side Effect 
Fields Searched: ab=abstract, af= all fields, fs=floating subheading, rn=registry 
number, ti=title 
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 Published adverse effects search filters for MEDLINE and Appendix H:
EMBASE for Chapters 12 and 13 
 
Search Strategies excluding specified named adverse effects terms 
MEDLINE 
Badgett
427, 428
 
(ae OR co OR po OR de).fs OR CASE REPORT/ and HUMAN/ (no need to preselect 
specific adverse drug reactions) 
 
Golder
360
 
Most sensitive search strategy excluding use of specified named adverse effects 
(ae OR co OR de).fs OR (safe OR safety OR side effect* OR undesirable effect* OR 
treatment emergent OR tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects 
OR reaction OR reactions OR event OR events OR outcome OR outcomes)).ti,ab 
 
EMBASE 
Golder
360
 
Most sensitive search strategy excluding use of specified named adverse effects 
DRUG/ae, to OR (safe OR safety OR side effect* OR undesirable effect* OR treatment 
emergent OR tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR effects OR 
reaction OR reactions OR event OR events OR outcome OR outcomes))).ti,ab 
 
Search Strategies including specified named adverse effects terms 
MEDLINE 
BMJ Clinical Evidence
432
 
Specified named adverse effect AND (ae OR to OR po OR co).fs. OR (safe OR safety).ti,ab. 
OR side effect$.ti,ab. OR ((adverse OR undesirable OR harm$ OR serious OR toxic) adj3 
(effect$ OR reaction$ OR event$ OR outcome$)).ti,ab. OR exp product surveillance, 
postmarketing/ OR exp adverse drug reaction reporting systems/ OR exp clinical trials, 
phase iv/ OR exp poisoning/ OR exp substance-related disorders/ OR exp drug toxicity/ OR 
exp abnormalities, drug induced/ OR exp drug monitoring/ OR exp drug hypersensitivity/ OR 
(toxicity OR complication$ OR noxious OR tolerability).ti,ab. OR exp Postoperative 
Complications/ OR exp Intraoperative Complications/ 
 
Buckingham
434
 
Step 1. Source of harm with possible subheadings  
Adverse Effects (AE), Mortality (MO) (not always an option), Contraindications (CT) 
Poisoning (PO), Toxicity (TO)  
Step 2. Disease or disorder/outcome with possible subheadings  
Abnormalities (AB), Chemically Induced (CI), Epidemiology (EP), Etiology (ET) 
Mortality (MO), Transmission (TM)  
Step 3. Combine Previous Searches with a Quality Filter 
Combine the first two search statements, using the boolean operator "and" and combine the 
final subject statement with the quick filter (hedge) below.  
case control studies/ OR cohort studies/ OR risk/ 
 
Golder
360
 
Most sensitive search strategy 
Specified named adverse effects/ci OR (ae OR co OR de).fs OR (safe OR safety OR side 
effect* OR undesirable effect* OR treatment emergent OR tolerability OR toxicity OR adrs 
OR (adverse adj2 (effect OR effects OR reaction OR reactions OR event OR events OR 
outcome OR outcomes)).af 
 
Wieland
121, 430
 
Exploding MeSH term search 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND breast neoplasms [mh] 
AND contraceptives, oral [mh] AND (risk [mh] OR follow-up studies [mh] OR case-control 
studies [mh]) 
 
Maximise Precision: MeSH term search with major topics and subheadings 
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1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast neoplasms” 
[majr:noexp] AND (contraceptives, oral [mh:noexp] OR contraceptives, oral/pharmacology 
[mh] OR contraceptives, oral/therapeutic use [mh] OR estrogens/therapeutic use [mh] OR 
contraceptives, oral/adverse effects [mh]) AND (risk [mh:noexp] OR risk factors [mh:noexp] 
OR follow-up studies [mh:noexp] OR odds ratio [mh:noexp]) 
 
MeSH term search without study methodology terms 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast neoplasms” 
[majr:noexp] AND (contraceptives, oral [mh:noexp] OR contraceptives, oral/pharmacology 
[mh] OR estrogens/therapeutic use [mh] OR contraceptives, oral/therapeutic use [mh] OR 
contraceptives, oral/adverse effects [mh])  
 
Maximise Sensitivity: MeSH term search without intervention terms 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast neoplasms” 
[majr:noexp] AND (risk [mh:noexp] OR risk factors [mh:noexp] OR follow-up studies 
[mh:noexp] OR odds ratio [mh:noexp]) 
 
Text word search with automatic term mapping 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND breast cancer AND (oral 
contraceptive OR oral contraceptives OR estrogen OR estrogens OR hormones OR 
hormonal) AND (risk OR follow-up OR epidemiologic) 
 
Text word search with truncation and double quotes 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast cancer” AND 
(oral contraceptive* OR “estrogen” OR “hormones” OR “hormonal”) AND (“risk” OR 
“epidemiologic”) 
 
Text word search without study methodology text words 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast cancer” AND 
(oral contraceptive* OR “estrogen” OR “hormones” OR “hormonal”)  
 
Maximise Sensitivity: Text word search without intervention text words 
1966:1995 [dp] AND “human” [MESH] AND journal article [pt] AND “breast cancer” AND 
(“risk” OR epidemiolog*) 
 
EMBASE 
BMJ Clinical Evidence
432
 
Specified named adverse effect AND (ae OR si OR to OR co).fs. OR (safe OR safety).ti,ab. 
OR side effect$.ti,ab. OR ((adverse OR undesirable OR harm$ OR serious OR toxic) adj3 
(effect$ OR reaction$ OR event$ OR outcome$)).ti,ab. OR exp adverse drug reaction/ OR 
exp drug toxicity/ OR exp intoxication/ OR exp drug safety/ OR exp drug monitoring/ OR exp 
drug hypersensitivity/ OR exp postmarketing surveillance/ OR exp drug surveillance 
program/ OR exp phase iv clinical trial/ OR (toxicity OR complication$ OR noxious OR 
tolerability).ti,ab. OR exp postoperative complication/ OR exp Peroperative Complication/  
 
Golder
360
 
Most sensitive search strategy 
Specified named adverse effects OR (safe OR safety OR side effect* OR undesirable effect* 
OR treatment emergent OR tolerability OR toxicity OR adrs OR (adverse adj2 (effect OR 
effects OR reaction OR reactions OR event OR events OR outcome OR outcomes))).ti,ab 
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 Adverse effects terms in database records in Chapter 13 Appendix I:
Table 15.23 Accepted adverse effects terms 
Accepted terms in title or 
abstract 
Accepted indexing terms, keywords and 
subheading terms 
GENERIC:  
adverse effect(s), adverse 
drug effects, adverse 
event(s), adverse 
experiences, adverse 
medication effects, adverse 
CV events, adverse 
reactions, harm, safe, safety, 
side effect, tolerability, 
tolerated, toxicity, toxicities, 
toxic effect, untoward events, 
well-tolerated 
 
SPECIFIC:  
bleeding, blood loss, edema, 
oedema, cancer, 
hypokalemia, cardiac failure, 
heart failure, myocardial 
infarction, cardiovascular 
events, cardiovascular 
outcomes, cardiovascular 
mortality, cardiovascular risk, 
weight, thrombocytopenia, 
lymphoma, heart failure, 
cardiovascular outcomes, 
cardiovascular disease, 
cardiovascular event, 
myocardial infarction, 
cardiovascular disease, 
coronary heart disease, 
pneumonia 
GENERIC:  
MEDLINE: drug toxicity/, adverse effects (ae), 
chemically induced (ci) 
EMBASE: drug fatality/, drug induced disease/, side 
effect/, unspecified side effect/, drug safety/, drug 
tolerability/ drug tolerance/, adverse drug reaction 
(ae), side effects (si) 
Science Citation Index (SCI): drug toxicity, safety, 
tolerability, toxicity, tolerance. 
 
SPECIFIC:  
MEDLINE: postoperative hemorrhage/, myocardial 
infarction/, heart failure/ cardiovascular diseases/, 
weight gain/, thrombocytopenia/, heart failure/ 
cardiovascular diseases/ myocardial infarction/, 
EMBASE: postoperative hemorrhage/, leg edema/, 
edema/, peripheral edema: cancer/, hypokalemia/ 
congestive heart failure/, heart failure/, heart 
infarction/, heart arrest/, heart muscle ischemia/, 
acute heart infarction/, ischemic heart disease/ 
cardiovascular risk, body weight/ weight change/, 
weight Gain/, body weight disorder/, jaw 
osteonecrosis/, thrombocytopenia/, heart atrium 
fibrillation/, heart failure/, heart infarction/, 
congestive heart failure/ heart death/, heart disease/ 
cardiovascular disease/, nonhodgkin lymphoma/, B 
cell lymphoma/, lymphoma/, heart failure/, heart 
infarction/, heart atrium fibrillation/, ischemic heart 
disease/, congestive heart failure/ cardiovascular 
risk/ cardiovascular disease, heart atrium 
fibrillation/, heart failure/, congestive heart failure/ 
heart death, heart disease/ cardiovascular disease/, 
pneumonia/ 
Science Citation Index (SCI): blood-loss, acute 
myocardial-infarction, myocardial-infarction, 
coronary heart-disease, congestive-heart-failure, 
cardiovascular thrombotic events, weight-gain, 
bisphosphonate-associated osteonecrosis, 
thrombocytopenia, congestive-heart-failure, 
lymphoma, heart-failure, congestive-heart-failure. 
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Table 15.24 Records in each review with ‘adverse effects’ related terms in the 
title, abstract or indexing in MEDLINE or EMBASE 
Reference Topic Adverse 
effects 
terms in 
title or 
abstract 
Adverse 
effect 
indexing 
terms in 
MEDLINE 
or 
EMBASE 
Retrievable 
by a 
combined 
search 
Agbabiaka 
2009598 (N=15) 
Adverse effects with 
serenoa repens 
8 (53%) 13 (87%) 13 (87%) 
Albavera-
hernandez 
2009599 (N=14) 
Safety of botulinum toxin 
A 
3 (21%) 11 (79%) 11 (79%) 
Alghamdi 2007239 
(N=1) 
Bleeding with aspirin 1 
(100%) 
1 (100%) 1 (100%) 
Berlie 2007600 
(N=23)  
Edema with 
Thiazolidinediones 
20 
(87%) 
21 (91%) 22 (96%) 
Bonovas 2007601 
(N=4) 
Cancer with pravastatin 2 (50%) 4 (100%) 4 (100%) 
Cao 2010602 
(N=6) 
Hypokalemia with 
cetuximab-based therapy 
6 
(100%) 
6 (100%) 6 (100%) 
Chavez-Tapia 
2009603 (N=9) 
Adverse effects with 
rimonabant 
9 
(100%) 
9 (100%) 9 (100%) 
Chen 2007604 
(N=15) 
Myocardial infarction with 
COX-2 inhibitors 
13 
(87%) 
14 (93%) 14 (93%) 
Correll 2007605 
(N=19) 
Weight gain/metabolic 
effects of mood 
stabilizers/antipsychotics 
17 
(89%) 
18 (95%) 18 (95%) 
Dugoua 2009606 
(N=7) 
Safety of probiotics 2 (29%) 1 (14%) 3 (43%) 
Ford 2008607 
(N=9) 
Adverse effects of 
bismuth salts 
6 (67% 8 (89%) 8 (89%) 
Gehling 2009608 
(N=8) 
Side-effects of intrathecal 
morphine combined with 
spinal anaesthesia 
7 (88%) 7 (88%) 8 (100%) 
Johansson 
2009609 (N=20) 
Adverse effects of 
orlistat, sibutramine and 
rimonabant 
12 
(60%) 
17 (85%) 18 (90%) 
Lakhdar 2008610 
(N=6) 
Safety and tolerability of 
ACE inhibitors and 
angiotensin receptor 
blocker 
3 (50%) 4 (67%) 4 (67%) 
Luykx 2009611 
(N=9) 
Adverse effects of 
topiramate 
8 (89%) 9 (100%) 9 (100%) 
Mauri 2009612 
(N=5) 
Osteonecrosis of the jaw 
with bisphosphonates 
4 (80%) 5 (100%) 5 (100%) 
Morris 2007613 
(N=4) 
Thrombocytopenia with 
heparin 
3 (75%) 4 (100%) 4 (100%) 
Phillips 2007614 
(N=4) 
Adverse effects of 
blockers/inhibitors 
3 (75%) 4 (100%) 4 (100%) 
Ravindran 2009615 
(N=4) 
Safety of glucocorticoid 
therapy 
4 
(100%) 
4 (100%) 4 (100%) 
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Table 15.24 Records in each review with ‘adverse effects’ related terms in the 
title, abstract or indexing in MEDLINE or EMBASE 
Reference Topic Adverse 
effects 
terms in 
title or 
abstract 
Adverse 
effect 
indexing 
terms in 
MEDLINE 
or 
EMBASE 
Retrievable 
by a 
combined 
search 
Rodrigo 2008616 
(N=18) 
Safety of B-agonists 11 
(61%) 
14 (78%) 16 (89%) 
Rodrigo 2009617 
(N=13) 
Cardiovascular events 
with tiotropium 
5 (38%) 12 (93%) 12 (93%) 
Siegel 2009278 
(N=18) 
Lymphoma with anti-
tumor necrosis factor and 
immunomodulator 
therapy 
14 
(78%) 
18 
(100%) 
18 (100%) 
Silva 2007619 
(N=4) 
Adverse effects of statins 2 (50%) 4 (100%) 4 (100%) 
Singh 2007620 
(N=4) 
Cardiovascular events 
with rosiglitazone 
2 (50%) 4 (100%) 4 (100%) 
Singh 2008621 
(N=9) 
Cardiovascular events 
with anticholinergics 
4 (44%) 8 (89%) 8 (89%) 
Singh 2009622 
(N=5) 
Pneumonia with 
corticosteroids 
4 (80%) 5 (100%) 5 (100%) 
Average 
percentage of 
records 
All reviews 69% 90% 92% 
 
N = number of references from each review containing adverse effects data 
published in English later than 2001 and available from MEDLINE or EMBASE. 
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Table 15.25 Performance of individual search terms in MEDLINE and EMBASE 
MEDLINE EMBASE 
Floating 
Subheadings 
(N=231)  
Number of Relevant 
Records (N=231) 
Floating 
Subheadings  
Number of Relevant 
Records (N=222) 
Adverse Effects 
(ae) 
117 (51%) Adverse Drug 
Reaction (ae) 
185 (83%) 
Complications (co) 41 (18%) Complication 
(co) 
24 (11%) 
Drug Effects (de) 62 (27%) Drug Toxicity 
(to) 
2 (1%) 
Poisoning (po) 0 Side Effect (si) 185 (83%) 
Toxicity (to) 0   
Subheadings 
attached to 
Intervention 
(N=231) 
 Subheadings 
attached to 
Intervention 
 
Adverse Effects 
(ae) 
117 (51%) Adverse Drug 
Reaction (ae) 
185 (83%) 
Contraindications 
(ct) 
0 Drug Toxicity 
(to) 
2 (1%) 
Mortality (mo) 0   
Pharmacology (pd) 22 (10%)   
Poisoning (po) 0   
Therapeutic use 
(tu) 
177 (77%)   
Toxicity (to) 0   
Subheadings 
attached to 
Disease or 
Disorder/Outcome 
(N=119) 
   
Abnormalities (ab) 0   
Chemically 
Induced (ci) 
7 (6%)   
Epidemiology (ep) 2 (2%)   
Etiology (et) 0   
Mortality (mo) 3 (3%)   
Transmission (tm) 0   
MeSH Terms 
(N=231) 
 EMTREE Terms 
(N=222) 
 
Exp abnormalities, 
drug induced/ 
0 exp adverse 
drug reaction/ 
43 (19%) (0 adverse 
drug reaction, one 
chemotherapy 
induced emesis, 
eight drug eruption, 
10 drug fatality, 4 
drug fever, four drug 
hypersensitivity, six 
drug induced 
disease, seven drug 
induced headache, 
eight flu like 
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Table 15.25 Performance of individual search terms in MEDLINE and EMBASE 
MEDLINE EMBASE 
syndrome, three 
injection site 
reaction, six 
unspecified side 
effect) 
Exp adverse drug 
reaction reporting 
systems/ 
0 exp drug 
hypersensitivity/ 
4 (2%) (drug 
hypersensitivity) 
Case control 
studies/ 
1 (0.5%) exp drug 
monitoring/ 
0 
Exp case control 
studies/ 
8 (3%) exp drug safety/ 85 (38%) 
Case report/ 0 exp drug 
surveillance 
program/ 
0 
Exp clinical trials, 
phase iv as topic/ 
0 exp drug 
toxicity/ 
0 
Cohort studies/ 3 (1%) exp intoxication/ 0 
exp drug 
hypersensitivity/ 
2 (1%) (both drug 
hypersensitivity/) 
  
Exp drug 
monitoring/ 
0   
Exp drug toxicity/ 3 (1%) (1 drug 
toxicity/ and two 
Serum Sickness/) 
  
Exp follow-up 
studies/ 
24 (10%)   
Human/ 231 (100%)   
Exp Intraoperative 
Complications/ 
3 (1%) (1 
Intraoperative 
Complications and 
two Blood Loss, 
Surgical) 
  
odds ratio/ 1 (0.5%)   
Exp poisoning/ 4 (2%) (1 Drug-
Induced Liver Injury, 
one drug toxicity 
and two Serum 
Sickness) 
  
Exp Postoperative 
Complications/ 
1 (0.5%) (1 
Postoperative 
Hemorrhage) 
  
Exp product 
surveillance, 
postmarketing/ 
0   
Risk/ 6 (3%)   
Exp Risk/ 28 (12%) (6 risk, 
three Risk 
Assessment, 19 
Risk Factors) 
  
Risk factors/ 19 (8%)   
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Table 15.25 Performance of individual search terms in MEDLINE and EMBASE 
MEDLINE EMBASE 
Exp Substance-
related disorders/ 
6 (3%) (1 Substance 
Withdrawal 
Syndrome, one 
Substance-related 
disorders, one Drug-
Induced Liver Injury, 
one drug toxicity 
and two Serum 
Sickness) 
  
Terms in the Title 
or Abstract 
 Terms in the 
Title or 
Abstract 
 
adrs 0 adrs 0 
adverse adj2 effect 4 (2%) adverse adj2 
effect 
4 (2%) 
adverse adj2 
effects 
17 (%)  adverse adj2 
effects 
15 (7%)  
adverse adj3 
effect$ 
19 (8%) (4 adverse 
effect, 13 adverse 
effects, one adverse 
medication effects, 
two adverse side 
effects, one adverse 
drug effects) 
adverse adj3 
effect$ 
19 (9%) (4 adverse 
effect, 12 adverse 
effects, one adverse 
medication effects, 
one adverse side 
effects, one adverse 
side-effect, one 
adverse drug 
effects) 
adverse adj2 event 14 (6%)  adverse adj2 
event 
13 (6%) 
adverse adj2 
events 
67 (29%)  adverse adj2 
events 
63 (28%) (11 
adverse event, 51 
adverse events, one 
adverse CV events) 
adverse adj3 
event$ 
75 (32%) (12 
adverse event, 66 
adverse events, one 
adverse CV events) 
adverse adj3 
event$ 
71 (32%) (13 
adverse event, 62 
adverse events, one 
adverse CV events) 
adverse adj2 
outcome 
0 adverse adj2 
outcome 
0 
adverse adj2 
outcomes 
0 adverse adj2 
outcomes 
0 
adverse adj3 
outcome$ 
0 adverse adj3 
outcome$ 
0 
adverse adj2 
reaction 
0 adverse adj2 
reaction 
0 
adverse adj2 
reactions 
3 (1%) (3 adverse 
reactions) 
adverse adj2 
reactions 
3 (1%) (3 adverse 
reactions) 
adverse adj3 
reaction$ 
3 (1%) (3 adverse 
reactions) 
adverse adj3 
reaction$ 
3 (1%) (3 adverse 
reactions) 
complication$ 7 (3%) (6 
complications, one 
complication) 
complication$ 7 (3%) (6 
complications, one 
complication) 
 418 
Table 15.25 Performance of individual search terms in MEDLINE and EMBASE 
MEDLINE EMBASE 
epidemiolog* 0 epidemiolog* 0 
epidemiologic 0 epidemiologic 0 
follow-up 29 (13%) (25 follow-
up, four follow up) 
follow-up 28 (13%) (25 follow-
up, four follow up) 
harm$ adj3 effect$ 0 harm$ adj3 
effect$ 
0 
harm$ adj3 event$ 0 harm$ adj3 
event$ 
0 
harm$ adj3 
outcome$ 
0 harm$ adj3 
outcome$ 
0 
harm$ adj3 
reaction$ 
0 harm$ adj3 
reaction$ 
0 
noxious 0 noxious 0 
risk 64 (27%) risk 61 (27%) 
safe 17 (7%) safe 17 (8%) 
safety 71 (31%) safety 63 (28%) 
serious adj3 
effect$ 
1 (0.5%) (1 serious 
side-effects) 
serious adj3 
effect$ 
1 (0.5%) (1 serious 
side-effect) 
serious adj3 
event$ 
15 (6%) (1 serious 
adverse event, 11 
serious adverse 
events, one serious 
cardiovascular 
events, one serious 
CV thromboembolic 
events, one serious 
and non-serious 
adverse events, one 
serious symptomatic 
adverse event) 
serious adj3 
event$ 
12 (5%) (1 serious 
adverse event, nine 
serious adverse 
events, one serious 
cardiovascular 
events, one serious 
CV thromboembolic 
events, one serious 
and non-serious 
adverse events, one 
serious symptomatic 
adverse event) 
serious adj3 
outcome$ 
0 serious adj3 
outcome$ 
0 
serious adj3 
reaction$ 
2 (1%) (2 serious 
adverse reactions) 
serious adj3 
reaction$ 
2 (1%) (2 serious 
adverse reaction) 
side effect$ 22 (10%) (1 side 
effect, 17 side 
effects, five side-
effects) 
side effect$ 23 (10%) (1 side 
effect, 18 side 
effects, five side-
effects) 
tolerability 23 (10%) tolerability 24 (11%) 
toxic adj3 effect$ 2 (1%)  toxic adj3 
effect$ 
2 (1%) (2 toxic 
effects) 
toxic adj3 event$ 0 toxic adj3 
event$ 
0 
toxic adj3 
outcome$ 
0 toxic adj3 
outcome$ 
0 
toxic adj3 
reaction$ 
0 toxic adj3 
reaction$ 
0 
toxicity 11 (5%) toxicity 11 (5%) 
treatment 
emergent 
0 treatment 
emergent 
0 
undesirable effect* 0 undesirable 0 
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Table 15.25 Performance of individual search terms in MEDLINE and EMBASE 
MEDLINE EMBASE 
effect* 
undesirable adj3 
effect$ 
0 undesirable 
adj3 effect$ 
0 
undesirable adj3 
event$ 
0 undesirable 
adj3 event$ 
0 
undesirable adj3 
outcome$ 
0 undesirable 
adj3 outcome$ 
0 
undesirable adj3 
reaction$ 
0 undesirable 
adj3 reaction$ 
0 
All fields   All fields   
adrs 0 adrs 0 
adverse adj2 effect 4 (2%) adverse adj2 
effect 
4 (2%) 
adverse adj2 
effects 
16 (7%) (13 adverse 
effects, one adverse 
medication effects, 
two adverse side 
effects, one adverse 
drug effects) 
adverse adj2 
effects 
15 (7%) (12 adverse 
effects, one adverse 
medication effects, 
one adverse side 
effects, one adverse 
side-effects one 
adverse drug 
effects) 
adverse adj2 event 12 (5%) adverse adj2 
event 
70 (32%) 
adverse adj2 
events 
67 (29%) (66 
adverse events, one 
adverse CV events) 
adverse adj2 
events 
63 (28%) (1 adverse 
cv events) 
adverse adj2 
outcome 
0 adverse adj2 
outcome 
0 
adverse adj2 
outcomes 
0 adverse adj2 
outcomes 
0 
adverse adj2 
reaction 
0 adverse adj2 
reaction 
0 
adverse adj2 
reactions 
3 (1%) adverse adj2 
reactions 
3 (1%) 
safe 17 (7%) safe 16 (7%) 
safety 72 (31%) safety 62 (28%) 
side effect* 22 (10%) (1 side 
effect, 17 side 
effects, five side-
effects) 
side effect* 18 (8%) 
tolerability 23 (10%) tolerability 24 (11%) 
toxicity  11 (5%) toxicity  11 (5%) 
treatment 
emergent 
0 treatment 
emergent 
0 
undesirable effect* 0 undesirable 
effect* 
0 
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 Sensitivity of searches in case study systematic review and Appendix J:
selection of databases in systematic reviews of adverse effects. 
 
Database Sensitivity of searches in case 
study systematic review in 
Chapter 11 (N=58) 
Percentage of reviews that 
search each source in survey 
in Chapter 10 (N=849) 
Science Citation 
Index (SCI) 
60% 5% 
BIOSIS Previews 47% 8% 
EMBASE 41% 54% 
MEDLINE 33% 96% 
Scirus (journal 
sources) 
29% 0% 
Derwent Drug File 28% 0% 
PASCAL 28% 1% 
British Library Direct 26% 0% 
Thomson Reuters 
Integrity 
26% 0% 
TOXLINE 24% 2% 
ADIS Clinical Trials 
Insight 
22% 0% 
Iowa Drug 
Information Service 
(IDIS) 
21% 1% 
Manufacturer 17% 13% 
International 
Pharmaceutical 
Abstracts (IPA) 
12% 3% 
CINAHL 10% 13% 
Conference 
Proceedings Citation 
Index-Science 
10% 0% 
CENTRAL 9% 24% 
Medscape DrugInfo 7% 0% 
Conference Papers 
Index (CPI) 
3% 0% 
Inside Conferences 0% 0% 
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Abbreviations 
 
ADE – Adverse Drug Effect 
ADR – Adverse Drug Reaction 
AE – Adverse Event 
CCIS - Micromedex Computerized Clinical Information Service 
CDSR – Cochrane Database of Systematic Reviews 
CHM – Commission on Human Medicines 
CI – Confidence Interval 
COSTART - Coding Symbols for a Thesaurus of Adverse Reaction Terms 
CPI – Conference Papers Index 
CPRD – Clinical Practice Research Datalink 
CRD – Centre for Reviews and Dissemination 
DARE – Database of Abstracts of Reviews of Effects 
DDF - Derwent Drug File 
EMA – European Medicines Agency 
FDA – Food and Drug Administration 
HRT – Hormone Replacement Therapy 
IDIS - Iowa Drug Information Service 
IPA - International Pharmaceutical Abstracts 
IPD – Individual Participant Data 
MedDRA - Medical Dictionary for Regulatory Activities 
MHRA - Medicines and Healthcare products Regulatory Agency 
NHS – National Health Service 
NICE - National Institute for Health and Care Excellence 
NNH – Number Needed to Harm 
NSAIDs – Non-steroidal anti-inflammatory Drug 
NTIS - National Technology Information Service 
OR – Odds Ratio 
PDR - Physician’s Desk Reference 
PEM – Prescription Event Monitoring 
RAE – Routine Adverse Events 
RCT – Randomised Controlled Trial 
ROR – Ratio of Risk Ratios 
RR – Risk Ratio 
SADR – Serious Adverse Drug Reaction or Suspected Adverse Drug Reaction 
SAE – Serious Adverse Event 
SE – Standard Error 
SEDA - Side Effects of Drugs Annuals 
SCI – Science Citation Index 
SSCI – Social Science Citation Index 
WHO – World Health Organisation 
WHO-ART - World Health Organisation Adverse Reactions Terminology 
WMD – Weighted Means Difference 
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